Studies toward the mechanism of allosteric activation in phenylalanine hydroxylase by Soltau, Sarah Rose
Boston University
OpenBU http://open.bu.edu
Theses & Dissertations Boston University Theses & Dissertations
2014
Studies toward the mechanism of
allosteric activation in
phenylalanine hydroxylase
https://hdl.handle.net/2144/14146
Boston University
 BOSTON UNIVERSITY 
GRADUATE SCHOOL OF ARTS AND SCIENCES 
 
 
Dissertation 
 
 
STUDIES TOWARD THE MECHANISM OF ALLOSTERIC ACTIVATION IN 
PHENYLALANINE HYDROXYLASE 
 
by 
 
 
SARAH R. SOLTAU 
 
 
B.A., Skidmore College, 2007 
M.A., Boston University, 2010 
 
 
Submitted in partial fulfillment of the 
requirements for the degree of 
Doctor of Philosophy 
2014
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© Copyright by  
SARAH R. SOLTAU 
2014
Approval Page 
 
 
 
 
 
First Reader  ______________________________________________________ 
John P. Caradonna, Ph.D.  
   Associate Professor of Chemistry 
 
 
 
Second Reader ______________________________________________________ 
Adrian Whitty, Ph.D. 
   Associate Professor of Chemistry 
 
  
 iv 
 
Acknowledgments 
  
 I would like to thank my advisor, Prof. John Caradonna, for his support over the 
last six years and the amazing ideas which propelled my project forward.  Every time 
John suggested an experiment that I thought was unnecessary, it ended up being essential 
and very interesting.  He has a great talent for taking seemly strange ideas and shaping 
them into very interesting projects and encouraging people to become the best scientists 
possible. 
 I would also like to thank Gülbenk Anarat-Cappillino who taught me how to 
express and purify protein and became my model example of what a scientist should be 
like.  I cannot express how much I appreciated Gülbenk's help, especially our early 
mornings with the fermentor (followed by runs to Dunkin Donuts) or late nights waiting 
for protein to concentrate.  Dr. Jesse Karr, Breia Salsbery, and Dave Villarreal also 
helped make the bio-side a great place to work over the last six years.  I also want to 
thank the undergrads I have had the chance to work with: Rachel, Kim, Elif, Carmen, 
Alan, Alli, and Nick.  Nick and Alli, I expect you guys to carry on the bio-side and the 
good stuff we have going at the moment.  
 I would also like to thank the synthetic side of the Caradonna lab for their support.  
Gerard Rowe and Pat Cappillino, who could talk about science in any environment, thank 
you for making me write out the amino acids on the back of a napkin at Cornwalls and 
for setting such a great tone in the lab.  I also want to thank Paul Tarves for providing a 
lot of comic relief when we needed it and encouraging everyone to relax a little.  Lauren 
 v 
 
Gregor and Josh McNally are also important for being here from the start and going 
through this crazy journey together.  I hope see you both graduating in the near future.  
Jeff Liu, for making my T-rides home this summer much more enjoyable and knowing 
how to always make me laugh with your typing games. 
 I would also like to thank Prof. Steven Frey and Prof. Michelle Frey from 
Skidmore College, for inspiring me to make chemistry my career and continue to 
challenge myself.  Without their inspiration and great teaching, I probably never would 
have been a chemistry major, and definitely would not have taken my current path. 
 Finally, I would like to thank my friends and family who have supported on this 
long trip through graduate school.  I would like to thank my friends in Boston who were 
willing to get together and listen to me vent about graduate school and help me find other 
outlets.  I want to thank June Lum for being the best possible roommate for three years 
and helping to keep me sane well after moving on to better things.  I also want to thank 
my family for all of their support over the years.  It has been wonderful to know that you 
are always available, either a phone call or bus ride away.   
  
 vi 
 
STUDIES ON THE MECHANISM OF ALLOSTERIC ACTIVATION IN 
PHENYLALANINE HYDROXYLASE 
(Order No.                    ) 
SARAH R. SOLTAU 
Boston University, Graduate School of Arts and Sciences, 2014 
Major Professor: John P. Caradonna, Associate Professor of Chemistry 
 
ABSTRACT 
 Phenylalanine hydroxylase (PAH, EC: 1.14.16.1) is a non-heme iron 
tetrahydropterin-dependent monooxygenase that maintains phenylalanine (L-Phe) 
homeostasis via conversion of L-Phe to L-Tyr. PAH is an allosteric enzyme that converts 
from an inactive T-state to an active R-state upon addition of substrate, L-Phe. Allosteric 
activation is correlated with physical and structural changes within the enzyme and a 
large activation energy. Crystal structures of PAH have not identified the location of the 
allosteric effector binding site. Herein, we report computational protein mapping efforts 
using the FTMap algorithm and experimental site-directed mutagenesis studies designed 
to define and screen possible L-Phe allosteric binding sites. Mass spectroscopic analysis 
of PAH proteolytic fragments obtained after photo-crosslinking with 2-azido-3-
phenylpropanoate overlapped with one computationally derived allosteric binding pocket 
containing residues 110-120 and 312-317. Ligand docking studies, fluorescence 
 vii 
 
measurements, binding affinity and activity assays on wild-type and mutant enzymes 
further characterized the shape and specificity of this pocket.   
 Thermodynamic studies using surface acoustic wave (SAW) biosensing 
determined the affinity of L-Phe for the allosteric site. Two L-Phe binding sites were 
observed upon SAW titrations, corresponding to the active and allosteric sites 
respectively (KD,app
on
 113 ± 12 µM active site, KD,app
on
 680 ± 20 µM allosteric site).  Site-
directed mutagenesis was performed to prepare mutant enzymes containing a single 
tryptophan (L-Trp) residue. The fluorescence signatures of each of the three native L-Trp 
residues in PAH were determined by titrations with L-Phe. Trp187 primarily reports L-
Phe induced allosteric conformational changes, while Trp120 reports active site L-Phe 
binding. Trp326 reports small signals of both active and allosteric site changes. 
 Variable temperature stopped-flow fluorescence kinetic studies elucidated a 
working mechanism for L-Phe allosteric activation of PAH. Fluorescent signals from 
wild-type, single, and double L-Trp PAH mutants have been used to build kinetic 
mechanisms for the L-Phe binding in each subunit and subsequent active site 
reorganization or allosteric conformational change.  In these mechanisms, the enzyme has 
reduced activity (1-2% of wtPAH) until both L-Phe induced active and allosteric site 
conformational changes have occurred.  Failure of either activation step prevents enzyme 
turnover and is the chemical-based cause of the metabolic condition phenylketonuria. 
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CHAPTER 1 
Introduction and Overview of Phenylalanine Hydroxylase and Allosteric Activation 
1.1 Chemistry of the mononuclear non-heme iron containing enzymes 
Mononuclear non-heme iron containing enzymes catalyze extremely challenging 
reactions that activate dioxygen in order to perform oxidase and oxygenase reactions (1).  
Many of these enzymes are members of the 2-His-1-carboxylate facial coordination 
family, wherein the ferrous center in the enzyme active sites are coordinated by two 
histidine residues and one aspartate or glutamate residue, leaving three open sites for the 
coordination of dioxygen, coenzyme, or solvent molecules (1).  The diversity of the 
observed reaction chemistry supported by these systems includes C-H hydroxylation, ring 
opening processes, and olefin epoxidation processes (2).   
These enzymes are thought to follow a single generally accepted mechanism.  The 
cycle begins in a resting state with a six coordinate iron(II) center containing the 
His2Asp/Glu ligand set and three labile (H2O, 
-
OH) ligands.  The coordination of 
coenzyme to the Fe(II) center and the binding of substrate in the enzyme active site prime 
the enzyme for reaction with dioxygen by inducing a change in the primary coordination 
sphere of the iron center from six- to five-coordinate (3).  Upon subsequent dioxygen 
bonding to the iron(II) center, an iron(III)-superoxo intermediate is proposed to form.  
Additional reducing equivalents from the coenzyme are utilized to generate an iron-
peroxy species that ultimately leads to formation of a high-valent iron(IV)-oxo 
intermediate.  This iron(IV)-oxo intermediate quickly reacts with substrate, leading to 
product release and returning the enzyme to its resting iron(II)
 
state (2-4).  Differences 
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between the specific types of 2-His-1-carboxylate non-heme iron monooxygenases will 
be further discussed herein.  Table 1.1 depicts some of the different reaction classes and 
activation mechanisms for the class of Fe(II)/2-His-1-carboxylate containing enzymes. 
 
Table 1.1 Different types of 2-His-1-carboxylate non-heme iron monooxygenases 
discussed and their activation mechanism which are herein. 
Enzyme Type Activation 
Mechanism 
Rep. 
Enzymes
a 
Ref. 
Extradiol-cleaving catechol dioxygenases (EDCs) 
 
 
Substrate binding 
to Fe
2+
, followed 
by O2 binding to 
Fe
2+ 
CTD 
HPCD 
LigAB 
(5) 
(6) 
(7) 
α-Ketoglutatarate dependent dioxygenases (α-KGDs) 
 
 
Coenzyme 
binding to Fe(II) 
center, followed 
by O2 binding to 
Fe
2+ 
TauD 
HppD 
CmaB 
(8) 
(9) 
(10) 
Rieske cis-diol forming dioxygenases (Rieske) 
 
 
Electron transfer 
from Rieske 
[2Fe-2S] cluster 
to mononuclear 
Fe
2+
 center 
NDO 
PDO 
BDO 
(11) 
(12) 
(13) 
Tetrahydrobiopterin dependent hydroxylases (e.g. PAH) 
 
 
Substrate binding 
in active site and 
allosteric control 
by regulatory 
domain 
PAH 
TyrOH 
TrpOH 
(14) 
(15) 
(16) 
 
a
CTD (catechol 2,3-dioxygenase), HPCD (homoprotocatechuate 2,3-dioxygenase), LigAB (protocatechuate 
4,5-dioxygenase), TauD (taurine/α-KG dioxygenase), HppD (4-hydroxyphenylpyruvate dioxygenase), 
NDO (naphthalene 1,2-dioxygenase), PDO (phthalate dioxygenase), BDO (benzoate dioxygenase), PAH 
(phenylalanine hydroxylase), TyrOH (tyrosine hydroxylase), TrpOH (tryptophan hydroxylase). 
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1.1.1 Extradiol-cleaving catechol dioxygenases 
Extradiol-cleaving catechol dioxygenase (ECD) enzymes are essential for 
aromatic ring cleavage in soil bacteria as they enable the final step in the conversion of 
aromatic products into aliphatic chain products (17).  The ECD enzymes are 
distinguishable from the closely related intradiol-cleaving catechol dioxygenase (ICD) 
systems in that ECD enzymes typically employ a ferrous
 
active site
 
center, while the ICD 
systems utilize an ferric active site center (Figure 1.1) (18).  ICD enzymes are only 
known to catalyze cleavage reactions with catechol and various substituted catechols, 
while ECD proteins are more robust and react with catechols as well as many other 
compounds including gentisate, hydroquinone, salicylate, and 2-aminophenol and even 
some aromatic amino acids (19).  There are three known classes of ECD enzymes based 
on bioinformatic phylogenetic analysis (20), but most follow the same general 
mechanism and contain a 2-His-1-carboxylate facial triad bound to an iron(II) center.  A 
few of the ECD enzymes, however, have been noted to contain manganese(II) centers 
(18, 19).   
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Figure 1.1 Reaction and active site iron environment of ICD and ECD enzymes.  
Adapted from Ref. (19). 
 
 
1.1.1.1 Catalytic mechanism and reactivity 
The mechanism of ECD enzymes has been well characterized for a number of 
systems.  The first step in the mechanism typically consists of the aromatic substrate 
binding in a bidentate fashion to the six-coordinated ferrous center through deprotonated 
hydroxyl groups.  Substrate binding causes immediate loss of the remaining bound water 
molecule to form an iron(II) square pyramidal complex (1, 2, 19), which is shown in 
Figure 1.2.   
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Figure 1.2 Proposed catalytic mechanism of the extradiol-cleaving catechol dioxygenase 
enzymes. Adapted from reference (1). 
 
In 2,3-dihydroxybiphenyl 1,2-dioxygenase (DHBD), however, binding of its 
preferred substrate has been shown to be monoanionic by resonance Raman 
spectroscopy, indicating a conformational change upon substrate binding that is different 
from dianionic substrate binding modes known for other EDC enzymes (21).  The 
enzyme-substrate complex (shown as intermediate 2 in Figure 1.2) then binds dioxygen 
resulting in an iron(II)-superoxide adduct that concertedly activates the substrate by 
abstracting an electron from the substrate (intermediate 3 of Figure 1.2), giving rise to 
radical delocalization throughout the iron(II)-superoxide catechol adduct, wherein a 
radical is delocalized over the superoxide, while another radical is delocalized over the 
catechol adduct (shown as intermediate 3 of Figure 1.2) (1).  Attack of the bound 
superoxo species on the carbon radical generates a putative ferrous-alkylperoxo 
intermediate, which upon subsequent O-O bond cleavage though a proposed concerted 
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Criegee rearrangement (1, 6, 19) (intermediate 4 of Figure 1.2) forms a seven-membered 
lactone, which then opens up to the final reaction product (intermediates 5 and 6 in 
Figure 1.2) (2).  
The oxygen insertion process in homoprotocatechuate 2,3-dioxygenase (HPCD) 
has been crystallographically studied using the alternative substrate, 4-nitrocatechol (6).  
The crystallization conditions have allowed the various subunits of the protein to be 
isolated in different states of the catalytic mechanism including the ternary complex 
(Figure 1.3a), the alkylperoxo-iron(II)
 
intermediate complex (Figure 1.3b) and the ring-
opened final product (Figure 1.3c).  These crystallographic studies support the assertion 
that binding of dioxygen to the iron center occurs in a side-on manner (6).  This 
conclusion was opposite to what had previously been inferred from nitric oxide 
accessibility studies, which had suggested end-on binding (1-binding) of dioxygen to the 
active site iron center (22).  
 
Figure 1.3 Crystallographically observed catalytic states of HPCD: (a) Ternary complex 
with 4-nitrocatechol substrate bound, (b) 4-nitrocatechol-alkylperoxo-Fe
2+
 intermediate 
complex, (c) final ring opened product.  Figures created in PyMol (23) using PDB file 
2IGA (6). 
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1.1.1.2 Substrate activation process 
There have been many detailed studies concerning the catalytic mechanism of 
extradiol-cleaving catechol dioxygenases; however, details of the substrate activation 
process itself have remained somewhat elusive.  Recently, several groups have begun to 
look at the substrate activation process in order to develop a substrate based activation 
mechanism.  Mechanistic studies of AkbC, a methylcatechol 2,3-dioxygenase enzyme 
from Rhodococcus species strain DK17 involved in alkylbenzene metabolism, 
demonstrate that while the enzyme contains the canonical 2-His-1-carboxylate iron(II) 
active site, there is also an additional tyrosine residue, Tyr 253, which is located 
approximately 2.8 Å away from the iron center (24).  This residue, which is proposed to 
be involved in deprotonation of a hydroxyl group on the substrate, is also conserved in 
other members of the ECD enzyme family (21, 24).  The C-terminal tail of AkbC lies 
directly over the substrate-binding site, which could restrict access of various large and 
bulky substrates to the active site cavity as well as prevent oxidation of the substrate-
binding pocket.  Crystallographic studies examining the orientation of the natural 
substrate of AkbC, 3-methylcatechol, suggested that Tyr 253 serves as a ligand in the 
active site until substrate binding occurs (shown in Figure 1.4).  The bound catechol 
substrate protonation state is proposed to be monoanionic, similar to the previously 
discussed catechol coordination mode in the DHBD system.  The ferrous center adapts a 
five-coordinate, square pyramidal coordination environment upon the binding of 3-
methylcatechol, which leads to a second rearrangement of the catechol ligation to a 
bidentate coordination mode with concurrent release of Tyr 253 from the iron center.  
8 
 
 
 
This substrate bound state, with 2-His-1-carboxylate coordination, is now ready for 
dioxygen binding and subsequent catalysis as is shown in Figure 1.5 (24).  The role of 
the iron center in the ECD enzymes is to polarize and activate the substrate at the active 
site, as no high-valent iron species is proposed to form (1).  The binding of substrate 
facilitates the one electron reduction of dioxygen and helps orient the superoxide for 
attack at the substrate radical species generated by the transfer of a catechol electron the 
to the iron center.  Other 2-His-1-carboxylate enzymes follow a very different 
mechanistic path, utilizing high-valent iron(IV)-oxo intermediates in contrast with the 
mechanism of substrate activation in the ECD enzymes (vide infra).    
 
 
Figure 1.4 a) Active site of AkbC enzyme with coordination from Tyr253 in absence of 
substrate. Figure created in PyMol (23) using PDB file 2WL3 (24).  B) Active site of 
AkbC enzyme in the presence of substrate, 3-methylcatechol. Figure created in PyMol 
(23) using PBD file 2WL9 (24). 
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Figure 1.5 Substrate activation process in AkbC, adapted from reference (24). 
 
1.1.2 α-Ketoglutarate dependent dioxygenases 
The largest category of the 2-His-1-carboxylate enzymes is the α-ketoglutarate (α-
KG) dependent dioxygenases.  These enzymes rely on an α-keto acid, typically α-KG, to 
act as a coenzyme to supply electrons to the iron center.  The proposed mechanism of 
dioxygen activation and subsequent catalysis is substantially different from the ECD 
enzymes discussed previously (1).  This class of enzyme also catalyzes the widest variety 
of reactions within the substructure of the 2-His-1-carboxylate mononuclear non-heme 
iron centers. These types of reactions include hydroxylation, desaturation, ring closure 
and expansion, epimerization, and chlorination reactions (2, 25). 
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1.1.2.1 Catalytic mechanism and reactivity 
The catalytic mechanism of the α-KG dependent dioxygenases begins with an 
enzyme active site consisting of a six-coordinate ferrous center ligated by two histidine 
residues, an aspartate or glutamate residue, and three water or solvent molecules (1).  
These enzymes then bind α-KG or another α-keto acid in a bidentate fashion, with loss of 
the water molecules, as shown in intermediate 2 of Figure 1.6 (25).  This α-KG bound 
state has been well characterized crystallographically (26) and spectroscopically (8, 27) 
in the case of taurine dioxygenase (TauD) (Figure 1.7).  Electron paramagnetic 
resonance (EPR) experiments with nitrosyl adducts of TauD have suggested the presence 
of two binding modes for α-KG in the enzyme in a 75:25 ratio (28), while the addition of 
substrate to the α-KG-nitrosyl adducts converts the enzyme to a single species (29).  The 
binding of the α-keto acid coenzyme to the iron center, combined with the presence of 
substrate in the active site is proposed to generate an iron(III)-superoxo species when 
exposed to dioxygen (Figure 1.6, intermediate 3) (2, 25).  The anion that forms during 
this reaction then attacks the carbonyl carbon of the bound α-keto acid, leading to 
decarboxylation of the α-keto acid through the release of carbon dioxide as a byproduct.  
This process is proposed to go through a persuccinate or cyclic peroxide intermediate 
(Figure 1.8) which collapses to form an iron(IV)-oxo intermediate (25) shown in Figure 
1.6,  intermediate 4.  The oxygen activation process reduces the length of the bound α-
keto acid by one carbon, which the case of α-KG forms succinate, and incorporates one 
atom the dioxygen molecule into the new carboxylic acid (succinate) (1).   
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Figure 1.6 Proposed catalytic mechanism for the α-KG dependent dioxygenase TauD.  
Figure adapted from reference (1). 
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Figure 1.7 Active site of TauD with α-KG bound and taurine present.  Figure created in 
PyMol (23) using PDB file 1GQW(26). 
 
 
 
Figure 1.8 Possible intermediates found in α-KG dependent dioxygenases. Adapted from 
reference (25). 
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The ferryl-intermediate species has been spectroscopically characterized in TauD 
by Mössbauer (8, 27), EXAFS (30), and resonance Raman (31) spectroscopies.  In TauD, 
the iron(IV)-oxo intermediate proceeds to produce the hydroxylated product, 
incorporating the other atom of oxygen into the product.  Additionally, TauD closes the 
catalytic cycle by releasing succinate and returning to its resting state after the 
hydroxylation reaction (1).   
There are several related enzymes that do not directly utilize an α-keto acid – 
isopenicillin N synthase (IPNS), 1-amino-1-cyclopropanecarboxylic acid oxidase 
(ACCO), and (S)-2-Hydroxypropylphosphonic acid epoxidase (HPPE) – but also involve 
similar catalytic mechanisms that utilize an iron(IV)-oxo intermediate generated through 
pathways that utilize reducing equivalents from the substrate itself.  These enzymes are 
involved in desaturation, oxidation, and epoxidation respectively, and speak to the wide 
diversity of chemistry that this class of enzymes is able to support (25).  
1.1.2.2 Substrate activation process 
The binding of both substrate and coenzyme in the enzyme active site activates 
the α-KG dependent oxygenases for catalysis.  Various spectroscopic-based studies have 
examined the importance of the order of addition of substrate and coenzyme in these 
enzymes (32-34).  Spectroscopic studies of nearly every α-KG dependent oxygenase 
show coenzyme, α-KG or another α-keto acid, binding before substrate (35).  
Interestingly, no kinetic studies have been performed to determine the order of addition 
of substrate and coenzyme owing to challenges of easily monitoring product formation 
without the use of radioactive isotopes.  For the α-keto acid dependent enzymes involved 
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in halogenation reactions such as SyrB2 (36) and CmaB (10), the order of addition of the 
halide has not been determined (35).  For oxygenase enzymes in vitro, coenzyme addition 
is predicted to occur first, followed by substrate binding, and finally dioxygen binding.  
Nonetheless, some studies disagree with this consensus for order of substrate addition 
(33, 34).  Experiments on prolyl-4-hydroxylase (P4H) appear to indicate that dioxygen 
binds before either α-KG or the substrate (33, 34); while crystallographic and DFT 
studies on deacetoxycephalosporin-C synthase (DAOCS) have suggested that there is not 
sufficient space for α-KG and substrate to bind concurrently, and invoke a different 
mechanism with formation of a high valent iron-oxo species and dissociation of the α-KG 
decarboxylation product prior to binding of substrate (37). 
The substrate activation process in TauD has been studied in much greater depth 
than those of many of the other α-KG dependent oxygenases.  Hydrogen / deuterium 
(H/D) exchange experiments in TauD indicate that oxygen binding and activation can be 
modulated to produce varying amounts of C-H bond cleavage (38).  This work has shown 
that F159 in TauD is essential to determining the ratio of sulfite produced to dioxygen 
consumed.  If F159 is substituted with a smaller residue, the ratio decreases, suggesting 
that F159 is involved in coupling the reactive Fe(IV)-oxo intermediate with C-H bond 
cleavage (38) (Figure 1.9a).  Further studies on this particular site demonstrated greatly 
decreased catalytic activity for mutant enzymes with smaller residues in place of F159, 
which also caused a 2- to 4-fold increase in kinetic isotope effect with respect to the wild 
type enzyme (39).  The tuning of this binding pocket, by changing the residue at position 
159, has been proposed to give rise to the great diversity of chemistries catalyzed by the 
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α-KG dependent oxygenases, despite their similar active site structures (38, 39).  
Examples of this diversity include the α-KG dependent enzyme DAOCS, which performs 
ring expansion of isopenicillin N to deacetoxycephalosporin C.  In DAOCS, there is no 
residue located in the same structural location in the active site as F159 in TauD, which 
would allow for a larger substrate binding site to accommodate the larger product 
resulting from the ring expansion (Figure 1.9b) (40).  Clavaminate synthase (CAS) also 
lacks this phenylalanine residue, having instead an aspartate in the same location, which 
may allow salt bridge formation between the substrate and the protein (Figure 1.9c).  
CAS catalyzes two subsequent oxidations of proclavaminic acid to clavaminic acid, and 
it is believed that charged interactions between the protein residues and substrate help 
this to occur (41).  The diversity of the immediate environment around the active site of 
the iron(II) center in this family of enzymes can be seen in Figure 1.9. 
 
Figure 1.9 Active sites of α-KG dependent dioxygenases showing residues near substrate 
binding pocket. a) TauD with F159 present, b) DAOCS with no nearby residues in 
substrate binding pocket, c) CAS with D202 present.  Figure created in PyMol (23) using 
PDB files 1OS7 (27), 1DRT (41), 1RXG (40), and 1W2O (42). 
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1.1.3 Rieske cis-diol forming dioxygenases  
The Rieske cis-diol forming dioxygenases are differentiated from the other 2-His-
1-carboxylate facial triad enzymes by the fact that they contain both a non-heme iron 
center active site as well as a separate Rieske-type [2Fe-2S] cluster.  The Rieske cluster, 
involved in electron transfer to the mononuclear iron center, is located about 12 Å from 
the non-heme iron center in an adjacent subunit.  The cluster within the same subunit is 
located about 45 Å away and is too far away to be involved in electron transfer (Figure 
1.10) (1, 2).  The Rieske cis-diol forming dioxygenases also contain a separate reductase 
component which uses electron transfer proteins to couple Rieske cluster reduction and 
NADH oxidation (1).  These proteins differentiate themselves from the α-KG dependent 
oxygenases and catechol dioxygenases as they usually contain a bidentate carboxylate at 
the non-heme mononuclear iron center, as opposed to the monodentate carboxylate 
typically found in the other classes of enzymes (11-13). 
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Figure 1.10 Trimeric structure of naphthalene dioxygenase with Rieske center involved 
in electron transfer located in adjacent subunit. a) Trimeric structure of naphthalene 
dioxygenase; b) Close-up of Rieske center located in magenta subunit, with non-heme 
iron center located in green subunit.  Figure created in PyMol (23) from PDB file 1NDO 
(43). 
 
1.1.3.1 Catalytic mechanism and reactivity 
The common catalytic mechanism of the Rieske cis-diol forming dioxygenases 
begins with a six-coordinate iron(II) active site containing two His residues, an aspartate 
residue (bound in a bidentate fashion), and two bound water molecules (1).  Binding of 
substrate in the active site induces a loss of a water ligand, forming a five-coordinate iron 
center that is proposed, based on spectroscopic studies, to facilitate dioxygen binding (2).  
Additional proposals suggest that the water loss may not be a strict requirement for 
oxygen binding, as iron(II) - water exchange rates are on the order of 10
6
 sec
-1
 in model 
systems (44) and at least 10
4
 sec
-1
 in proteins (45).  Upon oxidation of the Rieske center 
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and electron transfer, dioxygen reacts with the metal center forming a peroxo or 
hydroperoxo iron(III) species (1).   
Different pathways for the hydroxylation reaction have been proposed from this 
common peroxo or hydroperoxo iron(III) intermediate.  In one pathway, an iron(V)-oxo-
hydroxo species is thought to form by initial O-O bond cleavage.  This pathway has been 
shown to exist in naphthalene dioxygenase (NDO), which utilizes radical intermediates to 
insert dioxygen into the substrate (46) (Figures 1.11, 1.12).  In a second mechanism of 
oxygen insertion, the peroxo or hydroperoxo-iron(III) species acts as an independent 
reactive species and directly attacks the substrate.  This binding causes direct insertion of 
dioxygen to the substrate (Figure 1.13) proceeding through an hydroxyl-iron(IV)-oxo 
species proposed for phthalate dioxygenase (PDO) (12).  Recent DFT studies have 
suggested that the peroxo or hydroperoxo-iron(III) species must go through a transient 
iron(IV)-oxo or iron(V)-oxo intermediate in order to perform ortho-hydroxylation 
chemistry (47).  The DFT calculations predict that the iron(V)-oxo species is favored by 
34.8 kJ/mol over the iron(IV)-oxo species, suggesting that the iron(V)-oxo is the likely 
hydroxylating intermediate (47).  In both cases, the complex collapses to an iron(II) 
species with insertion of both atoms of oxygen into the substrate with the same 
stereochemistry at adjacent carbons (2).  The product is then released and subsequent 
reduction of the Rieske center returns the enzyme to its resting state (1).  
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Figure 1.11 Active site of NDO, with bound Fe(III)-OOH and indole substrate. Figure 
created in PyMol (23) using PDB file 107N (11). 
 
 
 
Figure 1.12 Catalytic mechanism of the Rieske cis-diol dioxygenase naphthalene 
dioxygenase (NDO).  Figure adapted from ref. (1). 
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Figure 1.13 General catalytic mechanism in phthalate dioxygenase (PDO).  Figure 
adapted from ref. (12). 
 
1.1.3.2 Substrate activation process 
The Rieske dioxygenase enzymes activate dioxygen through the use a Rieske-type 
[2Fe-2S] cluster located in an adjacent subunit (1).  The electron transfer through 
multiple subunits makes the activation process in the Rieske dioxygenases quite distinct 
from the other non-heme iron dioxygenases discussed herein.  From spectroscopic studies 
of the enzymes, substrate binding has been proposed as an initial priming step which 
enhances the reactivity of dioxygen with the metal center (2).  Kinetic studies suggest 
that both substrate and coenzyme must be present for enhanced dioxygen reactivity.  
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Additionally, the redox state of the Rieske coenzyme has been reported to play a role in 
allosterically controlling the reactivity at the mononuclear iron center (2).  In 2-
oxoquinoline 8-monooxygenase (OMO), reduction of the Rieske center caused 
protonation of His108, which is ligated to the Rieske center, allowing conformational 
changes to occur at this site (48).  These conformational changes are thought to allow 
communication between the subunits and provide a site for dioxygen binding (2, 48).  
Upon one electron reduction of the Rieske center, dioxygen binds to the mononuclear 
iron(II) center with the addition of the extra electron transferred from the Rieske center.  
Once dioxygen is bound, the enzyme proceeds through one of the catalytic cycles 
discussed above.  
1.1.4 Tetrahydrobiopterin dependent hydroxylases 
Tetrahydrobiopterin dependent hydroxylase enzymes are crystallographically 
characterized as a member of the class of 2-His-1-carboxylate enzymes that hydroxylate 
aromatic amino acids, L-phenylalanine (L-Phe), L-tyrosine (L-Tyr), and L-tryptophan (L-
Trp).  These enzyme contain two histidine residues and one glutamic acid residue ligated 
to the active site iron center at all times (49).  There is some question as whether there 
may be an additional carboxylate ligand involved in some activation states of the enzyme 
(50), and thus these enzymes are referred to herein as an apparent class of 2-His-1-
carboxylate enzymes.  Phenylalanine hydroxylase (PAH) is involved in phenylalanine 
clearance from the blood stream, while tyrosine hydroxylase (TyrOH) and tryptophan 
hydroxylase (TrpOH) are involved in the biosynthesis of the neurotransmitters 3,4-
dihydroxyphenylalanine (L-Dopa) and serotonin, respectively (1, 49).  These enzymes 
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utilize a tetrahydrobiopterin (BH4) coenzyme to generate a high-valent iron(IV)-oxo 
species as the active oxygen atom transfer species (Figure 1.14).  PAH has been found in 
many organisms including mammals, lower order animals and protists such as slime 
molds (51), various bacterial species (52, 53), and most recently in non-flowering plants, 
although in this latter species the enzyme is 10-formyl-tetrahydrofolate (10-CHO-FH4) 
dependent and has not been well studied (54).  TyrOH and TrpOH, however, have only 
been found in mammals, consistent with their roles in physiology (2).  TrpOH has been 
discovered to have two distinct isoforms; TrpOH-1, which is peripheral, and TrpOH-2, 
which is neuronal (55).  All of the tetrahydrobiopterin dependent hydroxylases share 
significant sequence similarity in their catalytic (residues 118-427, PAH numbering) and 
tetramerization (residues 428-452) domains, but diverge in their regulatory domains 
(residues 1-117) (Figure 1.15).  This family of enzymes has been noted to be quite 
distinct from other enzymes; no homologs to the catalytic domain have yet been 
discovered.   
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Figure 1.14 Hydroxylation reaction performed by tetrahydrobiopterin dependent 
hydroxylase enzymes.  
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TrpOH-2_human      ------------------------------------------------MQPAMMMFSSKY 12 
TrpOH-1_human      ------------------------------------------------------------ 
PAH_human          ------------------------------------------------------------ 
TyrOH_human        MPTPDATTPQAKGFRRAVSELDAKQAEAIMVRGQGAPGPSLTGSPWPGTAAPAASYTPTP 60 
                                                                                
 
TrpOH-2_human      WARRGFSLDSAVPEEHQLLGSSTLNKPNSGKNDDKGNKGSSKREAATESGKTA-VVFSLK 71 
TrpOH-1_human      -----------------------------MIEDNKENKDHS-----LERGRAS-LIFSLK 25 
PAH_human          -------MSTAVLENPGLG----------RKLSDFGQETSYIEDNCNQNGAIS-LIFSLK 42 
TyrOH_human        RSPRFIGRRQSLIEDARKEREAAVAAAAAAVPSEPGDPLEAVAFEEKEGKAVLNLLFSPR 120 
                                                   .:  :          :      ::** : 
 
TrpOH-2_human      N-EVGGLVKALRLFQEKRVNMVHIESRKSRRRSS---EVEIFVDCECG-KTEFNELIQLL 126 
TrpOH-1_human      N-EVGGLIKALKIFQEKHVNLLHIESRKSKRRNS---EFEIFVDCDIN-REQLNDIFHLL 80 
PAH_human          E-EVGALAKVLRLFEENDVNLTHIESRPSRLKKD---EYEFFTHLDKRSLPALTNIIKIL 98 
TyrOH_human        ATKPSALSRAVKVFETFEAKIHHLETRPAQRPRAGGPHLEYFVRLEVR-RGDLAALLSGV 179 
                     : ..* :.:::*:   .:: *:*:* ::       . * *.  :      :  ::  : 
 
TrpOH-2_human      KFQTTIVTLNPPENIWTEEEELEDVPWFPRKISELDKCSHRVLMYGSELDADHPGFKDNV 186 
TrpOH-1_human      KSHTNVLSVNLPDNFTLKEDGMETVPWFPKKISDLDHCANRVLMYGSELDADHPGFKDNV 140 
PAH_human          RHDIGATVHELS-----RDKKKDTVPWFPRTIQELDRFANQILSYGAELDADHPGFKDPV 153 
TyrOH_human        RQVSEDVRSPAG----------PKVPWFPRKVSELDKCHHLVTKFDPDLDLDHPGFSDQV 229 
                   :                       *****:.:.:**:  : :  :..:** *****.* * 
 
TrpOH-2_human      YRQRRKYFVDVAMGYKYGQPIPRVEYTEEETKTWGVVFRELSKLYPTHACREYLKNFPLL 246 
TrpOH-1_human      YRKRRKYFADLAMNYKHGDPIPKVEFTEEEIKTWGTVFQELNKLYPTHACREYLKNLPLL 200 
PAH_human          YRARRKQFADIAYNYRHGQPIPRVEYMEEEKKTWGTVFKTLKSLYKTHACYEYNHIFPLL 213 
TyrOH_human        YRQRRKLIAEIAFQYRHGDPIPRVEYTAEEIATWKEVYTTLKGLYATHACGEHLEAFALL 289 
                   ** *** :.::*  *::*:***:**:  **  **  *:  *. ** **** *: . :.** 
 
TrpOH-2_human      TKYCGYREDNVPQLEDVSMFLKERSGFTVRPVAGYLSPRDFLAGLAYRVFHCTQYIRHGS 306 
TrpOH-1_human      SKYCGYREDNIPQLEDVSNFLKERTGFSIRPVAGYLSPRDFLSGLAFRVFHCTQYVRHSS 260 
PAH_human          EKYCGFHEDNIPQLEDVSQFLQTCTGFRLRPVAGLLSSRDFLGGLAFRVFHCTQYIRHGS 273 
TyrOH_human        ERFSGYREDNIPQLEDVSRFLKERTGFQLRPVAGLLSARDFLASLAFRVFQCTQYIRHAS 349 
                    ::.*::***:******* **:  :** :***** **.****..**:***:****:**.* 
 
TrpOH-2_human      DPLYTPEPDTCHELLGHVPLLADPKFAQFSQEIGLASLGASDEDVQKLATCYFFTIEFGL 366 
TrpOH-1_human      DPFYTPEPDTCHELLGHVPLLAEPSFAQFSQEIGLASLGASEEAVQKLATCYFFTVEFGL 320 
PAH_human          KPMYTPEPDICHELLGHVPLFSDRSFAQFSQEIGLASLGAPDEYIEKLATIYWFTVEFGL 333 
TyrOH_human        SPMHSPEPDCCHELLGHVPMLADRTFAQFSQDIGLASLGASDEEIEKLSTLYWFTVEFGL 409 
                   .*:::**** *********:::: .******:********.:* ::**:* *:**:**** 
 
TrpOH-2_human      CKQEGQLRAYGAGLLSSIGELKHALSDKACVKAFDPKTTCLQECLITTFQEAYFVSESFE 426 
TrpOH-1_human      CKQDGQLRVFGAGLLSSISELKHALSGHAKVKPFDPKITCKQECLITTFQDVYFVSESFE 380 
PAH_human          CKQGDSIKAYGAGLLSSFGELQYCLSEKPKLLPLELEKTAIQNYTVTEFQPLYYVAESFN 393 
TyrOH_human        CKQNGEVKAYGAGLLSSYGELLHCLSEEPEIRAFDPEAAAVQPYQDQTYQSVYFVSESFS 469 
                   *** ..::.:******* .** :.** .. : .:: : :. *      :*  *:*:***. 
 
TrpOH-2_human      EAKEKMRDFAKSITRPFSVYFNPYTQSIEILKDTRSIENVVQDLRSDLNTVCDALNKMNQ 486 
TrpOH-1_human      DAKEKMREFTKTIKRPFGVKYNPYTRSIQILKDTKSITSAMNELQHDLDVVSDALAKVSR 440 
PAH_human          DAKEKVRNFAATIPRPFSVRYDPYTQRIEVLDNTQQLKILADSINSEIGILCSALQKIK- 452 
TyrOH_human        DAKDKLRSYASRIQRPFSVKFDPYTLAIDVLDSPQAVRRSLEGVQDELDTLAHALSAIG- 528 
                   :**:*:*.::  * ***.* ::***  *::*...: :    : :. ::. :. **  :   
 
TrpOH-2_human      YLGI 490 
TrpOH-1_human      KPSI 444 
PAH_human          ---- 
TyrOH_human        ---- 
        .. 
Figure 1.15 Multiple sequence alignment of human PAH, TyrOH, and TrpOH, isoforms 
1 and 2 using CLUSTAL-W2.  The regulatory domains of each protein are highlighted in 
cyan, the catalytic domains in yellow, and the tetramerization domains in magenta. 
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1.1.4.1 Catalytic mechanism and reactivity 
The commonly proposed mechanism for tetrahydrobiopterin dependent 
hydroxylase enzymes begins with a ferrous active site with two bound histidine residues 
and a glutamic acid residue, which is observed to bind in either a monodentate or a 
bidentate manner in different crystal structures (14-16).  The resting active site iron 
center is six-coordinate and typically found with two or three bound water molecules, 
depending on the mono- or bidentate coordination mode of the glutamic acid residue 
(Figure 1.16) (56-58).  Substrate (L-Phe, L-Tyr, or L-Trp) and coenzyme, BH4, bind in 
defined sites near the ferrous center, but neither directly ligates to the iron.  The binding 
order of substrate and coenzyme occurs in a semi-ordered fashion as shown from detailed 
enzyme kinetic studies.  However, when both substrate and coenzyme are present in the 
active site, a small conformational change occurs with a simultaneous loss of a water 
molecule that changes the active site iron from six-coordinate to five-coordinate 
(MCD/XAS spectroscopic data) (59).  The geometry change to a five-coordinate iron 
center opens a metal site for the binding of the putative tetrahydrobiopterin-peroxy 
species, which forms via the interaction of dioxygen with the reduced coenzyme in the 
active site (Figure 1.17).  This Fe(II)-peroxopterin species then undergoes heterolytic 
cleavage to form a highly reactive iron(IV)-oxo intermediate that has been 
spectroscopically characterized for both TyrOH (60) and bacterial PAH (61) by rapid-
freeze quench Mössbauer spectroscopy.  Heterolytic cleavage of the putative 
tetrahydrobiopterin-peroxy species also forms a C4a-hydroxydihydrobiopterin (C4a-OH-
BH2), which can be observed by UV/vis (62) and NMR spectroscopy (63).  The iron(IV)-
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oxo species rapidly hydroxylates the substrate and regenerates the six-coordinate iron(II) 
center through binding of an additional solvent molecule (50).  The oxidized C4a-OH-
BH2 then dissociates from the active site.  BH4 can be recycled by dihydropterin 
reductase and NADH or NADPH and a proton (63).  This process utilizes a quinonoid 
dihydropterin species.  The recycling of the pterins is discussed in more detail in Section 
1.2.2.  
 
 
 
Figure 1.16 Active sites of the tetrahydrobiopterin dependent enzymes as determined by 
crystal structures. All figures were created in PyMol (23).  a) PAH with bound substrate 
analog THA and coenzyme BH4, PDB file 1MMK (56); b) TyrOH with bound coenzyme 
7,8-BH2, PDB file 2TOH (64); c) TrpOH with bound imidazole, PDB file 3E2T (65).  
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Figure 1.17 General catalytic mechanism for the tetrahydrobiopterin dependent 
hydroxylases.  Adapted from ref. (1). 
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These tetrahydrobiopterin dependent enzymes are different from the other 2-His-
1-carboxylate enzymes, as neither substrate nor coenzyme directly coordinates to the iron 
center at any point in the catalytic mechanism (50).  It has been noted that the initial 
peroxo complex formed when BH4 reacts with dioxygen at the iron center is quite similar 
to the complex formed by the extradiol cleaving dioxygenases, as both peroxy species 
utilize iron(II) centers and are used to transfer reducing equivalents.  The key difference 
between the C4a-peroxo-pterin and the extradiol alkyl-peroxo species is that the C4a-
peroxo-pterin intermediate then forms a high valent iron(IV)-oxo intermediate, while the 
alkyl-peroxo remains iron(II) through its catalytic cycle.  The tetrahydrobiopterin 
dependent enzymes also share some catalytic similarities with the Rieske dioxygenases, 
as they both require additional electron donating coenzymes (pterin and the Rieske 
center) to activate dioxygen.  In the case of the tetrahydrobiopterin dependent enzymes, 
however, the reduced pterin can supply both electrons, while the Rieske dioxygenases 
must additionally abstract an electron from the mononuclear iron center, and therefore 
likely require the use of an iron(V) intermediate to do the hydroxylation chemistry, while 
the pterin dependent enzymes can utilize an iron(IV) intermediate (Figure 1.18) (1). 
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Figure 1.18 Electron transfer in Rieske dioxygenases and tetrahydrobiopterin dependent 
hydroxylases. 
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1.1.4.2 Substrate activation process 
The mechanism of substrate activation in the tetrahydrobiopterin dependent 
enzymes is somewhat enzyme dependent as will be discussed throughout this 
dissertation.  All of these enzymes are regulated by their divergent regulatory domains, 
which belong to the ACT domain family (66), a sequence motif of regulatory domains 
primarily found in proteins involved in amino acid or purine biosynthesis (67).  These 
enzymes will be discussed in more detail in Section 1.3.3.  The ACT domain enzymes 
frequently involve complex allosteric activation mechanisms, which often require 
substrate as an allosteric effector ligand (68, 69).  Initial studies on the 
tetrahydrobiopterin dependent hydroxylases demonstrated the presence the ACT domain 
in PAH and TrpOH (both isoforms); however, more recent studies have also suggested 
that there is an ACT domain present in part of the TyrOH regulatory domain (residues 
78-162 in human TyrOH) (66).   This portion of the regulatory domain in TyrOH is 
somewhat analogous to residues 35-110 in human PAH, which follows the same βαββαβ 
fold observed in the first crystallographically characterized member of the ACT domain-
containing proteins, 3-phosphoglycerate dehydrogenase (PGDH) (66).  The first portion 
of the PAH regulatory domain is referred to as the autoregulatory sequence.  
Crystallographic evidence in PAH structures suggests that this autoregulatory sequence 
may lead back to the active site, although there is no well-defined electron density for the 
first 19 amino acids in the only crystal structures that include the regulatory domain (14, 
70).  The regulatory domains of TyrOH and TrpOH have not been crystallographically 
characterized, so they cannot be compared to that of PAH.  
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Intra-protein regulation pathways are essential to understanding how dioxygen is 
activated and how the substrate is ultimately hydroxylated within the tetrahydrobiopterin 
dependent hydroxylases.  Among all these enzymes, phosphorylation is used a 
mechanism of regulation, typically at serine residues in the autoregulatory sequence 
upstream of the main ACT domain fold (71-74).  The mechanisms of regulation by 
phosphorylation and conditions under which phosphorylation occurs are different in each 
of the hydroxylases; phosphorylation of TyrOH is proposed to induce negative 
cooperativity of substrate (73), while phosphorylation in PAH facilitates activation by 
substrate but does not independently induce enzymatic activation (75). 
In PAH, regulation is also controlled through allosteric regulation by both the 
natural substrate, L-Phe, and the natural coenzyme, BH4; L-Phe acts as a positive 
allosteric effector, while BH4 acts as negative allosteric effector.  This mechanism will be 
discussed in more detail in Section 1.3; however, it is important to note that PAH activity 
is turned on by binding of L-Phe to the allosteric effector binding site, such that substrate 
and coenzyme binding alone in the active site will not induce enzyme activity (49).  
Multiple studies have suggested that the substrate and allosteric binding sites are distinct 
(76); this data will be discussed in greater detail in Chapter 2.  TyrOH is also regulated 
by feedback inhibition from various catecholamines in its biosynthetic pathway (77) as 
well as by substrate (L-Tyr) inhibition (73).  Furthermore, studies have demonstrated that 
BH4 is a negative allosteric effector for TyrOH, and phosphorylation amplifies the 
negative cooperativity (78).  Positive cooperativity has not been reported for TyrOH to 
date.  TrpOH has not been well studied in terms of its regulatory properties; however, the 
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ACT domains for TrpOH-1 and TrpOH-2 have been predicted to correspond to residues 
18-94 and 66-142 respectively (66).  This enzyme has not demonstrated any regulation by 
substrate or coenzyme to date, but there is no reason to suspect that TrpOH will be 
devoid of allostery when both PAH and TyrOH possess it.  
Direct activation of dioxygen in all three tetrahydrobiopterin dependent 
hydroxylases occurs when substrate and coenzyme are bound in distinct locations in the 
active site; however, each enzyme appears to have its own individual mechanism for 
priming the active site for catalysis, as the regulation processes are different.  Until the 
active site priming step is completed through phosphorylation, allosteric activation, or 
another combination of yet unknown steps the enzyme will not turn over substrate to 
product and may face negative cooperativity from its coenzyme or substrate.  Further 
studies are required to understand the steps involved in priming the active site for 
catalysis in these enzymes.  This dissertation intends to study these allosteric activation 
processes in PAH in more detail. 
1.1.5 Chemistry of the 2-His-1-carboxylate enzymes 
 The 2-His-1-carboxylate enzymes utilize a simple active site coordination 
geometry of two histidine residues and one carboxylate residue ligated to a mononuclear 
iron(II) center to perform a wide variety of reactions.  These enzymes employ high-valent 
iron reactive intermediates to perform such challenging reactions.  While these enzymes 
are frequently grouped together, their catalytic cycles and substrate activation processes 
are quite diverse.  The ECD enzymes use an iron(II) center to dihydroxylate and cleave 
aromatic rings.  The α-KG dependent enzymes perform highly diverse chemical 
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transformations through the action of an iron(IV)-oxo intermediate.  The Rieske cis-diol 
forming dioxygenases dihydroxylate aromatic compounds via possible iron(IV)-oxo or 
iron(V)-oxo intermediates.  The tetrahydrobiopterin dependent hydroxylases perform 
hydroxylation of aromatic amino acids with an iron(IV)-oxo intermediate.  These four 
classes of enzymes that appear to have structurally analogous active sites in fact execute 
quite diverse chemistry and demonstrate the levels of complexity that nature can provide 
through subtle modifications of a common iron coordination environment. 
1.2 Biochemistry of phenylalanine hydroxylase 
1.2.1 Phenylketonuria and hyperphenylalaninemia 
Phenylalanine hydroxylase (PAH) catalyzes the hydroxylation of L-Phe to L-Tyr 
as the basis for the sole pathway for maintaining phenylalanine homeostasis.  Disruption 
of the catalytic activity of PAH leads to a buildup of neurotoxic metabolites that cause 
severe and irreversible mental retardation.  This condition, which was the first known 
inborn metabolic disorder, is known as phenylketonuria (PKU) and affects 1 in 10,000 
births in Europeans, but the incidence varies widely by country or region (79).  The 
severity of PKU can vary from slightly elevated blood plasma levels of phenylalanine 
without obvious phenotypic responses known as hyperphenylalaninemia (HPA) (plasma 
L-Phe levels > 120 μM) to classic PKU (plasma L-Phe levels > 1000 μM).  Classic PKU 
manifests with symptoms including decreased cognitive function, lowered IQ scores, 
decreased motor coordination and decreased attention span.  There are also reports of 
many PKU patients developing epilepsy (79).  More than 500 missense, nonsense, 
deletion, and insertion mutations have been located within the PAH gene and noted to 
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cause mild or classical PKU (80).  Many other mutations have been implicated in HPA 
(80).  To date, there is no cure for PKU.  Patients with this condition are typically subject 
to a low L-Phe diet for life with supplementation of a special medical formula containing 
the other needed amino acids while consuming a low protein diet (79).  Recent 
developments include using synthetic BH4 (sapropterin dihydrochloride) as treatment for 
patients with PKU-inducing mutations near the active site where enhanced coenzyme 
concentrations can restore enzyme activity (81).  These efforts allow patients who 
respond to the treatment to eat a more liberal diet; however, this treatment does not work 
equally for all patients with PKU and many do not respond at all (82).  This is not 
surprising since different mutations are thought to induce low PAH activity via different 
chemical reasons.  Additionally, there are many PKU-inducing mutations in PAH that are 
remote from the active site, including the most common clinical mutation causing PKU, 
R408W, which is located approximately 22 Å from the enzyme active site (Figure 1.19) 
(83).  In order to further understand and develop treatments for PKU it is important to 
gain a detailed understanding of the biochemical properties of wild-type PAH. 
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Figure 1.19 Location of R408W mutation in PAH monomer.  Figure was created in 
PyMol (23) using PDB files 2PHM (14) and 2PAH (84). 
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1.2.2 Molecular and structural properties 
 PAH is found in a wide diversity of species, as discussed in section 1.1.4.  
Bacterial PAH, such as the PAH from Chromobacterium violaceum (cvPAH), contains 
only a catalytic domain (52).  The plant PAH enzymes have been found to have a 
catalytic domain and a unique putative targeting peptide domain (54).  Mammalian PAH 
is isolated as a homotetrameric enzyme with 52 kDa subunits.  Each subunit is composed 
of an N-terminal regulatory domain (residues 1-117), a catalytic domain (residues 118-
427), and a C-terminal tetramerization domain (residues 428-452) (85).  Each subunit of 
the catalytic domain contains a non-heme iron center that is directly ligated by two 
histidine residues (His285 and His290) and a glutamic acid residue (Glu330), which 
shows either monodentate or bidentate coordination in the different crystal structures 
reported to date (56, 58).  Additionally, each subunit uses BH4 and dioxygen to produce 
L-Tyr and C4a-hydroxydihydrobiopterin (C4a-OH-BH2) in a reaction where each 
turnover of oxygen incorporates one atom of oxygen into L-Tyr and the other atom of 
oxygen into C4a-OH-BH2 (86). The oxidized C4a-hydroxy-pterin species can be recycled 
to BH4 through 4a-carbinolamine dehydratase (DCoH) and dihydropteridine reductase 
(DHPR).  DCoH and DHPR reduce the quinonoid dihydropterin and 7,8-dihydropterin 
species, respectively.  The 7,8-dihydropterin species is formed after tautomerization of 
the quinonoid species (49).  Possible physiological redox transformations of the pterin 
species are shown in Figure 1.20. 
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Figure 1.20 Tetrahydrobiopterin cycle in PAH.  Solid arrows indicate productive coupled 
pathway, dashed arrows indicate non-enzymatic pathway of uncoupled oxidation. 
 
 
 
 Currently, crystal structures of PAH are available only for various truncated forms 
of the resting inactive form of the enzyme, called the T-state (tense, in the traditional 
hemoglobin nomenclature).  While there are no structures of the complete wild-type 
enzyme, a composite model can be constructed using structural alignments in PyMol (23) 
of crystal structures containing catalytic and regulatory domains and the catalytic and 
tetramerization domains (Figure 1.21) (14, 84).  These structures demonstrate that the 
active site is buried 13 Å inside the protein in a 10 Å wide pocket lined by 34 primarily 
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hydrophobic residues, with the exception of three glutamic acid residues, two histidine 
residues, and a tyrosine residue (73).  The iron center is not directly accessible in the 
wild-type enzyme, as there is 16 Å long channel leading to the active site which may 
control substrate access to the active site (73).  This channel is in part formed by the 
presence of the N-terminal autoregulatory sequence, which is predicted to cover the 
catalytic active site.  The autoregulatory sequence (residues 1-26) is proposed to be 
involved in regulation of the protein, as phosphorylation at Ser16 has been suggested to 
assist in the activation the protein (71).  The only crystal structures of this region lack 
electron density for the first 18 amino acids suggesting that is a highly flexible region of 
the protein (14), and might lead back toward the active site and control substrate access.  
There are also no PAH crystal structures currently available with bound L-Phe.  There 
are, however, structures of PAH with the substrate analogs, 3-(2-thienyl)-L-alanine 
(THA) and L-norleucine; both substrate analogs were soaked in after crystallization.  In 
these reports, it was noted that attempts to add L-Phe after crystallization lead to crystal 
cracking and disintegration, indicating a major conformational change in the crystal upon 
addition of L-Phe (56, 57).  Efforts to co-crystallize PAH with L-Phe by the Caradonna 
Lab have so far been unsuccessful; however, these structures will be necessary to 
understand the structural magnitude of changes that occur when L-Phe binds to the 
protein and induces an allosteric conformational change.  Small angle X-ray scattering 
(SAXS) and analytical ultracentrifugation studies on PAH have indicated an 
approximately 10-11% increase in volume upon activation with L-Phe, but do not give 
indication into the location or shape of structural change within the protein (87).  
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Figure 1.21 Composite model structure of tetrameric wild-type mammalian PAH 
including the regulatory domain (yellow), catalytic domain (green), tetramerization 
domain (cyan).  Figure was created in PyMol (23) using a structural alignment of PDB 
files 2PAH (84) and 2PHM (14). 
 
1.2.3 Specificity for substrate, coenzyme, and allosteric effectors 
1.2.3.1 Allosteric effector specificity 
 PAH utilizes L-Phe and BH4 as its natural substrate and coenzyme.  PAH also 
utilizes L-Phe as an allosteric effector required to turn on catalytic activity.  The 
activation of PAH occurs at concentrations less than 1 mM L-Phe (88).  Several 
alternative activators have been previously identified for PAH.  At high concentration (28 
mM), L-methionine (L-Met), L-norleucine, D-phenylalanine (D-Phe), THA, and L-Trp 
have all been reported to activate enzymatic activity by 20-30 fold.  The actual rates of 
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turnover or evidence of the presence of dimeric forms of PAH were not reported; 
however, lower concentrations of these substrates were not shown to substantially 
activate the enzyme (89).  L-[2,5-H2]-Phenylalanine has also been reported to weakly 
activate PAH at concentrations of 20 mM (90).  Studies by the Caradonna lab to address 
these amino acid-like potential alternative allosteric activators will be discussed in 
Chapter 2.  Treating the wild-type enzyme with cationic detergents such as lysolecithin 
also activates PAH to nearly the same extent as L-Phe.  Lysolecithin has been shown to 
be a weakly cooperative (n = 1.3) activator of PAH and is suggested to activate PAH by 
disrupting the tetrameric form of the protein into separate dimers that act as catalytically 
competent units (91, 92).  Other methods for activating PAH include treatment with N-
ethylmaleimide (NEM), which alkylates the Cys237 residues to form a catalytically 
active dimeric form of PAH, and by increasing the pH, which likely deprotonates Cys237 
favoring dimer formation by creating a negatively charged residue in a hydrophobic 
pocket (49, 91).  
1.2.3.2 Substrate specificity  
PAH can hydroxylate a variety of additional substrates after allosteric activation 
with lysolecithin or another alternative method of activation (e.g. truncation of the 
regulatory domain).  These substrates are reported in Table 1.2.  L-Phe cannot be used as 
an activator in studies with alternative substrates, as it will be preferentially hydroxylated.  
The alternative substrate studies demonstrate that the activated enzyme will hydroxylate 
many substrates and is not particular in its substrate specificity.  It is interesting to note 
that para-substituted phenylalanines are all hydroxylated with the exception of L-[2,5-
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H2]-Phenylalanine which forms an epoxide, which is a proposed reaction intermediate for 
PAH (see section 1.2.5) (90).  Other aromatic amino acids without a phenyl ring, 
including L-Trp and THA, are also readily hydroxylated, although higher substrate 
concentrations (20-30 mM) are required to overcome less effective alternative substrate 
active site binding properties; in addition, the rate of L-Phe hydroxylation is 30 times 
greater than the rate of L-Trp hydroxylation (93).  The hydroxylation products of the 
THA reaction with PAH have not been studied, although THA can be used as both a 
substrate and activator for PAH, like L-Phe (89).  Aliphatic compounds such as L-Met 
and L-norleucine are also oxidized, demonstrating that aromaticity is not necessarily a 
requirement for enzymatic activity (89).  This wide diversity of catalytic substrate 
activity suggests an important role for the regulation of PAH that must dictate which 
substrates have access to the active site and allow catalysis to occur.  It also indicates that 
the active hydroxylating species can perform many types of "oxygen atom" transfer 
chemistry.  The diversity of chemistry that the iron(IV)-oxo intermediate in PAH 
performs includes alkane and arene hydroxylation, arene epoxidation, and S-oxidation 
reactions, which is similar to that observed for the P450 enzymes (94). 
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Table 1.2 Alternative substrates reported for PAH. 
Alternative Substrate Product(s) Reference 
p-F-phenylalanine 
 
Tyrosine 
 
(95) 
p-Cl-phenylalanine 
 
3-Cl-tyrosine 
 
(95) 
p-Br-phenylalanine 
 
3-Br-tyrosine 
 
(95) 
p-methyl-phenylalanine 
 
4-hydroxymethyl-phenylalanine, 3-methyl-tyrosine 
,  
(96, 97) 
o-methyl-phenylalanine 
 
2-methyl-tyrosine 
 
(98) 
L-methionine 
 
L-methionine sulfoxide 
 
(89) 
L-norleucine 
 
ε-hydroxy-L-norleucine 
 
(89) 
L-tryptophan 
 
5-hydroxy-L-tryptophan 
 
(93) 
L-[2,5-H2]-phenylalanine 
 
3,4-epoxide-L-phenylalanine 
 
(90) 
L-cyclohexylalanine 
 
7-hydroxy-L-cyclohexylalanine 
(90%), (10%) 
(97) 
m-tyrosine 
 
L-DOPA 
 
(92) 
3-(2-thienyl)-L-alanine 
 
Not determined (89) 
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1.2.3.3 Coenzyme specificity 
Although BH4 is the natural coenzyme of PAH, the enzyme tolerates many 
substitutions of the pterin coenzyme (Figure 1.22).  In BH4, the L-erythro-1’2’-
dihydroxypropyl tail only utilizes the R isomer configuration at carbon 6 (63, 99).   While 
the natural coenzyme uses the R isomer, both the R and S isomers of the L-erythro tail are 
active in PAH, with Vmax for the R isomer approximately 4 times greater than that of the S 
isomer with no affect on KM or coupling of coenzyme oxidation  (49, 100).  In the rat 
liver enzyme, carbons 6 and 7 can be methylated with only moderate stereochemical 
effects (63) and these two carbons have been substituted with a wide variety of 
substituents without significant change in the catalytic activity (49).  The carbon 6-
position is also where typical modifications occur to the BH4 coenzyme in different 
species of PAH.  The natural cofactor in Pseudomonas aeruginosa PAH has been 
reported as tetrahydromonapterin (MH4) (101), while the natural cofactor in the plant 
PAH species has been shown to be 10-CHO-FH4 (54).  Other studies have shown that the 
Dictyostelium discodium PAH (DictyoPAH) utilizes both BH4 and tetrahydrodictyopterin 
(DH4) as coenzymes due to the prevalence of DH4 in its natural environment, and 
suggests that DH4 is the native coenzyme for DictyoPAH (51). 
Altering the coenzyme structure can, though, lead to uncoupled oxidation of the 
coenzyme.   Uncoupled oxidation occurs when dioxygen reacts with coenzyme to form 
the quinonoid dihydropterin and hydrogen peroxide instead of forming the C4a-OOH-
BH4 species and hydroxylating the substrate.  The coupled pathway directly takes one 
substrate molecule (L-Phe) to one product molecule (L-Tyr) while oxidizing one 
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equivalent of pterin.  The uncoupled pathway does not use substrate at all to oxidize one 
equivalent of pterin (49).  The reaction of PAH with 6-methyltetrahydropterin (6MPH4) 
or BH4 is >98% coupled, so each pterin oxidation leads to tyrosine production (49, 102).  
The reactions of 6,6-dimethyltetrahydropterin (6,6-MPH4), and 6,7-
methyltetrahydropterin (6,7-MPH4) are also completely coupled to tyrosine production 
(103). The reaction of PAH with 7-methyltetrahydrobiopterin (7MPH4), however, is only 
34% coupled to tyrosine formation, and uses the uncoupled pathway 66% of the time 
(102). 
BH4 is also an allosteric inhibitor for PAH, and has been demonstrated to inhibit 
activation of the enzyme to the catalytically active R-state (resting in the traditional 
hemoglobin nomenclature) when the enzyme is first incubated with BH4 prior to 
incubation with L-Phe.  The experimentally determined KI for BH4 is 0.06 μM (104).  For 
this reason most in vitro kinetic assays of PAH are performed with 6MPH4, which allows 
for maximal activity of the wild-type enzyme with no coenzyme inhibition.  The 
experimentally reported KI for 6MPH4 is 115 μM; however 6MPH4 inhibition is not 
observed under standard assay conditions for PAH activity that utilize 1 mM L-Phe 
concentrations (104).  
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Figure 1.22 Structures of pterin coenzymes for PAH. Top panel, natural coenzymes of 
PAH a) 5,6,7,8-Tetrahydrobiopterin (BH4); b) 5,6,7,8-Tetrahydrodictopterin (DH4); c) 
5,6,7,8-Tetrahydromonapterin (MH4); d) 5,6,7,8-Tetrahydrofolate (FH4).  Bottom panel, 
synthesized coenzymes of PAH used in biochemical analysis e) 6-methyl-5,6,7,8-
tetrahydropterin (6MPH4); f) 6,7-dimethyl-5,6,7,8-tetrahydropterin (6,7MPH4); g) 5-
deaza-6-methyl-5,6,7,8-tetrahydropterin (5-deaza-6MPH4). 
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Additionally, some modifications to the ring structure of the pterin coenzymes 
have been reported to be tolerated by PAH: substitution of the 4-oxo group with an amino 
group still is tolerated (105), as is methylation of the 2-amino group (106).  Some 
bacterial species of PAH have utilize tetrahydrofolate (FH4) as a coenzyme (51), however 
FH4 has been shown to block activity of mammalian PAH (107).  These results suggest 
coenzyme specificity has evolved with the PAH enzyme utilized in different species to be 
specialized for the catalytic role in that species, as the phenylalanine homeostasis 
pathways in mammalian species are very different than the proposed metabolic pathway 
of PAH in plant species. The redox role of all the active site coenzymes are the same, 
despite their different R groups, as the coenzyme serves to reduce dioxygen by two 
protons and two electrons. 
1.2.4 Active site coordination and properties 
 Spectroscopic and crystallographic studies have allowed insight into the state-
dependent active site iron coordination geometries and properties.  PAH utilizes ferrous 
iron in its active site, which has a spin state of S = 2, and is effectively EPR silent.  This 
fact has made the initial spectroscopic analysis of the iron center in PAH more 
challenging than for some other well known enzymes such as the Cytochrome P450 
enzymes (49).  The ferric oxidation state of the enzyme, which is not catalytically 
competent, was studied initially, due to its increased accessibility by UV-visible 
absorption and EPR.  The UV-visible absorption spectra of the inactive T-state and active 
R-state of PAH are unremarkable, demonstrating a broad trailing absorbance that 
continues past 500 nm (ε = 3,000 M-1cm-1) which have been assigned as His-to-Fe3+ 
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ligand-to-metal charge transfer bands (91).  EPR studies of the ferric T-state of the 
enzyme demonstrate broad axial signals from 600-1400 G, suggesting a variety of 
possible conformations in the active site as has been seen for other 2-His-1-carboxylate 
enzymes such as HppD (91, 108).  Additionally, ferric
 
EPR spectra of the T-state and R-
state enzyme show a dominant feature at geff = 4.3.  In the R-state ferric EPR spectra, 
there is also a feature with geff = 4.5; no broad axial signals as was observed with T-state 
spectra.  Taken together these results suggest that there are only minor changes in the 
electronic environment of the iron center in the inactive, ferric state in the presence or 
absence of substrate (91). 
 Additional spectroscopic approaches (MCD and XAS techniques) have allowed 
insight into the coordination state of the ferric and ferrous center in the various states of 
the enzyme.  MCD studies on ferrous PAH in a wide variety of accessible states (Figure 
1.23) reveal that activation of the enzyme from the T-state to the R-state does not affect 
the iron center; however addition of L-Phe to the active site shifts the MCD bands to 
higher energy which indicates a change in the iron environment.  Variable-temperature 
variable-field (VTVH) MCD and XAS studies demonstrated that the iron(II), empty, un-
activated enzyme (Fe
2+
-PAH
T
[  ]), and the iron(II), un-activated L-Phe bound enzyme 
(Fe
2+
-PAH
T
[L-Phe]) states are nearly identical in their electronic enviromments, while 
the activated L-Phe bound enzyme (Fe
2+
-PAH
R
[L-Phe]) shows some differences 
(enhanced ligand field strength), but all are consistent with a six-coordinate iron center 
(109).  Further VTVH MCD studies with coenzyme, utilizing the redox inactive 
coenzyme, 5-deaza-6MPH4 (Figure 1.22g), indicate that pterin binding alone maintains a 
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six coordinate distorted octahedral Fe(II) active site.  The addition of both the substrate 
(L-Phe) and coenzyme (5-deaza-6MPH4), however, leads to formation of a five-
coordinate square pyramidal active site iron.  This change in coordination enviromnent is 
thought to provide an open site for interacting with the peroxo-pterin species in the 
formation of the active hydroxylating intermediate (110).  XAS studies also led to the 
proposal that the identity of the ligand that is absent in the five-coordinate ternary 
complex is a water molecule (111).  
 
  
Figure 1.23 Accessible activation states of PAH.  PAH
R
NEM is an off pathway state, 
and is indicated in red. 
 
 Further spectroscopic studies with the PKU-inducing mutants, R158Q and 
E280K, demonstrate that the R158Q fully loaded active site forms a distorted five-
coordinate ternary complex while the E280K system forms a six-coordinate ternary 
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complex.  The two PKU mutants also show drastically reduced coupling of pterin 
oxidation to tyrosine production (23% and 18%, respectively), and lead to uncoupled 
peroxide production (112).  These studies helped to elucidate the role of coenzyme 
orientation in some PKU mutations, and that the mechanism of dysfunction in each PKU-
inducing mutant will vary depending of the structural effects of that mutation on the 
enzyme (112). 
From the currently available crystal structures, it was determined that the iron 
center in PAH is directly ligated by two histidine residues (His285 and His290) and a 
glutamic acid (Glu330) residue which adopt either a monodentate or bidentate mode of 
binding (56, 85) (Figure 1.24).  Residues within 5 Å of the iron center include Glu286, 
Tyr325, and Ala345.  Unpublished experiments performed by Breia Salsbery in the 
Caradonna Lab have indicated that Glu286 may be a transient ligand in some activation 
states of the enzyme.  Glu286 is located approximately 4.3 Å from the iron center in the 
available T-state crystal structures of truncated PAH (Figure 1.24a) and its position does 
not change significantly upon incubation of the enzyme with the coenzyme BH4 or 
substrate analog THA (Figure 1.24b-c) (56, 58).  From the crystal structures, it appears 
that the coenzyme position moves about 1.5 Å closer to the iron center upon incubation 
of the substrate analog THA, which is the resolution of the crystal structures (1J8U: C4a 
of BH4 to Fe distance is 5.9 Å, 1MMK: C4a of BH4 to Fe distance is 4.4 Å) (56, 58).  
This result agrees with ESEEM studies performed on PAH where iron-nitrosyl (Fe
2+
-NO) 
adducts were formed to measure the distances of substrate and coenzyme from the active 
site in various states of the enzyme (50).  These experiments were conducted to measure 
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the differences in signal from deuterated coenzyme and substrate in the T and R states of 
the enzyme.  Analysis of these data suggests that 5-deaza-6MPH4, a redox inactive 
cofactor that binds to the protein in the same way as 6MPH4, moves 1.8 Å closer to the 
iron center in the activated state. The carbon-deuterium bond at the 5 position of the 
coenzyme is estimated to be 5.3 Å away from the iron in the T-state, but only 3.1 Å away 
from the iron in the R-state.  These experiments also demonstrated that L-Phe is greater 
than 5 Å from the iron center in the T-state of the enzyme, and moves closer to the iron or 
re-orients itself upon activation to the R-state; however, due to signal to noise limitations 
the actual distance has not yet been properly simulated.  Further experiments with 
fluorinated substrates are underway to determine this L-Phe to Fe distance (50).  
 
 
Figure 1.24 Active site coordination of PAH and residues within 5 Å of the iron center.  
a) No substrate or coenzyme present, PDB file 1J8T (58); b) Coenzyme BH4 present in 
the active site, PDB file 1J8U (58); c) Substrate analog and coenzyme BH4 present in the 
active site, PDB file 1MMK (56). Figure created in PyMol(23). 
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 1.2.5 Proposed steady state kinetic mechanism 
 The kinetic mechanism of PAH involves multiple processes, including L-Phe 
binding to the allosteric effector site, followed by substrate, coenzyme, and dioxygen 
binding in the active site (49).  The effect of allosteric activation will be discussed in 
more detail in Section 1.3.  The kinetic mechanism proposed by the Caradonna Lab 
combines all known information from previously discussed studies about the active site 
iron center as well as information about the allosteric activation steps that will be 
discussed as necessary in this section.  The mechanism in Figure 1.25 begins with the 
proposed T-state structure of PAH with a six-coordinate active site iron bound by His285, 
His290 and Glu330.  Note Glu330 is drawn as bidentate due to a subset of crystal 
structures indicating this conformation (56-58), but may be either mono or bidentate 
(species A). There is at least one water molecule present in the resting state structure, and 
the identity of the sixth ligand has not been determined.  ESEEM experiments currently 
underway should help to elucidate the identity of the sixth ligand and determine the 
number of water ligands in both the full length and regulatory domain truncated (crystal 
structure form) forms of PAH (50).  Allosteric activation by L-Phe does not change the 
active site environment (109), so the enzyme remains six-coordinate in the activated state 
with L-Phe present.  L-Phe binding also causes a small secondary active site 
reorganization (~ 5 kcal/mol, see Section 1.3), which is thought to move the substrate 
slightly closer to the iron center in the active site.  ESEEM data indicate that allosteric 
activation reorients the pterin binding site, which moves the pterin binding site about 1.8 
Å closer to the iron center (50).  The additional binding of BH4 causes the active site 
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coordination geometry to change to five-coordinate with the loss of a water molecule 
(110, 111); the enzyme is now primed to react with dioxygen (species B).  Dioxygen 
forms a putative tetrahydrobiopterin-peroxy-iron(II) species which has not been 
spectroscopically characterized to date.  Dioxygen is proposed to react at the pterin rather 
than the iron(II) center because the iron(II) oxidation by molecular oxygen occurs in 
about 40 minutes, while pterin oxidation occurs significantly faster (50).   
Tetrahydrobiopterin reduces dioxygen to the peroxo level before forming the 
iron(II)-tetrahydro-C4a-peroxy intermediate (species C) (62, 63). Heterolytic cleavage of 
this intermediate yields the iron(IV)-oxo species and C4a-OH-BH2 (species D).  The 
iron(IV)-oxo species in Chromobacterium violaceum PAH (cvPAH) has recently been 
detected by Mössbauer spectroscopy and is presumed to be the catalytic intermediate in 
all species of PAH (61).  The identity of the C4a-OH-BH2 species had been previously 
determined by UV/vis (62) and 
13
C
 
NMR spectroscopy (63, 113).  The iron(IV)-oxo 
intermediate rapidly hydroxylates the substrate and the C4a-OH-BH2 species is recycled 
to BH4 as discussed in Section 1.2.2.  The resting six-coordinate active site is regenerated 
and additional molecules of L-Phe and BH4 binding in the active site re-prime the enzyme 
for additional cycles of catalysis (species E) (1).  The allosteric activation steps of the 
kinetic mechanism are still being investigated and will be discussed in more detail in 
Chapter 5. 
53 
 
 
 
Figure 1.25 Proposed kinetic mechanism for PAH. Allosteric activation is shown in box 
at the top.  Adapted from proposed working mechanism from ref. (50). 
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1.3 Regulation of phenylalanine hydroxylase and related enzymes 
 This section aims to describe the currently available knowledge of the regulation 
of PAH by allosteric and other methods and place that information in a framework with 
other characterized allosteric enzymes.  PAH is regulated both by its natural substrate, L-
Phe, and by its natural coenzyme, BH4.  In addition, PAH is also subject to regulation by 
phosphorylation at Ser16 in the regulatory domain which lowers the barrier to allosteric 
activation (49).  The protein can also be regulated in vitro by alternative activators that 
partially or fully turn on enzymatic activity and may or may not involve the same 
physiological changes as L-Phe induced activation.  All of these regulatory behaviors will 
be discussed in this section.  This section will also detail the mechanism of hemoglobin 
allosteric activation, and discuss structural implications of published structures of 
characterized allosteric ACT domain containing enzymes to help guide the understanding 
of allosteric activation in PAH. 
1.3.1 Regulatory behavior in PAH 
 The regulation of PAH has been discussed to some extent since the early 1970’s 
when it was found that incubation of the enzyme with phospholipids such as lysolecithin 
could increase the rate of hydroxylation by the enzyme by as much as 50-fold (114).  
Later studies have shown that this regulation is actually a complex set of processes, 
primarily controlled by the binding of substrate to the allosteric effector binding site, but 
also regulated by BH4 binding and by phosphorylation (115).  An alternative pathway, 
which is not controlled by BH4 and L-Phe, can also be used to circumvent the regulation 
processes in PAH.  Alternative activators, such as lysolecithin, induce a similar catalytic 
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rate to that which is observed by L-Phe activation, but by a different mechanism.  Herein, 
each of these types of regulatory behavior will be described and discussed in more detail. 
1.3.1.1 Phosphorylation at Ser16 
 PAH is subject to post-translational modification by cAMP-dependent protein 
kinase (PKA) at Ser16 (49).  Early studies demonstrated an increase in kinetic rates of 
reactions catalyzed by the protein when the level of phosphorylation increased from the 
0.3 mol phosphate / subunit seen in the rat liver enzyme as isolated, to 1.0 mol phosphate 
/ subunit in glucagon stimulated rats, and suggested that the activation changes in PAH 
may be completely due to this phosphorylation (116, 117).  Further studies on the 
phosphorylation of PAH using glucagon to induce phosphorylation in vivo, in perfused 
rat liver, and in vitro, demonstrated that the activity of the enzyme was actually 
controlled by the L-Phe dependent activation of the enzyme (117).  The as isolated 
enzyme was activated 1-4% by its native phosphorylation as compared to enzyme 
completed stripped of phosphate, while the glucagon stimulated and fully phosphorylated 
enzyme only demonstrated 5-7% activation.  These studies established that 
phosphorylation of PAH enables easier activation by L-Phe, but does not by itself induce 
full catalytic activity; this is kinetic effect that facilitates faster L-Phe induced allosteric 
activation (75).   Additionally, rat liver PAH has been shown to contain 0-2 phosphate 
molecules per tetramer, suggesting that the native enzyme is not consistently 
phosphorylated in all subunits (49).   
 More recent site-directed mutagenesis studies of the phosphorylation of PAH 
showed that the site of PAH phosphorylation is located early in the autoregulatory 
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sequence, at Ser16 (71).  These experiments replaced Ser16 with charged and neutral 
amino acids and found that neutral residues (alanine) at Ser16 would not activate the 
enzyme, while negatively charged residues (glutamic acid or aspartic acid) would activate 
the enzyme to approximately the same extent as phosphorylation (71, 72).  These studies 
also suggested that there are electrostatic interactions between Ser16 in the regulatory 
domain and the active site (71, 72).  It should also be noted that Ser16 lies within the part 
of the autoregulatory domain that could not be resolved in the crystal structure the 
regulatory domain.  The crystal structures suggest this region is in a very flexible loop 
and may have interactions with the active site (14).  Additional mutagenesis studies 
involving the early portion of the regulatory domain have shown that residues 16-26 
serve an inhibitory role in the regulatory of PAH, and are proposed to interact with the L-
erythro side chain of BH4 (118).  These studies suggested that phosphorylation does play 
a role in the regulation of PAH, but it is not the key contribution toward regulating the 
catalytic activity of this enzyme. 
1.3.1.2 Allosteric inhibition by BH4 
 Regulation of PAH is also controlled by allosteric inhibition by the native 
coenzyme, BH4 (49).  There is a defined binding pocket for BH4 in the crystal structures 
of the inactive T-state enzyme where BH4 is involved in hydrogen bonding interactions 
with Leu249 and Ser251, and the aromatic ring of BH4 may be involved in -stacking 
interactions with Phe254 (58).  Fluorescence titration experiments, using 2,3-
dihydroxynapthalene as a fluorescence reporter molecule and BH4, 6MPH4, and 5-deaza-
6MPH4, have shown that L-Phe activation of the enzyme causes the pterin binding site to 
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both shift and decrease its affinity for BH4 binding (119).  These experiments use a 
bidentate fluorescence reporter molecule that would likely block any open sites for 
further reactivity of the enzyme with dioxygen and disrupt or inhibit the pterin binding 
site.  These studies also indicate that 6MPH4 and 5-deaza-6MPH4 binding to the active 
site are not inhibited by activation with L-Phe, and that the substituted pterins have the 
same Kd in the presence and absence of L-Phe.  These results are consistent with the L-
erythro side chain of BH4 inhibiting the active site of PAH, and causing the coenzyme to 
inhibit PAH activity (120).  Determinations of KI for BH4 have demonstrated that BH4 
inhibits allosteric activation by L-Phe in linear fashion with KI values of 0.26 and 0.10 
μM at 0.5 and 5 mM L-Phe concentrations, respectively.  These data suggest that 
increasing L-Phe concentrations increase the effectiveness of BH4 inhibition.  These data 
also demonstrated that BH2 is also a good inhibitor L-Phe activation (KI of 5 and 2 μM at 
0.5 and 5 mM L-Phe, respectively) and that 6MPH4 is a weak inhibitor of L-Phe 
activation (KI  = 115 ± 35 μM at 5 mM L-Phe), but its inhibition cannot be measured at 
standard assay conditions of 1 mM L-Phe.   
 Xia, Gray and Shiman proposed the model in Figure 1.26 for the inhibitory 
effects of BH4 on PAH activation (104).  This model proposes that in the absence of BH4, 
L-Phe binds at an allosteric site to activate PAH, and then BH4, L-Phe, and dioxygen can 
bind to the enzyme active site and perform catalysis. BH4 is thought to bind to an inactive 
form of PAH and inhibit activation of the enzyme even in the presence of L-Phe.  This 
process forms an implicit internal regulation method, ensuring that the enzyme does not 
generate its reactive intermediate until all reagents are present at their appropriate binding 
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sites in the active site.   The ordering of these reagents is thought to be semi-random in 
nature.  In vivo experiments also implied that BH4 turnover in cells is directly linked to 
PAH activity, and that BH4 inhibition is a significant regulatory process in PAH catalysis 
(121).  The use of 6MPH4, which is not present physiologically, at lower concentrations 
(< 5 mM) in most in vitro studies allows researchers to eliminate the negative allosteric 
effect of BH4, however any studies of a cellular nature require understanding of this 
inhibition.  
 
 
  
 
Figure 1.26 Model for BH4 allosteric inhibition of PAH and affects on catalysis.  
Adapted from ref. (104). 
 
 
 
 Kinetic studies of wtPAH and PKU-inducing mutants have shown that it is 
possible to induce additional positive cooperativity on PAH with BH4 if the enzyme is 
first preincubated with L-Phe (122).  The results showed traditional hyperbolic kinetic 
behavior for PAH with BH4 when the protein was not preincubated with 1 mM L-Phe, 
while demonstrating sigmoidal kinetic behavior when PAH was preincubated with 1 mM 
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L-Phe prior the addition of BH4 (122).  These results suggest that BH4 acts as a positive 
allosteric effector for PAH only when the enzyme is already activated by L-Phe (122).  
These results are consistent with the BH4 mechanism originally worked out by Xia, Gray, 
and Shiman, suggesting that BH4 inhibition occurs in the absence of L-Phe, and that in 
the presence of L-Phe, BH4 can bind in the active site, as BH4 is necessary for turnover to 
occur (Figure 1.26) (104). 
1.3.1.3 Allosteric activation by L-Phe 
 The primary regulation process occurring in PAH is allosteric activation by L-
Phe.  There are two distinct binding sites for L-Phe within PAH.  The first binding site is 
in the enzyme active site where the L-Phe will be converted to L-Tyr.  The second 
binding site is located in a previously undefined location (see Chapter 2) that had been 
characterized as being distinct from the active site L-Phe binding site by elegant 
experiments with 
14
C-labeled phenylalanine (76).  In these experiments, isotopically 
labeled L-Phe was incubated with the protein to activate the enzyme, at a concentration of 
one L-Phe molecule per subunit.  L-Trp, which is hydroxylated with 30-fold lower 
affinity (KM,L-Trp = 6.8 mM) (see Section 1.2.3.2), was added to the protein at very high 
concentrations (93).  Upon enzymatic assays, L-Trp was found to be hydroxylated, while 
the 
14
C-labeled L-Phe remained bound to the protein and was not hydroxylated (88).  
These experiments suggested that L-Trp was binding at the active site of PAH and that 
14
C-labeled L-Phe was binding at a physically distinct and non-overlapping allosteric site 
somewhere else in the protein.  This binding site was shown by gel filtration studies to 
exist in each subunit of the tetrameric protein (76).  The L-Phe induced activation of the 
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enzyme has been associated with a large activation energy required to convert between 
the T and R states of the enzyme.  For the unphosphorylated enzyme this temperature 
dependent Arrhenius activation energy was estimated to be 33.5 kcal/mol for the T to R 
transition (88), however this experiment was limited to steps that could be measured by 
standard UV-visible spectroscopic methods.  Rapid steps that occur at lower temperatures 
cannot be measured by this method, and if such additional steps are detected by rapid 
kinetic methods, they may alter the understanding of this very large activation parameter, 
which does not seem plausible on a physiological level.  For comparison, the activation 
energy for catalysis has been determined by for both the rat liver and rat recombinant 
enzyme and found to be 12 kcal/mol and 14.6 kcal/mol respectively (88, 91). 
L-Phe activation of PAH induces a large number of physical changes to the 
enzyme. Upon allosteric activation the enzyme becomes highly hydrophobic (this 
hydrophobicity is used to purify the enzyme in high yield) (123).  This change in 
hydrophobicity is a classically used characteristic to understand the activation state of the 
enzyme.  Dynamic light scattering and gel filtration experiments demonstrate that the 
solution radius of the enzyme increases from 55 ± 1 to 57 ± 1 Å upon activation with L-
Phe.  This finding is consistent with an apparent 10-11% increase in the total volume of 
the PAH tetramer upon allosteric activation (91).  Small angle X-ray scattering 
experiments also demonstrate an approximately 10% change in the relative volume 
between the T and R states of the enzyme (87).   
Tryptophan fluorescence experiments have demonstrated an approximately 8 nm 
shift in the emission maximum of the enzyme, from ~335 nm to ~343 nm, upon 
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incubation with L-Phe (91, 124).  Furthermore, individual Trp to Phe mutant enzymes 
have been prepared to determine the contribution of each of the three Trp residues to the 
overall tryptophan fluorescence signal. Residues Trp120, Trp187, and Trp326 (Figure 
1.27), have been reported to contribute 61, 13, and 26% of the total fluorescence signal 
intensity of the protein, respectively.  Trp120 has been noted to be the most solvent 
exposed Trp residue and most mobile in the protein (124).  
 
 
Figure 1.27 L-Trp residues in orange in PAH monomer, relative percentage of overall 
fluorescence intensity is given below each residue.  Figure was created in PyMol (23) 
using PDB file 2PHM (14). 
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It has been proposed that an allosteric binding site for L-Phe might be located in a 
loop region between residues 111-117, as this region is a hinge region for the catalytic 
and regulatory domains where domain movements would be expected (14).  This region 
is shown in Figure 1.28.  The hinge region containing residues 111-117 in one subunit 
does not interact with same hinge region in a different subunit in the currently available 
crystal structures of the inactive T-state enzyme, but upon allosteric activation with L-
Phe, domain movements may occur allowing the hinge regions to interact with each 
other.   It should also be noted that this region is directly adjacent to Trp120, which is 
located about 4.5 Å from residue Arg111 (14).  This loop would therefore have high 
solvent exposure like Trp120, and be more flexible and able to participate in allosteric 
interactions.  
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Figure 1.28 Loop region of PAH proposed to contain allosteric L-Phe binding site.  
Residues 111-117 are shown in orange; a) a single monomer of PAH; b) PAH tetramer. 
The figure was constructed as a composite of PDB files 2PHM (14) and 2PAH (84) in 
PyMol (23). 
 
 
The activation of PAH by L-Phe has also been studied by other biophysical 
methods, which have given some potentially conflicting results concerning the location of 
the allosteric effector binding site.  Differential scanning calorimetry (DSC) studies 
revealed two irreversible transitions for the thermal denaturation of tetrameric human 
PAH, which were interpreted to correspond to the irreversible unfolding of the four 
regulatory domains and subsequent unfolding of the two of the four catalytic domains 
and then irreversible denaturation of the protein (125).  This study suggested that L-Phe 
did not precipitate  with the regulatory domain so that an L-Phe binding site could not be 
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located in that domain (125); however, the authors did not offer other possible 
explanations or assignments for this data such as the L-Phe binding sites might bridge the 
region between multiple domains, as suggested by the crystal structures (14).  These 
authors also suggested that their data indicated the presence of homotropic cooperative 
binding at the active site (125), instead of the distinct binding site that was demonstrated 
by Shiman (76).  These conclusions are not supported by their data, as they are 
interpreting equilibrium thermodynamics from irreversible transitions observed by this 
method, which significantly challenge any real conclusions from these data.  In order to 
properly analyze the DSC results, conditions would need to be developed to report 
reversible unfolding and refolding of the protein. At this time, the irreversible nature of 
the DSC results suggest that the enzymatic studies indicating two separate binding sites 
give the correct mechanism for allosteric binding in PAH.    
Additional studies involving the regulatory domain of PAH include protein NMR 
studies using 
1
H-
15
N HSQC with 
15
N labeled protein, which showed a change in the 
chemical shift of the regulatory domain in the presence of high concentrations of L-Phe 
(126).  These studies, however, did not assign the resonances of that shift and therefore 
could not establish residues for a specific binding site for L-Phe (126).  These results 
directly contradict the DSC studies suggesting the L-Phe does not bind in the regulatory 
domain, although neither study gives evidence concerning the actual binding location of 
L-Phe in the protein.   
Surface plasmon resonance (SPR) studies on PAH have observed an L-Phe 
dependent ΔRU response in the SPR signal.  The author's report this change is consistent 
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with a conformational change that occurs upon the T-state to R-state transition in PAH, 
as the signal observed from L-Phe binding was too large to correlate a mass only change.  
These experiments showed that the full-length wild type enzyme demonstrated these 
conformational changes, while a dimer of the catalytic domain only (Δ1-102/Δ428-452-
PAH) did not.  A hyperbolic dependence on L-Phe concentration was observed, with a Kd 
of 98 ± 7 µM for L-Phe binding.  This is consistent with binding parameters for L-Phe 
binding in the active site (KM,L-Phe = 180 µM) (127), however, it does not reflect the 
binding of L-Phe at a second, allosteric binding site, which is likely a weaker affinity 
binding site as metabolically PAH must turn on activity after consumption of protein, 
when L-Phe levels rise to nearly 1 mM (79).  Additional studies into the binding of the 
substrate analog THA demonstrated a similar SPR response with a slightly weaker 
binding affinity (Kd,THA = 251 ± 35 µM).  These studies led to the conclusion that 
allosteric activation and conformational change in PAH must involve both the catalytic 
and regulatory domains as the regulatory domain removal led to an absence of L-Phe 
induced SPR signal (128).  
H/D exchange experiments monitored by mass spectrometry have demonstrated 
that some areas of the regulatory domain of PAH are more solvent accessible in the 
presence of L-Phe.  The peptides 39-59, 54-61, 82-91, and 85-112 demonstrated faster 
rates of H/D exchange in the presence of L-Phe; these data may suggest that these 
peptides become more solvent exposed upon allosteric activation with L-Phe.  In the 
catalytic domain, peptides 164-174, 220-227, 249-250, 309-317, and 370-376 all show 
significant increases in rates of H/D exchange in the presence of L-Phe.  This method was 
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unable to detect any peptides in the region of 111-117 (129), which has been pointed out 
to be a flexible loop and possibly involved in hinge or domain movement (14).  The H/D 
exchange experiments on Δ1-117-PAH do not show any peptides with large increases in 
deuterium exchange upon incubation with L-Phe, suggesting that there is little or no 
conformational change in the protein without the regulatory domain present (129) which 
agrees well with previous kinetic (50) and spectroscopic studies (127, 128).  
1.3.1.4 Activation by alternative activators 
 PAH has also been shown to be regulated by other small molecules and effectors 
besides substrate and coenzyme.  These regulators serve to activate the enzyme by 
eliminating the activation barrier required to transition the enzyme from the T state to the 
R state.  When PAH is incubated with the phospholipid lysolecthin, and L-Phe and BH4 
are added immediately prior to the start of an assay, there is immediate turnover, just like 
with the L-Phe preincubated enzyme.  The observation of immediate turnover suggested 
that lysolecthin stimulated the enzyme by the same relative amount, resulting in the same 
relative activity as L-Phe.  Enzymatic rates in terms of KM or kcat were not provided for 
comparison (88).  It was also shown that PAH activation by lysolecthin occurs by a 
different pathway then L-Phe activation, as lysolecithin activated enzyme demonstrated 
hyperbolic Michaelis-Menten kinetics, while the L-Phe incubated enzyme displayed 
sigmoidal kinetics with respect to the substrate concentration (114).  Further studies have 
demonstrated that lysolecthin activation is weakly cooperative with respect to the 
substrate (Hill coefficient 1.3) (91).  DTNB (5,5'-dithiobis-(2-nitrobenzoic acid)) studies 
with PAH and lysolecthin indicate that lysolecthin activation partially exposes buried 
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cysteine residues in the protein (92).  Our more recent assessment of lysolecithin 
activation is that lysolecthin appears to alter the oligomeric state of the protein to 
generate exclusively the dimeric form, but the lysolecthin activated form of PAH has not 
been well characterized.    
 Chymotrypsin has also been implicated as a stimulator for PAH.  It appears to 
activate the enzyme slightly less effectively than lysolecithin, and works by cleaving the 
enzyme and likely breaking tetramers into dimers.  It was shown that chymotrypsin 
activation forms a dimer of 36 kDa catalytic subunits, which removes the N-terminal 
regulatory and C-terminal tetramerization domains (130).  Chymotrypsin activation does 
not induce the same type of structural perturbations to PAH as lysolecthin activation at 
low concentrations; however, higher concentrations of chymotrypsin cannot be used for 
activation without significant proteolysis and low levels of chymotrypsin do not activate 
the enzyme as well as similar levels of lysolecthin (49, 131).  
 Chemically modifying the enzyme with N-ethylmaleimide (NEM) will also 
activate the enzyme.  NEM modification of PAH has been shown to alkylate Cys237. 
Alkylating this residue provides steric bulk that physically separates the subunits and 
forces the enzyme adopt a dimeric form rather than its customary tetramer form (Figure 
1.29) (49).  NEM activation of PAH was studied by MCD spectroscopy, and the effect of 
NEM activation on the active site iron environment in PAH was equivalent to that of the 
wild-type enzyme in the presence of either L-Phe or 5-deaza-6MPH4 (109, 110).  NEM 
activated enzyme also demonstrates hyperbolic rather than sigmoidal kinetics with L-Phe 
and only demonstrated binding of L-Phe to the active site (132).   
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Figure 1.29 Location of Cys237 (orange) in PAH. a) Tetrameric PAH indicating Cys237 
locations in all subunits. b) Close view of subunits indicated in box of a) showing 25 Å 
distance between Cys237 residues in T-state crystal structures. Figure created in PyMol 
(23) from PDB file 2PHM (14) and 2PAH (84). 
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 PAH can also be stimulated by increasing the pH to 8.5 or greater.  Increasing the 
buffer pH in the presence of BH4 (but not 6MPH4) is observed to enhance enzyme 
activity.  Additional fluorescence studies on PAH show that the T-state fluorescence 
emission at pH 9.5 is nearly the same as the R-state fluorescence emission at pH 6.8.  
There is no additional shift in the R-state fluorescence emission at pH 9.5, which was 
interpreted to imply that the enzyme is already fully activated at pH 9.5 (133).  The 
formation of dimeric PAH is favored at higher pH values, which also suggests that the 
formation of dimers leads to an activated form of PAH (91).  This dimer formation may 
be due to a change in the protonation state of a reactive cysteine residue, such as Cys237.  
Cationic, anionic, and bulky residues have been substituted for Cys237 and the dimer is 
the predominant oligomeric form in all of these mutant enzymes (87) suggesting that 
Cys237 is essential for tetramer formation.   
 In all of these cases of alternative activation of PAH, dimeric, cleaved, or 
conformationally different species of PAH are proposed to form.  It is likely that the 
activation process in the alternative activation states is different from the pathway that is 
observed when PAH is activated by L-Phe.  Disruption of the tetrameric form of the 
protein into dimers or other conformers would alter the contacts between subunits that are 
suggested to occur during L-Phe allosteric activation and would therefore require a 
different activation process. 
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1.3.1.5 Proposed allosteric activation mechanisms 
A recent proposal for the allosteric activation mechanism of PAH involves the use 
of a morpheein allostery model (134, 135).  In this model, protein assembly and 
disassembly together is part of the allostery process.  Higher order oligomers can 
dissociate into lower order oligomers, undergo a conformational change, and then reform 
into higher order oligomers of the same or different oligomeric state.  A schematic 
example of this type of protein interaction is shown in Figure 1.30.   This model tries to 
account for the fact that dissociative processes are typically not included in common 
views of protein allostery and this method allows for a greater view of protein dynamics 
and ensembles of different protein conformations (135). 
 
 
Figure 1.30 Morpheein allostery model adapted from ref. (135). 
  
 Jaffe and coworkers have recently suggested that the morpheein model works for 
PAH, based on modeling studies of other ACT domain proteins.  This model uses a 
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homology model of the PAH regulatory domain, which aligns the regulatory domain of 
the ACT domain protein, PGDH, with PAH to study the differences between the T and R 
states of the enzyme.  Using this homology model, a structural model of allosteric 
activation in L-Phe was constructed (136).  The alignment of the regulatory domain of 
PGDH and the regulatory domain are shown in Figure 1.31, which also indicates the 
location of the L-serine (L-Ser), the allosteric ligand in PGDH (137), and the flexible 
loop in PAH which has been previously suggested to be possible site of protein motion 
(14).   These two sites are shown to be non-overlapping in this structural analysis.  In the 
computational homology representation proposed by the morpheein model, a mechanism 
is suggested where a tetrameric inactive form of the enzyme dissociates into an inactive 
dimer.  This inactive dimer then undergoes a conformational change into an active dimer 
form, which then finds another active dimer, and binds L-Phe to form the fully active, L-
Phe bound tetramer (Figure 1.32).  Based on kinetic studies of PAH, a dimer of any kind 
is catalytically active with no "activation step" required for catalysis (91).  In this manner, 
the morpheein model is not consistent with the proposed kinetic models of PAH (Figure 
1.26) (104).  The morpheein model also proposes that higher order oligomers (hexamer, 
octamer, etc.) of PAH may form in PKU-inducing mutants as a resulting disease state 
(136).  This has been observed for aggregation diseases such as ALA porphyria, wherein 
disease causing point mutations lead to an increased formation of low activity hexamers 
(138).  This model appears to be a simplistic view of the allostery process in light of the 
more complex mechanisms which been accepted for hemoglobin, a classically 
characterized tetrameric allosteric enzyme (139).  These mechanisms of hemoglobin 
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allosteric control will be discussed in Section 1.3.2.  Furthermore, this morpheein model 
has not been successfully applied to hemoglobin kinetics.  Despite its inherent simplicity, 
however, the morpheein view of understanding PAH allosteric activation may play a role 
in the cellular, in vivo, environment and should be further examined by future studies and 
analysis of kinetic information in this area.   
 
Figure 1.31 Alignment of PAH regulatory domain (green) with ACT regulatory domain 
from 3-PGDH (fuchsia).  Residues 111-117 of PAH are shown in orange as a flexible 
loop likely to participate in protein conformational change.  The allosteric ligand, L-Ser, 
in PGDH is shown in cyan. Figure was created in PyMol (23) from PDB files 2PHM 
(14), 2PAH (84), and 1PSD (137). 
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Figure 1.32 Morpheein model of allosteric activation proposed for PAH.  The regulatory 
domain is shown in blue, the catalytic domain is shown in red, the tetramerization domain 
is shown in green, and the L-Phe binding site is shown in white.  a) The catalytic pathway 
leading to an fully activated tetramer; b) inactive pathway, leading to formation of higher 
order oligomers in disease states. Adapted from ref. (136). 
  
 The most common mechanism of allosteric activation by L-Phe has been 
proposed by Xia, Gray and Shiman (Figure 1.26) and involves both regulation by L-Phe 
and BH4, as both are involved in the physiological regulation of PAH as discussed in 
Section 1.3.1.2 (104).  This mechanism does not differentiate between dimeric and 
tetrameric PAH nor does it address the cooperativity of L-Phe binding to all subunits.  
Given the amount of structural and regulatory information that is now available for PAH, 
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this model is now too simplistic to address all of the known information about this 
allosteric activation process (115).  The actual kinetic steps of the allosteric activation 
process by L-Phe in PAH are still unknown.  While kinetic and structural mechanisms 
have been proposed, there is a lack of direct evidence to support any particular 
mechanism.  Unlike the catalytic mechanism, where most steps have been investigated by 
multiple spectroscopic approaches, the allosteric mechanism has been much more 
difficult to study since it is impossible to completely uncouple the effects of allosteric 
activation from substrate hydroxylation.  In this dissertation, evidence will be presented 
as to how allosteric activation from the T state to the R state occurs in an isolated in vitro 
system; however additional factors may be involved in PAH regulation in vivo and 
require further study.  Additionally, guidance from other characterized allosteric enzymes 
such as hemoglobin will guide the development of an allosteric activation mechanism in 
PAH. 
 
1.3.2 Allosteric control in hemoglobin  
 An understanding of other classically characterized enzymes such as hemoglobin 
will be extremely useful in order to fully understand the allosteric mechanism of PAH.  
This section provides a historical and modern day overview of the hemoglobin allostery 
model so that it can be used to help describe a potential model for allosteric activation in 
PAH. 
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1.3.2.1 Hemoglobin regulation by dioxygen 
 Hemoglobin has been the most well characterized allosteric enzyme beginning 
from Bohr's observations from the early 1900's that dioxygen binding to hemoglobin is 
sigmoidal rather than hyperbolic (139).  Linus Pauling was first able fit this binding 
behavior to a two parameter model, with a square symmetric arrangement of the binding 
hemes (140).  Max Perutz first solved the crystal structure of hemoglobin in both the 
oxygenated and deoxygenated forms and detected movement of the β-subunits closer 
together upon oxygenation (Figure 1.33) (141-143).   
 
Figure 1.33 Tetrameric structure of hemoglobin. a) Deoxygenated human hemoglobin, 
PDB file 2HHB (144); b) oxygenated human hemoglobin PDB file 1HHO (145);  c-d) 
overlay of both oxygenated and deoxygenated hemoglobin, where the heme of β-subunit 
(yellow) moves closer to the center upon oxygenation.  Figure created in PyMol (23).  
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 With a beginning understanding of the structural perturbations occurring in 
hemoglobin upon dioxygen binding, a new field began attempting to explain this 
behavior.  The initially proposed kinetic models, the Monod, Wyman, and Changeux 
(MWC) model (146) and the Koshland (KNF) model (147), are still regularly referenced 
today when discussing allosteric enzymes.  These two models can be summarized in 
Figure 1.34, which demonstrates the nature of the allosteric transitions in hemoglobin.  
The MWC model proposes that tense "T" state of the enzyme is a low affinity state and 
that the relaxed "R" state of the enzyme is high affinity state.  Cooperativity occurs 
within in the MWC model occurs when the ligand population moves from the low 
affinity state to the high affinity state with increasing oxygen pressure (left or right side 
of Figure 1.34).  The binding of dioxygen to hemoglobin is independent of how many 
oxygen molecules are already bound and the affinity change only occurs at either the 
beginning or end of the process (139).  The KNF model proposes that binding of 
dioxygen to a subunit forms an intermediate species, and each of the intermediate species 
sequentially move to the fully liganded R state (center of Figure 1.34) (147).  The MWC 
model has been proposed to only account for positive cooperativity, while the KNF 
model accounts for both positive and negative cooperativity (148).  Crystallographic and 
spectroscopic studies have demonstrated that hemoglobin violates the symmetry rules of 
MWC model, as the binding of dioxygen to one subunit, triggers the Fe
2+
 ion of the heme 
group to move into the plane of the heme as a part of the allosteric transition (148).  
Perutz attempted to synthesize these two models together with a stereochemical model 
for hemoglobin allostery that allows for a combination of the concerted and sequential 
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processes in various conditions (142).  This model served as the basis for hemoglobin 
study for many years and qualitatively described the enzyme until quantitative techniques 
could provide more insight into this interesting cooperativity and kinetic behavior (139).  
These two models have also served as the basis for the discussion of enzyme allostery for 
most of the past 50 years.  It is only recently that new models have regularly been 
discussed to replace or supersede the MWC or KNF models (149, 150). 
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Figure 1.34 Concerted and sequential mechanisms for hemoglobin allostery implicated 
by the MWC and KNF models respectively.  Adapted from ref. (148). 
 
 
1.3.2.2 Kinetic mechanism of hemoglobin allostery 
 Initial kinetic studies of hemoglobin had supported the MWC and KNF models of 
hemoglobin allostery, wherein the enzyme exists only in T or R state, which was named 
the two-state model.  Early evidence suggesting that a two-state model of allostery is 
insufficient was obtained using laser photolysis experiments to describe microsecond to 
millisecond time scale conformational changes.  These experiments could not be fit to a 
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two-state model, and suggested that the MWC model may not describe all cases of 
hemoglobin allostery (151). 
 In the late 1980s's and early 1990's, additional kinetic studies of oxygen binding 
to hemoglobin enabled the identification of more stable microstates in the T to R 
conversion of hemoglobin.  The model proposed by Ackers and coworkers demonstrated 
that allostery in hemoglobin is controlled by the dimeric units in hemoglobin.  
Hemoglobin is composed of 2 α/β dimers, and according to Acker's model, the entire 
tetrameric hemoglobin molecule behaves as if it is activated (R-state) when dioxygen is 
bound to at least one subunit in each of the two dimers.  If the dioxygen is bound in both 
subunits of one dimer, but not bound in the second dimer, the enzyme behaves as if it is 
still in the resting (T) state (Figure 1.35). This model also noted that dimers did not 
independently demonstrate cooperativity or high affinity for dioxygen.  The association 
of two dimers together to form a tetramer was associated with this increase in 
cooperativity and affinity for dioxygen.  This model also assisted with understanding of 
the activation energy needed to convert between the T and R states of the enzyme, 
demonstrating that cooperative process requires a total cooperative free energy (ΔGc) of 
6.3 kcal/mol, whereas the independent binding processes were associated with a larger 
activation process using each of the individual steps.  Through this framework, the MWC 
and KNF models were found to be outdated as many intermediate steps are required in 
addition to the entirely concerted or sequential processes.  It was noted, however, that 
when limits were placed on the system, it could be described by the traditional models 
(148, 152).    
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Figure 1.35 Model proposed by Ackers for hemoglobin allostery involving activation of 
the dimer subunits.  Adapted from ref. (148). 
 
 Further studies by Ackers and coworkers over the years led to a more complete 
understanding of the kinetic and thermodynamic mechanism of hemoglobin, which is no 
longer dependent on the assignment of the T and R states (two-state model) and proposes 
that hemoglobin may exist in a variety of microstates and uses all of these distinct 
microstates with varying levels of population (153).  Binding of a dioxygen molecule to 
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one subunit in each dimer of the hemoglobin tetramer does not show positive 
cooperativity as measured by a Hill coefficient.  However, binding of two dioxygen 
molecules to the same dimer of the hemoglobin tetramer demonstrates high cooperativity. 
This observation of high cooperativity suggests that the Hill coefficient is not a rigorous 
measure of cooperativity, and in many cases can be replaced by stepwise analysis of the 
binding parameters of dioxygen reactivity (154, 155).  This hypothesis has led to the 
formation of a new kinetic model for hemoglobin allostery involving these microstates 
(Figure 1.36).  The revised Holt and Ackers model predicts that forming species 22, 23, 
or 24 is a non-cooperative process, while forming species 21 is a cooperative process.  
This model indicates that cooperative steps are actually the least favored steps kinetically 
and require the most free energy to occur.  Ackers and Holt report that the Hill coefficient 
represents all of the statistically possible variety of microstates, and includes both 
cooperative and non-cooperative steps.  The high cooperativity of some steps, most 
specifically the binding of the third molecule of dioxygen, hides the non-cooperative 
effects of other binding steps, and makes the apparent Hill coefficient much higher.  The 
mechanism provided in Figure 1.36, demonstrates the cumulative effects of the stepwise 
binding of dioxygen to all heme binding sites, and demonstrates the equivalent binding 
sites in tetrameric hemoglobin (154). 
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Figure 1.36 Revised model of Holt and Ackers to account for hemoglobin allostery using 
microstates rather than T/R nomenclature.  All boxed microstates are energetically 
equivalent.  The pathway on the right side is lower in energy than the pathway on the left 
side.  The numbers represent the possible binding states of oxygen in each microstate.  
Adapted from ref. (154). 
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 More recent photolysis studies with hemoglobin continue to propose MWC-like 
two-state models for hemoglobin allostery.  The Tertiary Two State (TTS) model (Figure 
1.37),  based on the results of these experiments, is suggested to serve as the most likely 
structural model for hemoglobin (156).  The TTS model proposes an extension of the 
traditional MWC model, which allows for the presence or absence of allosteric effectors 
and demonstrates consistency with Perutz's structural models of the movement of the β-
subunits upon dioxygen binding.  This model assigns the t state conformation to subunits 
that appear like the unliganded state, regardless of their actual ligation state, and the r 
state conformation to subunits that appear like the liganded state. (157).  This model 
helps to describe the structural and photolysis data about hemoglobin (156), but does not 
provide a kinetic explanation in the same way as the Ackers' models discussed above.  
The TTS model cannot accurately predict the population of doubly deoxygenated species, 
and does not address the dimeric binding differences discussed by Ackers (156).  The 
TTS model needs to be able to fully address the kinetic studies before it should replace 
the Ackers models discussed above. 
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Figure 1.37 Tertiary two-state (TTS) model for hemoglobin allostery, adapted from ref. 
(157).  Unliganded subunits are indicated as squares, liganded subunits are indicated as 
circles.  Subunits in the t form are open, subunits in the r form are filled.  Conformational 
changes that have been observed crystallographically are indicated by the conformation 
of the model from the T to R states.  
 
 
 None of the models presented to date has been shown to be consistent with all of 
the known experimental data.  However, most of the recent studies have focused on 
reporting crystal structures in each state of the protein, to demonstrate the possible 
binding modes of dioxygen in hemoglobin (158).  While this information may help 
demonstrate the most stable forms of hemoglobin, it does not help elucidate the kinetic 
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mechanism of hemoglobin and may not be as useful to the overall understanding of 
hemoglobin allostery.  The Ackers models discussed above seem to provide the best 
kinetic framework for the study of hemoglobin, although some of the implications of the 
positive and negative allosteric effectors from TTS model should be included in the 
Ackers model, to fully reflect the regulation of hemoglobin.  The Ackers models will be 
discussed in more detail in Chapters 4 and 5 to provide a kinetic framework for 
developing a kinetic mechanism of allosteric activation in PAH. 
1.3.3 ACT domain allosteric enzymes 
 The ACT domain is a regulatory domain motif found in a wide variety of 
proteins, including PAH, which primarily regulate amino acid metabolism (69).  The vast 
majority of these proteins have been determined to be allosterically regulated by amino 
acids and some of these regulatory proteins have also been crystallographically 
characterized (68).  An understanding of how some of the ACT domain proteins undergo 
allosteric regulation may assist determination of the allosteric activation mechanism in 
PAH.  A table of X-ray crystallographically characterized ACT domain proteins, 
including their regulatory ligands, is provided in Table 1.3.  Sequence homology studies 
and database searching using InterPro (159) have also located the ACT domain in several 
additional proteins, which are shown in Table 1.4.  Additional possible regulatory 
domain searches and sequence identity studies of PAH have been examined in the 
literature (160).  The structural implications of allosteric regulation in several of the 
crystallographically characterized ACT domain containing proteins will be discussed 
herein. 
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Table 1.3 Crystallographically characterized ACT domain proteins and characteristics. 
Protein Regulatory Ligands Crystal Structures References 
3-phosphoglycerate 
dehydrogenase 
L-Ser (-) 1PSD, 1YBA (137, 161) 
Acetohydroxyacid synthase L-Val (-). L-Ile (-) 2F1F (162) 
Aspartate kinase L-Lys (-), L-Thr (-) 2CDQ, 3C1N (163, 164) 
Chorismate mutase L-Trp (+), L-Phe (-) 1CSM, 2CSM (165, 166) 
Formyltetrahydrofolate 
deformylase 
L-Met (+), L-Gly (-) 3NRB (68) 
Homoserine dehydrogenase L-Thr (-) 1EBF, 1EBU (167) 
Prephenate dehydrogenase L-Phe (-) 2QMW, 2QMX (168) 
Phenylalanine hydroxylase L-Phe (+), BH4 (-) 1PHZ, 2PHM (14) 
Threonine deaminase L-Val (+), L-Ile (-) 2GN0, 2GN1, 2GN2 (169) 
 
Table 1.4 Other ACT domain proteins identified by sequence identity studies (68, 159). 
 
Protein Regulatory Ligands 
Acetolactate synthase Val(-), Ile(-) 
GTP Pyrophosphokinase Unknown 
Protein PII uridylyl transferase Gln(+), Glu(-) 
Threonine dehydratase Ile(-) 
Tryptophan hydroxylase Unknown 
Tyrosine hydroxylase Unknown 
TyrR (amino acid transcription factor) Tyr(-) 
 
 3-Phosphoglycerate dehydrogenase (PGDH) is a well-characterized member of 
the ACT domain family which performs the first step in the biosynthesis of L-Ser.  This 
protein has been crystallized as a tetrameric enzyme with a nucleotide binding domain, a 
substrate-binding domain, and an ACT or regulatory domain (Figure 1.38a).  The 
enzyme has been shown to display allosteric inhibition in the presence of L-Ser.  
Interestingly, the binding site for L-Ser inhibition is greater than 30 Å from the active site 
of the enzyme (137).  Upon binding of L-Ser, there is noted hinge movement in PGDH 
that causes the ACT domain and substrate binding domain to rotate by about 15º between 
the L-Ser bound and L-Ser free structure (Figure 1.38b-c).  PGDH appears to follow non-
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competitive inhibition, where the presence of an inhibitor prevents closing of the active 
site cleft through this hinge motion, rather than the prevention of substrate binding in the 
active site (161). Additional studies have also involved the mutation of residue W139, 
which is located at the interface between the nucleotide binding domain and the substrate 
binding domain, to a glycine.  When the W139G mutant protein is incubated with L-Ser, 
there is a loss of cooperativity and a rotation of the nucleotide binding domain by 42º 
toward the substrate binding domain, which causes a 600-fold decrease in Vmax (170). 
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Figure 1.38 PGDH structure indicating location of L-Ser binding sites in ACT domain.  
a) L-Ser bound structure of PGDH indicating location of particular binding domains.  
Figure was created from PDB file 1PSD (137) in PyMol (23).  b-c) Side and top views 
respectively of ACT domains in PGDH in both the L-Ser bound and unliganded crystal 
structures.  The unliganded structure is shown in green; the L-Ser bound structure is 
shown in salmon.  Figure was created with PDB files 1PSD (137) and 1YBA (161) in 
PyMol (23). 
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 Aspartate kinase (AK) catalyzes the phosphorylation of aspartate in the presence 
of ATP and is inhibited by L-lysine (L-Lys) and/or L-threonine (L-Thr) depending upon 
the organism (171).  AK demonstrates allosteric inhibition involving the ACT domain, 
which provides binding sites for the inhibitory ligands.  Crystal structures of the AK from 
Arabidopsis thaliana have demonstrated that two ACT domains found a dimer bound by 
the two catalytic domains of the protein.  These structures form a inhibitory loop where 
the inhibitor L-Lys or an additional inhibitor S-adenosylmethionine (SAM) can bind and 
block access to the active site (Figure 1.39) (164).  Other AK enzymes have a more 
complicated system of regulation and may coordinate as many as four ACT domain 
subunits per monomer, and provide binding sites for both L-Thr and L-Lys in the 
regulatory subunits.  In all crystallographically characterized forms of AK, there have 
been interactions between at least two ACT domains in each monomer.  The interactions 
within the monomer units are suggested to create branch points in the aspartate metabolic 
pathway as needed by the organism.  These ACT domains are all oriented to interact and 
align in the inhibited structures such that at least two ACT domains are interacting at all 
times (163).  
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Figure 1.39 ACT domain dimer formation in the crystal structure of AK from A. 
thaliana. Figure was created from PDB file 2CDQ (164) in PyMol (23). 
 
 
 Chorismate mutase (CM) and prephenate dehydratase (PD) are two additional 
enzymes that contain structurally characterized ACT domains.  CM catalyzes the 
intermolecular rearrangement of chorismate to prephenate that is then followed by the PD 
catalyzed decarboxylation and dehydration of prephenate to phenylpyruvate, which 
immediately precedes L-Phe or L-Tyr formation in plants (165).  In E. coli, both CM and 
PD can be found in a bifunctional P-protein that contains three domains, the CM domain, 
the PD domain, and an ACT domain involved in regulation (66).  The CM component of 
the E. coli P-protein is inhibited by binding of the product L-Phe in the active site, which 
causes movement of the ACT domain component.  Crystallographic studies of yeast CM, 
which is an individual protein containing a regulatory ACT domain, demonstrated that L-
Trp could be used as an activator of yeast CM, and that incubation with L-Trp induces an 
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8º rotation of CM of away from the allosteric binding site.  When the inhibitor L-Tyr was 
bound in the allosteric site, it was found to induce a rotation in the opposite direction by 
22º (Figure 1.40) and tightens the allosteric binding pocket.  This 22º rotation was 
observed to cause a very small physical conformational change upon allosteric activation 
as opposed to the larger movement that is noted for PGDH (172).   
 
 
Figure 1.40 Crystal structure of CM with allosteric inhibitor, L-Tyr, bound (green) and 
allosteric activator, L-Trp, bound (purple). Figure was created in PyMol (23) with PDB 
file 2CSM (166) and 5CSM (173).  
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 PD is inhibited by L-Phe when it is an isolated protein, and not part of the 
bifunctional P-protein complex, such as in the enzyme from Staphylococcus aureus.  The 
inhibition by L-Phe causes the enzyme to block access to the active site when L-Phe is 
present.  PD contains a prephenate dehydrogenase domain and an ACT domain and is 
found catalytically as a tetramer.  The ACT domains in PD align as a dimer, and provide 
two binding sites for L-Phe in the ACT domain dimer, which is at the interface of the two 
prephenate dehydrogenase domains (Figure 1.41).  The L-Phe binding site is located 
approximately 21 Å from the active site, which is similar to the other known ACT 
domain enzymes (168). 
 
Figure 1.41 ACT domain dimer in PD.  Figure was created in PyMol (23) using PDB file 
2QMX (168). 
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 The crystallographically characterized ACT domain proteins show several 
different architectures, all of which exhibit interactions between two or more ACT 
domains in structures containing the allosteric effector molecule (160).  Typically these 
interactions are present in the structures without the allosteric effector molecule present 
as well.  While PAH contains a crystallographically characterized ACT domain in each 
subunit, which comprises the majority of the regulatory domain, the currently available 
crystal structures do not show any interaction of the ACT domain subunits in the T-state 
of the enzyme (14).  It is possible that there are interactions of the ACT domain subunits 
when L-Phe is present, as a major conformational change must occur, but without further 
information about the location of the allosteric effector binding site and R-state crystal 
structures of PAH, it will be hard to determine this kind of interaction.  Additionally, the 
crystallographically characterized ACT domain enzymes demonstrate large distances (20-
30 Å) between the allosteric effector binding sites and the active sites of the enzyme.  
This requires some kind of intra-protein signaling or communication in order to regulate 
activity.  The flexible loop at residues 111-117, which is located on the edge of the ACT 
domain in PAH is about 20-25 Å from the iron center (14).  If this loop is in fact involved 
in the regulation of proteins, intra-protein signaling and communication at a distance 
would also be required in PAH.  The region around residues 111-117, does not appear to 
be directly in the ACT domain region of PAH, but instead is located on the interface of 
the catalytic and regulatory domains.  This orientation of the flexible in PAH, would not 
be consistent with the ACT domain binding sites that have been observed in other 
proteins containing ACT domains.  The known ACT domain organizations and function 
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should help to elucidate the structural reorganization occurring PAH upon allosteric 
activation. 
1.4 Prospective summary 
 The aim of this dissertation is to advance our understanding of the physical, 
thermodynamic, and kinetic processes involved in allosteric activation of PAH.  Three 
primary methods have been developed for understanding allostery in PAH.  First, detailed 
computational and experimental studies were employed to locate the allosteric effector-
binding site in PAH (Chapter 2).  This study used computational protein mapping and 
docking to elucidate possible binding pockets in PAH and study their potential 
specificity.  Site-directed mutagenesis and photo-chemical crosslinking studies were also 
conducted to determine the exact location of this allosteric effector binding site.  Second, 
thermodynamic studies were conducted to analyze the binding affinity of L-Phe for active 
and allosteric sites using surface acoustic wave biosensing (Chapter 3).  Finally, stopped 
flow fluorescence was used to understand the roles of reporter tryptophan residues in the 
overall fluorescence of PAH in order to determine a kinetic mechanism for allosteric 
activation (Chapters 4 and 5).  This model will provide the framework for understanding 
allostery in PAH and the role that allostery plays in the disease state PKU. 
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CHAPTER  2 
Determination of the location of the allosteric effector binding site in phenylalanine 
hydroxylase 
2.1 Background and perspective 
Phenylalanine hydroxylase (PAH, phenylalanine 4-monoxygenase, E.C. 
1.14.16.1) is a non-heme iron dependent monooxygenase which is involved in L-
Phenylalanine (L-Phe) homeostasis by efficiently catalyzing the hydroxylation of L-Phe 
to L-Tyrosine (L-Tyr) in the presence of reduced coenzyme tetrahydrobiopterin 
(H4biopterin, BH4) and dioxygen (49).  Decreased activity of PAH leads to a continuum 
of clinical disorders including phenylketonuria (PKU) and hyperphenylalaninemia 
(HPA).  Classic PKU is the most common clinically significant inherited disorder of 
amino acid metabolism (approximately 1 in 15,000 US births) (174) and is characterized 
by almost complete lack of PAH activity (< 5% wild-type).  This condition causes severe 
and progressive mental retardation due to the build-up of toxic L-Phe metabolites.   
Benign or transient HPA conditions can also result which have no clinical phenotypes 
and be distinguished by relatively minor decreases in enzyme activity (> 90% wild type) 
(175). 
 PAH exists as a homotetramer with each 52 kDa subunit containing a regulatory 
domain (residues 1-117), catalytic domain (contains iron center, residues 118-410), and a 
tetramerization domain (residues 411-452) (14, 49, 84).  The active site consists of a 
single ferrous iron atom coordinated by His285, His290 and Glu330 following a His-X5,6-
His-Xn-Glu/Asp motif reported for the Rieske centers but distinct from the -
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ketoglutarate (His-X1-Glu/Asp-Xn-His) or extradiol dioxygenase (His-X≈60-His-Xn-
Glu/Asp) consensus sequences (1, 2).  Current mechanistic proposals suggest that 
dioxygen reacts with the active site BH4 cofactor to generate a C4a-hydroperoxy-H4pterin 
that readily undergoes heterolytic O-O bond cleavage when bound to the Fe(II)
 
center 
leading to the generation of the reactive Fe(IV)=O species (60, 61).  Such a pathway is 
distinct from the mechanistic path exhibited by the Rieske center containing enzymes 
where O2 is proposed to bind directly to the Fe(II) center during its activation and 
conversion to an Fe(IV)=O species (1).   
The in vivo regulation of PAH is challenging owing to the relatively high intrinsic 
activity of the catalytically functioning form of the enzyme, the absence of vertebrate de 
novo synthetic pathways for L-Phe production, the thermodynamically irreversible nature 
of C-OH bond formation, and the strict maintenance of the L-Phe pool required for 
protein synthesis.  PAH activity is physiologically controlled  through tight regulation by 
both substrate (positive allosteric effector) and coenzyme (negative allosteric effector) 
interactions and through a glucagon-dependent phosphorylation pathway (79).   
The initial observation of a temperature-dependent lag time prior to observed 
enzymatic activity that could be eliminated by preincubation of PAH with L-Phe first 
suggested the occurrence of a requisite substrate-dependent allosteric activation process 
(176).  The cooperative structural and functional transformation (Hill coefficient of 2.4-
2.6) (63, 91) is characterized by a significant Arrhenius activation energy (> 33 kcal/mol) 
for the unphosphorylated enzyme (88).  The activation energy for the allosteric changes 
in PAH was determined using steady state kinetic analysis with traditional UV-vis 
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spectroscopy.  In these studies, data could not be collected until 10-15 seconds after the 
addition of substrate and coenzyme (88).  Kinetic and physical binding studies indicate 
that one L-Phe molecule binds in the allosteric site per PAH subunit.  L-Trp is a 
competitive inhibitor of L-Phe, but does not activate PAH at concentrations < 5 mM, 
suggesting the presence of distinct activation and catalytic binding sites (89).  Elegant 
studies involving 
14
C-labeled L-Phe demonstrated that substrate and allosteric effector 
binding sites existed in distinct locations and that L-Phe bound in the allosteric site does 
not turn over to product, suggesting the presence of non-overlapping activation and 
catalytic binding sites (see Section 1.3.1.3) (88).   
Based on these and other data, Shiman and coworkers consequently proposed that 
the enzyme has two binding orientations near the active site for the cofactor BH4, as well 
as two distinct binding sites for L-Phe, specifically the active site substrate binding 
location and the allosteric effector binding site.  In this mechanism, BH4 binds in an 
inactive orientation in T-state PAH prior to allosteric activation to the catalytically 
competent R-state form by L-Phe binding.  This conformational change is proposed to 
cause BH4 to reorient and adopt a position near the iron center that supports coupled 
cofactor/substrate oxidation (104, 119, 120).   
The structural changes that accompany allosteric activation induce global changes 
in the tetrameric form of PAH.  These structural changes include enhanced 
hydrophobicity, an 8 nm shift in tryptophan fluorescence maxima (124), and an apparent 
10% increase in the volume of the enzyme as determined by low angle X-ray scattering 
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(87) and gel filtration studies (91).  Release of L-Phe from the allosteric effector site 
returns the enzyme to the inactive T-state structure.     
 Phosphorylation of Ser16 in the autoregulatory domain of PAH appears to 
decrease the concentration of L-Phe required for enzyme activation (71).  Current 
theories suggest that phosphorylation does not directly regulate PAH activity; as such a 
process would rapidly deplete blood plasma levels of L-Phe in an uninhibited fashion. It 
is proposed that the glucagon-dependent phosphorylation of PAH occurs during enhanced 
intracellular protein degradation, allowing for greater L-Phe clearance than would occur 
with the unphosphorylated enzyme.  The current evidence shows that unphosphorylated 
and phosphorylated PAH are regulated by L-Phe activation under both in vivo and in vitro 
situations (79).  In Sections 1.3.1.1 and 1.3.1.4, regulation of PAH was further discussed 
including replacement of Ser16 with charged residues, activity of PAH as a dimeric 
enzyme, and alternative methods of activation for PAH.  One reason for the interest in 
regulation of PAH activity via phosphorylation comes from the unusually high activation 
energy for the unphosphorylated enzyme (>33 kcal/mol).  This issue will be addressed 
later in this dissertation (Chapters 4-5). 
Crystal structures of PAH have been solved for various truncated forms of the 
enzyme involving the catalytic domain, and the catalytic domain with either the 
regulatory domain (14) or tetramerization domain (84) (Section 1.2.2).  No crystal 
structures of the full-length mammalian enzyme are available nor are structures in the 
presence of the substrate L-Phe; resting state crystals are reported to degrade in quality 
when exposed to L-Phe (56-58).  Given these limitations, the location of the 
99 
 
 
 
fundamentally critical allosteric effector binding site remains undefined.  Recent NMR 
studies of the regulatory domain have been performed to study possible L-Phe binding 
sites in this domain.  These studies report non-specific L-Phe binding to the regulatory 
domain, but could not locate a specific L-Phe binding site in the regulatory domain (126). 
In this chapter, experimental evidence is provided for the location of the allosteric 
activation binding pocket in PAH using a combination of state-of-the art computational 
methods and molecular biological studies.  The locations of potential allosteric sites were 
identified by computational fragment-based methodologies in addition to sequence 
conservation studies.  Potential sites were ranked and experimentally probed through the 
use of binding assays, fluorescence measurements, and mutagenesis studies, resulting in 
experimental support of the computationally determined allosteric effector binding site.  
Corroborating evidence was then obtained through photo-induced crosslinking mass 
spectroscopy studies using 2-azido-3-phenylpropanoate (azido-L-Phe).  The location of 
the allosteric effector binding site in PAH and its subsequent implications in mechanistic 
studies for both the wild-type enzyme and PKU-inducing mutants will be discussed. 
2.2 Experimental section 
2.2.1 Materials 
 All commercial reagents were of the highest possible purity and used without 
further purification expect when noted.  Glycerol was purified through activated carbon 
to remove contamination according to reference (123).  Glycerol, L-Phe, D-Phe, 4-
morpholinepropanesulfonic acid (MOPS), catalase, dithiothreitol (DTT), 3(2-thienyl)-
DL-alanine (THA), L-Trp, L-Tyr were purchased from Sigma-Aldrich (St. Louis, MO). 
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Potassium chloride, tris(hydroxymethyl)aminomethane (Tris-Base), and iron standards 
for atomic absorption were purchased from Fisher Scientific (Pittsburgh, PA).  Yeast, 
tryptone, sodium chloride, monobasic and dibasic potassium phosphate were purchased 
from VWR (Radnor, PA).  2-Azido-3-phenylpropanoate (azido-L-Phe) was purchased 
from Chiralix, (Nijmegen, the Netherlands), p-methyl-L-Phe was purchased from Alfa 
Aesar (Ward Hill, MA), and cyclohexyl-L-alanine was purchased from Novabiochem 
(Darmstadt, Germany).  Total iron content was determined by atomic absorption using a 
Varian AA280 spectrometer with a Zeeman GTA120Z graphite furnace attachment at 
248.3 nm.  Automated protein purification was performed with a Pharmacia LKB FPLC 
system (Uppsala, Sweden). 
2.2.2 Computational protein mapping studies 
2.2.2.1 Protein mapping studies 
Mapping studies were performed by Raeanne Napoleon and Dima Kozakov as 
part of a collaboration with the Vajda lab in the department of Biomedical Engineering at 
Boston University.  Initial mapping was performed using the FTMap server 
(http://ftmap.bu.edu/) which uses a basic set of 16 molecular probes (Table 2.1), 
followed by a more detailed mapping using an expanded set of 93 probes (Figure 2.1).  
The FTMap algorithm has been described previously (177) and is comprised of four 
steps.  The first step is the rigid-body fragment docking to probe the protein surface.  The 
best 2,000 poses are then minimized and re-scored in the second step of the algorithm.  
The CHARMM potential with the Analytical Continuum Electrostatic model is used for 
minimization, where the atoms in the fragments are allowed to move while the protein 
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coordinates remain fixed.  The new conformations are then clustered and ranked to create 
probe clusters in the third step of the algorithm.  The probe positions from the extended 
mapping were clustered based on the position of functional groups. The coordinates of 
specific moieties (e.g., of the amide group) were extracted from the retained probe 
representatives, and these coordinates were then clustered using a radius of 3 Å.  The size 
of each cluster was normalized by the number of different types of probes that contained 
the specific moiety, thereby generating a score for each functional group.  This current 
application focused on the positions of the six-membered aromatic ring and amide 
moieties.  
Table 2.1 Set of 16 drug fragment probes used in initial mapping studies. 
 
Ethanol 
 
acetaldehyde 
 
dimethyl ether  
isobutanol 
 
 
 
 
 
Isopropanol 
 
acetamide 
 
acetone 
 
N,N-dimethylformamide 
 
Cyclohexane 
 
benzene 
 
phenol 
 
benzaldehyde 
 
Ethane 
 
acetonitrile 
 
methylamine 
 
urea 
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Figure 2.1 Set of 93 drug-like probes used in expanded mapping. 
 
2.2.2.2 Analysis of residue conservation 
Initial conservation studies used UniProt (178, 179) to first search for orthogonal 
sequences of PAH and then to perform multiple sequence alignments (MSA) in order to 
identify sequence similarities that may be a consequence of functional relationships. 
After the MSA was attained, the amino acid conservation scoring was done with the 
ConSurf 7 (180, 181) server and algorithm. ConSurf generates a conservation score for 
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each amino acid in a given PDB by comparing it to the residues at that position in the 
MSA.  If the residue is exactly present in each species or is mutated to a very similar 
amino acid, then the residue is ranked higher and is considered highly conserved.  
Conversely, if it is highly variable and does not match well throughout evolution, then it 
is considered not conserved.  
2.2.2.3 Ligand docking studies 
Auto Dock Vina 1.1.0 (182) and DOCK 6.3 (183) were used to predict placement 
of alternative allosteric activators within the PAH site. L-Phe and possible alternative 
activators were geometry optimized using Gaussian03 prior to docking.   All ligands were 
docked to the crystal structure 2PHM (14) using the standard settings of Auto Dock Vina, 
restricted to a box of the size of 9Å around the center of the binding site predicted by the 
mapping.  For each pose, each atom corresponding to a six-membered ring substructure 
was summed by the atomic density within 0.4Å of the atom within the benzene cluster, 
and separately each backbone atom was summed based on atomic density within 0.4Å of 
the atom within the amide cluster to give benzene and amide overlaps. 
2.2.3 Site-directed mutagenesis 
2.2.3.1 Vectors for enzyme expression 
The pKKPAH vector was used as described previously for protein over 
expression (91).  The QuikChange II Site-Directed Mutagenesis kit (Agilent) was used to 
replace Lys 113 with A, Q, or R, Lys 115 with A, Q, or R and Val 118 with A or T using 
the oligonucleotide primers shown in Table 2.2.  The new expression constructs were 
verified by automated DNA sequencing of the full PAH gene (Genewiz). 
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Table 2.2 Oligonucleotide primers used to create mutations in PAH. 
Mutation Oligonucleotide 
K113A 5’-CCCGAGACGCGGAAAAGAACACAGTGCCCTGG-3’ 
K113Q 5’-CCCGAGACCAGGAAAAGAACACAGTGCCCTGG-3’ 
K113R 5’-CCCGAGACAGGGAAAAGAACACAGTGCCCTGG-3’ 
K115A 5’-CCCGAGACAAGGAAGCGAACACAGTG-3’ 
K115Q 5’-CCCGAGACAAGGAACAGAACACAGTG-3’ 
K115R 5’-CCCGAGACAAGGAAAGGAACACAGTG-3’ 
V118A 5’-GAACACAGCGCCCTGGTTC-‘3 
V118T 5’-GAACACAACGCCCTGGTTC-‘3 
 
2.2.3.2 Bacterial cell growth and protein purification 
Recombinant wtPAH and mutant forms of PAH were over expressed in 
Escherichia coli BL21(DE3) cells that have been described previously (91, 110).  
Purification of wtPAH and mutants forms of PAH followed the previously described 
procedure using phenyl-sepharose affinity chromatography (GE Healthcare) followed by 
DEAE-cellulose anion-exchange chromatography (Sigma-Aldrich) (91, 123).  The 
purified enzyme was stored at -80°C in 50 mM MOPS/0.3 M KCl pH 7.2 until use. 
2.2.4 Studies on the mutant enzymes 
2.2.4.1 Phenyl-sepharose binding affinity assays 
Phenyl-sepharose fast flow affinity resin (GE Healthcare) was used for binding 
affinity assays, using the hydrophobic nature of the activated enzyme as reported by 
Shiman (123).  Enzyme was activated with 1-19 mM L-Phe at 25°C for 10 minutes.  The 
enzyme extract was applied to the phenyl-sepharose column pre-incubated with 1 bed 
volume of Buffer A (184 mM KCl, 30 mM Tris-Base, 1-19 mM L-Phe or alternative 
activator, depending on activation concentration, pH 7.2 at 4°C).  The column was then 
washed with 2 bed volumes of Buffer A with 5% N,N-dimethylformamide, 1 bed volume 
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of Buffer B (15% Glycerol, 30 mM Tris-Base, 1 mM L-Phe or alternative activator, 50 
µM EDTA pH 7.2 at 4°C), and 3 bed volumes of Buffer C (22.6% Glycerol, 45 mM Tris-
Base, 50 µM EDTA, pH 7.2 at 4°C).  The L-Phe induced hydrophobic change in the 
enzyme was determined by observing elution of PAH in particular fractions from the 
phenyl sepharose affinity resin using denaturing polyacrylamide gel electrophoresis and 
activity assays on each of the eluted fractions.  Unactivated PAH elutes in the void 
volume under these conditions while allosterically activated enzyme adheres to the 
column until eluted with buffer containing no L-Phe (123).  
2.2.4.2 Fluorescence studies 
Fluorescence spectra were obtained on a SpectraMaxM5 microplate reader 
(Molecular Devices) working in fluorescence emission mode or a Jobin Yvon 
FluoroMax3 spectrometer (Horiba) with an external temperature control.  Fluorescence 
emission spectra were recorded from 320-370 nm with an excitation wavelength of 293 
nm at 25°C in 0.1 M phosphate buffer, pH 6.8 with stirring during the assay.  Depending 
on sample intensity, spectra of samples of 50-1000 μg/ml protein were collected.  R-state 
enzyme samples were pre-incubated with 10 mM L-Phe for 5 minutes at 25°C, prior to 
recording spectra.   
2.2.4.3 Enzyme activity assays 
All kinetic assays were performed on an 8452 diode array spectrophotometer 
(Hewlett-Packard).  The total iron content of the enzymes was determined using an 
AA240Z atomic absorption spectrometer (Varian).  The catalytically competent fraction 
of the iron in the protein was measured through the quantification of the formation of a 
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catechol adduct as previously described (91).  Enzyme activity with 1 mM L-Phe was 
quantified using the standard PAH (Shiman) assay, where the production of L-Tyr from 
L-Phe was monitored at 275 nm for 60 seconds after pre-incubation with 1 mM L-Phe for 
3 minutes at 25°C, in the presence of 60 µM 6MPH4 and 6 mM DTT in 0.1 M phosphate 
buffer, pH 6.8, containing 3000 units/mL catalase (88).  Enzyme activity with the 
substrate analog p-methyl-L-Phe (Alfa-Aesar) was quantified using the same assay, 
where 1 mM p-methyl-L-Phe replaced the 1 mM L-Phe in the assay mixture and 
hydroxylated product formation was observed at 275 nm.  Assays using azido-L-Phe as 
an alternative activator were also monitored by product formation at 275 nm after pre-
incubation with 1 or 10 mM alternative activator for 3 minutes at 25°C, in the presence of 
60 µM 6MPH4 and 6 mM DTT in 0.1 M phosphate buffer, pH 6.8, containing 3000 
units/mL catalase, where 1 mM L-Phe or 1 mM p-methyl-L-Phe was added just before 
monitoring product formation.  Relative activity of the mutant enzymes was determined 
by the average activity of the mutant enzyme with 1 mM L-Phe in a standard activity 
assay, compared on a percentage scale to the average activity of a sample of wtPAH with 
1 mM L-Phe in a standard activity assay.  Kinetic parameters for some of the mutant 
enzymes were derived with a Hill fit equation in Origin 9.0: 
                 
  
     
   
In this equation, y is the initial velocity, and x is the concentration of L-Phe.  Vmax, k, and n 
are experimentally derived kinetic parameters, and Vi is the initial velocity at the lowest 
concentration tested.  
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2.2.5 Small molecule binding studies in putative allosteric effector binding site 
2.2.5.1 Phenyl-sepharose binding affinity assays 
 Binding assays were performed as discussed for the mutant enzymes (Section 
2.2.3.1), however, the enzyme was activated with alternative activator and buffers A and 
B were prepared with alternative activator at concentrations of 1-19 mM instead of L-
Phe. 
2.2.5.2 Fluorescence studies 
 Fluorescence studies were performed as discussed for the mutant enzymes 
(Section 2.2.3.2), however, the enzyme was activated with 10 mM of alternative activator 
instead of L-Phe. 
2.2.5.3 Enzyme activity assays 
Enzyme activity assays with 1 mM L-Phe were performed as discussed for the 
mutant enzymes (Section 2.2.3.3).  Enzyme activity with the substrate analog p-methyl-
L-Phe (Alfa-Aesar) was quantified using the same assay, where 1 mM p-methyl-L-Phe 
replaced the 1 mM L-Phe in the assay mixture and hydroxylated product formation was 
observed at 275 nm.  Assays using azido-L-Phe as an alternative activator were also 
monitored by product formation at 275 nm after pre-incubation with 1 or 10 mM 
alternative activator for 3 minutes at 25°C, in the presence of 60 µM  6-MPH4 and 6 mM 
DTT in 0.1 M phosphate buffer, pH 6.8, containing 3000 units/mL catalase, where 1 mM 
L-Phe or 1 mM p-methyl-L-Phe was added just before monitoring product formation.  
Relative activity of the alternative activators were all measured using the same wtPAH 
sample, where the average activity of the enzyme activated by 1 or 10 mM alternative 
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activator was calculated, using 1 mM L-Phe or 1 mM p-methyl-L-Phe as substrates.  The 
average activities with the alternative activators were compared on a percentage scale to 
the average activity of wtPAH with 1 mM L-Phe, as measured by the standard PAH 
activity assay.  
2.2.6 Photo-chemical crosslinking studies with 2-azido-3-phenylpropanoate 
2.2.6.1 Photo-chemical crosslinking studies 
Samples of wtPAH in 50 mM MOPS/0.3 M KCl, pH 7.2 at 4°C were buffer 
exchanged at least three times into 50 mM MOPS, pH 7.2 at 4°C using an Amicon Ultra 
30K centrifugal device (Millipore) to remove all KCl from the protein solution for mass 
spectrometry.  Photo-induced crosslinking samples were then incubated with 5 mM with 
azido-L-Phe (Chiralix) at 25°C for 10 minutes to activate the enzyme in the dark to 
prevent extraneous photo-crosslinking of the un-activated enzyme.  The samples were 
irradiated in a UV-photo chamber containing a UV-lamp with a Uranium filter to cut off 
light below 350 nm.  Samples were irradiated for either 1 minute or 30 minutes and then 
subject to proteolytic digestion with α-chymotrypsin (Sigma-Aldrich).  Approximately 1 
mg of both UV-irradiated and non-irradiated samples were treated with 3 mM DTT and 
two equivalents of 6-MPH4 per subunit at room temperature for 15 minutes to reduce the 
iron.  The samples were then treated with 6 mM iodoacetamide at room temperature for 
15 minutes to alkylate free cysteine residues prior to proteolytic digestion.  Samples were 
then digested with 1 mg of α-chymotrypsin at 37°C for 30 minutes.   
109 
 
 
 
2.2.6.2 Mass spectrometry 
Peptide fragments were analyzed at the Core Research Facility at the Ein-Karem 
Campus of the Hebrew University of Jerusalem on a LC/MS MicroMass QTOF-II 
instrument.   
2.3 Results 
2.3.1 Computational protein mapping studies 
2.3.1.1 Protein mapping studies and amino acid sequence conservation studies 
The FTMap protein mapping algorithm (177) has been shown to be an effective 
and robust method for computationally identifying the thermodynamically preferred 
regions on a protein surface that significantly contribute to the free energy of ligand 
binding.  We mapped the monomeric forms of PAH using a set of 16 small molecules as 
probes (Table 2.1), which are the standard small molecule probes used in the FTMap 
algorithm.  These mapping studies used T-state crystal structures, and enabled elucidation 
of the T-state allosteric effector binding site.  Since there are no crystal structures of the 
R-state enzyme, we cannot propose what, if any, alteration occurs to the binding site 
upon allosteric activation with L-Phe.  Whether these conformational changes occur 
within the individual subunits or within the entire tetramer cannot be determined without 
crystal structures of the R-state enzyme.   Initial studies utilized the x-ray structure of the 
dephosphorylated protein (PDB code 2PHM) that includes both the catalytic and 
regulatory domains (70).  Initial efforts found the most preferred binding sites occupying 
the active site cavity.  The interior positions on the catalytic domain active site surface 
were then blocked in a second round of studies to locate additional L-Phe binding sites 
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owing to biochemical data supporting non-overlapping active-site and allosteric effector 
binding sites (49, 104, 119, 120). 
Mapping efforts identified three consensus sites that bind large numbers of probe 
clusters. Site 1 is formed by residues 82 and 126-28, and binds 23 probe clusters; site 2 
includes residues 113-119, with 21 probe clusters; and site 3 of residues 38-40, 78-79, 
and 123 binds 19 probe clusters (Table 2.3, Figure 2.2a-b) (177).  The area around site 1 
is lined with polar and charged residues, with minimal hydrophobic residues.  The 
residues in close proximity to site 2 contain more hydrophobic residues including proline 
and valine residues.  This site also contains several charged residues that could be 
involved in stabilizing the zwitterionic backbone of the L-Phe.  Site 3 contains several 
non-polar residues (isoleucine and phenylalanine) as well as several charged residues.  
 
 
Table 2.3 FTMap derived thermodynamically preferred regions for small molecule 
binding sites. The unmasked sites were analyzed on the entire 2PHM crystal structure, 
while the masked sites were analyzed on the 2PHM crystal structure which blocked the 
active site. 
 
 CS Rank CS Size Residues 
Unmasked 
1 29 S23,S251,F254,Y325 
2 28 R270,T278,P281,H285,E330,G346,S349,S350 
3,4 15,15 V245,G247,L249,F254,H264,C265,T266,E286 
5 2 T22,S23,I25 
Masked 
1 23 Y82,Q126,E127,D129,R130 
2 21 I38,F39,S40,E78,F79,R123,V423 
3 19 K113,E114,T117,V118,P119,G312,P314,R408 
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The ConSurf server was then used to analyze the conservation of residues 
involved in these three sites as the true allosteric site is assumed to consist of amino acid 
residues that are highly conserved among all mammalian PAH sequences due to their 
reported requirement for allosteric control (180).  This sequence conservation method 
was used a preliminary screen for possible allosteric binding sites.  As shown in Figure 
2.3, apart from residues 127 and 128, relatively limited conservation was observed at the 
top site consisting of 23 probe clusters (residues 82 and 126-128).  The overall 
conservation is higher at the two other putative allosteric sites.  Initial efforts focused on 
the site lined by residues 113-119 (shown in Figures 2.2c-d, 2.3) due to the slightly 
greater number of probe clusters versus the third site (Table 2.3).  Additionally, a 
comparison to ACT domain protein binding sites (discussed in more detail in Section 
2.4.3), did not show any of the three binding sites overlapping with the previously 
determined binding site for many ACT domain proteins such as PGDH (67).  Subsequent 
experimental crosslinking data supported assignment of site 2 as the allosteric effector 
site, and hence the third site was not further studied (vide infra).  
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Figure 2.2 FTMap simulation for thermodynamically preferred binding sites in PAH. 
The mapping from the masking simulation where the 3 top ranked consensus sites are 
shown explicitly as sticks a) in tetrameric PAH, and b) the monomer of PAH containing 
only the catalytic and regulatory domains. The circled region is the proposed allosteric 
site in the vicinity of V118.  c) A close up view of the circled region from (b) with 
surrounding residues shown in sticks; V118 is shown in blue.  d) A second close up view 
of the same spot, where the protein is shown as a surface, sequence conservation in the 
binding site is shown by color gradient.  The most highly conserved residues are shown 
in magenta, the least conserved residues are shown in cyan. Figure was created in PyMol 
(23) from PDB files 2PHM (14) and 2PAH (84). 
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Figure 2.3 Multiple sequence alignment and conservation results for PAH.  Aligned 
sequences of PAH for residues comprising each hot-spot.  A conservation score of 1 
indicates that the residue is highly variable through evolution, 9 indicates a highly 
conserved residue. 
 
2.3.1.2 Extended mapping of PAH and ligand docking studies with L-Phe 
A combination of mapping and docking calculations was then used to better 
understand the most likely binding mode of the L-Phe. The putative allosteric site was 
mapped using an expanded probe set consisting of 93 fragments that included the 
functional moieties that most frequently occur in drugs (Figure 2.1) (184). The extended 
mapping and clustering of the functional groups across different probes enable the 
identification of potential sub-sites located within the hydrophobic pocket with 
preference for binding aromatic ring, protonated amine, and carboxylate moieties, i.e., the 
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groups corresponding to the side chain and peptide backbone portions of L-Phe, 
respectively.  The concept behind this computational approach is to independently 
determine the actual binding sites of each functional group, so as to not bias the routine 
for one particular molecule, as would be expected if L-Phe were directly used as a probe.  
The observed clusters of these functional groups were then used to calculate the densities 
of the specific atoms involved, where the atomic densities served as the guide for 
selecting the most likely binding modes/orientations of L-Phe and related molecules. This 
routine was performed in collaboration with Raeanne Napoleon and Dima Kozakov of 
the Vajda lab.  
Simultaneously with the mapping studies of PAH, L-Phe was docked to the 
proposed allosteric effector binding site using Autodock Vina 1.1.0 (182) and DOCK 6.3 
(183).  The identified site contains a highly hydrophobic pocket that anchors the benzene 
ring, and is bracketed by several polar residues capable of forming hydrogen bonds with 
the zwitterionic protonated cationic amine and anionic carboxylate groups of L-Phe.  Due 
to the large and partially exposed pocket (113-118) with several hydrogen bond donors 
and acceptors (Lys113, Glu114, Lys115), docking to the site yields a number of potential 
orientations with very similar energies, meaning that the energy function does not 
provide sufficient information for selecting the most likely pose.  Potential poses for L-
Phe in the allosteric binding site are shown in Figure 2.4. The results of both methods 
were plotted and AutoDock Vina results were further characterized.  The nine lowest 
energy poses for both ligands were retained, which were then used to calculate the degree 
of overlap with the density of the corresponding atoms obtained in the mapping result 
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(Table 2.4).  These overlaps were then normalized based on the maximum benzene and 
amide overlap scores.  Poses that had normalized overlaps in excess of 0.5 for both 
benzene and amide clusters were considered to be good poses within the site; the pose 
with the best overlap is shown in bold.  Pose 6 of L-Phe shows both groups overlapping 
perfectly with clusters of the corresponding functional groups (Figure 2.5).  
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Figure 2.4 Poses of L-Phe docking into putative allosteric effector binding site with 
AutoDock Vina 1.1.0 (182). Figure was created in PyMol (23) using PDB file 2PHM 
(14). 
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Table 2.4 Overlap scores for each pose for selected docked ligands with benzene and 
amide subclusters. 
Ligand (Pose) 
Normalized 
Benzene Overlap 
Normalized 
Amide Overlap 
phe_1 0.00 0.00 
phe_2 0.00 0.00 
phe_3 0.88 0.02 
phe_4 0.38 0.83 
phe_5 0.00 0.00 
phe_6 0.99 0.74 
phe_7 0.95 0.00 
phe_8 0.23 0.00 
phe_9 0.99 0.30 
azido-L-Phe (1) 0.99 0.98 
azido_phe_2 0.00 0.00 
azido_phe_3 0.02 0.00 
azido_phe_4 0.00 0.00 
azido_phe_5 0.00 0.00 
azido_phe_6 0.00 0.00 
azido_phe_7 0.78 0.30 
azido_phe_8 0.07 0.00 
azido_phe_9 0.80 0.46 
 
 
 
Figure 2.5 Computationally determined orientation of L-Phe in the putative allosteric 
effector binding site. Orientation determined from extended mapping routine shown in 
mesh, while the orientation determined from Pose 6 of AutoDock Vina is shown in sticks. 
Figure was created in PyMol (23) from PDB file 2PHM (14). 
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2.3.1.3 Ligand docking studies with alternative allosteric activators 
The same docking routines (AutoDock Vina and Dock 6.3) were then used to 
dock other small molecules in the allosteric effector binding site to gain insight of the 
shape and specificity of this binding pocket for other molecules (Figure 2.6).  These 
studies demonstrated that while L-Trp, p-methyl-L-Phe, THA, azido-L-Phe, and L-Phe 
based derivatives containing non-polar substituents on the aromatic ring  (Figure 2.6a-d) 
each bind in slightly different orientations versus what was observed for L-Phe, each 
demonstrates good overall alignment with the orientation of L-Phe.  Additionally, these 
studies show that polar para-substituents are not tolerated within the binding pocket, as 
neither p-fluoro-L-Phe nor L-Tyr (Figure 2.6e-f) show any good poses.  Good poses, 
with good overall alignment, were defined as orientations where both the aromatic ring 
and backbone align well with the extended mapping alignment of L-Phe.  The overlap 
scores for the nine lowest energy poses with AutoDock Vina were calculated for azido-L-
Phe (Table 2.4) as this molecule was also used as photo-crosslinking reagent that is 
discussed in Section 2.3.5. The computationally selected pose shows that the benzene 
ring is fully aligned with that of L-Phe, and the azido group is free to react with the 
surrounding protein molecule (Figure 2.6d) 
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Figure 2.6 Alternative activators docked in allosteric effector binding site.  Orientation of 
L-Phe from extended mapping in shown in green mesh, docked orientation from 
AutoDock Vina is shown in sticks. Figure was created in PyMol (23) from PDB file 
2PHM (14). (a) L-Trp; (b) p-methyl-L-Phe; (c) THA; (d) azido-L-Phe; (e) p-fluoro-L-
Phe; (f) L-Tyr. 
 
2.3.2 Site-directed mutagenesis 
The potential allosteric site bordered by residues 113-119 was further probed 
using site-directed mutagenesis methods. The target residues of interest were selected on 
the basis of mapping and docking results.  These simulations suggested that Lys113 is 
directly involved in hydrogen bonding interactions with both the amine and carboxylic 
acid groups of L-Phe bound at the allosteric site, while Lys115 forms hydrogen bonding 
interactions specifically with the amine group of the bound L-Phe. The hydrophobic floor 
of the putative allosteric site consists of Val118, Pro119, Ala313, Pro314, Pro407, and 
Pro409, forming a network of hydrophobic residues on the inner most side of the ring.  
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Residues Ala313, Pro314, Pro407, and Pro409 are reasonably well conserved binding 
sites in crystal structures containing only the regulatory domain (PDB files 1J8U (58) and 
1MMK (56)), with relatively low β-factors, however, Val118 and Pro119 are in a very 
flexible loop with much higher β-factors, which are similar in both the phosphorylated 
and dephosphorylated structures of  PAH containing the regulatory domain (PDB files 
1PHZ and 2PHM (14)).  A series of site-specific mutants was therefore selected to 
rationally alter the relative size, polarity, and hydrogen bonding capabilities of the 
residues lining this site (Figure 2.7). 
 
121 
 
 
 
 
Figure 2.7 Mutations modeled in potential allosteric site.  The mutations to the pocket 
are shown in orange while L-Phe is shown in green.  Figure was created in PyMol (23) 
using PDB file 2PHM (14). (a) K113A; (b) K113Q; (c) K113R; (d) K115A; (e) K115Q; 
(f) K115R; (g) V118A; (h) V118T. 
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 Mutations of Lys113 were selected, as this residue appeared to have the strongest 
role in hydrogen bonding to the backbone of the allosteric L-Phe residue from the 
extended mapping and protein docking studies (vide supra).  Mutating Lys113 to alanine 
was expected to weaken the interactions holding L-Phe into the allosteric effector binding 
site, without blocking or interfering with the binding pocket.  Changing Lys113 to a 
glutamine or an arginine residue was expected to not only weaken the interactions 
responsible for holding L-Phe in place, but also to physically block access to the 
allosteric effector binding site owing to the increased Van der Waals volumes of these 
larger residues (Figure 2.8).  The effects of charge alterations on the bulky residue could 
be studied by the differences in the Lys to Arg mutants versus the Lys to Gln mutants.  
 
 
 
 
Figure 2.8 Modeled clash of residues in K113R mutant of PAH, as predicted by 
mutagenesis tool in PyMol (23).  Figure was created using PDB file 2PHM (14). 
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 The proposed mutations at the Lys115 site were similar in effects to Lys113, as 
Lys115 is also proposed to be involved in hydrogen bonding interactions to the charged 
amino and carboxyl moieties of L-Phe.  Mutating this residue to an alanine should reduce 
the hydrogen bonding interactions without destroying the binding site or blocking L-Phe 
access to the binding site.  The mutations of Lys115 to glutamine or arginine were 
proposed to block access to the allosteric site as well as alter the electrostatic properties 
of the binding site.  Lys115 is more surface-exposed than Lys113, which made the 
prediction of the orientation of the mutated residues more challenging.  Lys115 could 
bend toward the backbone of the L-Phe in the allosteric site or point away from the 
protein surface.  If Lys115 bends away from the protein surface, the effects of 
mutagenesis of Lys115 were expected to be less severe than if Lys115 bends toward the 
allosteric site.  Hydrogen bonding and salt-bridge interactions between either Lys113 or 
Lys115 with Asp315 were also predicted (Figure 2.9).  Interfering with either of these 
residues may block the hydrogen-bonding network near the allosteric site and prevent L-
Phe binding.   
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Figure 2.9 Interactions of K113 and K115 in the allosteric effector binding site to the 
docked allosteric L-Phe molecule and D315.  Alteration of K113 likely interferes with 
hydrogen bonding to D315 or L-Phe.  K115 may also participate in these interactions, but 
in the crystal structure is not shown to be close enough to participate in these interactions.  
Figure was created in PyMol (23) with PDB file 2PHM (14). 
 
 
 In addition, we looked at possible mutations to the hydrophobic surface of the 
allosteric site.  The hydrophobic floor of the target site is comprised of four proline 
residues on three independent peptide strands that surround the allosteric site as well as a 
Val118 and Ala313.  We did not want to alter the proline residues in the binding pocket 
as altering proline residues is likely to cause global structural changes and affect protein 
folding (Figure 2.10).  Instead, we chose to study Val118, which was thought to provide 
hydrophobicity and the appropriate space for a phenyl group.  It was predicted that 
mutating this residue to an alanine would have minimal effects of on the allosteric site, as 
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it would not interfere with the L-Phe binding pocket.  Additionally, mutations of Val118 
to threonine were also proposed.  This mutation was expected to alter allostery by adding 
a polar substituent of about the same size to the binding pocket.  Given the hydrophobic 
nature of the floor of this pocket, it was expected that any polar residues would inhibit L-
Phe binding in the allosteric site.  
 
 
Figure 2.10 Stacking of proline and phenylalanine residues forming the hydrophobic 
floor of the allosteric binding site near V118.  Figure was created in PyMol (23) with 
PDB file 2PHM (14). 
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2.3.3 Studies on the mutant enzymes 
Several types of assays were employed to study the changes that occur in wild-
type PAH upon allosteric activation.  The allosteric activation process facilitates a 
conformational change in the tetrameric structure of unphosphorylated PAH, leading to 
enhanced hydrophobicity as well as tightly supporting coupled BH4-dependent substrate 
turnover(49).  Additionally, there is an ~8 nm shift in the fluorescence maxima of the 
enzyme upon the conversion the T-state to R-state as well as a regulation of enzyme 
activity (91, 124).  Utilization of these known biophysical properties was employed to 
characterize the activation state of the mutant enzymes and investigation of the shape and 
specificity of the allosteric effector binding site.  These assays together will give 
information regarding the affinity of L-Phe for these enzymes, the physical changes that 
occur in the enzymes upon activation with L-Phe, and ability of these enzymes to perform 
catalysis at standard conditions of 1 mM L-Phe.  
2.3.3.1 Phenyl-sepharose binding affinity assays 
Phenyl-sepharose affinity resin can be used to qualitatively measure the L-Phe 
induced hydrophobicity change that accompanies activation of wild-type enzyme and 
selected PAH mechanistic mutants (49, 123).  Wild-type PAH binds tightly to this resin 
at low L-Phe concentration (1 mM) and it is expected that introduction of alanine 
mutations, which do not block the allosteric effector binding site (K113A, K115A, and 
V118A) would also do so under equivalent experimental conditions.  Replacing any of 
the residues involved in hydrogen bonding to L-Phe with a larger residue or altering the 
hydrophobic floor of the allosteric binding pocket with a more polar residue should serve 
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to inhibit the protein conformational change associated with L-Phe binding at low 
concentrations of effector but might still support the saturation of the weakened effector 
site at significantly higher L-Phe concentrations (K113Q, K113R, K115Q, K115R, and 
V118T).  Experimental results from the phenyl-sepharose binding assay indicated that the 
typical low concentration threshold of 1 mM L-Phe is sufficient to induce the 
conformational change for all examined alanine mutations.  The arginine, glutamine, and 
threonine mutations, however, only underwent the L-Phe induced hydrophobicity change 
at a significantly higher concentration (19 mM) (Table 2.5).  These data are consistent 
with the interpretation that the larger substituents in the K113Q/R and K115Q/R mutants 
negatively alter the hydrogen bonding network between the protein backbone of the 
allosteric site and the L-Phe effector, thereby reducing the site’s affinity for L-Phe 
(Figure 2.9).  Different docking orientations of L-Phe (Figure 2.4), showed multiple 
possible orientations for the ring and backbone of L-Phe in the allosteric site, therefore, 
some liberties were taken in assigning possible interactions between the putative 
allosteric site and L-Phe.   
These binding studies also suggest that the polarity of the hydroxyl substituent on 
V118T interferes with ring stacking interactions of nearby phenylalanine and proline 
residues and the aromatic ring of the L-Phe effector molecule, serving to decrease the 
overall affinity of L-Phe for the modified allosteric sites (Figure 2.10).  It is interesting to 
note, however, that all mutants examined demonstrate L-Phe induced change in 
conformation and hydrophobicity at high concentration (19 mM).  The hydrophobic floor 
residues serve to provide a binding site for the phenyl ring of L-Phe that is supported by 
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the nearby residues.  The surrounding ring of residues in the 113-117 loop provide the 
needed hydrogen bonding interactions to stabilize the backbone of L-Phe in the allosteric 
site and anchor L-Phe to the binding pocket. 
 
Table 2.5 Summary of assay results for allosteric PAH mutants and comparison to 
wtPAH. 
 wt K113A K113Q K113R K115A K115Q K115R V118A V118T 
Phe-
Seph 
Binding 
Assay 
1 
mM  
+ + - - + - - + - 
19 
mM 
+ + + + + + + + + 
Fluorescence 
Shift 
7.6 
nm 
2.1 nm 1.8 nm 0.5 nm 3.9 nm 0.6 nm 0.8 nm 0.6 nm 0.6 nm 
Relative 
Activity 
100
% 
8.9% 4.0% 1.4% 17% 16% 4.4% 13% 2.4% 
 
 
2.3.3.2 Fluorescence studies 
The structural rearrangement that occurs as a consequence of the T  R allosteric 
activation of wild-type PAH induces a shift in the fluorescence maxima (337 nm  345 
nm) of the set of three Trp residues (W120/187/326) due to their enhanced solvent 
accessibility in the R-state (91, 124).  This characteristic fluorescence signature is 
frequently used as an indicator of the requisite catalytic site structural changes required to 
support substrate turnover.  Each effector site mutant was therefore independently 
examined to probe the correlation between L-Phe induced (10 mM) fluorescence maxima 
shifts with both hydrophobic column binding (global structural change) and catalytic 
activity (local active site structural rearrangements).  
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All examined PAH mutants showed significantly reduced fluorescence maxima 
shifts in the presence of 10 mM L-Phe (Table 2.5, Figure 2.11).  This phenomena is due 
to the reporting effects of the L-Trp residues that will be discussed in more detail in 
Chapter 4.  The shift in fluorescence maxima of the mutant enzymes was compared to 
the negative control, D-Phe with wtPAH, which shows no appreciable shift in the 
fluorescence maxima (Table 2.7, Figure 2.13).  Trp120 is the closest L-Trp residue to the 
allosteric effector site. Previous investigations indicated that Trp120 was the most solvent 
exposed L-Trp residue in PAH and that it is responsible for approximately 61% of the 
overall fluorescence signal intensity associated with allosteric activation (124).  
Fluorescence studies with the allosteric site mutant enzymes demonstrate (vide infra) that 
the mutants with the greatest catalytic activity (K113A, K115A/Q) also show the greatest 
shifts in fluorescence (2-4 nm).  The K115A mutant demonstrates about 52% of the 
fluorescence shift of the wild-type enzyme, as it is likely that this residue does not 
directly interact with L-Phe.  Both K113A and K115Q mutants demonstrate fluorescence 
shifts that are approximately 20-30% of what is observed with the wild-type enzyme, 
suggesting that the less structurally intrusive mutations still reflect some linkage to the 
active site reorganization that occurs upon successful enzyme activation.  The more 
sterically bulky and projected deleterious mutations appear to completely eliminate the T 
 R shift in max by either blocking L-Phe binding to the allosteric effector site due to 
increased steric volume, changes in site polarity and/or local structural reorganization that 
weakens the affinity of the site.  The polarity of the allosteric site pocket is highly tuned 
to prevent product (L-Tyr) binding and therefore cannot be activated when a polar 
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substituent is added to the binding pocket.  Fluorescence titrations studies in Chapter 4 
will inform a better understanding of this decrease in overall fluorescence shift with the 
allosteric mutant enzymes. 
 
Figure 2.11 Relative fluorescence shifts of the allosteric mutants upon incubation with 
10 mM L-Phe. 
 
2.3.3.3 Enzyme activity assays 
The active site structural reorganization that accompanies the L-Phe induced 
allosteric activation process is required for full enzymatic activity.  The steady-state 
activity of each of the mutant enzymes was tested after incubation with 1 mM L-Phe, and 
therefore the observed differences in activity among these enzymes could reflect either (i) 
a fully active enzyme that requires > 1 mM L-Phe to achieve activation, (ii) an 
impairment in the ability of the enzyme to be activated (i.e. at any L-Phe concentration), 
(iii) indirect inhibition of the active site catalytic pathway itself, or (iv) a combination of 
each of these effects.  The relative activity of each of the allosteric mutant enzymes is 
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decreased relative to the wild-type enzyme (Table 2.5).  The K113Q/R mutations are of 
particular interest, as they drastically reduced enzyme activity (4.0% and 1.4% of wtPAH 
activity respectively) demonstrates the importance of K113 in either anchoring L-Phe in 
the allosteric site or maintaining the proper binding site pocket geometry.  The V118T 
mutation also has a substantial impact on activity (2.4% of wtPAH activity), suggesting 
that the polar hydroxyl substituent of the threonine side-chain possibly is not tolerated at 
this site as it may inhibit the highly hydrophobic L-Phe ring from anchoring against the 
allosteric site.  This low activity result suggests that introduction of a polar substituent 
into this pocket interferes with the ability of the aromatic ring to position itself in the 
binding pocket, causing an inhibitory shift in the L-Phe orientation.   
Full kinetic studies were undertaken with three of these mutant enzymes, K113R-
PAH, K115A-PAH, and V118A-PAH, as these mutant enzymes demonstrate the 
extremes of the changes to the L-Phe binding pocket.  K113R-PAH is proposed to 
interfere with hydrogen bonding interactions to the amino and carboxyl groups of L-Phe 
and blocks access to the allosteric site, V118A-PAH probes the importance of 
hydrophobicity the hydrophobic pocket, and K115A-PAH may play a very small role in 
the hydrogen bonding network anchoring L-Phe to the allosteric site.  The kinetic 
parameters of these enzymes are listed in Table 2.6 and the Michaelis-Menten kinetic 
plots are shown in Figure 2.12.  These mutant enzymes all display a significant reduction 
of enzymatic activity that is characteristic of many mutations made to PAH.  The rates of 
turnover (kcat) for all the mutant enzymes are approximately similar and are nearly five 
times lower than that observed for wild-type enzyme.  The experimentally determined 
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Hill coefficients for the mutant enzyme were all between 0.53-0.63, suggesting negative 
cooperativity with L-Phe.  This negative cooperativity may suggest that L-Phe binding in 
the allosteric site occurs very weakly, as these mutations block the binding site and/or 
that intra-protein communication of allostery is altered by the changes in the allosteric 
site.  However, the values of the Hill coefficients may likely be artifacts of the fitting 
parameters, as the enzymes are most likely affected by the loss of cooperativity, not 
actual negative cooperativity. 
 
Table 2.6 Kinetic parameters of allosteric mutant enzymes. Uncertainty was derived 
from kinetic fits to the data using a Hill equation in Origin 9.0. 
 
Enzyme KM, L-Phe (μM) Vmax (units/mg) kcat (s
-1
) Hill Coefficient 
wtPAH 180 ± 10 7.8 ± 1.0 6.8 ± 0.9 2.4-2.6 
K113R-PAH 130 ± 50 1.4 ± 0.2 1.2 ± 0.1 0.63 ± 0.25 
K115A-PAH 570 ± 130 1.5 ± 0.6 1.3 ± 0.5 0.53 ± 0.15 
V118A-PAH 60 ± 10 1.2 ± 0.1 1.0 ± 0.1 0.57 ± 0.23 
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Figure 2.12 L-Phe dependent kinetics of selected allosteric mutant enzymes.  Fits were 
determined in Origin 9.0 with a Hill equation, as described in the Experimental Methods. 
Black, K115A-PAH; Red, K113R-PAH; Blue, V118A-PAH. The data for wtPAH, also 
fit to a Hill equation in Origin 9.0, are shown in an inset for comparison.  Data are 
representative of five independent replicates. 
 
 
 The allosteric site mutant PAH enzymes all demonstrate significant perturbation 
of the activation processes.  The assays used to analyze the mutant enzymes report 
separate processes, however, when analyzed together, they help to understand the extent 
of cooperativity and activation in these enzymes.  The alanine mutations (K113A, 
K115A, and V118A), which do not block the allosteric effector site, all demonstrate 
approximately 10-20% of wtPAH activity, fluorescence shifts of 2-3 nm, as well as 
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hydrophobicity changes at low concentrations of L-Phe.  The mutant PAH enzymes 
containing these alanine substitutions appear closest to duplicating wild type kinetic and 
activation properties.  The K113Q and K115Q mutants show intermediate levels of 
perturbation to the enzyme, as they still show 2-3 nm fluorescence shifts and appreciable 
activity, but do not show fluorescence changes at low concentrations of L-Phe.  The most 
deleterious mutations, which block access of L-Phe to the allosteric site (K113R, K115R, 
and V118T), all do not show hydrophobicity changes at low concentration, only 
demonstrate 0-1 nm shifts in their fluorescence maxima, and have very low activity with 
1 mM L-Phe.  The activity and binding assay results of the mutant enzymes correlate 
quite well, wherein mutations to alanine result in the greatest residual activity and 
hydrophobicity changes at low concentration.  The fluorescence shift data appears more 
complicated and indicates that fluorescence shifts decrease drastically upon any 
perturbation to this site, but cannot be explained well by these data.  Fluorescence shifts 
in PAH, particularly the roles of each Trp residue in reporting the fluorescence shifts will 
be discussed in more detail in Chapter 4. 
2.3.4 Small molecule studies in putative allosteric effector binding site 
 The ligands analyzed in the ligand docking studies in section 2.3.1.3, were also 
studied as possible alternative activators for PAH.  These molecules were studied by the 
same general methods as the mutant enzymes, which enabled analysis of the effects on 
allosteric activation by these small molecules within the wild-type enzyme.  
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2.3.4.1 Phenyl-sepharose binding affinity assays 
Structural analogs to L-Phe were examined using binding assay with phenyl-
sepharose affinity resin.  The structural analogs were the small molecules that had 
previously been docked into the allosteric binding (Section 2.3.1.3) and it was hoped that 
these assays would give more insight to the docking information.  Previous studies by 
Kaufman and co-workers showed that D-Phe, L-Trp, and THA were as effective as L-Phe 
at activating the enzyme when present at high concentrations (28 mM).  These studies 
demonstrated that L-Phe incubation stimulates PAH by 25 fold, while D-Phe, L-Trp, and 
THA incubation all stimulate PAH by similar amounts (27, 22, and 33 fold respectively, 
actual or relative activity values were not provided in the prior report) (89).  Our activity 
data for the alternative activators is reported by comparison to the activity of wtPAH 
activated with 1 mM L-Phe, which is our standard assay condition.  The concentration of 
each activator and substrate used in the assays are provided in Table 2.7.  The data 
presented in Table 2.7 agree with Kaufman et al. regarding THA activation that is 
comparable to that exhibited by L-Phe at low concentration (1 mM).  However, additional 
experiments demonstrate that L-Trp can only induce hydrophobic changes at slightly 
higher concentration (5 mM) and D-Phe only induces hydrophobic changes in the enzyme 
at very high concentration (19 mM).  Further studies using other potential alternative 
activators, azido-L-Phe and p-methyl-L-Phe demonstrate that these small molecules also 
induce hydrophobic changes in the enzyme at low concentration (1 mM); however, p-
fluoro-L-Phe and L-Tyr do not induce these changes at any concentration tested (1-19 
mM).   
136 
 
 
 
These results suggest that the pocket is designed to accept only small, non-polar 
single-ring aromatic amino acid structures that utilize the C substituents in hydrogen 
bond interactions with nearby residues.  Consequently, individual activators with a lower 
affinity for the allosteric site may still serve to fully activate the enzyme.  THA is likely 
to fully activate the enzyme with a lower affinity and serves as an alternative activator 
owing to its small aromatic ring and its analogous L-amino acid functionality.  In the case 
of L-Trp, the necessity of increasing L-Trp concentration to observe activation suggests 
that the larger polyaromatic ring structure is not as well tolerated in the pocket due to 
steric constraints despite having the analogous amino acid functionality and 
hydrophobicity as L-Phe.  It is less likely that L-Trp can completely activate the enzyme 
due to its larger size.  These studies also demonstrate that D-amino acids are not well 
tolerated in the pocket owing to the fact that D-amino acid binding reverse the orientation 
of the ring or the orientation of the protonated amine and carboxylate groups which 
anchor the positioning of the effector molecule in the site.  It is therefore not expected 
that D-Phe will activate the enzyme to any appreciable extent. 
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Table 2.7 Summary of results of phenyl-sepharose binding assays, fluorescence assays 
and relative activity of wtPAH with alternative activators compared to the effect of L-
Phe.  Relative activity of wtPAH assays were conducted with both L-Phe and p-methyl-
L-Phe as substrates. Nd, Not determined.  
 L-Phe D-Phe L-Tyr L-Trp  p-
fluoro-
L-Phe 
p-
methyl-
L-Phe  
THA  azido-
L-Phe 
Cyclohexyl-
L-ala 
Phe-
Seph 
Binding 
Assay 
1 mM + - - - - + + + Nd 
5 mM + - - + - + + + Nd 
19 
mM 
+ + - + - + + + Nd 
Fluorescence 
Shift 
7.6 
nm 
0.7 nm Nd Nd Nd 11.5 
nm 
11.0 
nm 
8.2 
nm 
1.9 nm 
Concentration of 
Alternative 
Activator Used in 
Activity Assays 
1 mM 10 mM 10 
mM 
Nd Nd 1 mM  10 
mM 
10 
mM 
Nd 
Activity — 
1 mM L-Phe 
Substrate 
100% 15%* 0% Nd Nd 71% 56% 26% Nd 
Activity — 1 mM 
p-methyl-L-Phe 
Substrate 
107% 14%* 0% Nd Nd 26% 73% 10% Nd 
*Assays with D-Phe used 1 mM L-Phe or 1 mM p-methyl-L-Phe as substrates that have also been shown to 
activate the enzyme independently.  The low level of activity observed in these assays is residual activity 
from the substrate itself activating the enzyme. 
 
2.3.4.2 Fluorescence studies 
The capability of alternative allosteric activators to induce the global 
conformational change in wtPAH as indicated by the observation of the 8-10 nm shift in 
the fluorescence maxima is shown in Table 2.7 and Figures 2.13 and 2.14 (91, 124).  As 
expected, D-Phe is unable to effectively activate the enzyme in the same manner as L-Phe 
and induces no appreciable shift in the fluorescence maxima, agreeing with results from 
the hydrophobic column binding studies that demonstrate the strict requirement of L-
amino acid activators.  These results demonstrate that THA, p-methyl-L-Phe, and azido-
L-Phe all induce a significant (7-10 nm) fluorescence shift, similar to that observed for 
the L-Phe activation process, and consistent with the hydrophobic column binding assay 
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data.  Additionally, the 7-10 nm shift in the fluorescence maxima with THA, p-methyl-L-
Phe, and azido-L-Phe suggests that these activators maintain the local structure around 
Trp120 as observed with the allosteric mutants discussed previously and are in fact linked 
to the catalytic site structural changes required for enzyme activity. 
 
 
Figure 2.13 Fluorescence shifts of 50 μg/mL wtPAH with and without 10 mM alternative 
allosteric activators.  The presence of alternative activators is indicated by the R-state 
(red), while the absence of alternative activator is indicated by the T-state (blue). (a) L-
Phe; (b) D-Phe; (c) p-methyl-L-Phe; (d) THA; (e) azido-L-Phe 
 
d e 
b c a 
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Figure 2.14 Relative fluorescence shifts of 50 μg/mL wtPAH with 10 mM alternative 
activators. 
 
2.3.4.3 Enzyme activity assays 
Correlating the conformational effects of activating PAH using potential 
alternative activators with the catalytic site reorganization was conducted using enzyme 
activity.  Alternative allosteric activators were used in place of L-Phe, with p-methyl-L-
Phe added as a substrate to observe the hydroxylation reaction.   Siegmund and Kaufman 
had previously reported that p-methyl-L-Phe hydroxylation results in multiple products 
(4-hydroxymethyl-L-Phe and 3-methyl-L-Tyr) that can be observed spectroscopically 
(96).   The relative activity of wtPAH with 1 mM L-Phe as both substrate and activator 
was considered 100% activity (Table 2.7).  The alternative activator THA showed the 
greatest activity compared to the other alternative activators, in agreement with the 
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binding assay and fluorescence data suggesting that THA is fully capable of activating 
PAH at 10 mM (1 mM for L-Phe).  Note that when L-Phe was used a substrate and p-
methyl-L-Phe was used as an activator, slightly higher levels of activity were observed 
then when L-Phe was used alone.  Interestingly, somewhat higher levels of activity were 
observed when the enzyme was activated with 1 mM p-methyl-L-Phe and 1 mM L-Phe 
was used as a substrate then when p-methyl-L-Phe was used as both substrate and 
activator.  These activity assay results demonstrated an unexpected activating role for p-
methyl-L-Phe at 1 mM, and is consistent with the results observed from the hydrophobic 
column binding assays and fluorescence studies.  It is also noteworthy that azido-L-Phe 
supported appreciable catalytic activity with either substrate, induced the fluorescence 
maxima shift, and bound to the hydrophobic affinity column, demonstrating that this C 
substituted molecule binds in the effector site and activates PAH.  It was expected from 
binding assay and fluorescence studies that D-Phe would not activate PAH, and our 
assays show very low levels of activity that are likely from activation by the substrate.  L-
Tyr also does not show activity with either substrate as it is speculated that the presence 
of the catalytic product should inhibit allosteric activation.  Other non-polar substituents 
such as L-norleucine and L-methionine have also been reported to activate the enzyme at 
extremely high concentrations (28 mM) (89), and although those substituents were not 
tested, their non-polar nature of their side chains suggests that they could fit in the site 
and bind, but likely have very low affinity, since they are not structurally analogous to L-
Phe. 
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Our studies with possible alternative activators for PAH show two limiting groups 
of possible molecules that will or will not activate the enzyme.  The group of possible 
activating molecules (either partially or fully) include THA, p-methyl-L-Phe, and azido-
L-Phe.  There is also a group of small molecules that have been shown to be unable to 
activate the enzyme at any concentration.  These small molecules include L-Tyr, p-
fluoro-L-Phe, and D-Phe.  There are several other small molecules that do not appear to 
cause substantial activation of the enzyme, but may be able to partially activate the 
enzyme at high concentrations.  These molecules include L-Trp and cyclohexyl-L-Ala.  
Further assays need to be completed with cyclohexyl-L-Ala to determine whether it will 
activate the enzyme, but it seems unlikely given the initial fluorescence studies and its 
lack of an aromatic ring. In the case of L-Trp, it appears that there is too much steric bulk, 
which inhibits L-Trp from obtaining full occupancy of the allosteric site, therefore 
leading to lower levels of activation with L-Trp. 
2.3.5 Photo-chemical crosslinking studies with 2-azido-3-phenylpropanoate 
The detailed computational mapping simulations predicted the location of the 
allosteric effector binding site in the hydrophobic pocket near residues 113-119. Residues 
312-314 and 407-409 line the other side of the pocket.  In order to experimentally 
challenge the result of our binding simulations, the allosteric effector (vide infra) azido-
L-Phe was used to first activate PAH prior to undergoing UV-light photo activation to 
generate a C-based nitrene reactive intermediate that covalently reacts with nearby 
residues thereby allowing identification of its location through proteolytic digestion of 
the crosslinked enzyme followed by a comparative mass spectroscopic analysis of the 
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resulting fragments with those from unmodified enzyme (185).  Any crosslinking of 
azido-L-Phe to the buffer would not be observed in our analysis as we analyzed larger 
peptide fragments by mass spectrometry.  We observed 48% coverage of the protein with 
mass spectrometry, which was expected given the small fragments obtained after 
digestion with α-chymotrypsin.  Proteolytic digestion with α-chymotrypsin was required 
because trypsin would cleave in the middle of our expected fragment (Table 2.8).   
 
Table 2.8 Expected fragmentation of PAH by trypsin and α-chymotrypsin.  
Fragmentation near allosteric effector binding site (residues 113-118) is indicated in 
yellow. Trypsin is expected to cleave peptide of interest in multiple places, while α-
chymotrypsin is expected to provide one fragment for peptide of interest. 
Trypsin Digest 
   Start   End  Mol. Weight  Peptide 
      1     42    4560.112  MAAVVLENGVLSRKLSDFGQETSYIEDNSNQNGAISLIFSLK 
    298    335    4273.867  SFAQFSQEIGLASLGAPDEYIEKLATIYWFTVEFGLCK 
    221    252    3591.056  EDNIPQLEDVSQFLQTCTGFRLRPVAGLLSSR 
    421    452    3511.091  VEVLDNTQQLKILADSINSEVGILCNALQKIK 
    342    371    3283.827  AYGAGLLSSFGELQYCLSDKPKLLPLELEK 
    271    297    3076.495  HGSKPMYTPEPDICHELLGHVPLFSDR 
    124    150    3049.346  TIQELDRFANQILSYGAELDADHPGFK 
     51     74    2894.283  VLRLFEENDINLTHIESRPSRLNK 
    372    396    2877.128  TACQEYSVTEFQPLYYVAESFSDAK 
    200    215    1952.218  THACYEHNHIFPLLEK 
     75     86    1625.755  DEYEFFTYLDKR 
    401    413    1462.715  TFAATIPRPFSVR 
    100    111    1311.417  NDIGATVHELSR 
    160    169    1260.371  QFADIAYNYR 
    262    270    1166.363  VFHCTQYIR 
     87     96    1055.326  TKPVLGSIIK 
    177    184    1026.065  VEYTEEEK 
    116    123    1016.167  NTVPWFPR 
    253    261     995.146  DFLGGLAFR 
    185    192     994.118  QTWGTVFR 
    414    420     941.996  YDPYTQR 
     43     50     815.922  EEVGALAK 
    170    176     803.919  HGQPIPR 
    151    155     648.717  DPVYR 
    336    341     647.683  EGDSIK 
    216    220     644.746  YCGFR 
    156    159     529.643  ARRK 
143 
 
 
 
    196    199     493.604  ALYK 
     97     99     374.440  SLR 
    193    195     360.454  TLK 
    397    398     275.305  EK 
    114    115     275.305  EK 
    399    400     273.335  VR 
    112    113     261.278  DK 
    453    453     105.093  S 
 
Chymotrypsin Digest  
   Start   End  Mol. Weight  Peptide  
     25     37    1374.427  IEDNSNQNGAISL 
    110    120    1359.505  SRDKEKNTVPW 
    169    179    1351.531  RHGQPIPRVEY 
     99    109    1224.339  RNDIGATVHEL 
     63     72    1195.344  THIESRPSRL 
    393    402    1180.326  SDAKEKVRTF 
    278    287    1153.272  TPEPDICHEL 
    434    444    1117.221  ADSINSEVGIL 
    334    343    1113.251  CKEGDSIKAY 
    180    187    1050.090  TEEEKQTW 
    205    212    1006.129  EHNHIFPL 
    121    128    1003.166  FPRTIQEL 
    220    227     984.077  REDNIPQL 
    370    377     971.050  EKTACQEY 
    155    161     961.138  RARRKQF 
     84     91     956.153  DKRTKPVL 
    269    276     925.117  IRHGSKPM 
    403    410     872.035  AATIPRPF 
     56     62     845.861  EENDINL 
    418    424     843.979  TQRVEVL 
    143    149     757.758  DADHPGF 
     42     48     744.843  KEEVGAL 
    228    233     723.737  EDVSQF 
    199    204     721.829  KTHACY 
    425    430     717.734  DNTQQL 
     92     98     716.876  GSIIKSL 
    359    364     686.806  SDKPKL 
     19     24     683.673  GQETSY 
     73     77     667.673  NKDEY 
    235    240     655.723  QTCTGF 
    312    317     650.643  GAPDEY 
    264    268     650.707  HCTQY 
    303    308     645.710  SQEIGL 
    150    154     620.703  KDPVY 
    243    248     611.742  RPVAGL 
    295    299     610.624  SDRSF 
    250    254     610.624  SSRDF 
    449    453     602.732  QKIKS 
    378    382     581.623  SVTEF 
    132    136     557.647  ANQIL 
    388    392     551.597  VAESF 
    162    166     551.597  ADIAY 
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      7     11     530.578  ENGVL 
    411    414     523.590  SVRY 
    289    293     521.617  GHVPL 
    318    321     501.624  IEKL 
     12     15     502.614  SRKL 
    328    331     494.545  TVEF 
      2      6     471.597  AAVVL 
    322    325     466.535  ATIY 
    214    216     438.481  EKY 
    129    131     436.468  DRF 
     49     52     429.560  AKVL 
    188    191     422.481  GTVF 
    261    263     420.512  RVF 
    445    448     419.496  CNAL 
    415    417     393.397  DPY 
    192    194     388.467  RTL 
    139    142     388.421  GAEL 
    431    433     372.508  KIL 
     16     18     367.359  SDF 
    300    302     364.401  AQF 
    383    385     356.422  QPL 
    365    367     341.451  LPL 
    349    351     339.348  SSF 
    195    197     330.428  KAL 
    217    219     325.383  CGF 
    352    354     317.342  GEL 
    344    347     316.357  GAGL 
    355    356     309.322  QY 
    167    168     295.295  NY 
     78     79     294.307  EF 
    309    311     289.332  ASL 
    241    242     287.362  RL 
     53     54     287.362  RL 
     81     82     282.296  TY 
     38     39     278.351  IF 
    137    138     268.269  SY 
    368    369     260.290  EL 
    256    258     245.278  GGL 
    259    260     236.271  AF 
    357    358     234.313  CL 
     40     41     218.253  SL 
    326    326     204.228  W 
    332    333     188.227  GL 
    387    387     181.191  Y 
    386    386     181.191  Y  
    277    277     181.191  Y 
    198    198     181.191  Y 
    327    327     165.192  F 
    294    294     165.192  F 
     80     80     165.192  F 
     55     55     165.192  F 
      1      1     149.208  M 
    348    348     131.175  L 
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    288    288     131.175  L 
    255    255     131.175  L 
    249    249     131.175  L  
    234    234     131.175  L 
    213    213     131.175  L 
     83     83     131.175  L 
 
 
 
After proteolytic digestion with α-chymotrypsin both wtPAH and crosslinked 
PAH gives rise to a number of fragments (48% coverage of the entire protein, with 
coverage over approximately 75% of surface exposed residues) including the peptide 
containing the putative allosteric effector binding site at residues 110-120 
(SRDKEKNTVPW) with a mass/charge of 1361.1 m/z.  Residues in this fragment are 
proposed (vide infra) to anchor the protonated amine and carboxylate functional group of 
the allosteric effector molecule in the binding site and to provide part of the hydrophobic 
pocket where the aromatic ring stacks.  A shift in the relative mass of the 110-120 peptide 
to 1548.4 m/z was observed after photo-crosslinking, consistent with a covalent linkage 
of the nitrene-based L-Phe fragment to the sequence (Table 2.9, orange in Figure 2.15 
and Figure 2.16).  Upon prolonged photo-illumination, a second weak crosslink in the 
binding pocket was observed at fragment 312-317 (GAPDEY, 840.5 m/z), which was not 
observed prior to the photoreaction.  As mentioned, this second linkage is located on the 
distal side of allosteric effector binding site from residues 110-120, and thus the result 
demonstrates that the highly reactive nitrene could react with either side of the binding 
pocket (shown in yellow in Figure 2.15).  These covalent modifications define the 
location of the allosteric effector binding site in PAH.  Extraneous crosslinking of azido-
L-Phe to sites outside the effector site were not expected as the highly reactive nitrene 
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radical reacts under diffusion-controlled conditions within the immediate vicinity of the 
already bound conformation (186).  No sites outside the computationally identified 
binding site were observed experimentally to react with the nitrene radical; a third 
observed crosslinked fragment corresponding to residues 110-128 (2424.2 m/z) arises 
from incomplete proteolysis with α-chymotrypsin (Table 2.9).  No experimental 
evidence was observed to indicate that azido-L-Phe reacts with interior active site 
residues, consistent with the high selectivity of L-Phe as substrate and the inability of 
azido-L-Phe to serve as a substrate.   
Table 2.9 Mass spectrometry fragments and assigned masses near allosteric effector 
binding site. 
Mass (m/z)   Assigned Peptide  
840.5  312-317 + Crosslink  
1003.7  121-128  
1112.3  309-317 + Crosslink  
1180.7  393-402  
1361.1  110-120  
1548.4  110-120 + Crosslink  
1714.3  388-402  
2032.6  393-410  
2040.0  19-37  
2534.6  110-128 + Crosslink  
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Figure 2.15 Docking of alternative allosteric activators into the predicted allosteric site 
with mesh representations of benzene (green) and amide (red and blue) crossclusters from 
extended mapping. Crosslinked peptide fragments from mass spectrometry are shown in 
allosteric binding site with (a) L-Phe, (b) azido-L-Phe.  Residues 110-120 are shown in 
orange, and residues 312-317 are shown in yellow.  Figure was made in PyMol (23) from 
PDB file 2PHM (14). 
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Figure 2.16 Mass spectrometry spectra of wtPAH photo-crosslinked with 5 mM azido-L-
Phe for 30 minutes and proteolytically digested with α-chymotrypsin.  (a)  Fragmentation 
of sample in reflectron mode. (b) Fragmentation of sample in normal mode. 
 
149 
 
 
 
2.4 Discussion 
A combination of predictive computational methods and biophysical experiments 
was used to identify the allosteric effector site of phenylalanine hydroxylase.  
Computational protein mapping identified three potential binding regions distinct from 
the active site, which were then further differentiated through the analysis of amino acid 
conservation, which validated the elimination of one potential site.  One of the remaining 
two sites was found to form crosslinks with photoactivated azido-L-Phe, consistent with 
covalent modification of the allosteric effector site.  Further insights into the properties of 
this site were obtained through extended protein mapping and docking calculations, 
coupled with hydrophobic binding and activity assays and fluorescence studies on both 
wild-type and selected mutant forms of PAH.   
The locations of the four individual allosteric binding sites in tetrameric T-state 
PAH (Figure 2.17) suggest that there are not interactions between the effector molecules 
in the T-state.  The changes in fluorescence maxima, hydrophobicity, and activity upon 
activation with L-Phe suggest that a significant conformational change must occur upon 
substrate activation; however the global structural details of this change are yet 
undefined.  The T-state allosteric effector binding sites in PAH are about 40-60 Å apart.  
The L-Phe molecules diagonal to each other in the tetrameric interface are the closest 
together, ~40 Å apart, while the L-Phe molecules in adjacent subunits are 55-60 Å apart.  
The movements of the regulatory domains or the subunit - subunit interactions are all still 
unknown.  Future studies will require structural characterization of full-length R-state 
PAH using either L-Phe or an alternative activator to define the conformational changes 
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that occur both in individual subunits as well as at the various interfaces between 
subunits.   
 
 
 
Figure 2.17 Location of L-Trp residues in PAH.  L-Trp residues are shown in orange and 
the modeled allosteric site L-Phe residue is shown in green.  (a) Location of L-Trp 
residues in monomeric PAH.  (b) Proximity of Trp120 to the allosteric site of PAH.  (c) 
Location of allosteric site L-Phe molecule and L-Trp residues in tetrameric PAH. Figure 
was created in PyMol(23) using a composite of PDB files 2PHM (14) and 2PAH (84). 
 
 
151 
 
 
 
 Previously reported H/D exchange experiments with wild-type and Δ1-117-PAH 
were not able to locate any peptides in wtPAH containing residues 113-128 or 402-417, 
as Fitzpatrick and coworkers digested the protein with trypsin rather than α-chymotrypsin 
(129).  These studies analyze the solvent accessibility of the fragment from 309-317 that 
demonstrated a greater rate of H/D exchange in the presence of 5 mM L-Phe (129).  The 
increased rates of H/D exchange in the 309-317 peptide fragment are consistent with an 
allosteric conformational change occurring in this site as we have reported herein, as this 
region should be flexible and involved in dynamic protein movement.  Additionally, in 
the regulatory truncated enzyme fragments representing residues 309-317 and 403-425, 
which are located near the allosteric effector binding site, did not demonstrate a change in 
solvent accessibility with 5 mM L-Phe (129).  These results agree with our data that the 
major allosteric conformational change does not occur in the regulatory truncated enzyme 
as part of the L-Phe binding site is removed. 
Molecular dynamics studies by the Martinez group previously suggested that the 
regulatory domain of one subunit of the protein closely interacts with the tetramerization 
domain of another subunit and that mutating residues in the next subunit can affect the 
solvent accessibility of Trp120 and lead to a decreased fluorescence shift upon L-Phe 
binding (125, 187).  This model proposes that L-Phe binding interactions only occur in 
the active site (125, 187), an assumption that is not supported by the data reported herein 
or other prior work involving kinetic and physical binding measurements (76).  The 
changes in solvent accessibility of Trp120 reported by Martinez mirror those that we 
have observed with the mutations in the allosteric effector binding site.  These results 
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suggest that the earlier proposals involving an L-Phe induced conformational change in 
the overall structure of the enzyme when L-Phe binds in the allosteric site (49, 76, 88) are 
more accurate for the description of allostery in PAH.  
Recently, an NMR study observed a binding site for L-Phe in the regulatory 
domain of PAH.  This report could not determine the location of the binding site in the 
protein, and reported this non-specific binding of L-Phe as an indication of the allosteric 
binding site in the regulatory domain (126).  While our isolated binding site is partially in 
the regulatory domain, studies of only the regulatory domain would be unlikely to locate 
the site.  It is the domain interface that creates this binding site in the T-state enzyme, 
which is different than what is known for other ACT domain proteins (see Section 2.4.1).  
The extent to which this binding site changes or moves in the R-state of the enzyme is 
still unknown. 
Spectroscopic studies of PAH using magnetic circular dichroism (MCD) methods 
and X-ray absorption spectroscopy (XAS) have demonstrated that the enzyme active site 
Fe(II) coordination geometry changes from six-coordinate when L-Phe is bound in the 
absence of pterin, to five-coordinate when L-Phe and pterin are both present (110, 112).  
Ongoing studies will need to focus on changes in the catalytic active site upon allosteric 
activation in order to fully understand the mechanism(s) of enzyme regulation. The 
results provided herein indicate the location of the distinct allosteric effector binding site 
that we can use to separate the effects of substrate binding from allosteric effector 
binding.  Furthermore, the continued use of advanced computational methodologies in 
the study of particular substrate and cofactor binding sites within the catalytic site will 
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serve to more fully develop a chemical understanding of these particular sites and the 
basis for the observed specificity. 
2.4.1 Relationship of wtPAH allosteric binding site to ACT domain proteins 
PAH is associated with a number of other proteins involved in amino acid 
metabolism and homeostasis that have structurally similar regulatory (ACT) domains and 
show differing effects of allosteric control (68, 69).  Kobe and colleagues reported the 
similarity of the regulatory domain of PAH to that of phosphoglycerate dehydrogenase 
(PGDH) (14), which is regulated by L-serine (L-Ser) and is responsible for the first step 
of the biosynthesis of L-Ser (137).  PGDH is one of the first proteins to be characterized 
as part of the ACT domain and has been characterized crystallographically to undergo a 
hinge movement of approximately 15° when the enzyme is allosterically activated (See 
Section 1.3.3, Figure 1.38) (161).  Multiple monomers of the ACT domain in PGDH 
interact in a side-by-side fashion, while other enzymes containing the ACT domain, 
including the transcription factor NikR have been demonstrated to have end-on 
interactions of their ACT domain subunits.  PAH, however, does not show any 
interaction of the regulatory domains in the presently available resting state crystal 
structures (67).   
Another member of the ACT domain family, chorismate mutase (CM), which is 
involved in the early steps of L-Phe biosynthesis, is involved in a much smaller 8° shift of 
an α-helix upon allosteric activation with its activator, L-Trp (See Section 1.3.3, Figure 
1.40) (166, 188).  The majority of other known allosteric enzymes demonstrate some type 
of domain movement, hinge movements, or strand turning upon allosteric activation, and 
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that has not yet been shown the with the currently available crystal structures of PAH.  
Further crystallographic studies of the activated enzyme will be required to determine if 
the interactions that must occur between the ACT domains of PAH are more similar to 
the interactions observed for PGDH, CM, or another different motif. 
The location of the allosteric binding sites in PDGH, aspartate kinase (AK), 
prephenate dehydratase (PD), and PAH are shown in Figure 2.18.  These binding sites 
are all defined by a number of hydrophobic residues (Val, Leu, Ile, and Phe) and a 
number of charged residues (Glu, Asp, Lys, and Arg).  In the case of PAH, the binding 
pocket is surrounded by several proline residues, which may serve to provide structure to 
the binding pocket.  The other proteins also contain some polar uncharged residues (Gln, 
Asn, Tyr, and Thr) in their allosteric binding pockets.  These residues may be involved in 
charge stabilization of the various charged or polar substituents on the relevant allosteric 
effector molecules, which are not as non-polar as L-Phe.   
Additionally, the location of the binding allosteric binding sites in the other ACT 
domain proteins is different than what we have discovered for the T-state allosteric 
binding site in PAH.  In other ACT domain proteins structurally characterized to date, the 
allosteric binding site was observed to be at the interface between related ACT domains 
(see Section 1.3.3); however in the T-state of PAH we do not observe interactions of 
different ACT domain subunits.   If we overlay the ACT domain of PAH with the ACT 
domain of PD (Figure 2.19), we observe very different binding sites.  The binding site of 
PD appears to fully form by the presence of the second ACT domain subunit, while the 
PAH binding site appears to be fully formed at the catalytic and regulatory domain 
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interface.  The separation of these binding sites in PAH may suggest that the 
conformational change that occurs upon allosteric activation induce a domain movement 
bringing two ACT domains in close contact in an activated crystal structure. 
 
Figure 2.18 Allosteric binding sites of some ACT domain containing proteins.  a) L-Ser 
binding to PGDH; b) L-Lys binding to AK; c) L-Phe binding to PD; d) L-Phe binding to 
PAH, as modeled by docking studies with AutoDock Vina. Figure was created in 
PyMol(23) using PDB files 1PSD (161), 2CDQ (164), 2QMX (168), and 2PHM (14).  
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Figure 2.19 Overlay of L-Phe binding sites in PAH (gray, L-Phe magenta) and PD (teal, 
L-Phe salmon).  The two ACT domain monomers in PD are indicated in the boxes.  The 
PAH only contains one ACT domain monomer in this alignment and is shown in the left 
box only.  Figure was created in PyMol (23) using PDB files 2PHM (14) and 2QMX 
(168).  
 
2.4.2 Relationship of allosteric effector binding site to PKU disease states 
Determining the location of the allosteric effector binding site in PAH has 
interesting implications for the study of PKU, particularly in patients that the mutations 
causing this disease are located near the allosteric effector binding site.  The R408W 
mutation is the most common clinically observed mutation causing PKU in humans and 
when over expressed in E.coli does not demonstrate any of the expected change in 
hydrophobicity even at high concentrations of L-Phe. (Soltau, S. R, Tsui, R. & 
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Caradonna J. P., unpublished data)  Additionally this mutation is iso-structural with a 
mutation in TrpOH (R441H) that is correlated with uni-polar major depression (189).  
These mutations draw attention to the role of allosteric activation in the disease state of 
PAH (and the related enzymes TyrOH and TrpOH) mutants found in the human 
population.  Although these enzymes have different regulatory domains, they all contain 
conserved regions around the area analogous to Trp120, as well as residues 312-313 and 
408-409 in PAH (Figure 2.14).  This particular region of amino acid binding in PAH 
may also be available in TyrOH and TrpOH with differing structural and functional 
parameters to account for the larger and/or more polar substituents.  Interestingly, no 
mutations have been reported in the PAH database (> 500 known missense, nonsense, or 
frameshift mutations listed) (80) involving the residues directly in the center of the 
hydrophobic pocket near Val118 where we have demonstrated that L-Phe will bind in the 
allosteric site of PAH, however several PKU-inducing point mutations are known to exist 
on the highly homologous strands 312-315 and 407-410 (Figure 2.20, Table 2.10).  Any 
mutations to this particular pocket may be so deleterious as to prevent the enzyme from 
overcoming the activation energy needed for catalysis and thereby are not tolerated 
during fetal development.  Nearby mutations such as the R408W mutation may still allow 
L-Phe binding in the allosteric pocket, but completely alter the local structure preventing 
the conformational changes in the enzyme to lower the activation energy for catalysis.  If 
methodologies to re-activate mutant enzymes with a distorted allosteric site pocket can be 
developed it may be possible to regain enzyme function in these patients as the active site 
environment is not altered.  
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Figure 2.20 Positions of PKU-inducing mutations (orange) near the allosteric effector 
binding site of PAH. Figure created in PyMol (23) using PDB file 2PHM (14). 
 
Table 2.10 PKU-inducing point mutations known in PAH located with 10 Å from the 
allosteric effector binding site. 
PKU Mutant Distance to L-Phe 
L-Phe Cα-Cα, Å L-Phe Cα-Cγ, Å 
S110L 9.8 9.2 
W120X 9.8 9.5 
G312V 8.0 7.4 
A313T 6.8 7.0 
A313V 6.8 7.0 
P314H 3.8 5.2 
P314S 3.8 5.2 
P314T 3.8 5.2 
D315Y 6.0 8.2 
P407L 8.2 7.3 
P407S 8.2 7.3 
R408Q 8.7 7.0 
R408W 8.7 7.0 
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2.4.3 Use of protein mapping as a predictive tool for identifying small molecule 
binding sites 
 Previous protein mapping methods had only been used for the evaluation of 
known small molecule binding sites (177, 184, 190, 191).  This dissertation provides a 
new paradigm for studying unknown small molecule binding sites that requires a 
combination of computational and experimental efforts.   The FTMap algorithm used in 
this chapter is available free of charge via the internet (192), and is currently used 
primarily for fragment based drug design and discovery.  This method can be easily 
utilized by protein biochemists striving for a better understanding of their experimental 
system and who wish to computationally determine the potential locations of substrate, 
cofactor, allosteric effectors or other small molecule binding sites.  In order to take full 
advantage of this method, experimentalists must be able to test any thermodynamically 
preferred regions identified by the computational routine.  Site-directed mutagenesis will 
provide a good starting point for this kind of analysis, combined with other assays 
methods appropriate for the system as described herein.  When computational and 
experimental results are utilized in tandem, they can provide substantial evidence for new 
paradigms of study within a particular system.  While future work in the field of protein 
mapping is focusing on fragment-based drug discovery and drug design,  protein 
biochemists should exploit these resources for the intrinsic fundamental benefit of their 
own studies. 
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2.5 Conclusion 
In this chapter, computational and experimental evidence for the location of the 
allosteric effector binding site in PAH was presented.  These results suggest that the 
allosteric effector binding site is located in hydrophobic pocked at the interface between 
the catalytic and regulatory domains.  A single pocket was clearly supported through 
computational, site-directed mutagenesis, ligand docking, and photo-crosslinking studies.  
This work will provide new areas of study for both enzymologists trying to understand 
challenging allosteric enzymes as well the medical community trying to develop better 
treatments for PKU.  This study also demonstrates the use of computational methods to 
predict ligand binding sites and power of these studies to guide experimental work. 
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CHAPTER 3  
Differentiation of active and allosteric site binding of L-Phe in phenylalanine 
hydroxylase by surface acoustic wave biosensing   
3.1 Background and perspective 
 Allosteric L-Phe binding in PAH regulates enzyme's ability to perform catalysis.  
Binding of L-Phe in the allosteric effector site, which causes an overall T  R transition 
within the enzyme, has been correlated with many global structural changes within the 
quartnary, homotetrameric protein structure.  The structural changes include an apparent 
increase in hydrodynamic size (91) and an increase in hydrophobicity (123).  These 
structural changes induce a shift in the tryptophan fluorescence maxima of the protein to 
a higher emission wavelength (91, 124).  Additionally, it is reported that there is a >33 
kcal/mol activation barrier in the unphosphorylated enzyme between the T and R states of 
the protein (88).  In Chapter 2, the location of this particular important binding site in 
PAH was elucidated and the implications of this site for the regulation of the enzyme 
were initially discussed. In this chapter, the differences in binding affinity of L-Phe for 
the allosteric and active site will be explored.  To date, no one has directly measured the 
binding affinity for L-Phe in the allosteric site.  
Surface acoustic wave (SAW) biosensing is an emerging biosensing technique 
that exploits acoustic waves induced in a piezoelectric crystal as the sensor modality 
(193).  As with other biosensors such as surface plasmon resonance (SPR), this technique 
requires a biological ligand such as a protein to be immobilized on the sensor surface and 
analyte solutions injected through microfluidics over the surface.  These instruments use 
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interdigital transducers (IDT) on a surface to detect very small amplitude and phase 
changes to the mass, viscosity, or conductivity of the sample (194).  SAW instruments 
utilize a polydimethylsiloxane (PDMS) flow cell with electrical connections of the IDTs 
directly integrated into the flow cell assembly to carry the analyte over the surface (193, 
194) (Figure 3.1).   
 
 
Figure 3.1 Schematic of the SAW flow cell design.  Each gold coated quartz SAW chip 
contains five sensor elements (shown as hashed regions) and seals with a serpentine 
microfluidic cell PDMS flow cell. Each individual sensor element, shown schematically 
at right, contains an input and output IDT to launch and collect the surface acoustic wave.  
The gold surface of the sensor element is chemically modified to allow attachment of 
protein as described in the text. Adapted from reference (193). 
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Because of the number of different types of devices used in biosensing and the 
differences in their modes of operation, it is difficult to make quantitative comparisons 
between the approaches and consequently, there is no consensus in the interpretation of 
the resulting conclusions (195).   There are two broad categories of acoustic wave based 
biosensors, the bulk acoustic wave (BAW) sensors such as quartz crystal microbalance 
QCM and quartz crystal microbalance with dissipation QCM-D, which are also called 
TSM (thickness shear mode) sensors, and the surface acoustic wave (SAW) sensors of 
various types such a horizontally polarized shear wave HPSW devices or Love wave 
devices that contain a guided layer to reduce attenuation by the liquid (195).  SAW 
devices have higher sensitivity than BAW since they operate at substantially higher 
frequencies and the sensing element is highly localized to the sample in liquids (193).  
For all devices, two different electrical signals are measured, but device and detection 
design dictates how these data are collected.  For resonator type systems, oscillator 
frequency and impedance (also called dissipation, or resistance) changes are reported; for 
delay line type systems, phase delay and amplitude change or insertion loss changes are 
presented (195, 196).    
 Acoustic wave biosensors were originally developed as chemical sensors for 
detecting gasses and vapor, but were later modified and the technique expanded to study 
binding phenomena of solution based analytes (193, 195).  In the initial movement 
toward studying liquid solutions, antibody – antigen systems were employed (197), 
before studying more complicated systems, which included histidine tagged proteins 
through a nitrilotriacetic acid linker (198), and peptide – lipid interactions (199).  Since 
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the acoustic response of the sensor is related to the properties of the material in which the 
acoustic wave propagates, it is possible to correlate the response with physical and 
structural characteristics (such as conformation) of  the  immobilized protein at the sensor 
surface. Gizelli and coworkers correlated the mechanical properties of immobilized 
single- and double-stranded DNA with film thickness, strand length and stiffness (200, 
201), as well as hydration of protein layers where upon they concluded that changes in 
hydration or expulsion or uptake of water accounted for most of the changes in the 
dissipation signal.   
 Several other groups have also studies ligand binding induced conformational and 
structural modifications of adsorbed proteins.  Thompson and co-workers' performed 
(202) qualitative studies of conformational changes of calmodulin immobilized on a 9 
MHz QCM from the resonance frequency (F) and the motional resistance (Rm.) (203) 
that allowed determination of more quantitative dose response curve.  The study of 
protein mutants (204) has also been attempted by acoustic methods, although these 
studies did directly compare their data with other methods. 
Many analogous based biosensor measurements have been previously performed 
with SPR.  SPR methods, however, measure mass changes based differences in the 
refractive index, while the SAW approach is reported to be sensitive to mass, density, and 
viscosity changes in a particular sample, as well as to the acoustic coupling that occurs 
when a wave propagates over the sensor and biological sample (193).  The acoustic 
response from SAW studies can be interpreted and fit to give rise to kinetic and 
thermodynamic binding parameters.  These experiments are performed when an analyte, 
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which can bind to that surface (or to an adsorbed species on the surface), is injected over 
a surface.  After a period of time that allows for chemical equilibration of the analyte and 
surface species, the analyte is then released from the surface by flowing buffer without 
the presence of the analyte returning the surface species to its original free-of-analyte 
state. (Figure 3.2).  Note that the SPR method is limited by the physical effects of solvent 
or buffer or analyte to change the refractive index of the system, which must be 
recalibrated for each experiment.  SAW biosensing methods are not subject to this 
limitation (193). 
 
Figure 3.2 Schematic showing a sensorgram for reversible association and dissociation 
of analyte.  The baseline is interpolated linearly based on several anchor points in a 
region before and after each injection (anchor point regions are shown by the asterisks).  
The change in phase  (Δphase) is computed from the equilibrated region in the middle of 
the injection, after association is complete and before dissociation has begun. 
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Previously, thermodynamic studies of PAH have been attempted with differential 
scanning calorimetry (DSC) methods (125).  These data demonstrated irreversible 
denaturation of PAH and were interpreted as an initial unfolding of the regulatory 
domains at low temperatures, followed by unfolding of two of the four catalytic domains 
at high temperatures. Irreversible denaturation of the remaining protein was reported to 
follow this partial unfolding process (125).  The authors extended their interpretation of 
these results to indicate that the L-Phe binding sites could therefore not exist in the 
regulatory domain of PAH and that PAH allostery must exist through homotropic 
cooperative interactions of L-Phe binding in the active site (125).  This hypothesis was 
not supported by our studies locating the T-state allosteric effector binding site from 
Chapter 2 nor from other data indicating that there are separate binding sites for L-Phe in 
the active and allosteric sites (76).  The irreversible nature of the transitions observed in 
the DSC studies suggests that these observed changes are unlikely to be physically 
interpretable transitions, since they cannot they be performed in a reversible manner. 
The L-Phe induced conformational changes of PAH were previously studied by 
SPR (127, 128).  These studies report SPR detection of L-Phe and BH4 binding events to 
wtPAH, despite the mass changes being so small that they are at the theoretical limit of 
SPR detection.  The SPR studies immobilize the protein to the sensor chip surface at very 
low pH (5.4), which Flatmark and coworkers report will stabilize the tetrameric form of 
the protein (127), but we observe to induce protein precipitation (vide supra).   The 
quantitative studies showed that THA will induce a SPR signal and that D-Phe will not 
cause any SPR response (128), which agrees with our alternative activator studies in 
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Section 2.3.4.  These experiments also report that the SPR signals are minimized or 
eliminated by truncations of the C- and N-terminal domains of the protein (128).  The 
data obtained with the truncated forms of PAH are expected if the SPR signal 
corresponds to an overall conformational change upon allosteric activation since removal 
of the regulatory domain eliminates the requirement for allosteric activation.  It has 
previously been shown that Δ1-117-PAH kinetically behaves as if it is allosteric activated 
at 25ºC (50).  The SPR data also indicated a hyperbolic response to L-Phe binding (127) 
that was not expected based on kinetic studies demonstrating the allosteric effects on L-
Phe and its high Hill coefficient (2.4-2.6) (88, 91, 124).   The reported SPR-based binding 
affinities for L-Phe for the wild-type tetramer and dimer species are consistent with active 
site binding of L-Phe (97 ± 6 µM, 158 ± 11 µM respectively) (128).   
The same studies performed with C-terminal, tetramerization domain truncated 
enzyme, Δ428-452-PAH, shows a significantly weaker binding affinity for L-Phe (756 ± 
64 µM) (128), suggesting that the protein conformation is significantly altered in the C-
terminal truncated protein adsorbed on the chip surface.  This protein construct does not 
contain the tetramerization domain, but does contain the catalytic and regulatory domains 
in its isolated dimeric form.  These adsorbed dimer structures may aggregate or block the 
allosteric or active site to weaken L-Phe binding affinity in this protein.   It is possible 
that the SPR data are not sensitive to L-Phe binding in the allosteric site, and can only 
observe mass changes upon L-Phe active site binding.  The use of SAW biosensing, 
which should be able to detect both mass and conformational changes, will allow us to 
better detect allosteric activation.  The authors assert that hyperbolic response to L-Phe is 
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caused by homotropic cooperative L-Phe binding of L-Phe in the active site (128).  The 
data provided in their study do not give unique evidence to support their conclusion that 
L-Phe binding causes homotropic cooperativity (127, 128), and again is in disagreement 
with well established studies by Shiman (76) and our work (see Chapter 2).  In addition, 
the Georgiadis lab has been unable to reproduce the published SPR signals reported by 
Flatmark and coworkers owing to insufficient signal to noise limitations despite using the 
approaches reported in the paper and additional related approaches.  
In this chapter, we will investigate L-Phe and 5-deaza-6MPH4 binding to PAH 
with SAW biosensing and utilize this information determine the binding affinity of L-Phe 
for the active and allosteric sites of wtPAH and selected mutants and other forms of PAH.   
We will compare our results to previously determined data from the literature absorption 
kinetics, fluorescence studies, and SPR.  
3.2 Experimental section 
3.2.1 Materials 
All commercial materials were of the highest grade available and were used 
without further purification unless otherwise specified.  Glycerol was purified by 
filtration through activated carbon as discussed in Chapter 2.  Glycerol, L-Phe, D-Phe, L-
Trp, MOPS, NEM, catalase, DTT, N-Hydroxysuccinimide (NHS), and hydrogen 
peroxide were all purchased from Sigma-Aldrich (St. Louis, MO).  Potassium chloride, 
sulfuric acid, acetic acid, and 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide 
hydrochloride (EDC) were purchased from Fisher-Scientific (Pittsburgh, PA).  
Monobasic and dibasic potassium phosphate salts were purchased from VWR (Radnor, 
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PA). 1-hexadecanethiol was purchased from Alfa Aesar (Ward Hill, MA). Phenyl-
sepharose fast flow was purchased from GE Healthcare (Pittsburgh, PA).  SAW sensor 
elements were purchased from SAW Instruments (Bonn, Germany).  Magnetic 
microspheres were purchased from Bangs Laboratories, Inc. (Fishers, IN).  Total iron 
content was determined by atomic absorption as was discussed in Chapter 2.  
3.2.2 Expression and purification of proteins 
3.2.2.1 Preparation of wtPAH, Δ1-117 PAH, and Trp mutant enzymes 
 Recombinant rat wtPAH and Δ1-117 PAH vectors were used as previously 
described (91, 110).  Vectors for site-directed mutagenesis were constructed using 
custom oligonucleotides (Invitrogen) using a Quik-Change II site-directed mutagenesis 
kit (Agilent Genomics) (Table 3.1) and the full genes sequenced in both directions 
(Genewiz).  BL21-(DE3) cells were grown for protein expression and harvested as 
previously described including 20 mg FeCl3 per liter of cell culture (91).  No additional 
iron was added after purification.  Purification of wtPAH and all site-directed mutant 
enzymes followed the method of Shiman using phenyl-sepharose and DEAE column 
chromatography (91, 123). 
 
Table 3.1 Primers used in site-directed mutagenesis. 
Mutation Oligonucleotide 
K113R-PAH 5’-CCCGAGACAGGGAAAAGAACACAGTGCCCTGG-3’ 
W120F-PAH 5’-AACACAGTGCCCTGGTTCCCAAGGACC-3’ 
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3.2.2.2 Preparation of N-ethylmaleimide (NEM) dimer of wtPAH 
N-ethylmaleimide (NEM) dimers of wtPAH were prepared by incubating purified 
wtPAH with freshly prepared solutions of NEM prepared in wtPAH buffer at a 
concentration ratio of 1:1, therefore diluting the final concentration in half.  The protein – 
NEM mixture was incubated for 45 minutes at room temperature and centrifuged for 10 
minutes at 3000 rpm to insure equilibration and remove any precipitation.  Non-
denaturing polyacrylamide gel electrophoresis was used to confirm that the protein was in 
the dimer form rather than in its normal equilibrium of dimers and tetramers. 
3.2.3 Magnetic bead assay for enzyme activity of surface attached protein 
The activity of surface bound protein was determined in a kinetic time course 
assay that monitored the formation of L-Tyr at 275 nm.  Magnetic microspheres (beads) 
with a 0.97 µm diameter were purchased from Bangs Laboratory (Fishers, IN) with a 
carboxylic acid functionalization to mimic the functionalization on the sensor chip 
surface prior to protein immobilization.  Protein was covalently attached to the surface of 
the beads using the same coupling (NHS/EDC) chemistry used for attachment to SAW 
chips.  Before functionalization, a sample of 100 µl of the COOH-terminated beads was 
washed three times with 900 µl each of 50 mM MOPS/0.3 M KCl pH 6.0 using 
centrifugation (14,000 rpm, 2 min) to separate the beads from the storage solution and the 
supernatant was removed after each wash.  Before covalent immobilization of protein, the 
beads were activated with a freshly prepared mixture of 900 µl of 50 mM NHS/0.2 M 
EDC and incubated with shaking for 8 minutes and centrifuged as above.  Finally, 900 µl 
of 1 µM wtPAH was added to the pre-activated beads and incubated for 5 minutes with 
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shaking followed by centrifugation and collection of the supernatant.  Enzyme activity on 
the beads was determined by assaying a mixture (suspension) of beads with 6 mM DTT, 
68 µM 6MPH4, 1 mM L-Phe in 50 mM MOPS/0.3 M KCl pH 7.2 with 3000 units/ml 
catalase, similar to the continuous assay used to determine wtPAH activity in solution 
(123).  For this assay, a strong rare earth magnet was used to attract the magnetic beads 
the side wall of the cuvette, out of the beam path of spectrophotometer, before kinetic 
time course assays were recorded on a HP 8453 UV-visible spectrophotometer.  The rate 
of turnover was calculated based on an estimated concentration of protein bound to bead 
based on the formation of L-Tyr at 275 nm.   
3.2.4 Surface acoustic wave biosensing assay 
3.2.3.1 Instrument and sensor chip parameters 
Surface acoustic wave biosensing experiments were performed on the Sam5 Blue 
instrument from SAW Instruments GmbH (Bonn, Germany) using sensor chips that 
contain five surface sensor elements, or sensing regions, within a single flow cell.  For 
initial testing and condition optimization, gold-coated sensor chips were used as obtained 
(SAW Instruments) with three different surface coatings, referred to by the manufacturer 
as carboxylic acid terminated self-assembled monolayer, two-dimensional and three-
dimensional carboxylic acid terminated dextran. The overall acoustic response of all 
chips was similar with all surface modifications, and no significant difference in the 
overall acoustic response was observed for L-Phe concentrations, when referenced to the 
equivalent D-Phe concentration,   
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Based on extensive trial and error efforts, optimized procedures and experimental 
systems were developed that allowed reproducible data to be accumulated using different 
protein preparations and regenerated chip surfaces.  The surface layer of the sensor 
element chip could be removed which resulted a clean gold surface.  Surface cleaning 
was achieved by soaking the chip for 5 minutes in room temperature piranha solution (7:3 
concentrated sulfuric acid: 30% hydrogen peroxide) followed by copious rinsing with 
deionized water and 100% ethanol.  Cleaned sensor elements were recoated overnight 
with 1 mM 1-hexadecanethiol (MHDA) in ethanol with 5% acetic acid to form a 
covalently bound self-assembled monolayer.  The chips then were sonicated for 15 
minutes in ethanol with 5% acetic acid to remove any bilayer thiol from the sensor 
element surface.  These chips with terminal carboxylic acid functionalized thiol 
monolayer sensor elements on all five channels are referred to as MHDA chips.  Sensor 
chip quality was the evaluated by standard network analysis using the spectrum feature in 
the SensMaster software from (SAW instruments).  Sensor chips were rated on their 
acoustic response and "good" chips were reused. ("Good" chips displayed amplitude > 
0.5 with rounded amplitude features as well as relatively sharp phase features, and 
circular I-Q graphs; see Figure 3.3 for an example.)  MHDA chips have been etched and 
reused as many as eight times without degradation of signal quality.  All buffers were 
prepared to the precise pH and were thoroughly degassed before use.  Sensor chips were 
inserted in the instrument and equilibrated with running buffer (either 50 mM MOPS/0.3 
M KCl, pH 6.0 for increasing L-Phe experiments, or 50 mM MOPS/0.3 M KCl/1 mM L-
Phe, pH 6.0 for decreasing L-Phe experiments) for about 10 minutes while spectra quality 
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and instrument baselines were checked by monitoring the response of control solutions 
(0.5-2% glycerol).  Signal quality and reproducibility among the five channels of each 
sensor chip was tested.   
 
 
 
Figure 3.3 Example spectrum of a "good" SAW sensor chip.  All of the channels are 
quite reproducible.  The phase signals show sharp lines, the amplitude signals have a high 
maximum amplitude (~0.7) and rounded edges, and the I-Q and I-Q corrected graphs are 
circular.  
 
 
3.2.3.2 Attachment chemistry 
For protein attachment, the sensor chip surface was activated at flow rate of 40 
µl/min for 8 minutes with a freshly prepared mixture of 50 mM NHS/0.2 M EDC in 
MOPS/KCl pH 7.2.  Successful protein immobilization protocols required injection of 3 
µM enzyme in 50 mM MOPS/0.3 M KCl pH 6.0 at a flow rate of 40 µl/min for 10 
minutes.  The attachment was pH optimized for this reaction.  At pH ≥ 6.5 the amount of 
protein immobilization was insufficient, however at pH ≤ 5.5 the protein precipitated and 
degraded.  At least 10º phase of immobilization of protein was required for good signal to 
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noise.  Multiple injections of 3 µM enzyme were sometimes needed obtain adequate 
protein immobilization (at least 10° phase).   
3.2.3.3 Sample handling and general experimental procedures 
Protein was immobilized to the sensor chip surface, was found to have a 6-8 hour 
lifespan on the chip surface before the protein degraded.  This 6-8 hour lifespan of the 
protein on the chip correlated to approximately 30-40 sequential injections on the chip 
surface.  When performing sequential injections of analytes, a flow rate of 40 µl/min was 
used, with an injection time of 5 minutes.  All assayed analytes were prepared in from 
solids in 50 mM MOPS/0.3 M KCl pH 6.0.  Typical regeneration solutions (high pH, low 
pH, high salt and sodium dodecyl sulfate) led to protein degradation, so these were 
avoided for the concentration dependent assays.  Since the acoustic response was 
observed to return to baseline after an injection was completed, running buffer wash 
intervals of 5 - 10 of minutes were provided for the baseline to stabilize between 
sequential injections instead of a regeneration step between injections.  Data for 
concentration dependence studies were double referenced, that is, baseline drift was 
subtracted and then referenced to the response for an injection of D-Phe at the same 
concentration.  These subtractions were performed to control for the effect of the non-
activating zwitterion contributions in the data.  There is always a solute dependent effect 
on the SAW signals, so subtraction of the D-Phe signals allowed observation of the L-Phe 
signals alone.  These assays were performed with 3-5 replicates per concentration in a 
tiled fashion.  Tiling was required because data for the entire concentration span could 
not be obtained on a single sensor chip without protein degradation, therefore some 
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concentrations were replicated to bridge the gaps between experiments.  Solutions of L-
Trp and 5-deaza-6MPH4 were also prepared in 50 mM MOPS/0.3 M KCl pH 6.0.  All 
data analysis including fitting, baseline subtraction and double referencing was 
performed Origin 9.0 (Northampton, MA).  Baselines were determined by linear 
interpolation using several anchor points in a region before and after each injection, 
Figure 3.2.  The change in phase  (ΔΦ) or change in amplitude (ΔΑ) was computed in 
the middle of the injection, after association is complete and before dissociation has 
begun, using the interpolated baseline as a lower bound and the flat signal as the upper 
bound.  Prof. Rosina Georgiadis kindly developed the baseline drift subtraction software 
used in these studies.  Double referenced L-Phe concentration dependent curves were fit 
to equations in Origin 9.0.  The spectra that demonstrate two inflection points were fit to 
a Bi-dose Response equation in Origin 9.0: 
             
 
                
 
   
                
  
In this equation, A1 is the initial value, A2 is the final value, LOGx01 is the first EC50 
value (center value), LOGx02 is the second EC50 value (center value), h1 is the slope of 
the first inflection point, h2 is the slope of the second inflection point, and p is the 
proportion of the population at each transition.  The spectra that only demonstrate one 
inflection point were fit to a single Dose Response equation in Origin 9.0: 
      
     
              
 
In this equation, A1 is the initial value, A2 is the final value, LOGx0 is the EC50 value 
(center value), and p is the slope of the inflection.  The Dose Response curves have been 
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shown to apply to data in the same manner as Hill equation (205), however to correlate 
the Dose Response data with a Hill equation, we also fit the second binding transition of 
L-Phe to the allosteric site to a Hill equation in Origin 9.0: 
                 
  
      
  
In this equation, Vi corresponds to the initial phase, Vmax, corresponds to the final phase, k 
corresponds to the experimentally determined KD,app
on
 for L-Phe binding in the allosteric 
site, and n corresponds to the experimentally determined Hill coefficient for the 
cooperativity of the binding transition.  
3.2.5 Fluorescence titrations 
Shifts in the fluorescence emission maxima for wtPAH, wtPAH-NEM, Δ1-117-
PAH, K113R-PAH, and W120F-PAH were determined in the presence of L-Phe or D-Phe 
using a FluoroMax 3 (Horiba Jobin Yvon) fluorescence spectrometer with external 
temperature control to within 0.1ºC.  Emission spectra were obtained at 25ºC after a 5 
minute incubation time after adding the substrate.  The enzyme concentration was 2 
mg/ml (38-52 µM, depending on enzyme which enzyme was assayed) while the L-Phe or 
D-Phe concentration ranged from 0-2000 μM in 0.1 M potassium phosphate buffer pH 
6.8.  The excitation wavelength was 293 nm, with 5 nm slit widths and the emission 
scans were taken from 320-370 nm with 5 nm slit widths.  Emission spectra for buffer 
containing L-Phe or D-Phe at all concentrations studied were subtracted from the 
corresponding protein spectra.  Peak maxima were found using non-linear least squares 
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fitting of the subtracted emission spectra using Origin 9.0.  Alexandria Georgadarellis 
assisted with performing fluorescence titrations on many of the mutant enzymes.  
3.3 Results 
3.3.1 wtPAH-NEM dimer protein preparation 
 It is known that wtPAH can be stabilized as a dimer when treated with NEM (92).  
This treatment alkylates a highly reactive thiol group located at Cys237 and generates a 
stable dimeric form of PAH by disrupting one dimer-dimer interface found in the 
tetrameric form of the enzyme.  This modification will make only 1-2 and 3-4 dimers due 
to the alkylation of Cys237 (Figure 3.4).  When this modification was performed on 
wtPAH, there is no observation of the tetrameric form of the protein by native 
polyacrylamide gel electrophoresis in the wtPAH-NEM lanes while both the tetramer and 
the dimer can be observed in wtPAH lanes (Figure 3.5). 
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Figure 3.4 Tetrameric wtPAH divided into monomers by numbered quadrants.  
Treatment with NEM will make 1-2 or 3-4 dimers only.  Figure created in PyMol (23) 
from PDB files 2PHM (14) and 2PAH (84). 
 
 
 
Figure 3.5 Native polyacrylamide gel electrophoresis of wtPAH-NEM (lanes 2 and 3) 
and wtPAH (lanes 5 and 6). The standards are marked: 1) Ferritin (440 kDa); 2) Catalase 
(232 kDa); 3) Lactate dehydrogenase (140 kDa); 4) Albumin (132 kDa); 5) Aconitase (85 
kDa). 
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3.3.2 Magnetic bead assay for enzymatic activity of surface bound protein 
 To test the activity of the wtPAH bound to a surface, a magnetic bead with 
carboxylic acid functionalized surface similar to that of a sensor chip was employed.  An 
activity assay performed to determine if the bound protein would still have catalytic 
activity in solution.  From this assay, a low level of turnover was observed, which was 
equivalent to 2% of the native solution phase assay with the same protein sample (1.1 
nmol of enzyme) (Figure 3.6).  The relative activity decreased from 6.2 units/mg with 
free, solution phase, wtPAH to 0.11 units/mg in the on-bead bound assay.  The protein 
concentration was determined assuming all of the protein added to the assay bound to the 
beads, although some of the protein could have remained in solution, so this is a low 
estimate of the total activity of the sample.  If some protein remained in solution and not 
bound the bead the percent of relatively activity could be much greater.  The actual 
oligomeric conformation of the protein on the surface is not known.  We may observe 
any combination of dimer or tetramer bound by one or more linker molecule (Figure 
3.7). The dimeric forms of PAH should still bind the bead surface, as there are 
approximately 35 free amines (lysine or arginine residues) that could be involved in 
coupling with NHS/EDC to the bead surface.  It should be noted that activity was 
calculated from 60-360 seconds in this assay, to account for the lag time of the assay as 
there was no pre-incubation of the enzyme with L-Phe (88).  This assay indicates that 
although the rates of turnover are significantly decreased, the enzyme is still capable of 
turnover even in a bound state.  No enzyme activity was observed in the retained 
supernatant, thus demonstrating that the protein quickly and effectively binds to the bead 
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or SAW sensor chip surface and is not easily washed off or released (bound tetramer 
releasing a dimeric form into solution) after being covalently attached to the surface. 
 
 
Figure 3.6 Turnover of L-Phe to L-Tyr at 275 nm by wtPAH bound to carboxylic 
terminated beads using amine coupling procedures. 
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Figure 3.7 Possible binding modes of PAH on surface of bead or sensor elements when 
amine coupled using NHS/EDC.  PAH may exist as either a tetramer or a dimer and be 
singly or multiply bound to the surface.  Tetrameric forms of PAH will demonstrate 
conformational changes as acoustic SAW responses, while dimeric forms of PAH will 
not demonstrate an acoustic SAW response. 
 
3.3.3 Surface acoustic wave (SAW) biosensing 
 Numerous rounds of optimization of the protein immobilization technique were 
required to obtain measurable, consistent, and reproducible SAW responses for L-Phe 
binding to wtPAH and related mutants.  These optimization techniques examined 
included (i) immobilizing a histidine tagged PAH on the chip surface with a nickel(II)-
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nitrilotriacetic (Ni
2+
-NTA) acid linker, (ii) immobilization using a biotinylated PAH to 
attach to the chip surface through neutravidin, and (iii) attachment of PAH directly 
through amine coupling with NHS/EDC.  The early attachment methods using Ni
2+
-NTA 
or biotinylated linkers were preferred since we assumed that there would only be one 
method of attachment for PAH on the surface.  Unfortunately, these methods did not give 
sufficient immobilization of protein on the surface, so we could not analyze L-Phe 
dependent signals.  Amine coupling through NHS/EDC gave the most consistent 
immobilization of protein and L-Phe dependent signals, so this was chosen as the 
preferred attachment technique, but is subject to many possible binding modes of PAH on 
the surface (Figure 3.7) that can give rise to a heterogeneous mixture of protein 
structures on the chip surface.  More detailed optimization was required to increase 
protein loading on the chip surface once the NHS/EDC had been chosen as the desired 
protein attachment technique.  These optimizations included the pH dependence of the 
protein and running buffer, protein concentration optimization, and the use of 
ethanolamine as protein capping reagent to prevent non-specific binding. 
 The pH dependence of both the sensor chip activation and the protein 
immobilization steps were essential to immobilizing a sufficient amount of protein on the 
sensor chip.  The most commonly used amine coupling reaction conditions dissolve the 
protein in pH 5-5.5 in acetate (78), since sensor chip activation step requires neutral or 
slightly basic pH to stabilize the carbodiimide in solution.  However wtPAH was found to 
precipitate under those conditions, so a slightly higher pH of 6.0 in 50 mM MOPS/0.3 M 
KCl buffer was utilized for the SAW immobilization.  At least 10º of phase was required 
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for sufficient protein loading to enable to good resolution of L-Phe dependent SAW 
signals, which was determined after many rounds of trial and error.  The activity of the 
bound protein had been previously tested using bead based activity assays that were 
described in more detail above in Section 3.3.2 (vide supra). 
  A typical sensorgram for sequential injections of different analytes over an 
MHDA chip demonstrated differential SAW signals (Figure 3.8) when wtPAH was 
immobilized on the sensor chip surface.  L-Phe binding was demonstrated by a 0.1-0.2º 
increase in the phase and a very small decrease (0.001 AU) in the amplitude, which is just 
above the limit of detection, upon injection of 1 mM L-Phe.  Exposure of immobilized 
wtPAH to injections of MOPS/KCl and 1 mM D-Phe did not cause appreciable 
differences in either phase or amplitude response.  Other small molecules (e.g., 5-deaza-
6MPH4 and L-Trp) demonstrated significantly different acoustic responses, wherein the 
phase decreased by about 0.1º and the amplitude increased by a small amount (0.005 AU) 
near the limit of detection.  When mixed solutions of 1 mM L-Phe and 1 mM 5-deaza-
6MPH4 were injected, they appear to cancel each other leaving a much reduced SAW 
signal.  The differential signals provided by each of these analytes have enabled more 
detailed studies on the concentration dependence of L-Phe and 5-deaza-6MPH4. The limit 
of detection from our analysis of the phase data is approximately 0.01º; the limit of 
detection from our analysis of the amplitude data is approximately 5 x 10
-4
 AU. 
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Figure 3.8 Representative sensorgram plotted as relative phase (upper panel) and relative 
amplitude (lower panel) as a function of time are shown for sequential injections (5 min 
duration) of the analytes indicated. The solid vertical lines indicate the start of an 
injection; the dashed vertical lines indicate the end of an injection.  Data have been 
corrected to account for any baseline drift, as shown in Figure 3.2.  All solutions were 
prepared by dilution of solid analyte into the running buffer ( 50 mM MOPS/0.3 M KCl 
pH 6.0). The flow rate was 40 µl/min. 
 
3.3.2.1 Binding of L-Phe to wtPAH 
As was shown in Figure 3.8, a significantly different acoustic response, in both 
amplitude and phase, is observed upon the injection of 1 mM L-Phe and D-Phe over 
wtPAH.   These experiments were performed in running buffer without any L-Phe (0 mM 
L-Phe).  The running buffer flows over the protein immobilized on chip to generate a 
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baseline, and then a sample with a known concentration of L-Phe (50-1000 µM) is 
injected over the protein-immobilized chip.  The sample injection generates an increase 
in phase and a decrease in amplitude as shown in Figure 3.8.  At the end of the injection, 
the running buffer again flows over the protein immobilized chip and the L-Phe 
concentration over the chip returns to 0 µM.  It is known that D-Phe will not bind or 
induce a conformational change in wtPAH (89, 206).  However, careful control 
experiments with escalating and deescalating concentrations of L-Phe and D-Phe (not 
shown) reveal a significant zwitterion dependent dose response even in the absence of 
protein.  In order to properly account for these zwitterion effects, all reported L-Phe 
binding data is referenced to the response for D-Phe at the same concentration.  The D-
Phe referencing of the L-Phe concentration dependent data maximized observation of the 
mass and conformational changes that occur with L-Phe binding to the active and 
allosteric sites of wtPAH. Dose response data, shown in Figures 3.9, 3.10, were analyzed 
by fitting to the non-linear least squares models (mono- or bi-dose response curves) in 
Origin 9.0, as explained in the Experimental Methods section.   
The dose response curves with increasing L-Phe shows two distinct features 
(Figure 3.9a), that suggests that two binding events are detected. These two features are 
also present but less pronounced for decreasing L-Phe concentrations and show 
somewhat different values for affinity constants are obtained from fitting dose dependent 
phase data for the escalating dose response compared with de-escalating dose response. 
These apparent binding affinities are tabulated as KD,app
on 
 and KD,app
off
  (Table 3.2).  The 
feature at lower concentration (KD,app
on
 110 ± 10 μM, KD,app
off
 90 ± 20 μM) is similar to 
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the KM, L-Phe value obtained from steady-state solution enzyme kinetic studies for L-Phe 
binding to the active site of wtPAH (reported KM, L-Phe, 180 ± 10 μM) (91), which 
suggests that the initial smaller binding event observed at low concentration is consistent 
with a mass change upon L-Phe binding in the active site of wtPAH.  These 
concentrations are also physiologically relevant to the native enzyme, as blood plasma 
levels of L-Phe are typically 50-100 μM (79), suggesting that L-Phe is nearly always 
present in the active site of the native enzyme, but the enzyme remains in a catalytically 
off state until the L-Phe levels rise.  It should also be noted that we did not observe this 
low concentration binding event in the amplitude data (Figure 3.10).  While this 
technique is still quite new, the data suggests that the amplitude spectra may detect large 
conformational or viscosity changes, but not smaller mass changes.   
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Figure 3.9 Phase dose response curves for titrations of wtPAH with increasing or 
decreasing concentrations of L-Phe (50-1000 µM).  The data points are the double 
referenced acoustic phase response (ΔΦL - ΔΦD) that has been baseline drift subtracted 
and referenced to the response for an injection of D-Phe at the same concentration.  
Panels a) and b) show wtPAH titrated with increasing and decreasing concentrations of 
L-Phe over the full concentration range.  Panels c) and d) are the same data as in b) for 
lower and higher concentration ranges For decreasing titrations, L-Phe is included in the 
running buffer at 1000 µM. Residuals of non-linear least squares dose response fits are 
shown in the insets to panels a, c, and d. 
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Figure 3.10 Amplitude dose response curves for the titrations of wtPAH with increasing 
or decreasing concentrations of L-Phe. The data points are the double referenced acoustic 
amplitude response (ΔAL - ΔΑD) that has been baseline drift subtracted and referenced to 
the response for an injection of D-Phe at the same concentration.  Residuals of non-linear 
least squares dose response fits are shown in the insets.  Panel a) shoes wtPAH response 
with escalating L-Phe does; panel b) wtPAH with decreasing L-Phe dose. 
 
 
Table 3.2 Kinetic and thermodynamic parameters for L-Phe binding to wtPAH and 
W120-PAH. Uncertainty values for SAW responses are calculated from Dose Response 
fits of the data using Origin 9.0.  Uncertainty values for kinetic data are calculated from 
Hill equations to the data using Origin 9.0 (see section 4.3.2).  
 Phase Amplitude Kinetics 
wtPAH KD,app
on
 (μM) KD,app
off
 (μM) KD,app
on
 (μM) KM,L-Phe (μM) 
Active Site 110 ± 10 90 ± 20 ----- 180 ± 10 
Allosteric Site 680 ± 20 ---- 710 ± 60 ----- 
W120F-PAH KD,app
on
 (μM) KD,app
off
 (μM) KD,app
off
 (μM) KM,L-Phe (μM) 
Active Site ----- ----- ----- 150 ± 30 
Allosteric Site 510 ± 20 ----- ----- ----- 
 
The second binding event was observed in both phase and amplitude data and 
occurred at about 700 μM in both directions, but the shape of the concentration 
dependence curves were very different.  The increasing L-Phe phase transition (Figure 
3.9a) shows a clearly defined inflection point in the bi-dose response curve (KD,app
on
 680 
± 20 μM) (Table 3.2) where L-Phe binds tightly to the allosteric effector binding site 
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causing a conformational change at this saturating concentration.  At concentrations 
between 100 – 650 μM L-Phe may bind in the allosteric effector binding site, but it does 
not cause any additional change in the L-Phe dependent acoustic response and does not 
induce a conformational change in the protein.   Once the protein is fully saturated with 
L-Phe ([L-Phe] > 600 μM), it undergoes a tightly coupled conformational change 
indicative of allosteric activation that causes a concurrent increase in the acoustic 
response that corresponds to an additional 0.06º.  The assignment of this binding events is 
also supported by the amplitude data (Figure 3.10a) that shows minimal change in the 
increasing L-Phe titration signals until approximately 700 μM L-Phe (KD,app
on
 710 ± 60 
μM) when there is a decrease of about 0.001 AU in the acoustic amplitude response, that 
is about twice the limit of detection for this instrument.  These data were consistently 
obtained by the aforementioned protocols using different enzyme preparation and chips. 
The data was fit to dose response curve, in order to enable analysis of the binding 
affinity of L-Phe for the active and allosteric sites.  Attempts were made to fit the entire 
data range to Hill or Michealis-Menten kinetic fitting equations, but these equations 
could not fit the entire range, because two binding transitions were observed.  The shape 
of our binding curves for wtPAH are similar to the curves observed in cooperative kinetic 
processes, which helps us to correlate the observed cooperativity of PAH in solution from 
kinetic data (91) to our surface bound PAH in the SAW binding measurements.  We also 
attempted to fit the second binding transition, corresponding the L-Phe binding to the 
allosteric site, to a Hill equation (see Section 3.2.3.3), shown in Figure 3.11.  The 
binding parameters and cooperativity of this transition are shown in Table 3.3, and 
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demonstrate the KD,app
on
 for L-Phe binding in the allosteric site, is the same as for protein 
fit by the bi-dose Response curves shown early (Figure 3.9, Table 3.2), however, the 
cooperativity, is too high to be reasonably interpreted (n = 22 ± 12).  The inability to 
obtain an adequate analytical fit is likely due to many factors, including the many 
orientations of PAH on the surface of the chip.  There are 35 free amines (Lys or Arg) on 
the protein surface that are accessible for binding to the surface through the standard 
amine coupling procedures. Each of these free amines can bind singly or multiply on the 
chip surface, and may or may not provide full access to the allosteric site.  We think that 
the high value of n, which is beyond what is reasonable for a cooperative tetrameric 
protein, may arise in part because of all of the possible microstates of the enzyme on the 
surface.  We are actually observing an ensemble of different microstates, which differing 
levels of cooperativity (or not) and are reflected as an inflated value of n.  This 
phenomenon has been previously reported for other dose-dependent ligand binding data, 
primarily in terms of drug screening efforts (205).  Additional attempts to fix the value of 
n physiologically relevant levels (n ≤ 4) are shown in Figure 3.12 and were not 
particularly successful, and values of  n less than 3.5 were unable to converge 
mathematically. 
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Figure 3.11 Phase dose response curves for titrations of wtPAH with increasing 
concentrations of L-Phe (200-1000 µM).  The data points are the double referenced 
acoustic phase response (ΔΦL - ΔΦD) that has been baseline drift subtracted and 
referenced to the response for an injection of D-Phe at the same concentration.  The data 
has been fit to a Hill equation (see Section 3.2.3.3) and thermodynamic and cooperativity 
parameters are provided in Table 3.3.  
 
 
Table 3.3 Thermodynamic and cooperativity parameters for L-Phe binding to the 
allosteric site of wtPAH and W120F-PAH when fit with a Hill equation (see Section 
3.2.3.3).  Uncertainty values for SAW responses are calculated from Hill equation fits of 
the data using Origin 9.0.  KD,app
on
 values for wtPAH where n  is fixed to values of 4 and 
3.5 respectively are shown in Figure 3.12. 
  
Enzyme KD,app
on
 (µM) Hill Coefficient (n) 
wtPAH 680 ± 20 22 ± 12 
W120F-PAH 510 ± 20 14 ± 5 
wtPAH, n = 4 830 ± 420 4 ± 5.3 
wtPAH, n = 3.5 860 ± 680 3.5 ± 6.1 
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Figure 3.12 Phase dose response curves for titrations of wtPAH with increasing 
concentrations of L-Phe (200-1000 µM).  The data points are the double referenced 
acoustic phase response (ΔΦL - ΔΦD) that has been baseline drift subtracted and 
referenced to the response for an injection of D-Phe at the same concentration.  The data 
has been fit to a Hill equation and n values were fixed to 4 and 3.5 in panels a and b 
respectively. Thermodynamic and cooperativity parameters are provided in Table 3.3.  
 
 
An additional concern with SAW data is whether we are observing a true 
equilibrium situation.  We attempted to measure L-Phe binding injections at several 
different durations (1, 5, and 10 minutes).  We still observed some apparent L-Phe 
binding effects with a one-minute injection, however, we did not observe any difference 
in the shape of the 5 and 10 minute injections, which was interpreted to mean that the 
system had reached equilibrium.  It is possible that the system does not reach true 
equilibrium until a much longer time scale, but due the degradation of the protein on the 
chip surface over a longer time scale we were unable to adequately test this hypothesis.  
The binding processes we observed in this measurement were too rapid to enable kinetic 
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analysis binding and conformational change by L-Phe (see Chapters 4 and 5), and 
therefore we are unable to measure the kinetic process occurring on the surface.   
Other issues possibly pertaining to the challenges of fitting the SAW response to a 
cooperative process involve the limiting number of data points that we could obtain 
before chip degradation as well as potential uncertainty of the actual concentration of L-
Phe interacting with the bound protein due to the possibility of analyte gradients near the 
surface of the chip.  The approach is also limited by the intrinsic uncertainty of the 
magnitude of each measurement (see measurement error bars), leading to challenges of 
accurately simulating dose-dependent data. 
In addition to observing the binding of L-Phe in the allosteric site, we were also 
interested in the release of L-Phe the allosteric site.  We wanted to analyze whether 
release of L-Phe from the allosteric site at the same concentration as L-Phe binding to the 
allosteric site.  It has been proposed that L-Phe release from the allosteric site would 
occur at a lower concentration of L-Phe then L-Phe binding to the allosteric site, which 
we have referred to as an "asymmetric switch".  The asymmetric switch for L-Phe release 
was proposed since PAH is involved in L-Phe homeostasis.  PAH requires a high 
concentration of L-Phe to activate the enzyme, but is required to return the L-Phe levels 
in the bloodstream back to 50-100 µM.  PAH activity should not, therefore, turn off by 
the release of the allosteric activation, until the L-Phe concentration is much lower.  
Therefore, we hypothesized that the decreasing L-Phe titration would demonstrate a 
different SAW response than the increasing L-Phe titration, as L-Phe may become 
kinetically trapped in the allosteric site in order for the L-Phe levels to drop sufficiently. 
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The decreasing L-Phe titrations used a concentration of 1000 µM L-Phe in the 
running buffer.  A lower concentration (50-900 µM) of L-Phe was injected over the 
protein-immobilized chip.  At the end of the injection, the running buffer with 1000 µM 
L-Phe flowed over the protein-immobilized chip, and the change in phase and amplitude 
responses were measured.  For the decreasing L-Phe titration, there is a nearly linear 
decrease in phase from 800-400 μM (Figure 3.9b,d).  The release of L-Phe from the 
allosteric site occurs with a shallow, gradual release of L-Phe from the allosteric effector 
binding site, such that an appropriate KD,app
off
 cannot be accurately calculated.  The 
inflection point of a non-linear least squares single dose-response fit, as described in the 
Experimental Methods section, to the upper portion of the titration occurs at 
approximately 700 μM, which is similar to the increasing L-Phe titration, however, the 
different shapes of the curves suggest that different structural processes are occurring 
when L-Phe binds to and releases from the allosteric effector binding site.   
L-Phe appears to follow a more shallow release response curve when leaving the 
allosteric site as the L-Phe concentration in solution decreases, and is observed not to 
completely revert back to the T-state conformation until the protein is about to release L-
Phe from the active site.  Such a process may occur if L-Phe is kinetic trapped in the 
allosteric site.  The process may happen if L-Phe binding to the T-state of the protein 
induces a conformational change in the enzyme that forms the R-state binding site with 
additional hydrogen bonding or other interactions in the allosteric site.  The enzyme can 
exist in either the T-state or R-state, but the rate of the formation of the R-state binding 
site is greater than the rate of return to the T-state binding site.  The differences in these 
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two rates might indicate that the system is under kinetic control, rather than 
thermodynamic control.  This kind of kinetic trapping may also suggest that the 
decreasing L-Phe titration is not completely at equilibrium and that these events are 
occurring as kinetic artifact of this control.  
At concentrations below 400 μM the L-Phe phase acoustic response is relatively 
constant until about 100 μM when L-Phe is released from the active site (Figure 3.9b,c).  
This narrow concentration effect leads to the loss of from the active site with a second 
conformational change in the decreasing L-Phe titration (KD,app
off
 90 ± 20 µM) (Table 
3.2).  The acoustic amplitude response for the decreasing L-Phe titration (Figure 3.10b) 
also demonstrates the presence only one conformational change that occurs at 
approximately 700 μM, and is consistent with L-Phe release from the allosteric site.  
3.3.2.2 wtPAH with 5-deaza-6-MPH4 titration 
When wtPAH was exposed to injections of 5-deaza-6MPH4, a linear 
concentration dependence was observed for the phase and amplitude acoustic response 
(Figure 3.13).  However, the signals are more scattered below 200 μM analyte 
concentration.  This linear concentration dependence of 5-deaza-6MPH4 may reflect the 
mass change (5-deaza-6MPH4: 180 g/mol, L-Phe: 165 g/mol) upon 5-deaza-6-MPH4 
binding in the active site.   From solution phase kinetic studies, the KM for 6MPH4 
binding has been determined to be 45-61 μM (91, 207); therefore binding of 5-deaza-6-
MPH4 at concentrations less than 200 μM was not surprising.  Nonetheless, these signal 
are very small, and nearly at the limit of detection for this instrument.  Amplitude 
acoustic responses only detect large conformational changes rather than small molecule 
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binding; therefore we were not expecting to see a binding change in the amplitude.  The 
linear concentration dependence of the acoustic response of 5-deaza-6-MPH4 to wPAH in 
both amplitude and phase was expected as there is a linear concentration dependence of 
increasing acoustic phase response observed to a increasing in concentration of analyte.  
This concentration dependence was also observed in the concentration dependence of L-
Phe and D-Phe (vide infra); although those titrations could be referenced to the D-Phe 
spectra at the equivalent concentration.  In the case of 5-deaza-6-MPH4, we could not 
reference 5-deaza-6-MPH4 to injections to a molecule that would not bind to the protein, 
so the effects of solute concentration were observed.  The linear concentration 
dependence with 5-deaza-6-MPH4 is likely a background artifact, while the plateau in 
phase signal (Figure 3.11a) at 0-200 µM 5-deaza-6-MPH4 may be a real effect of 
coenzyme binding in the active site. 
 
 
Figure 3.13 Baseline drift subtracted acoustic response for increasing concentration 
dependence of 5-deaza-6-MPH4 on 3 μM wtPAH bound on an MHDA sensor chip. a) 
Phase acoustic response; b) amplitude acoustic response. All samples were prepared in 
the running buffer (50 mM MOPS/0.3 M KCl, pH 6.0). 
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3.3.2.4 Non-allosterically activated proteins 
 Both regulatory domain truncated PAH (Δ1-117 PAH) and dimeric PAH 
(wtPAH-NEM) have been shown to kinetically behave as if activated at room 
temperature (50, 110) and therefore are not expected to demonstrate any conformational 
change related to allosteric activation.  Two site-directed mutant proteins, K113R-PAH 
(Chapter 2) and W120F-PAH (Chapter 4) were also studied by SAW methods.  K113R-
PAH replaces a lysine involved in anchoring L-Phe into the allosteric effector binding site 
with an arginine and has been shown to block allosteric activation within the protein 
(206).  W120F-PAH has also been reported to lose cooperativity and has been studied for 
its role in the Trp fluorescence spectra of the protein (124).  L-Phe concentration 
dependence SAW titrations were performed on these mutant proteins and the resulting 
data compared to the results of wtPAH with increasing and decreasing L-Phe (Figure 
3.13a,b).  It appears that there is no major change in the phase or amplitude signals for 
Δ1-117 PAH, wtPAH-NEM, and K113R-PAH (Figures 3.14c-e, 3.15) in the presence of 
L-Phe at various concentrations.  The L-Phe induced phase changes that have been 
observed with wtPAH are consistent with the effect of allosteric activation and are not 
solely a concentration dependent artifact, as was observed with 5-deaza-6MPH4 binding 
at high concentration.   
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Figure 3.14 L-Phe dose escalation response for wtPAH compared with the response for 
other forms of PAH or related mutant enzymes.  The data in panels a) wtPAH  with  
increasing L-Phe (black) ; b) wtPAH decreasing, red) are the same data  as in Figure 
3.9a-b. The fit to the data in panel a, shown as a gray line, is replicated in all five other 
panels as a guide to the eye.   The data points are the double referenced acoustic phase 
response (ΔΦL - ΔΦD) that has been baseline drift subtracted and referenced to the 
response for an injection of D-Phe at the same concentration. Panels c, d, e, f show the 
data for wtPAH-NEM (green), Δ1-117 PAH (blue), K113R-PAH (cyan), and W120F-
PAH (magenta) respectively. 
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Figure 3.15 Double referenced acoustic amplitude response (ΔAL - ΔΑD) that has been 
baseline drift subtracted and referenced to the response for an injection of D-Phe at the 
same concentration for various proteins with L-Phe. Black, wtPAH increasing; Red, 
wtPAH decreasing; Green, wtPAH-NEM; Blue, Δ1-117 PAH; Cyan, K113R-PAH; 
Magenta, W120F-PAH. 
 
 W120F-PAH (Figures 3.14f, 3.16) appears to show a small phase shift at with a 
KD,app
on
 of 510 ± 20 μM that is indicative of a change in conformation of the protein upon 
L-Phe binding allosteric site (active site binding from steady state kinetics: KM,L-Phe 150 ± 
30 µM).  The phase remains constant at concentrations consistent with L-Phe binding in 
the active site that suggests that L-Phe active site binding does not cause a mass or 
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conformational change in non-cooperative proteins; however, if the allosteric site is 
available there will be a significant change in conformation of the protein upon allosteric 
site binding and a representative phase increase is still observed.  The amplitude 
decreases with increasing L-Phe concentration as with wtPAH, however a KD,app
on
 value 
for amplitude could not be determined from the data as there was not a single definitive 
transition detected upon L-Phe binding (Figure 3.16).  The lack of a single-phase 
transition due to L-Phe binding may be due to the loss of cooperativity within the protein 
(see Section 4.3.2), as substrate binding to W120F-PAH has been determined to be non-
cooperative (n = 0.7 ± 0.1).  The phase transition observed in W120F-PAH associated 
with L-Phe binding to the allosteric site was also fit to a Hill equation (Figure 3.17) and 
the KD,app
on
 and n values for binding affinity and cooperativity were determine (Table 
3.3).  As with wtPAH, the KD,app
on
 values were the same when fit with a Hill equation 
(510 ± 20 µM) as when fit with a dose-response curve, however, the n values for 
cooperativity were not relevant (n = 14 ± 5).  These data again suggest that the protein 
population on the chip surface is actually (i) an ensemble of different populations that 
experience differing levels of cooperativity/non-cooperativity, (ii) an artifact of the small 
number of data points that can be accumulated, (iii) the inability to assure that the system 
is under thermodynamic control, and (iv) the intrinsic error/scatter of each measurement. 
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Figure 3.16 Acoustic phase and amplitude response from increasing L-Phe (50-1000 µM) 
titrations with W120F-PAH. The data points are the double referenced acoustic phase or 
amplitude response (ΔΦL - ΔΦD or ΔAL - ΔAD) that has been baseline drift subtracted and 
referenced to the response for an injection of D-Phe at the same concentration.  a) Phase 
dose response curve for titrations of W120F-PAH with increasing concentrations of L-
Phe.  The residual of the non-linear least squares single dose response fit is shown in the 
inset.  Dose Response fits are analyzed as described in the experimental methods.  b) 
Amplitude acoustic response for increasing concentrations of L-Phe with W120F-PAH.   
 
 
Figure 3.17 Acoustic phase response from increasing L-Phe (50-1000 µM) titrations with 
W120F-PAH. The data points are the double referenced acoustic phase response (ΔΦL - 
ΔΦD) that has been baseline drift subtracted and referenced to the response for an 
injection of D-Phe at the same concentration.  The data has been fit to a Hill equation as 
explained in section 3.2.3.3 and the Hill coefficient is provided in Table 3.3. 
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 The mass changes that occur when L-Phe binds to wtPAH are very small, but 
these mass change can be detected with this technique.  In wtPAH, the cooperativity of L-
Phe binding enables all four L-Phe molecules to bind effectively simultaneously, leading 
to a SAW response for L-Phe active site binding.  W120F-PAH is not cooperative, and 
therefore will only bind L-Phe in one binding site at a time (not simultaneously like 
wtPAH).  W120F-PAH will therefore only have one quarter of the mass change observed 
in wtPAH and therefore a SAW response may not be observed for active site binding, as 
this response in wtPAH is small, not far above the limit of detection, and might be lost in 
the intrinsic noise of the measurement.  This would also explain why no L-Phe binding 
signals are observed with K113R-PAH, which is also non-cooperative according to 
kinetic analyses in Chapter 2 (n = 0.63 ± 0.25).  In K113R-PAH, however, the allosteric 
site is blocked so that L-Phe cannot bind in the allosteric site, and no SAW response is 
observed at any L-Phe concentration.  
3.3.4 Fluorescence titrations 
 The L-Phe induced shift in the fluorescence emission maximum of the protein has 
been associated as a direct hallmark of allosteric activation within PAH (124).  There are 
three tryptophan residues in PAH (Trp120, Trp187, and Trp326), which correspond to 
61%, 13%, and 26% of overall fluorescence intensity in PAH, respectively (124).  The 
locations of the Trp residues in PAH are shown in Figure 3.18.  
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Figure 3.18 Location of Trp residues in wtPAH, shown in orange.  The allosteric effector 
binding site is indicated  in green, with L-Phe shown in magenta.  The active site ligands 
are shown in cyan.  The figure was created in PyMol (23) using PDB files 2PHM (14) 
and 2PAH (84). 
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 Traditionally, the fluorescence shifts in PAH have only been studied at high 
concentrations of L-Phe (1-10 mM), but not at lower concentrations.  Using high L-Phe 
concentrations, it was challenging to assign specific physical transformations to shifts in 
the fluorescence spectrum.  Fluorescence titrations performed herein for the first time 
demonstrate that wtPAH (Figure 3.19, black) undergoes a large and immediate shift in 
the fluorescence maxima upon incubation of L-Phe even at very low concentrations (> 
100 μM), which indicates that the tryptophan solvent accessibility changes immediately 
upon L-Phe binding in the active site.  As L-Phe concentrations that saturate the allosteric 
site (~1000 μM), a second, more gradual shift in the fluorescence maxima is observed, 
resulting in an overall ~8 nm shift in the fluorescence maxima between the T and R states 
of the enzyme that has been previously reported (91, 124).  Earlier fluorescence studies of 
wtPAH have utilized concentrations of at least 1 mM L-Phe, so this concentration 
dependent effect has not been previously reported (91, 124).  As expected, when wtPAH 
is incubated with D-Phe there is no shift in the fluorescence maxima of the protein, nor is 
there a significant shift with the wtPAH-NEM dimer (0.05 and 0.9 nm at 2 mM L-Phe 
respectively) (Figure 3.19, red & green).  This fluorescence titration agrees with prior 
data that the wtPAH-NEM protein behaves as if it is already activated and is not required 
to undergo a fluorescence shift to demonstrate its activation (132).  It also suggests that 
detectable conformational changes that happen within wtPAH upon activation occur 
across the dimer - dimer interface, and not between the two monomers within a dimer 
complex.   
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Figure 3.19 Overlay of fluorescence emission peak shifts of wtPAH and related proteins 
upon incubation with varying concentrations of L-Phe or D-Phe.  
 
The W120F-PAH mutant that had previously been studied by SAW methods and 
shown to bind L-Phe in the allosteric site (vide supra) was also studied for its 
fluorescence signature.  Trp120 is the closest Trp residue to the allosteric effector binding 
site (9 Å from allosteric site); upon replacement of the Trp residue with L-Phe (W120F-
PAH) the fluorescence signal did not change at low concentration.  At higher 
concentrations (~600 μM), the fluorescence maxima shifts by about 4 nm, suggesting a 
response to allosteric activation of the protein that was also observed with the acoustic 
SAW response as described above (Figure 3.19, magenta).  The fluorescence titration 
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suggests that Trp120 is a reporter for the active site of the protein and its removal alters 
that portion of the fluorescence signal, which could also help explain the lack of SAW 
response for L-Phe active site binding that was observed for W120F-PAH.  It should also 
be noted that this enzyme lacks cooperativity, and that is reflected in the SAW response 
and may also be reflected in the fluorescence titration data.  These fluorescence signals 
will be discussed in greater detail in Chapter 4.  
The other two control enzymes used in the SAW biosensing experiments, K113R-
PAH and Δ1-117-PAH, were also studied by fluorescence titrations with L-Phe.  The 
K113R-PAH mutant protein that does not display cooperativity and blocks the allosteric 
site of PAH did not display any appreciable shift in the fluorescence maximum (Figure 
3.19, cyan).  Blocking the allosteric site alters the ability of the protein to undergo 
conformational change, which prevents observation of fluorescence signals at high L-Phe 
concentrations as observed for W120F-PAH.  Alteration of the local structural dynamics 
near Trp120, likely alters the ability to observe active site L-Phe binding.  The regulatory 
domain truncated enzyme, Δ1-117-PAH, demonstrates an approximately 1 nm decrease 
in the emission peak with increasing L-Phe concentration (Figure 3.19, blue).  While this 
is not currently well understood, it demonstrates an alteration in the local dynamics near 
Trp120, as this residue is now located only two residues from the edge of the protein in 
much less defined loop region. We also observe that the fluorescence maximum of this 
protein is already shifted from what is observed with the wild-type enzyme, before 
incubation with L-Phe.  The observed emission peak of T-state wtPAH is 339 nm, while 
the observed emission peak of T-state Δ1-117-PAH is 347 nm.  The initial shift of the 
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fluorescence maxima of Δ1-117-PAH, agrees well with prior data that indicates that the 
enzyme behaves is if is already allosterically activated at room temperature (50).  
3.4 Discussion 
 The role of PAH in L-Phe metabolism has been known for over 50 years (208), 
however it is only recently that structural and physical studies have enabled examination 
of mechanism of allosteric activation that turns on enzymatic activity.  In normal healthy 
patients, free blood plasma L-Phe concentrations are approximately 60 μM (209), 
however in patients with untreated classic PKU the blood plasma concentrations of L-Phe 
may reach greater than 1000 μM (79).  Using SAW biosensing and complementary 
fluorescence emission studies, we have been able span this range of L-Phe concentrations 
(0-1000 µM) and determine the affinity of L-Phe binding to the active and allosteric sites.  
These studies have demonstrated that active site L-Phe binding occurs at concentrations 
just above the normal physiological levels, which agrees well with solution phase steady 
state kinetic studies (91).  This technique also appears to demonstrate that a loss of 
cooperativity in the enzyme response to L-Phe impairs the ability of SAW to detect active 
site binding.   
 The relatively tight SAW signal response to a narrow L-Phe concentration range  
near ~680 µM is suggestive of a cooperative process.  While it is expected that L-Phe 
binding to the PAH allosteric site should occur in a cooperative manner, as shown in 
Figures 3.12 and 3.17, we are unable to either simulate or quantify the extent of 
cooperativity through modeling the experimental SAW data.  These data only generated 
abnormally high and physically unrealistic Hill coefficients when fit to a Hill equation.  It 
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is currently unclear whether the inability to obtain Hill coefficients with a reasonable 
magnitude is a direct consequence of the small number of SAW data points collected and 
used in these simulations or whether it is due to the nature of the indirect or surrogate 
(i.e., not enzyme activity based) indicators of surface bound PAH allosteric activation 
detected by the application of surface acoustic waves.  In the later case, the linkage (or 
not) between cooperative structural changes and measured signal, will need to be further 
established and investigated. 
 These results suggest that SAW is able to detect such a small, primarily mass 
related change due to the combined effect of four subunits working cooperatively to bind 
L-Phe in the active effector binding site.  If L-Phe binds in the active site of all four 
subunits of the tetrameric protein in cooperative manner, a mass change about of 660 
g/mol is expected.  This mass ratio for total protein to total ligand is 315:1.  In contrast, if 
L-Phe binds to an individual wtPAH monomer non-cooperatively, there is a mass change 
of 165 g/mol per subunit and in the tetrameric enzyme a protein to ligand mass ratio of 
1260:1, which may be below the detection limit of the instrument.  We think the 
coordination of the all four binding sites undergoing conformational change at nearly the 
same is what allows observation of active site binding wtPAH, but prevents observation 
of this change in W120F-PAH.  The protein to ligand mass ratio may explain why we 
observe active site L-Phe binding for the case of cooperative, tetrameric PAH, but do not 
observe L-Phe binding with dimeric (wtPAH-NEM) and regulatory domain truncated 
(Δ1-117 PAH) enzymes, neither of which are expected to display cooperativity. 
Additional work examining this phenomenon will need to be performed.   
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3.4.1 Binding affinity of L-Phe for two distinct binding sites in wtPAH 
 The SAW data obtained herein also allowed detection of thermodynamic binding 
parameters of for L-Phe in the allosteric effector binding site.  These data demonstrated 
for the first time the approximate concentrations of L-Phe needed to induce allosteric 
activation in the enzyme and turn on enzymatic activity.   When this data is extrapolated 
to a metabolic level, this finding is consistent with the notion that as L-Phe is consumed 
through the digestion of food, the blood plasma levels of L-Phe rise, and L-Phe binds in 
the active site of the enzyme.  Once the amount of L-Phe in the blood stream reaches a 
saturating level (~700 μM), the enzyme undergoes a conformational change, which is 
indicated by a tightly coupled SAW acoustic response, and is able to begin catalysis to 
remove the excess L-Phe from the blood stream.  Once the substrate L-Phe has been 
consumed by the enzyme, L-Phe begins to slowly dissociate from the allosteric site. 
Dissociation of L-Phe from the allosteric site results in a much weaker affinity SAW 
response than what is observed for the forward process of L-Phe binding to the allosteric 
site.  This observation suggests that the activated enzyme returns to the T-state over a 
wider range of L-Phe concentrations and that L-Phe does not completely release from the 
allosteric effector binding site until the L-Phe concentrations are below 400 μM.  This 
scenario is predicated on the assumption that the system is indeed under thermodynamic 
control and has not been kinetically trapped, which has not yet been established.  What is 
reproducible, however, is that the forward and reverse L-Phe titration curves give rise to 
reproducible, yet distinct shapes.   
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 Previous SPR studies have demonstrated a concentration dependent response with 
L-Phe or the substrate analog 3-(2-thienyl)-L-alanine (THA) with wtPAH (127, 128).  
These data demonstrate only one transition upon L-Phe binding in wtPAH and are not 
consistent with our findings.  These discrepancies are likely caused by the differences in 
sensitivity between SPR and SAW.  SPR is limited by its ability to only detect mass and 
refractive index changes that prevents measurement of the conformational change 
signals, and therefore the second transition corresponding the allosteric site activation and 
conformational change was not observed in the earlier SPR data.  Theoretically, the 
second binding site should be observable by SPR, since the mass change is the same what 
is observed for active site binding of L-Phe, which was observed in the SPR data.  The 
SPR data for L-Phe active site binding agrees well with our data (this work: KD,app
on
: 110 
± 10 μM, ref. (128): KD, L-Phe: 97 ± 6 μM), and suggests that SPR works effectively for 
detecting small molecule binding changes, but cannot detect larger conformational 
changes. SPR studies by the Georgiadis lab were unable to reproduce the published 
results of the SPR studies due to poor signal to noise and protein loading conditions.   
3.4.2  L-Phe binding in wtPAH and allosterically altered proteins 
The SAW data is in good agreement with the fluorescence titrations of L-Phe with 
wtPAH and related enzymes that demonstrate that cooperativity is correlated with an 
immediate change in fluorescence upon very low concentrations of L-Phe binding in the 
active site.  Non-cooperative forms of PAH do not show this immediate fluorescence 
change, and only demonstrate fluorescence shifts at higher concentrations that report the 
global conformational changes upon allosteric activation.  The lack of a fluorescence 
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shift was observed for both W120F-PAH and K113R-PAH, are both non-cooperative and 
do not directly interfere with the reporting L-Trp residue in the same way.  The W120F-
PAH mutation has demonstrated some of the most interesting features of this activation 
process.  It indicates that there is no detectable SAW signal for L-Phe active site binding 
in a non-cooperative mutant protein, but there is a change, at slightly lower L-Phe 
concentrations than wtPAH (~500 μM) for the allosteric site conformational change.  
W120F-PAH also demonstrates no shift in the fluorescence maximum until about 500 
μM, but above 600 μM demonstrates a shift of approximately 4 nm, which is consistent 
with a shift in solvent accessibility as a conformational change occurs with allosteric 
activation.  
3.4.3 Implications of the SAW technique for protein conformational change 
 The data provided herein represent a new way to of studying conformational 
changes within proteins using surface acoustic wave spectroscopy.  The primary methods 
of studying protein conformational change, X-ray crystallography and NMR, have 
worked well for proteins that are easy to isolate and crystallize or are small enough to be 
studied by NMR.  SAW biosensing, however, provides another method for studying 
those proteins that cannot easily be studied by either crystallography or NMR by enabling 
study of the thermodynamic properties associated with protein conformational change.  
Studies with calmodulin have previously established that SAW biosensing can be used to 
detect conformational changes associated with small molecule binding (202), however 
due to the newness of this technique there are few studies indicating the limits to the size 
of mass and conformational changes that SAW methods can detect.  Our studies have 
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begun to demonstrate the maximal limits of phase detection, by demonstrating that we 
can observe small molecule binding events in cooperative systems where the ratio of 
protein to small molecule is on the order 300:1, however, in non-cooperative systems 
when this ratio is on the order of 1200:1, we do not observe binding.  This mass ratio 
indicates that there is likely a minimal mass-binding threshold for this technique, and L-
Phe binding signals are quite close to this threshold.  We also observe binding of 5-deaza-
6-MPH4 at very low concentrations and these signals appear to be opposite to the signals 
observed in L-Phe binding.  These data cannot be well explained by the current data and 
more fundamental work to understand the type of signals observed in this technique is 
required to clarify this data.  Additionally, this data indicates that larger conformational 
changes can be detected by both the phase and amplitude signals to give similar 
conformational change binding constants; however, the binding is much clearer in the 
phase signals.  The amplitude results require further study in the physical technique in 
order to better understand what is occurring with those signals.  
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3.5  Conclusion 
 In this chapter a new biosensing technique has been utilized to provide initial 
insights into the differential binding of L-Phe in the active and allosteric binding sites of 
PAH.  This process has enabled elucidation of the apparent binding parameters involved 
in L-Phe binding to the active and allosteric sites of PAH.  Additionally this technique 
has allowed some investigation of the differential fluorescence signals that are caused by 
each tryptophan in the protein.  The L-Phe dependent fluorescence signals induced by 
these Trp residues will be examined in more detail in Chapter 4, however assisted with 
the initial framework for these experiments.  Further work with SAW biosensors should 
provide a new mechanism for studying interesting biophysical and conformational 
changes within proteins upon small molecule binding that help elucidate other 
mechanisms of protein motions in the absence of crystallographic or NMR structures of 
the various states of the protein. 
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CHAPTER 4 
Towards understanding the mechanistic basis of L-Phe induced phenylalanine 
hydroxylase allostery by stopped-flow fluorescence spectroscopy: Part I, Use of 
selected mutations to assign reporter roles of intrinsic Trp residues  
4.1 Background and perspective 
 In the previous two chapters of this dissertation, the allosteric effector binding site 
in PAH was located and the binding affinity of L-Phe for the allosteric effector binding 
site was determined.  In this chapter, we will expand upon those results and begin to 
examine the kinetic mechanism of allosteric activation by L-Phe in PAH through selected 
site-directed mutations in PAH. 
 As was shown by the experiments of Chapter 2, the allosteric effector binding 
site of PAH is located approximately 23 Å from the active site of PAH.  Despite this 
large physical distance, L-Phe binding at the allosteric effector binding site induces large 
physical conformational changes within PAH that ultimately prepare the active site to 
perform catalysis.  Currently, there is limited insight into how this allosteric activation 
process occurs within the enzyme as there are still no crystal structures of either the full 
length resting T-state enzyme or the activated R-state enzyme.  In lieu of activated state 
crystal structures, indirect methods must be applied to understand the mechanism of 
allosteric activation in PAH.  
 One indirect method that assists in understanding the activation state of the 
enzyme is fluorescence.  The wild-type enzyme has been observed to undergo an 8 nm 
shift in the overall fluorescence maxima upon incubation with saturating levels of L-Phe 
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(91, 124).  This fluorescence shift is used as a hallmark of the allosteric activation state of 
the enzyme (Figure 4.1) and is a measurable signal for the global activation state.  It is 
important to note that this fluorescence shift is an implied spectroscopic monitor for 
active site structural changes that turn on enzymatic activity, thereby initiating the 
conversion of L-Phe to L-Tyr.    
 
 
Figure 4.1 Shift of the fluorescence maxima of 2 mg/ml (38 µM) wtPAH in the presence 
of 10 mM L-Phe at 25 ºC when excited at 293 nm.  
 
 
 Allosteric L-Phe binding induces significant structural changes in tetrameric 
PAH: i) conversion from the inactive T-state to the active R-state, ii) an increase in 
hydrodynamic size by dynamic light scattering and gel filtration (87, 91), iii) an increase 
in the hydrophobicity of the enzyme (123), and iv) reorients or rearranges the enzyme 
active site, which is an additional process to the global TR change as it is observed in 
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Δ1-117-PAH that does not undergo the global T  R conformational change (50).  It has 
also been suggested that allosteric rearrangement is necessary to open potential gas 
channels to facilitate dioxygen binding and reactivity at the active site (50). 
 L-Phe induced activation provides the fundamental trigger required for regulation 
of enzyme catalytic activity.  The role of PAH is regulation of L-Phe metabolism.  Blood 
plasma levels of L-Phe need to be maintained at a basal level of 50-100 µM to support 
protein synthesis (79).  Upon ingestion of food, L-Phe levels in the blood stream rise to as 
high 900-1100 µM, and need to be rapidly cleared from the blood stream to prevent being 
metabolized by tyrosine metabolism enzymes (49).  Failure to clear L-Phe from the blood 
stream leads to HPA or PKU (as discussed in Section 1.2.1) (79).  In order to regulate L-
Phe metabolism, PAH must be maintained in an "off-state" at low concentrations of L-
Phe to allow the basal blood plasma level of L-Phe.  As L-Phe concentrations rise, the 
enzyme activity must "turn-on" to support clearance of the higher concentrations of L-
Phe.  If the enzyme were to remain in the catalytically on state all the time, all blood 
plasma L-Phe would be cleared from the blood stream in 4.5 minutes, in one pass of the 
blood stream through the liver (210).  L-Phe binding in the allosteric site triggers the 
activation of the enzyme and enables catalytic activity. Our SAW biosensing experiments 
from Chapter 3 indicate L-Phe binding to the allosteric site occurs with KD,app
on
 of 680 ± 
20 µM and binding and release of L-Phe to and from the active site occurs with KD,app
on
 
110 ± 10 µM and KD,app
off  
90 ± 20 µM respectively.  Given this information, we can 
analyze the regulation of PAH by monitoring the time dependent fluorescence changes 
induced by L-Phe.  
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  Three tryptophan residues, all located in the catalytic domain, are responsible for 
the observed protein fluorescence signal (124).  Trp120 is located on the surface of the 
catalytic domain adjacent to the allosteric effector binding site, while Trp326 is buried 
near the active site iron center.  The additional residue, Trp187, is also buried, about 17 Å 
from the active site and 40 Å from the allosteric site (Figure 4.2).  Trp120 has been 
correlated with approximately 61% of the overall fluorescence signal intensity in PAH, 
with Trp326 contributing 26% and Trp187 contributing 13% of the overall fluorescence 
intensity, which was determined by making single Trp mutant enzymes and analyze their 
total fluorescence contributions (124).  In this chapter we have prepared single and 
double Trp mutant enzymes that allow analysis of individual Trp fluorescence signals.  
We have examined the L-Phe dependent fluorescence shifts in the Trp mutant enzymes as 
a function of L-Phe concentration to further understand the reporting roles of the Trp 
residues in PAH.  We have also investigated the steady-steady and rapid kinetic 
properties of these mutant enzymes. 
218 
 
 
 
  
 
Figure 4.2 Location of Trp residues in monomer of wtPAH, shown in orange.  The 
allosteric effector binding site is indicated in green, with L-Phe shown in magenta.  The 
active site ligands are shown in cyan.  The figure was created in PyMol (23) using PDB 
files 2PHM (14) and 2PAH (84). 
 
 
 
219 
 
 
 
 The fluorescent properties of proteins with only a single Trp residue have 
typically been investigated in order to avoid deconvolution of multiple Trp spectroscopic 
contributions.  One example of such a protein is the azurin Pfl from Pseudomonas 
fluorescens. This protein is known to produce a hypsochromic shifted fluorescence 
spectra that is characteristic of a highly hydrophobic tryptophan residue (211).  Other 
well-characterized protein fluorescence signatures have been studied by site-directed 
mutagenesis to remove all but one tryptophan residue from the protein.  The azurin Pae 
from P. aeruginosa contains two native tryptophan residues, W48 and W118.  Single Trp 
mutant spectra have demonstrated that W48 is blue shifted with respect to the overall Trp 
fluorescence and that it is located in a more hydrophobic environment, while W118 is red 
shifted with respect to the overall composite Trp fluorescence spectrum and is consistent 
with being surface exposed (212).  Table 4.1 summarizes proteins with well-studied 
protein fluorescence signals along with the number of reporting Trp residues per subunit.  
Fluorescence characterization of other multi-tryptophan proteins has similarly been 
studied by site-directed mutagenesis of the native Trp residues.   
 Information about small molecule binding sites within a protein can be inferred 
through the addition of non-native tryptophan residues.  Calmodulin is a Ca
2+
 binding 
protein that does not contain any native Trp residues.  Four separate single Trp mutant 
enzymes were obtained, where Trp residues were inserted individually near the Ca
2+
 
binding sites.  In these mutant enzymes, fluorescence increases upon Ca
2+ 
binding at each 
of the binding sites could be observed (213).  Since PAH has three tryptophan residues, 
the fluorescence signature is expected to be substantially more complex than in many 
220 
 
 
 
other systems.  In order to study the PAH fluorescence signatures, a series of single and 
double Trp mutant enzymes have been analyzed. 
 
Table 4.1 Characterized systems of protein fluorescence and number of Trp residues. 
 
 
Protein Number of Trp Residues Reference 
Calmodulin 0 (214) 
Ribonuclease A 0 (214) 
Apo Azurin 1 (215) 
Glucagon 1 (215) 
Human Serum Albumin 1 (215) 
Melittin 1 (215) 
Pfl Azurin 1 (214) 
Tuna Myoglobin 1 (215) 
Bovine Serum Albumin 2 (215) 
Ferredoxin 2 (215) 
Pae Azurin 2 (214) 
Sperm Whale Myoglobin 2 (215) 
Barnase 3 (214) 
Human Hemoglobin 3 (215) 
T4 Lysozyme 3 (216) 
Lactate Dehydrogenase 6 (215) 
 
 
 Stopped-flow fluorescence spectroscopy was employed in order to develop a 
kinetic mechanism for the PAH activation process.  Stopped-flow kinetic analysis enables 
the observation of very fast processes through absorbance or fluorescence changes.  The 
Trp mutant enzymes should demonstrate less complex fluorescence signatures than the 
wild-type enzyme as there are fewer Trp residues contributing to the overall fluorescence 
changes in PAH.  A kinetic mechanism for L-Phe induced allosteric activation of the Trp 
mutant enzymes can be determined by global kinetic analysis of the fluorescence spectra.  
This mechanism will serve as an initial framework to describe the kinetic mechanism of 
allosteric activation in wtPAH, which will be further challenged by experimentation. 
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4.2 Experimental section 
4.2.1 Materials 
 All commercial materials were of the highest grade available and were used 
without further purification unless specified.  Glycerol was purified by filtration through 
activated carbon as discussed in Chapter 3.  Glycerol, L-Phe, D-Phe, MOPS, NEM, 
catalase, and DTT were all purchased from Sigma-Aldrich (St. Louis, MO).  Potassium 
chloride and iron atomic absorption standards were purchased from Fisher-Scientific 
(Pittsburgh, PA).  Monobasic and dibasic potassium phosphate salts were purchased from 
VWR (Radnor, PA).  
4.2.2 Preparation of the Trp mutant enzymes 
 Vectors for site-directed mutagenesis were constructed using custom 
oligonucleotides (Invitrogen) using a Quik-Change II site-directed mutagenesis kit 
(Agilent Genomics) (Table 4.2) and the full genes sequenced in both directions 
(Genewiz).  BL21-(DE3) cells were grown for protein expression and harvested as 
previously described including 20 mg FeCl3 per liter of cell culture (91).  No additional 
iron was added after purification.  Purification of wtPAH and all site-directed mutant 
enzymes followed the method of Shiman using phenyl-sepharose and DEAE column 
chromatography (91, 123).  The Trp mutant enzymes were further characterized through 
kinetic and spectroscopic assays.  Routine characterization of the enzymes included the 
following assays: enzymatic activity (formation of L-Tyr at 275 nm), chelation with 
catechol to determine the fraction of catalytically competent iron, and graphite furnace 
atomic absorption spectroscopy to determine total iron content (91). 
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Table 4.2 Primers used in site-directed mutagenesis. 
Mutation Oligonucleotide 
W120F-PAH 5’-AACACAGTGCCCTGGTTCCCAAGGACC-3’ 
W120F/W187F-PAH 5’-AACACAGTGCCCTGGTTCCCAAGGACC-3’ 
5’-CAGACCTCGGAACGGTGTTCAGG-3’ 
W120F/W326F-PAH 5’-AACACAGTGCCCTGGTTCCCAAGGACC-3’ 
5’-CTGGCCACAATTTACTTTTTTACTGTGGAG-3’ 
W187F-PAH 5’-CAGACCTCGGAACGGTGTTCAGG-3’ 
W187F/W326F-PAH 5’-CAGACCTCGGAACGGTGTTCAGG-3’ 
5’-CTGGCCACAATTTACTTTTTTACTGTGGAG-3’ 
W326F-PAH 5’-CTGGCCACAATTTACTTTTTTACTGTGGAG-3’ 
 
4.2.3 Kinetic analysis of the Trp mutant enzymes 
 Steady-state kinetic assays of the Trp mutant enzymes were conducted through 
the use of specific activity assays using the standard protocol described by Shiman (88), 
wherein L-Tyr formation at 275 nm is monitored.  In a 1 mL assay cuvette, 0.1 M 
potassium phosphate buffer, pH 6.8, 0.06 mg of enzyme, 6 mM DTT, 60 μM 6MPH4, and 
0.1-10 mM L-Phe were combined.  The enzyme was pre-incubated with L-Phe and buffer 
for 3 minutes to activate the enzyme prior to the addition of DTT and 6MPH4.  After this 
incubation, reductant and coenzyme are added sequentially and the formation of L-Tyr at 
275 nm is monitored for 30 seconds.  The initial velocity is reported in units/mg, where 
units is μmol of L-Tyr formed per min.  The initial velocities were normalized to account 
for changes in the molar extinction coefficient for wtPAH when Trp residues were 
replaced with Phe.  Replacement of each Trp residue with Phe was estimated using an 
ExPASy algorithm (217) to decrease the molar extinction coefficient of the protein by 
~13% and scaling factors of 1.134 and 1.311 were applied to normalized the initial 
velocities of the single and double Trp mutant enzymes respectively (217).  These data 
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were fit to non-linear fitting algorithms in Origin 9.0 to a Hill fit equation for each data 
set where y is the initial velocity, and x is the concentration of L-Phe.  Vmax, k, and n are 
experimentally derived kinetic parameters, and Vi is the initial velocity at the lowest 
concentration tested.  
                
  
     
  
4.2.4 Fluorescence titrations with the Trp mutant enzymes 
Intrinsic shifts in the fluorescence emission maxima for the Trp mutant enzymes 
were determined in the presence of L-Phe using a FluoroMax 3 (Horiba Jobin Yvon) 
fluorescence spectrometer with external temperature control as discussed in Chapter 3.  
Emission spectra were obtained at 25 ºC after a 5 minute incubation time after addition of 
the substrate.  The enzyme concentration was 2 mg/ml (38 µM) while the final L-Phe 
concentration ranged from 0-2000 μM in 0.1 M potassium phosphate buffer pH 6.8.  The 
excitation wavelength was 293 nm, with 5 nm slit widths and the emission scans were 
taken from 320-370 nm with 5 nm slit widths.  Emission spectra for buffer containing L-
Phe at all concentrations studied were subtracted from the corresponding protein spectra.  
Peak maxima were found using non-linear least squares fitting of subtracted emission 
spectra using Origin 9.0. Alexandria Georgadarellis assisted with performing 
fluorescence titrations on many of the mutant enzymes. 
4.2.5 Stopped flow fluorescence spectroscopy of the Trp mutant enzymes 
 Variable temperature stopped flow fluorescence spectroscopy of the Trp mutant 
enzymes was conducted to enable direct estimation of the activation energies for the 
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various kinetic steps in these enzymatic processes.  The observed kinetic steps will be 
used to elucidate general pathways of the overall fluorescence transitions in wtPAH upon 
incubation with L-Phe.  These measurements were conducted using a Hi-Tech SF-61DX2 
double mixing stopped-flow spectrophotometer (Salisbury, United Kingdom) with 
thermal attachments set up in fluorescence mode.  The instrument was operated in single 
mixing mode with the first syringe containing the protein solution (20-60 μM in 50 mM 
MOPS/0.3 M KCl pH 7.2) and the second syringe containing L-Phe (10 mM in 50 mM 
MOPS/0.3 M KCl pH 7.2).  These solutions were mixed and diluted 1:1 before kinetic 
assays were obtained.  The data was collected with excitation of the instrument at 290 nm 
using a cutoff filter at 320 nm.  Due to limitations of the instrument, it is not possible to 
monitor a particular spectral range, so instead absolute fluorescence intensity changes 
after excitation at 290 nm were recorded.  The absolute intensity shifts are given as 
percentage intensity of the solution used to blank the instrument.  Specifically in our 
stopped flow fluorescence assays, the instrument was blanked with 10-30 µM PAH in 50 
mM MOPS/0.3 M KCl pH 7.2.  The maximum (100%) intensity of a sample was 
recorded from the tryptophan fluorescence of a PAH sample used to blank the 
spectrometer. All protein samples were examined over a wide range of temperatures (3-
30 ºC).  For each data set, 640 data points were obtained in log time base and data was fit 
using SpecFit/32 or ReactLabKINETICS for global kinetic analysis.  Global kinetic 
fitting using SpecFit/32 or ReactLabKINETICS was performed by generating a kinetic 
model with a number of first and second order steps, followed by mathematical fitting of 
that model to the data.  In SpecFit/32 there is no limit on the number of steps or species in 
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the model, while in ReactLabKINETICS, the model is limited to a maximum of 11 
species.  The fit line in ReactLabKINETICS is generated by subtracting the residual from 
the data, rather than individually generated by the software.  In SpecFit/32 the fit line is 
generated by the software, and the residual is generated by subtraction of the fit from the 
data.  This results in somewhat noisier fit lines in data simulated by ReactLabKINETICS, 
as the noise of the actual data is noted in the fit to the data. 
4.3  Results 
4.3.1 Preparation of the Trp mutant enzymes 
 The Trp mutant enzymes were purified by established protocols from the 
Caradonna lab, which were adapted from the purification by Shiman (123).  Routine 
characterization of the mutant enzymes included enzymatic activity (123), active iron 
assays with catechol chelation to determine catalytically competent iron content, and total 
iron content that have been discussed previously.  Protein purity was determined by SDS-
PAGE.  Alexandria Georgadarellis assisted with the mutagenesis, purification, and 
kinetic assays of W120F-PAH, W120F/W187F-PAH, and W120/W326F-PAH. 
4.3.2 Kinetic analysis of the Trp mutant enzymes 
 Steady-state kinetic assays were performed on the Trp to Phe mutant enzymes to 
compare their activity and measured cooperativity to that of the wild-type enzyme.  All of 
these mutant enzymes demonstrated appreciable, although reduced (5-7 fold), activity 
compared to wtPAH (Figure 4.3).  Studies examining the L-Phe dependent kinetic 
properties using 6MPH4 as the coenzyme, showed that only two (W187F-PAH and 
W326F-PAH) of the six Trp to Phe mutant enzymes exhibited cooperative behavior.  The 
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other Trp to Phe mutant enzymes (W120F-PAH, W120F/W187F-PAH, W120F/W326F-
PAH, and W187F/W326F-PAH) did not demonstrate cooperativity as judged by the 
inability to fit the L-Phe-dependent kinetic data to a Hill equation in Origin 9.0, as 
discussed in the Experimental Methods.  Plots of the kinetic fits of these mutant 
enzymes are shown in Figure 4.3 and extrapolated kinetic parameters are given in Table 
4.3.   
 
 
 
Figure 4.3 Fits of L-Phe dependent kinetics of Trp to Phe mutations of wtPAH.  All Trp 
to Phe mutant enzymes were fit with a Hill equation in Origin 9.0 to extrapolate kinetic 
parameters, as explained in the Experimental Methods. The data are representative of 
five independent replicates.  a) W120F-PAH; b) W187F-PAH; c) W326F-PAH; d) 
W120F/W187F-PAH; e) W120F/W326F-PAH; f) W187F/W326F-PAH. 
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Table 4.3 Kinetic parameters of Trp to Phe mutations of wtPAH. Uncertainty was 
derived from kinetic fits to the data using a Hill equation in Origin 9.0. 
Enzyme KM, L-Phe (μM) Vmax (units/mg) kcat (s
-1
) Hill Coefficient (L-Phe) 
wtPAH 180 ± 10 7.80 ± 1.0 6.8 ± 0.9 2.4-2.6 
W120F-PAH 150 ± 30 1.37 ± 0.07 1.2 ± 0.1 0.7 ± 0.1 
W187F-PAH 600 ± 60 1.42 ± 0.03 1.2 ± 0.1 3.0 ± 0.9 
W326F-PAH 610 ± 40 1.16 ± 0.02 1.0 ± 0.1 3.3 ± 0.5 
W120F/W187F-PAH 420 ± 30 1.68 ± 0.06 1.5 ± 0.1 1.1 ± 0.1 
W120F/W326F-PAH 230 ± 50 1.96 ± 0.06 1.7 ± 0.1 0.6 ± 0.2 
W187F/W326F-PAH 690 ± 140 1.8 ± 0.1 1.6 ± 0.1 0.7 ± 0.1 
 
The decreased activity of each of the enzymes is fairly consistent with many 
PKU-inducing mutations to PAH that have been studied previously in the Caradonna 
Lab.  The affinity of L-Phe in the mutant enzymes varies with the particular location of 
the Trp mutation.  The KM, L-Phe values are somewhat increased in W187F-PAH, W326F-
PAH, and W187F/W326F-PAH, indicating that these mutant enzymes may bind L-Phe 
more weakly.  The effect of 6MPH4 or BH4 binding to these enzymes is not yet studied, 
so it is currently uncertain whether the weakened affinity for the active site is a direct 
consequence of localized structural perturbations to just the substrate binding site or if the 
weakened affinity is a byproduct of more global structural perturbations throughout the 
protein domain.  The mutant enzymes that remove Trp120 (W120F-PAH, 
W120F/W187F-PAH, W120F/W326F-PAH) each exhibit KM, L-Phe values closer to that of 
the wild-type enzyme, suggesting that active site L-Phe binding is not significantly 
altered in these enzymes.  These data help to explain the data SAW biosensing data for 
W120F-PAH from Chapter 3, which only showed one L-Phe dependent binding 
transition about 500 µM (KD,app
on
 510 ± 20 µM), while wtPAH demonstrates two binding 
transitions (KD,app
on
 110 ± 10 µM and 680 ± 20 µM for the active and allosteric sites 
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respectively).  The SAW-based binding transition in W120F-PAH is therefore associated 
with the allosteric site, since our kinetic studies show that L-Phe active site binding in 
W120F-PAH occurs with a KM, L-Phe of 150 ± 30 µM.  
Mutation of Trp to Phe, replaces the larger Trp residue (Van der Waals volume of 
163 Å
3
) with a smaller Phe residue (Van der Waals volume of 135 Å
3
) (218).  The 
smaller residue will result in under-packing of the interior domain for W187F-PAH and 
W326F-PAH, but not in the case of W120F-PAH which is located on the surface of the 
catalytic domain.  This under-packing may provide an opportunity for other side chains to 
move and alter direct communication pathways throughout the enzyme.  These kinetic 
assay results also indicate that there is an alteration in communication between subunits 
when Trp120 is changed in wtPAH.  Our current understanding of L-Phe induced 
activation in PAH assumes that L-Phe binds to one subunit of the protein in a surface 
exposed allosteric binding site, which activates the subunit and induces a conformational 
change in that subunit.  Ultimately, the tetrameric wild-type protein undergoes an 
allosteric cooperative process, implying that there is communication between individual 
subunits of the quaternary protein. 
Trp120 is the closest Trp residue to the allosteric effector binding site located and 
discussed in Chapter 2 (approximately 9 Å from the allosteric site).  Altering Trp120 to 
Phe does not appear to affect allosteric activation in the same manner as with the 
allosteric site mutants discussed in Chapter 2 (K113R-PAH and V118T-PAH).  The 
W120F-PAH enzyme undergoes a hydrophobicity change upon L-Phe binding and 
demonstrates a 4 nm shift in the fluorescence maximum as discussed in Chapter 3.  It is 
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likely that the W120F mutation interferes with the direct communication of the one 
subunit that has undergone an allosteric conformational change to other subunits.  This 
process is therefore non-cooperative and requires that each subunit must individually 
bind L-Phe to each surface activation site prior to individually undergoing conformational 
changes.  The two double mutants containing the Trp120 to Phe change (W120F/W187F-
PAH and W120F/W326F-PAH) also demonstrate the loss of cooperative activation.  This 
loss of cooperativity may either support the direct importance of Trp120 in inter-subunit 
communication and signaling, or simply reflect changes in local/global structural 
dynamics that negate inter-domain cooperative interactions.   
Interestingly, both W187F-PAH and W326F-PAH demonstrate cooperative 
behavior, suggesting that small perturbations to the enzyme structure, away from the 
allosteric site of the enzyme, which alter the KM, L-Phe  in the active site, do not appear to 
cause an immediate reduction in cooperative activation processes.  The region of the 
interior structure of PAH altered in either W187F-PAH or W326F-PAH is therefore 
unlikely to be directly or indirectly involved in the transmission of the structural changes 
involved in the cooperative process.  The W187F/W326F-PAH double mutant, however, 
does display a lack of cooperativity, with n = 0.7 ± 0.1, which is the same as was 
observed for W120F-PAH.  Additional structural perturbations may occur when multiple 
large residues are replaced with smaller residues and these changes have an additive 
effect on cooperative processes in PAH. 
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4.3.3 Fluorescence titrations with the Trp mutant enzymes 
The fluorescence titrations of the Trp mutant enzymes with L-Phe indicate 
potential reporter roles and contributions of each individual Trp residue to the overall 
fluorescence spectra of PAH.  The fluorescence titration spectra of wtPAH with L-Phe 
was examined in Chapter 3, and demonstrated the presence of two features 
corresponding to L-Phe binding in the active site at low L-Phe concentration (~200 µM) 
and L-Phe binding in the allosteric site at higher L-Phe concentrations (1125-1195 µM) 
(Figure 4.4a, 4.43 in the Appendix to Chapter 4).  The fluorescence intensity shift of 
dimeric PAH was also studied in Section 3.4.3.  These data in Figure 4.4b, demonstrate 
that NEM-modified dimeric PAH, does not undergo any appreciable fluorescence shift 
with L-Phe.  It is therefore implied that dimeric PAH does not report fluorescence 
changes with L-Phe and that we are only able to observe fluorescence changes in the 
tetrameric enzyme.  The fluorescence titration spectra of W120F-PAH, was also 
examined in Chapter 3 (Figure 4.4c).  This spectrum does not show the feature for L-
Phe binding in the active site, but only demonstrates L-Phe binding in the allosteric site at 
concentrations of about 600 µM or higher, as our kinetic fits suggest L-Phe binding in the 
active site at 150 µM.  These fluorescence titrations, in conjunction with the steady state 
kinetic data, for both wtPAH and W120F-PAH, have been used to help explain the SAW 
titration data.  These data show two L-Phe binding responses in wtPAH, but only one 
observable L-Phe binding site W120F-PAH that corresponds to L-Phe interacting with 
the surface allosteric site.   
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Figure 4.4 Normalized fluorescence shifts of wtPAH and related proteins upon 
incubation with varying concentrations of L-Phe or D-Phe. All panels wtPAH + L-Phe, 
black; a) wtPAH + D-Phe, red; b) wtPAH-NEM + L-Phe, yellow; c) W120F-PAH + L-
Phe, magenta; d) W187F-PAH + L-Phe, orange; e) W326F-PAH + L-Phe, violet; f) 
W120F/W187F-PAH + L-Phe, green; g) W120F/W326F-PAH + L-Phe, cyan; h) 
W187F/W326F-PAH + L-Phe, blue. 
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With a better understanding of the impact of fluorescence shifts in PAH, we 
performed and compared fluorescence titration experiments of each of the Trp to Phe 
mutant enzymes in order to analyze the fluorescence contributions reported by each 
individual Trp residue (Figures 4.4-4.5).   W187F-PAH (Figure 4.4d) shows a small 
shift of approximately 1 nm at very low L-Phe concentrations and then shows and an 
additional 1-1.5 nm shift at higher concentrations (~600 μM).  Both W326F-PAH and 
W187F/W326F-PAH (Figure 4.4e,h) show an immediate fluorescence shift of about 2 
nm at low L-Phe concentrations (< 100 μM) and then level off, no further shift in the 
fluorescence maximum with increasing concentration of L-Phe.  The W187F/W326F-
PAH double mutant indicates that the only Trp residue present in that enzyme, Trp120, 
reports active site binding rather than allosteric site binding, despite its location 9 Å from 
the allosteric site and 23 Å from the active site. 
The remaining two double Trp to Phe mutants give the best insight into potential 
reporter assignments of the individual L-Trp residues to the overall fluorescence of PAH.  
W120F/W187F-PAH (Figure 4.4f) demonstrates a small gradual shift in the fluorescence 
emission maximum of the protein by about 1 nm as the L-Phe concentration is increased 
from 0-1000 µM and then remains constant as a 1 nm shift at higher concentrations.  
W120F/W326F-PAH (Figure 4.4g) demonstrates no shift in the fluorescence emission 
maximum until about 500 µM L-Phe, and then shifts by approximately 3 nm, like the 
W120F-PAH enzyme.  This fluorescence signature suggests that Trp187, which is the 
only Trp residue present in this enzyme, is the major contributor to the shift in 
fluorescence corresponding to structural changes induced by the allosteric activation 
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process.  The contribution of Trp326 to the overall fluorescence spectrum of the wild-
type enzyme is quite small, and it is seen to report both active site binding and allosteric 
activation by L-Phe.   
The physical distances of the Trp residues from the sites they report suggest that 
the changes in the fluorescence maximum of the protein may be due to differences in the 
dynamics of the individual Trp environments.  As L-Phe induced activation occurs, it is 
possible that Trp120 moves closer to the active site and Trp187 moves closer to the 
allosteric site, likely in an adjacent subunit.  Early reports of PAH crystal structures 
suggested that the flexible loop from residues 111-117, which we have shown to be the 
allosteric effector binding site (see Chapter 2), would be involved in interactions with 
the active site upon L-Phe binding (14).  Trp187 might therefore need to move to support 
these interactions, and it could move closer to one of the allosteric sites in adjacent 
subunits as the allosteric site in the same subunit is 40 Å away, while the allosteric sites 
in adjacent subunits are approximately 45 Å away.  The fluorescence signatures of the 
individual Trp residues in PAH are summarized in Figure 4.5. 
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Figure 4.5 Fluorescence signatures for the individual Trp residues in PAH and wtPAH. 
a) Individual fluorescence signatures of the Trp mutant proteins; b) B-spline fit to each 
protein's fluorescence signature (black, blue, cyan, and green) in Origin 9.0.  A sum of 
the fluorescence shifts of each of the mutant proteins are shown in wine and fit with a B-
spline fit in Origin 9.0. 
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4.3.4 Stopped flow fluorescence spectroscopy 
 Stopped flow fluorescence spectroscopy was used to probe the kinetics of the 
fluorescent changes discussed above in order to understand the L-Phe induced activation 
processes in the Trp mutant enzymes.  Typically time resolved fluorescence studies of 
proteins are performed in systems with only one Trp residue in order to simplify the 
kinetic spectra.  In many proteins, site-directed mutagenesis is used to remove additional 
Trp residues for these time resolved studies.  Our work will utilize the single and double 
Trp mutant enzymes to develop a working kinetic model based on our observations from 
the fluorescence titration and steady-state kinetics of these enzymes.   While the Trp 
mutant enzymes do not all exhibit cooperativity as wtPAH, they all undergo an activation 
process with L-Phe that we can study with time resolved methods.   
 In our analysis of the Trp mutant enzymes, we analyzed data from approximately 
3-30 ºC and at time scales of 1-100 s, in a log base time scale that collects more data 
points at early time intervals, and fewer data points later in the collection time.  We found 
that the data sets typically reached a saturating curve within about 10 s, and therefore we 
analyzed the data within the first 10 s.  The L-Phe concentration ranged from 167-500 
times greater than that of the protein concentration (final concentrations after mixing: 5 
mM L-Phe, 10-30 µM enzyme). The dead time of our instrument when operating in 
fluorescence mode was determined to be 10-15 msec, using bathophenanthroline as a 
spectroscopic probe.  The residuals of the kinetic fits represent how well the kinetic 
model describes the data.  Time intervals where the model fits well to the data are a 
straight line at zero intensity, while time intervals where the model fits poorly to the data 
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are typically bumps or curves in the residual. In our kinetic models shown herein, the T-
state state of the enzyme is shown as squares, and the R-state of the enzyme is shown as 
circles.  L-Phe binding to the active site is represented by L-Phe inside the square or 
circle, while L-Phe binding to the allosteric site is represented by L-Phe on the outside of 
the square or circle.  Active site rearrangement is noted with an asterisk (*). Tetrameric 
species include four squares or circles arranged in a block, while dimeric species include 
two squares or circle arranged vertically. 
 Our kinetic studies also require several initial assumptions: i) PAH in our kinetic 
mechanisms remains tetrameric unless otherwise stated in the specific model (this will be 
discussed more in Section 4.4.2); ii) there is no photo bleaching of protein samples in the 
optical cell; iii) the only second order processes occurring are the binding of enzyme and 
L-Phe; and iv) the system is operating under pseudo-first order conditions in L-Phe.  
Additionally, it is important to note that these mutant enzymes are all undergoing the 
same processes that occur in wtPAH.  However, due to the fluorescence signatures of the 
various reporting Trp residues, we may or may not directly observe signals originating 
from each of the processes that occur with the wild-type enzyme.  The kinetic 
mechanisms that we have developed herein correspond to the data observed in the 
fluorescence titrations and binding phenomena. 
 The Trp mutant enzymes demonstrated significant differences in fluorescence 
spectral intensity as a function of temperature, with the observation of significant 
fluorescence signal bleaching with increasing temperature.  It is also important to note 
that while each of the higher temperature data sets can easily be fit with quite simple 
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models (two-step models such as A + B  C (k1) and C  D (k2) work quite well, 
Figure 4.6b), these models totally fail when applied to lower temperature (3-5 ºC) data 
(Figure 4.6a-b).  Efforts to simulate such temperature-dependent kinetic data 
consistently show that the various steps involved in the independent binding of L-Phe to 
both the active and allosteric sites and subsequent structural reorganizations are 
condensed (i.e., the fluorescence changes are insensitive to distinct steps) at higher 
temperatures.  Such a phenomenon is expected when the individual activation energy 
barriers are sufficiently small enough versus the bath temperature and when the 
magnitudes of the individual rates for a given stepwise binding or structural change in the 
homotetrameric form of the enzyme are relatively close to each other.  Consequently, 
additional steps are recognized at lower temperatures and should be included in any 
kinetic model over the full temperature range of investigation. For these reasons, we 
chose to analyze and simulate the lowest temperature data points first (3-5 ºC), as they 
more likely represent a complete description of all of the processes occurring in any 
proposed mechanism for the Trp mutant enzymes.  Observations indicate that the 
successful simulation of low temperature kinetic data lead to acceptable fits to the higher 
temperature data.  These types of analyses assume that these same observable 
mechanistic steps occur at higher temperatures, even though the maintenance of an 
enhanced number of individual steps is not necessary for an acceptable mathematical fit 
to the higher temperature data. 
 Initial analyses of the data were fit to a simple model where A + B  C (k1) and 
then C  D (k2), which is consistent with L-Phe binding to the protein followed by an 
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allosteric conformational change.  Kinetic modeling of these data involved two steps: k1 
as a fast binding step, followed by k2 as a slower conformational change step.  This model 
was applied to the data with little success, as many of these observed processes could not 
be adequately fit mathematically with only two steps as can be seen by the significant 
sinusoidal deviation of the residuals (Figure 4.6b-g).  Numerous attempts were made to 
alter the individual rates of these steps to help the model better fit the data, but accurate 
fits were not obtained without additional kinetic steps.  In order to further study the time 
dependent fluorescence spectra of the Trp mutant enzymes with L-Phe a more 
comprehensive global kinetic fitting approach was used for these enzymes.  In each of 
these mutant enzymes, two major changes were observed: a fast step likely corresponding 
to L-Phe binding and slow step likely corresponding to conformational change. 
Additional fitting steps, however, were required to develop a working kinetic mechanism 
for these mutant enzymes. 
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Figure 4.6 Kinetic fits of 10-30 µM of each of the Trp mutant enzymes with 5 mM L-Phe 
based on a two step fit (A + B  C, k1; C  D, k2).  The fits were obtained using global 
kinetic analysis with ReactLabKINETICS. a) 30 µM W120F/W187F-PAH, 3.1 ºC; b) 30 
µM W120F/W187F-PAH, 25ºC; c) 30 µM W120F/W326F-PAH, 3.3 ºC; d) 10 µM 
W187F/W326F-PAH, 5.3 ºC; e) 10 µM W120F-PAH, 4.0 ºC; f) 30 µM W187F-PAH, 3.5 
ºC; g) 10 µM W326F-PAH, 3.6 ºC. 
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 Numerous fits examining additional kinetic and mechanistic models were 
attempted for each of the Trp mutants at low temperature (3-5 ºC), which included 
additional steps to explain the kinetic processes occurring in these enzymes, only some of 
which are shown herein.  The approach utilized in these studies involves identifying 
kinetic fits (i.e., a series of first and second order steps) to the data, and then proposing 
physical processes based on the acceptable kinetic models.  When four to six-step kinetic 
simulations were attempted, poor fits to the data were globally obtained.  When a greater 
number of kinetic steps were attempted (8+) much closer fits to the data were obtained.  
There is a limit to the number of kinetic steps we can justify with our current 
understanding of the system; however, when we try to reduce the number of kinetic steps 
below eight, the kinetic models do not fit well to the data.  Given our current control of 
the experimental system and global kinetic fitting software, we cannot accurately 
determine the number of steps in the L-Phe induced activation process nor their absolute 
rates; however, we are able to provide kinetic models that enable us to propose 
intermediates for further studies by kinetic (pre-loading active site (Chapter 3) or using 
mutants that preclude allosteric site binding (Chapter 2) and spectroscopic (EPR-based 
rapid-freeze quench studies using build-up curves obtained from kinetic models) 
methods.  The following studies should be interpreted as general evidence for complex 
pathways involving a large number of steps. The following section intends to explain the 
attempted and current working kinetic models for the Trp mutant enzyme fluorescence 
with L-Phe.   
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4.3.4.1 W120F/W187F-PAH with L-Phe 
 The double Trp mutant W120F/W187F-PAH, which only contains Trp326, was 
expected to report a small fluorescence signal resulting from active site L-Phe binding as 
well as small fluorescence signal from L-Phe binding in the allosteric site based on 
previous fluorescence titration data (vide supra).  The overall fluorescence signal 
intensity for this mutant enzyme was expected to be relatively low, since there is only one 
Trp residue present, which contributes about 26% of the overall fluorescence signal in 
wtPAH (124).  Additionally, this mutant enzyme is not cooperative (n = 1.1 ± 0.1) as 
shown from steady state kinetic studies, which suggests that these processes likely occur 
independently in each subunit.  These results suggested that there may be a role for L-Phe 
induced active site and allosteric site conformational changes in the stopped flow 
fluorescence signals, however, these signals are so low in intensity that they may not be 
easily discriminated or determined in our kinetic model.  We will now discuss a partial 
series of kinetic mechanisms considered for this enzyme.  An example of an additional 
mechanism that did not fit the data well is shown in the Appendix to Chapter 4 (Figure 
4.44). 
 An initial simplistic kinetic model for W120F/W187F-PAH involved L-Phe 
binding to the allosteric site of all subunits of the protein, followed by subsequent binding 
of L-Phe to the active site of each subunit (Eqs. 1-8, Figure 4.7).  In this model, "A" is 
the tetrameric resting state enzyme, which binds L-Phe (B) to form the L-Phe bound 
species, C.  This L-Phe binding process continues in each subsequent binding step as 
depicted in Eqs. 1-8.  This model could also be represented as L-Phe binding to the active 
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site first, and then binding to the allosteric site second, as the models are the same from a 
kinetic perspective.  This overall model, which did not fit well to the data at 3.1 ºC, gave 
a sinusoidal residual as shown in Figure 4.8.  
     A + B → C k1   (Eq. 1) 
     B + C → D k2   (Eq. 2) 
     B + D → E  k3   (Eq. 3) 
     B + E → F  k4   (Eq. 4) 
     B + F → G k5   (Eq. 5) 
     B + G → H k6   (Eq. 6) 
     B + H → I k7   (Eq. 7) 
     B + I → J k8   (Eq. 8) 
 
Figure 4.7 Possible mechanism for W120F/W187F-PAH with L-Phe fluorescence. 
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Figure 4.8 Kinetic fit of 30 µM W120F/W187F-PAH with 5 mM L-Phe at 3.2 ºC to the 
model proposed in Figure 4.7 (Eqs. 1-8). The data is shown in black while the fit is 
shown in red; the inset shows the residual of the fit. 
 
 The time-dependent fluorescence data were then fit to a different mechanism, 
where L-Phe binds effectively simultaneously in the active and allosteric sites of one 
particular subunit, and the enzyme continues to bind L-Phe sequentially until each of the 
subunits are filled.  At that point the subunits undergo sequential conformational changes 
to the activated state (Eqs. 9-16, Figure 4.9).  The first four steps of this mechanism are 
second order processes, while the subsequent four steps are first order processes.  This fit, 
Figure 4.10, was a better fit, but still showed residual features in the first two seconds, 
indicative of incomplete portrayal of early time processes.   
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     A + B → C k1   (Eq. 9) 
     B + C → D k2   (Eq. 10) 
     B + D → E  k3   (Eq. 11) 
     B + E → F  k4   (Eq. 12) 
     F → G  k5   (Eq. 13) 
     G → H k6   (Eq. 14) 
     H → I  k7   (Eq. 15) 
     I → J  k8   (Eq. 16) 
 
 
Figure 4.9 Proposed mechanism for W120F/W187F-PAH with L-Phe fluorescence. 
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Figure 4.10 Kinetic fit of 30 µM W120F/W187F-PAH with 5 mM L-Phe at 3.2 ºC to the 
model proposed in Figure 4.9 (Eqs. 9-16). The data is shown in black while the fit is 
shown in red; the inset shows the residual of the fit. 
 
 A nine-step mechanism, where an active site L-Phe binding step was added after 
individual binding of L-Phe to the allosteric sites of each of the subunits and subsequent 
conformational change, was also examined (Eqs. 17-25, Figure 4.11).  While the 
residual of this fit was comparable to that observed for the eight-step mechanism 
proposed in Figure 4.9,  there was, however, a very high standard deviation for the rates 
k6 and k9 (Figure 4.12, Table 4.10).  The high standard deviation for these two steps 
suggests that this mechanism may provide more parameters than can be explained by the 
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data.  The simplest mechanism that fits the data is preferred, therefore this mechanism 
does not provide justification for an additional step. 
     A + B → C k1   (Eq. 17) 
     B + C → D k2   (Eq. 18) 
     B + D → E  k3   (Eq. 19) 
     B + E → F  k4   (Eq. 20) 
     F → G  k5   (Eq. 21) 
     G → H k6   (Eq. 22) 
     H → I  k7   (Eq. 23) 
     I → J  k8   (Eq. 24) 
     B + J → K k9   (Eq. 25) 
Since the residual for the nine-step mechanism proposed in Figure 4.11, was not better 
than the eight-step mechanism proposed in Figure 4.9, the simpler mechanism was 
accepted as the working mechanism for W120F/W187F-PAH with L-Phe.  Additional 
mechanistic schemes were attempted did not converge to the data mathematically.  An 
example of one of those mechanistic schemes is shown in the Appendix (Figure 4.44). 
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Figure 4.11 Possible mechanism for W120F/W187F-PAH with L-Phe fluorescence. 
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Figure 4.12 Kinetic fit of 30 µM W120F/W187F-PAH with 5 mM L-Phe at 3.2 ºC to the 
model proposed in Figure 4.11 (Eqs. 17-25). The data is shown in black while the fit is 
shown in red; the inset shows the residual of the fit. 
 
 Stopped flow fluorescence spectra from 3.1-24.6 ºC were fit to the model in 
Figure 4.9, and fits are shown in Figures 4.10, 4.45-4.48 (higher temperature data is 
provided in the Appendix to Chapter 4).  These data were extrapolated to determine an 
Arrhenius activation energy plot (Figure 4.13) and the activation parameters are provided 
in Table 4.4. The activation parameters show that the L-Phe binding steps to the active 
and allosteric sites, occur rapidly with minimal activation energy, while the subsequent 
conformational change steps occur more slowly with a greater activation barrier (~10 
kcal/mol). These data are likely indicative of the additional energy required to re-orient 
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and reorganize each individual subunit of the enzyme to undergo conformational 
changes.  
 
 
Figure 4.13 Temperature dependent Arrhenius activation energy plot for the reaction of 
W120F/W187F-PAH with L-Phe. 
 
 
Table 4.4 Temperature dependent Arrhenius activation energies for intermediates in the 
reaction of W120F/W187F-PAH with L-Phe. 
 
Reaction Rate Activation Energy 
(kcal/mol) 
A + B → C k1 2.0 ± 1.0 
B + C → D k2 0.4 ± 0.2 
B + D → E k3 0.1± 0.2 
B + E → F k4 1.4 ± 0.5 
F → G k5 7.8 ± 1.8 
G → H k6 9.0 ± 4.0 
H → I k7 7.2 ± 3.3 
I → J k8 11.2 ± 1.6 
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4.3.4.2 W120F/W326F-PAH with L-Phe 
 The W120F/W326F-PAH double mutant enzyme only contains Trp187 that is the 
primary reporter of the structural changes induced by allosteric site binding (vide supra).  
Additionally, this mutant enzyme was expected to have the lowest signal intensity, as 
Trp187 been shown to only contribute 13% of the overall fluorescence intensity in 
wtPAH (124).  This double mutant was shown to be non-cooperative by steady-state 
kinetic analysis, which again implicates the removal of Trp120 with alteration of inter-
subunit communication.  We expected that W120F/W326F-PAH would only demonstrate 
L-Phe binding to the allosteric site and subsequent conformational changes, given its 
fluorescence titration signature, and that these processes would occur independently in 
each subunit due to the lack of cooperativity between subunits in this enzyme.  
 The W120F/W326F-PAH mutant demonstrated an initial rapid decrease followed 
by a slower increase in fluorescence intensity as a function of time.   It should be noted 
that these signals were also quite small, and required higher concentrations of enzyme (30 
µM after mixing) to observe appreciable fluorescence signals.  An initially proposed 
mechanism (Eqs. 26-33, Figure 4.14) accounts for the direct binding of L-Phe to 
allosteric site and subsequent conformational change.  This mutant did not demonstrate 
cooperativity according to kinetic studies, so each subunit was reported to bind L-Phe and 
undergo conformational change separately.  This mechanism fit quite well to the data 
with very little deviation in the residual as shown in Figure 4.15.  
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     A + B → C k1   (Eq. 26) 
     B + C → D k2   (Eq. 27) 
     B + D → E  k3   (Eq. 28) 
     B + E → F  k4   (Eq. 29) 
     F → G  k5   (Eq. 30) 
     G → H k6   (Eq. 31) 
     H → I  k7   (Eq. 32) 
     I → J  k8   (Eq. 33) 
  
 
Figure 4.14 Proposed mechanism for W120F/W326F-PAH with L-Phe fluorescence. 
252 
 
 
 
 
Figure 4.15 Kinetic fit of 30 µM W120F/W326F-PAH with 5 mM L-Phe at 3.2 ºC to the 
model proposed in Figure 4.14 (Eqs. 26-33). The data is shown in black while the fit is 
shown in red; the inset shows the residual of the fit. 
 
 An additional model was also examined where L-Phe would bind to one subunit, 
and then immediately undergo conformational change in that subunit, followed by 
additional L-Phe binding and conformational change in each subunit until the all four 
subunits had completed the activation process. This process, which was modeled by Eqs. 
34-41, is shown in Figure 4.16. 
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     A + B → C k1   (Eq. 34) 
     C → D  k2   (Eq. 35) 
     B + D → E  k3   (Eq. 36) 
     E → F  k4   (Eq. 37) 
     B + F → G k5   (Eq. 38) 
     G → H k6   (Eq. 39) 
     B + H → I k7   (Eq. 40) 
     I → J  k8   (Eq. 41) 
The when this model was applied to the data, it showed a slightly noisier residual with 
sinusoidal character (Figure 4.17), implying that the model is not better supported by the 
data than the previous model in Figure 4.15.  This fit suggested that the first model of L-
Phe binding to all subunits, followed by consecutive conformational changes was a better 
fit to the data.  Other models attempted to fix rates of the model in Figure 4.14, but 
would not converge to the data.  Given the lack of cooperativity in this enzyme, the 
models tested were expected to bind L-Phe and undergo conformational change 
independently, so many models were initially eliminated.  This model was applied to data 
from 3.2 - 30.4 ºC and fits are shown in Figures 4.15, 4.49-4.53.    
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Figure 4.16 Possible mechanism of W120F/W326F-PAH with L-Phe fluorescence. 
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Figure 4.17 Kinetic fit of 30 µM W120F/W326F-PAH with 5 mM L-Phe at 3.2 ºC to the 
model proposed in Figure 4.16 (Eqs. 34-41). The data is shown in black while the fit is 
shown in red; the inset shows the residual of the fit. 
 
 
 The rates obtained from a series of temperature-dependent fits were used to 
construct an Arrhenius activation energy plot (Figure 4.18) that yielded estimates of the 
activation energies for each step (Table 4.5).  The activation energy barrier for each the 
L-Phe binding steps are quite low (~ 2 kcal/mol), as is the activation energy barrier for 
each of the conformational change steps.  These data suggest that this mutant enzyme 
rapidly binds L-Phe and undergoes allosteric conformational change, which may be 
facilitated by direct reporting of the allosteric binding through Trp187.  
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Figure 4.18 Temperature dependent Arrhenius activation energy plot for the reaction of 
W120F/W326F-PAH with L-Phe. 
 
 
Table 4.5 Temperature dependent Arrhenius activation energies for intermediates in the 
reaction of W120F/W326F-PAH with L-Phe. 
 
Reaction Rate Activation Energy 
(kcal/mol) 
A + B → C k1 3.3 ± 1.2 
B + C → D k2 1.2 ± 0.5 
B + D → E k3 2.7 ± 0.8 
B + E → F k4 0.4 ± 0.2 
F → G k5 1.7 ± 0.7 
G → H k6 2.8 ± 1.2 
H → I k7 0.1 ± 0.2 
I → J k8 0.1 ± 0.2 
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4.3.4.3 W187F/W326F-PAH with L-Phe 
 The double Trp mutant enzyme, W187F/W326F-PAH also contains a single Trp 
residue, Trp120.  The fluorescence titrations with Trp120 demonstrated that this enzyme 
only reports active site L-Phe binding, and is insensitive to any allosteric binding or 
conformational change with increasing L-Phe concentrations (vide supra).  This mutant 
also demonstrated non-cooperative kinetics, suggesting that each subunit should undergo 
independent conformational changes.  The W187F/W326F-PAH mutant enzyme was 
similarly studied by stopped flow fluorescence spectroscopy.   
 Several possible mechanisms for kinetic fitting of this mutant were attempted.  At 
low temperature the enzyme demonstrated much more complicated fluorescence spectra, 
suggesting that multiple kinetic steps would be required and that there was likely an 
active site reorganization process occurring in this enzyme as has been previously 
observed for Δ1-117-PAH, wherein there are two binding sites for L-Phe in the active 
site, and L-Phe activation facilitates L-Phe movement from the T-state site to the R-state 
site (see Section 1.2.5 for more details) (50).  In this mutant, kinetic steps post active site 
L-Phe binding will not be observed, as the reporter chromophores do not exist.  However, 
if subunit (allosteric) reorganization induces the movement of L-Phe in the active site, 
then the time-dependent Trp120 fluorescence may reflect these changes. Initial kinetic 
fitting focused on the lowest temperature data, so that a mechanism including the active 
site reorganization could be tested. This spectrum (Figure 4.19) demonstrated a very fast 
decrease in fluorescence intensity over the first 250 ms, followed by short lag of about 
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250 ms, and then a slower increase in intensity for the duration of the observation time 
(10-100 s). 
 
Figure 4.19 Stopped flow fluorescence spectra of 10 µM W187F/W326F-PAH with 5 
mM L-Phe at 5.3 ºC. 
 
 
 These data were initially fit to an eight-step mechanism shown in Figure 4.20 
(Eqs. 42-49) where each subunit of wtPAH binds L-Phe individually in the active site 
and then immediately undergoes and active site reorganization or substrate binding site 
shift (noted by the star in the mechanism).  Please note that this may or may not be a 
different process than subunit activation and conformational change.   
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     A + B → C  k1   (Eq. 42)  
     C → D  k2   (Eq. 43) 
     B + D → E k3   (Eq. 44) 
     E → F  k4   (Eq. 45) 
     B + F → G k5   (Eq. 46) 
     G → H k6   (Eq. 47) 
     B + H → I k7   (Eq. 48) 
     I → J   k8   (Eq. 49) 
 
 
 
Figure 4.20 Possible kinetic mechanism for W187F/W326F-PAH fluorescence with L-
Phe. 
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Figure 4.21 Kinetic fit of 10 µM W187F/W326F-PAH with 5 mM L-Phe at 5.3 ºC to the 
model proposed in Figure 4.20 (Eqs. 42-49). The data is shown in black while the fit is 
shown in red; the inset shows the residual of the fit.  
  
 The fit to these data, shown in Figure 4.21, demonstrated a residual with a 
significant deviation of the residual from linearity.  This model also suggests that the 
process of L-Phe active site reorganization is completely uncoupled from cooperativity, 
as each subunit undergoes this transition independently.  This observation was not 
consistent with previously discussed kinetic data (Section 4.3.2, vide infra), so a new 
model was proposed.  The new model suggests that L-Phe binds in each of the active sites 
independently and is then followed by an active site reorganization that would occur in 
each of those binding sites (Eqs. 50-57, Figure 4.22). 
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     A + B → C  k1   (Eq. 50)  
     B + C → D k2   (Eq. 51) 
     B + D → E k3   (Eq. 52) 
     B + E → F k4   (Eq. 53) 
     F → G  k5   (Eq. 54) 
     G → H k6   (Eq. 55) 
     H → I  k7   (Eq. 56) 
     I → J   k8   (Eq. 57) 
 This set of equations provided a better fitting residual at low temperatures (Figure 
4.23) and were able to be fit at all temperatures (Figures 4.54-4.59).  The temperature 
dependent kinetic fits were used to determine the activation energy of L-Phe binding and 
active site reorganization in W187F/W326-PAH.  Several other models were attempted 
that examined dimer based activation mechanisms, which did not fit well to the data.  
Schemes for the additional mechanisms tested are shown in the Appendix (Figures 4.60-
4.61). 
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Figure 4.22 Proposed kinetic mechanism for W187F/W326F-PAH fluorescence with L-
Phe.  
 
 
 
 
Figure 4.23 Kinetic fit of 10 µM W187F/W326F-PAH with 5 mM L-Phe at 5.3 ºC to the 
model proposed in Figure 4.22 (Eqs. 50-57). The data is shown in black while the fit is 
shown in red; the inset shows the residual of the fit. 
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 The Arrhenius activation energies for each of the steps of L-Phe binding and 
active site reorganization were calculated and are reported below (Figure 4.24, Table 
4.6).  The activation barrier for each step of L-Phe binding are very low (~1 kcal/mol) for 
this double mutant enzyme, which is expected, as we are only able to observe active site 
binding of L-Phe that should occur rapidly at low concentrations of L-Phe.  Additionally, 
the steps for L-Phe dependent active site reorganization are also very low energy 
processes (>1 kcal/mol).  All four active site reorganization steps together may represent 
the ~5 kcal/mol process observed in Δ1-117-PAH (50), which has been associated with a 
likely reorganization of active site before catalysis. 
 
 
 
Figure 4.24 Temperature dependent Arrhenius activation energy plot for the reaction of 
W187F/W326F-PAH with L-Phe. 
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Table 4.6 Temperature dependent Arrhenius activation energies for intermediates in the 
reaction of W187F/W326F-PAH with L-Phe. 
 
Reaction Rate Activation Energy 
(kcal/mol) 
A + B → C k1 1.8 ± 1.3 
B + C → D k2 0.8 ± 0.4 
B + D → E k3 1.5 ± 0.4 
B + E → F k4 0.6 ± 0.1 
F → G k5 0.4 ± 0.1 
G → H k6 0.4 ± 0.1 
H → I k7 0.1 ± 0.05 
I → J k8 0.1 ± 0.05 
 
 
 
 
4.3.4.4 W120F-PAH with L-Phe 
 As described in Section 4.3.3, the W120F-PAH mutant enzyme demonstrates a 
fluorescence shift upon L-Phe allosteric activation of PAH.  However, the fluorescence 
titration of W120F-PAH, demonstrated no shift in the fluorescence maxima of the protein 
at low concentration of L-Phe and then demonstrated a shift of approximately 4 nm at L-
Phe concentrations greater than 500 µM.  This fluorescence shift was also correlated with 
a KD,app
on
 of 510 ± 20 µM for the SAW conformational change occurring with L-Phe 
binding in the allosteric site of PAH.  This enzyme has been demonstrated to be non-
cooperative (n = 0.7 ± 0.1) by enzyme kinetics, so the proposed kinetic mechanisms are 
expected to mirror this independent binding of L-Phe to each subunit, and subsequent 
independent subunit conformational change.  It was hypothesized that kinetic 
mechanisms for W120F-PAH would involve L-Phe binding to the allosteric site of the 
enzyme, followed by allosteric conformational change.  We did not expect to observe L-
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Phe binding to the active site because of the lack of a fluorescence shift at low 
concentrations of L-Phe.  
  Initially, kinetic fits to W120F-PAH with L-Phe fluorescence data included a 
possible pre-equilibrium of dimeric and tetrameric enzyme forms, prior to L-Phe binding.  
These mechanisms were considered as PAH exists in a pH and concentration dependent 
equilibrium (2*Dimer ↔ Tetramer).  In one of these possible models, both dimeric and 
tetrameric forms of W120F-PAH are initially present, however, only the tetrameric form 
can bind L-Phe and undergo the allosteric conformational change.  This assumption was 
made as it is known that dimeric forms of PAH do not require activation (49).  This 
model is shown in Figure 4.25, which was proposed with equal concentrations of species 
A and B present initially (Eqs. 58-67).      
     2*A → B  k1   (Eq. 58)  
     B + C → D k2   (Eq. 59) 
     C + D → E k3   (Eq. 60) 
     C + E → F k4   (Eq. 61) 
     C + F → G k5   (Eq. 62) 
     G → H k6   (Eq. 63) 
     H → I  k7   (Eq. 64) 
     I → J  k8   (Eq. 65) 
     J → K  k9   (Eq. 66) 
     K → L  k10   (Eq. 67) 
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This model was fit to the data in Figure 4.26, and shows a poor fit to the data 4.0 ºC.  
The data is noisy and the residual is sinusoidal suggesting that not all processes are fit by 
this mechanism.  Several other dimer-tetramer equilibrium-type processes were also 
tested and all showed poor fits to the data, additional examples of dimer-tetramer 
equilibrium mechanisms are shown in the Appendix (Figures 4.62-4.63).  Despite 
intensive efforts, we were unable to show the utility of the dimeric species in the kinetic 
process. 
 
 
Figure 4.25 Possible kinetic model for the fluorescence of W120F-PAH with L-Phe. 
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Figure 4.26 Kinetic fit of 10 µM W120F-PAH with 5 mM L-Phe at 4.0 ºC to the model 
proposed in Figure 4.25 (Eqs. 58-67). The data is shown in black while the fit is shown 
in red; the inset shows the residual of the fit. 
  
 
 
 Instead of the above mechanism, an eight-step mechanism was proposed 
(mechanism Figure 4.14, kinetic fit Figure 4.27).  In this mechanism, a dimeric species 
was not included, and L-Phe was assigned to directly bind to tetrameric W120F-PAH.  
This process, which is the same as the mechanism for W120F/W326F-PAH (Eqs. 26-33 
Figure 4.14), fit the data more closely with a smaller and more random residual (Figure 
4.27). 
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Figure 4.27 Kinetic fit of 10 µM W120F-PAH with 5 mM L-Phe at 4.0 ºC to the model 
proposed in Figure 4.13 (Eqs. 26-33). The data is shown in black while the fit is shown 
in red; the inset shows the residual of the fit. 
 
 
 Since the residual was still somewhat noisy, an additional fitting step was added 
to include an effect of the proposed active site rearrangement.  Studies with Δ1-117-PAH 
have observed a small (~5 kcal/mol) activation energy process involved with 
reorganization or rearrangement of the active site upon L-Phe binding prior to catalysis 
(50).  It was hoped that modeling this additional step would eliminate the additional noise 
in the residual.  This step could be modeled after either equation Eq. 71 (k4) or Eq. 75 
(k8) of the following set of reactions without any kinetic difference, and is shown in the 
following set of reactions as Eq. 76 (k9). 
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     A + B → C  k1   (Eq. 68)  
     B + C → D k2   (Eq. 69) 
     B + D → E k3   (Eq. 70) 
     B + E → F k4   (Eq. 71) 
     F → G  k5   (Eq. 72) 
     G → H k6   (Eq. 73) 
     H → I  k7   (Eq. 74) 
     I → J   k8   (Eq. 75) 
     J → K  k9   (Eq. 76) 
This additional step would allow all subunits of the protein to undergo this simultaneous 
active site rearrangement (Figure 4.28).  This process was not shown to be a better fit to 
the data than the previously obtained eight step process, as the residual in Figure 4.29 
showed more sinusoidal character than the earlier the eight-step fit in Figure 4.27. 
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Figure 4.28 Possible kinetic model for the fluorescence of W120F-PAH with L-Phe 
including active site rearrangement. 
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Figure 4.29 Kinetic fit of 10 µM W120F-PAH with 5 mM L-Phe at 4.0 ºC to the model 
proposed in Figure 4.28 (Eqs. 68-76).  The data is shown in black while the fit is shown 
in red; the inset shows the residual of the fit. 
 
 
 From these data, the eight step model in Figure 4.14 (Eqs. 26-33) was accepted 
as the best current fit to W120F-PAH data as it suggested a non-cooperative process 
where each subunit individually binds L-Phe and then each subunit individually 
undergoes a conformational change.  These processes are not necessarily linked and the 
rates of one step are not correlated with the next step.  When the kinetic rates of these 
steps are fixed such that the conformational changes are forced to speed up sequentially, 
such as in a cooperative process the data does not fit as well (Figure 4.30). 
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Figure 4.30 Kinetic fit of 10 µM W120F-PAH with 5 mM L-Phe at 4.0 ºC to the model 
proposed in Figure 4.14 (Eqs. 26-33), with the rates fixed to speed up in steps 5-8.  The 
data is shown in black while the fit is shown in red; the inset shows the residual of the fit. 
  
 The mechanism in Figure 4.14 was fit to the W120F-PAH with L-Phe data at 
variety of temperatures (4.0-29.9 ºC, Figures 4.27, 4.64-4.68).  These rate data were used 
to construct an Arrhenius activation energy plot  (Figure 4.31) and determine the 
activation energies (Table 4.7) of each step in the activation process.  The activation 
energy of the L-Phe binding steps show that activation barriers to bind the first two L-Phe 
molecules are very low (>1 kcal/mol), but subsequent L-Phe binding of the third and 
fourth L-Phe molecule is more challenging (~14 and 5 kcal/mol respectively).  
Additionally, for the conformational change steps, the activation energy for the first two 
conformational change steps are much higher (~4 and 10 kcal/mol respectively) than the 
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last two conformational change steps (~1 kcal/mol).  The activation steps are suggested to 
be independent processes and are not occurring with an inter-subunit cooperativity, which 
agrees with our kinetic data for this mutant enzyme. These models may not provide a 
perfect mechanism for this data, but are the best fits to the data that we have tested.  
Additional experimental work will be required to understand if these increases in the 
activation energy of k3 and k6 are real, or an artifact of this kinetic model.  
 
 
Figure 4.31 Temperature dependent Arrhenius activation energy plot for the reaction of 
W120F-PAH with L-Phe. 
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Table 4.7 Temperature dependent Arrhenius activation energies for intermediates in the 
reaction of W120F-PAH with L-Phe. 
 
Reaction Rate Activation Energy 
(kcal/mol) 
A + B → C k1 0.5 ± 0.2 
B + C → D k2 0.2 ± 0.3 
B + D → E k3 13.9 ± 0.3 
B + E → F k4 4.9 ± 0.1 
F → G k5 3.7 ± 0.2 
G → H k6 10.3 ± 0.6 
H → I k7 0.4 ± 0.1 
I → J k8 1.0 ± 0.1 
 
 
4.3.4.5 W187F-PAH with L-Phe 
 The W187F-PAH single Trp mutant enzyme showed a fluorescence shift of 
approximately 1 nm at low L-Phe concentrations, consistent with L-Phe binding in the 
active site.  The W187F-PAH mutant also demonstrated an additional shift of 
approximately 1 nm (total 2 nm fluorescence shift) at L-Phe concentrations greater than 
500 µM, which is consistent with allosteric site L-Phe binding.  Kinetic assays with this 
mutant still demonstrated cooperativity (n = 3.0 ± 0.9), suggesting that allosteric 
activation does occur with this mutant enzyme.  The cooperativity of the enzyme 
suggested that the kinetic mechanism for W187F-PAH may include effects of both active 
site L-Phe binding and allosteric site conformational change, however, both effects may 
not be observed due to signal intensity.  It is likely that the signal from Trp120, which is 
61% of the overall fluorescence signal intensity in wtPAH (124), would dominate the 
fluorescence of W187F-PAH.  Additionally, the signal of Trp326, is somewhat involved 
in reporting both allosteric site conformational change and active site organization, 
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however it only represents about 26% of the overall fluorescence in wtPAH (124), and 
therefore the contribution of Trp326 to the allosteric site L-Phe binding would be very 
small and may not be observed in this mutant.  
 The stopped flow fluorescence signals of the mutant enzyme were quite weak, 
and only remarkable at very low temperature (3.5 ºC) and high concentration (30 µM 
after mixing).  These signals were initially fit to a five-step model where L-Phe binds to 
subunit of the active site and then undergoes some simultaneous reorganization in all of 
the active sites (Eqs. 78-82, Figure 4.32).  This model was initially selected since this 
enzyme is cooperative. It was thought that a cooperative process may occur in all 
subunits essentially simultaneously, and therefore only one conformation change step 
would be required in this enzyme (k5). 
     A + B → C  k1   (Eq. 78) 
     B + C → D  k2   (Eq. 79) 
     B + D → E  k3   (Eq. 80) 
     B + E → F  k4   (Eq. 81) 
     F → G   k5   (Eq. 82)  
The data did not fit well to this model (Figure 4.33), and further models needed to be 
explored. 
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Figure 4.32 Possible kinetic model for the fluorescence of W187F-PAH with L-Phe 
including active site rearrangement. 
 
 
 
 
Figure 4.33 Kinetic fit of 30 µM W187F-PAH with 5 mM L-Phe at 3.5 ºC to the model 
proposed in Figure 4.32 (Eqs. 78-82). The data is shown in black while the fit is shown 
in red; the inset shows the residual of the fit. 
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 Several additional models were tested with active site L-Phe binding as a dimeric 
or tetrameric process with and without active site reorganization steps, but these were all 
unable to converge mathematically.  Examples of the models are given in the Appendix 
(Figures 4.69-4.70).  This led to the development of a new mechanism that included an 
eight-step model that proposed active site L-Phe binding to each subunit followed by 
subsequent active site reorganization steps in each subunit.  This is the same model that 
was proposed for the W187F/W326F-PAH double mutant.  This model, Eqs. 50-57, 
Figure 4.22, was fit to the data as shown in Figure 4.34.  The proposal was justified 
since the signal from Trp326 is quite small and contributes to both the active site binding 
signal and the allosteric binding signal. Since the active site binding signal from Trp120 
is so much larger than the small contribution to the allosteric site binding from Trp326, 
we are unable to observe allosteric conformation change in our fluorescence data.  
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Figure 4.34 Kinetic fit of 30 µM W187F-PAH with 5 mM L-Phe at 3.5 ºC to the model 
proposed in Figure 4.22 (Eqs. 50-57). The data is shown in black while the fit is shown 
in red; the inset shows the residual of the fit. 
 
 
 This model was a good fit to the data with a reasonably random residual.  
However, due to the fluorescence titration data suggesting the that W187F-PAH enzyme 
reported both active and allosteric site binding, an additional model was proposed with a 
L-Phe binding and activation step in all subunits after the active site binding and 
reorganization steps.  This model adds the additional step as the last step in the eight step 
kinetic model previously proposed (Eqs. 83-91, Figure 4.35). 
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     A + B → C  k1   (Eq. 83)  
     B + C → D k2   (Eq. 84) 
     B + D → E k3   (Eq. 85) 
     B + E → F k4   (Eq. 86) 
     F → G  k5   (Eq. 87) 
     G → H k6   (Eq. 88) 
     H → I  k7   (Eq. 89) 
     I → J   k8   (Eq. 90) 
     B + J → K k9    (Eq. 91) 
This model shows an equivalent fit to the data (Figure 4.36) as the eight-step model, 
however, it has a very high standard deviation for the fit of k9 (Table 4.15, in Appendix).  
For this reason, the eight-step model is favored as the model for W187F-PAH 
fluorescence with L-Phe.  The eight-step model fit well to the data at temperatures from 
3.5 - 27.2 ºC (Figures 4.34, 4.71-4.75) and was used to construct an Arrhenius activation 
energy plot (Figure 4.37) and determine activation energies of each step (Table 4.8).  
The activation energy of the L-Phe binding steps for W187F-PAH appears to be slightly 
higher in energy than the active site reorganization steps.  These data suggest that active 
site reorganization occurs rapidly as soon as L-Phe is bound in the active site of W187F-
PAH. 
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Figure 4.35 Possible kinetic model for the fluorescence of W187F-PAH with L-Phe 
including active site rearrangement. 
 
 
 
 
Figure 4.36 Kinetic fit of 30 µM W187F-PAH with 5 mM L-Phe at 3.5 ºC to the model 
proposed in Figure 4.35 (Eqs. 83-91). The data is shown in black while the fit is shown 
in red; the inset shows the residual of the fit. 
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Figure 4.37 Temperature dependent Arrhenius activation energy plot for the reaction of 
W187F-PAH with L-Phe. 
 
 
 
Table 4.8 Temperature dependent Arrhenius activation energies for intermediates in the 
reaction of W187F-PAH with L-Phe. 
 
Reaction Rate Activation Energy 
(kcal/mol) 
A + B → C k1 4.2 ± 0.5 
B + C → D k2 13.6 ± 2.3 
B + D → E k3 8.6 ± 3.5 
B + E → F k4 9.3 ± 4.0 
F → G k5 4.5 ± 1.7 
G → H k6 2.0 ± 0.9 
H → I k7 0.9 ± 0.5 
I → J k8 5.3 ± 2.1 
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4.3.4.6 W326F-PAH with L-Phe 
 The single Trp mutant enzyme W326F-PAH, demonstrated a fluorescence shift 
with L-Phe that was very similar to the W187F/W326F-PAH double mutant enzyme.  
These results were somewhat surprising as W326F-PAH contains both Trp120 and 
Trp187, which should demonstrate active site binding and allosteric site conformational 
change.  The relative intensity of Trp120, however, is so much greater than the relative 
intensity of Trp187, such that it may not be possible to observe the effects of Trp187 in 
this mutant enzyme, and therefore the observed fluorescence shift is similar to the 
W187F/W326F-PAH double mutant enzyme.  An immediate binding of L-Phe at low 
concentration was correlated with active site binding.  No additional L-Phe binding was 
observed at higher concentrations, suggesting that L-Phe induced fluorescence changes in 
the mutant enzyme only observe active site reorganization.  These results implied that the 
kinetic fits of W326F-PAH would be similar to those observed for the double mutant 
enzyme, W187F/W326F-PAH.  W326F-PAH also demonstrated cooperativity (n = 3.3 ± 
0.5), and therefore any proposed kinetic mechanism must allow for cooperative allosteric 
activation or active site reorganization.   
 Given the fluorescence titration data for W326F-PAH, it was expected that active 
site L-Phe binding would occur with active site reorganization rather than allosteric 
conformational change.  The mechanism proposed above for W187F/W326-PAH (Figure 
4.22, Eqs. 50-57) fit the requirements allowing for cooperativity and active site 
reorganization.  This mechanism fit well to the data at all temperatures (Figures 4.38, 
4.76-4.79) and was used to determine the Arrhenius activation energies of all steps in this 
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process (Figure 4.39, Table 4.9).  Several other fitting mechanisms were attempted that 
tried to account for both active site reorganization and allosteric conformational change 
and these mechanisms were unsuccessful.  Examples of these mechanisms are shown in 
the Appendix (Figures 4.80-4.81). 
 
  
Figure 4.38 Kinetic fit of 10 µM W326F-PAH with 5 mM L-Phe at 3.6 ºC to the model 
proposed in Figure 4.22 (Eqs. 50-57). The data is shown in black while the fit is shown 
in red; the inset shows the residual of the fit. 
 
 
 It was interesting to note that the rates of the L-Phe binding steps were 1-2 orders 
of magnitude faster in W326F-PAH than in the W187F/W326F-PAH mutant.  From these 
data, it appears that activation energy involved in the active site reorganization in 
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W326F-PAH is much higher than the activation energy observed for active site 
reorganization in W187F/W326F-PAH.  These activation energies suggest that Trp187 
may play an important role in modulating or facilitating access to the active site.  The 
activation energy steps for L-Phe binding in W326F-PAH are slightly lower than what is 
observed for the active site reorganization in W326F-PAH. 
 
 
Figure 4.39 Temperature dependent Arrhenius activation energy plot for the reaction of 
W326F-PAH with L-Phe. 
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Table 4.9 Temperature dependent Arrhenius activation energies for intermediates in the 
reaction of W326F-PAH with L-Phe. 
 
Reaction Rate Activation Energy 
(kcal/mol) 
A + B → C k1 5.9 ± 1.3 
B + C → D k2 6.4 ± 2.0 
B + D → E k3 1.2 ± 0.3 
B + E → F k4 1.3 ± 0.3 
F → G k5 5.7 ± 1.6 
G → H k6 9.2 ± 2.0 
H → I k7 8.3 ± 1.9 
I → J k8 5.4 ± 2.4 
 
 
 
4.4 Discussion 
 The role of individual Trp residues in PAH has not been established by prior 
studies.  Previous work has demonstrated that Trp120 is the major contributor to the 
fluorescence signals in PAH (61%), while Trp326 and Trp187 contribute 26% and 13% 
respectively based on the fluorescence intensity of single Trp mutant enzymes (124).  The 
cooperativity of Trp mutant enzymes has been previously reported for PAH expressed in 
a maltose binding fusion protein (124).  The Hill coefficients we report herein, agree well 
with their data, with the exception of W187F/W326F-PAH.  For W187F/W326F-PAH, 
they report n = 2.2 ± 0.3 (124), while we report n = 0.7 ± 0.1.  These results may be due 
to how the data is interpreted, as varying methods of interpretation can give wide 
variance in the Hill coefficient values, and the data itself was not shown in the previous 
report.   
 Herein we sought to understand the roles of the Trp residues in reporting the 
fluorescence shift that occurs in the protein upon the allosteric activation with L-Phe.  
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This allosteric activation with L-Phe is known to cause a major conformation and 
hydrophobicity change (49), that has previously been correlated with the shift in the 
fluorescence maximum of the protein as hallmark of allosteric activation.  We have 
discovered that Trp120, which is 23 Å from the active site is the primary reporter of L-
Phe active site binding, while Trp187 is the primary reporter of L-Phe allosteric site 
binding despite its location 40 Å from the allosteric site.  Trp326 has been shown to be a 
minor contributor to both L-Phe active site and allosteric site binding in PAH.  
 Additionally, we have analyzed the kinetic parameters of these Trp mutant 
enzymes and observed approximately 5-7 fold decreases in catalytic activity.  These 
decreases in activity are not all correlated to decreases in affinity of L-Phe for the active 
site, as KM, L-Phe only increases when either Trp187 or Trp326 is mutated to phenylalanine.  
Mutations of Trp120 to phenylalanine eliminate cooperativity in the enzyme, while single 
mutations to Trp187 or Trp326 do not affect cooperativity. 
 In this chapter, we sought to extend these studies by analyzing the concentration 
and time dependence of L-Phe fluorescence shifts in an attempt to understand the 
reporting Trp residues and the ordering and organization of L-Phe dependent binding and 
conformational changes in PAH.  The Trp to Phe mutant enzymes were used to create 
develop simpler frameworks for observing Trp dependent conformational change. 
4.4.1 Comparison of kinetic mechanisms of Trp mutant enzymes 
 The stopped flow fluorescence spectra of each of the Trp mutant enzymes fit well 
to an eight-step kinetic mechanism where L-Phe binds to each subunit of the protein first, 
and then undergoes some kind of conformational change.  The differences between the 
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individual Trp mutant enzyme mechanisms occur because of the differences in the 
specific signatures of the mutant enzymes that were uncovered by the fluorescence 
titration experiments.  These titrations indicated that Trp120 was the primary indicator 
for active site binding, while Trp187 was the primary indicator of allosteric site binding 
in PAH.  Trp326 was shown to have a small role in both active and allosteric site binding.  
These fluorescence signatures have been incorporated into the kinetic mechanisms 
developed in this chapter. In all of these titrations, the fluorescence intensity at 
approximately 335 nm decreases with increasing concentrations of L-Phe as the 
fluorescence maxima shifts to higher wavelength (Figure 4.83, Appendix to Chapter 4).  
This suggests that in our time dependent fluorescence studies with L-Phe that we should 
observe a decrease in the fluorescence intensity, which we observe in the spectra of all 
the Trp mutant enzymes.  
 In the enzymes where Trp120 was present (W187F/W326F-PAH, W187F-PAH, 
W326F-PAH), all the mechanisms presented focused on L-Phe binding to the active site 
and subsequent active site reorganization.  Since Trp120 is the largest contributor to the 
fluorescence in PAH (124), it may be overpowering the weaker features originating from 
Trp187 or Trp326 in the single Trp mutant enzymes (W326F-PAH and W187F-PAH 
respectively).  In the case of W187F/W326F-PAH, where only Trp120 was present, the 
effects of the other Trp residues were not an issue and the small conformational change 
that occurs in the active site upon L-Phe binding was the only observed fluorescent 
signal.   
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 The fluorescence signals of the W187F/W326F-PAH double mutant shows very 
large intensity changes (~10%) at low temperature (5 ºC), but those intensity changes 
decrease to <1% changes in intensity at temperatures of 8 ºC and greater.  The intensity 
changes in the fluorescence signals suggest that at higher temperatures, the fluorescence 
signature acts as if the enzyme is already activated and the active site reorganization 
occurs immediately upon L-Phe binding.  This process is perhaps too fast to observe in 
the stopped flow fluorescence time scale (dead time in fluorescence mode is about 10-15 
msec) or the magnitudes of the signals are too small to be influential in the simulations.  
The fluorescence signatures of the W326F-PAH mutant enzyme are quite similar, with 
~12% intensity changes at 3 ºC, ~3% at 8 ºC, and <1% at 12 ºC.  In the case of W187F-
PAH, the signal intensities are much lower, indicating that there may be some 
fluorescence quenching or bleaching that occurs with Trp120 and Trp326, and is 
stabilized the presence of Trp187.  The signal intensity changes in W187F-PAH, give rise 
a ~2% intensity change at three times the concentration of W326F-PAH and 
W187F/W326F-PAH.  Additionally, W187F-PAH and W326F-PAH demonstrate high 
cooperativity of L-Phe binding, which is not well explained by the time dependent 
fluorescence fits.  The cooperativity may facilitate easier L-Phe binding in the active and 
allosteric sites, but cannot be easily explained by these data.  
 In the absence of Trp120, the conformational change upon allosteric activation 
can be easily observed, as demonstrated by the fluorescence titrations.  All of the Trp 
mutant enzymes that remove Trp120 (W120F-PAH, W120F/W187F-PAH, and 
W120F/W326F-PAH) observe L-Phe binding in the allosteric site and conformational 
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change upon activation with L-Phe.  In the case of W120F-PAH and W120F/W326F-
PAH this was modeled as L-Phe binding in all subunits and subsequent conformational 
change in all subunits.  This model was suggested since the fluorescence titrations of 
W120F-PAH and W120F/W326F-PAH both demonstrate allosteric activation, with little 
to no effect of L-Phe active site binding.  In the case of W120F/W187F-PAH, L-Phe 
binding was modeled to occur simultaneously in the active and allosteric sites, followed 
by subsequent allosteric conformational change.  This model was suggested by the 
fluorescence titration of W120F/W187F-PAH that suggests that there is a small shift of 
L-Phe active site binding, followed by a small shift in L-Phe allosteric site binding and 
conformational change.   
 The relative signal intensity of the Trp120 mutant enzymes is also temperature 
dependent.  W120F-PAH demonstrates ~ 13% intensity change at 4 ºC, and <1% 
intensity change at 8 ºC.  The intensity changes in the double mutants are much weaker, 
presumably due to the decrease in the number of reporting Trp residues, or possibly due 
to an internal fluorescence quenching effect.  30 µM W120F/W326F-PAH (three times 
the concentration of W120F-PAH) demonstrates a ~2% intensity change at 3 ºC, and 
almost no change at 8 ºC.  30 µM W120F/W187F-PAH shows ~4% intensity change at 3 
ºC and <1% intensity change at 9 ºC.  In all six Trp mutant enzymes the fluorescence 
signals decrease in intensity and shape as the temperature increases, with significant 
losses in intensity occurring at about 7-8 ºC.  The time-dependent fluorescence spectra 
suggest that some steps in the activation process can be overcome by increasing the 
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temperature of the system and may not play such a large role in a physiological system 
that is maintained at 37 ºC. 
 The mechanism proposed for all of the Trp mutant enzymes fit to the same eight-
step kinetic mechanism.  This mechanism involves four L-Phe binding steps, which are 
predicted to be fast binding steps, followed by four conformational change steps that are 
predicted to be slower steps (e.g. Eqs. 9-16).  Based on the information from our 
fluorescence titrations, we were able to assign this kinetic mechanism to physical 
processes for each of the Trp mutant enzymes.  The Trp mutant enzymes that contain Trp 
120 (W187F-PAH, W326F-PAH, and W187F/W326F-PAH) have fluorescence 
signatures dominated by Trp120, which reports active site L-Phe binding (Figure 4.5h).  
In these mutant enzymes, we are unable to observe L-Phe binding and conformational 
change in the allosteric site, and therefore have assigned the eight-step kinetic mechanism 
to L-Phe binding in each active site, followed by rearrangement of each active site 
(Figure 4.22).  In the mutant enzymes that do not contain Trp120 (W120F-PAH, 
W120F/W187F-PAH, and W120F/W326F-PAH), we are able to observe the effects of 
the smaller reporting Trp residues that report allosteric conformational change, but do not 
observe the large active site L-Phe signals of Trp120.  In the case of W120F/W187F-
PAH, which only contains Trp326, we assigned the eight-step kinetic mechanism to a 
combination of active and allosteric site L-Phe binding occurring essentially 
simultaneously, followed conformational changes (Figure 4.9).  We justified this 
mechanism since both processes contribute nearly equally to the overall fluorescence 
shift of W120F/W187F-PAH (Figure 4.5f).  In the case of the W120F/W326F-PAH and 
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W120F-PAH, we considered the contribution of Trp187, which is only involved in 
reporting allosteric conformational change (Figure 4.5g), to be the major contributor to 
the fluorescence in those enzymes.  Using Trp187 as the major fluorescence contributor, 
we were able to assign the eight-step kinetic mechanisms of W120F/W326F-PAH and 
W120F-PAH to L-Phe binding in each allosteric site, followed by allosteric conformation 
changes in each subunit (Figure 4.14).   
4.4.2 Comparison of Trp mutant enzyme mechanisms to proposed models for PAH 
allostery 
 The presence of dimeric and tetrameric species were included in our kinetic 
models of the single and double Trp mutants, some of which have been presented herein, 
but none of the dimeric models or dimer - tetramer equilibrium models tested 
demonstrated good fits to the mutant enzyme data.  SAW biosensing studies in Chapter 
3 were consistent with in the interpretation that allosteric conformational changes do not 
occur in dimeric forms of the enzyme.  The fact that the Trp mutant enzymes do not fit 
well to a model containing a dimeric state also supports this assertion.  The lack of 
dimeric models for the L-Trp mutant enzymes suggests that the PAH mutants do not fit 
into the morpheein allostery model that has been recently proposed for wild-type PAH.  
The morpheein model suggests that an inactive tetramer dissociates into inactive dimers, 
that undergo conformational changes as a dimer and reform as an active tetramer (136).  
This work suggests that the Trp mutant enzymes undergo conformational changes in the 
presence of L-Phe to activate either the active or allosteric sites, but only do this in an 
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active tetrameric form.  Whether the wild-type enzyme fits with this model will be 
discussed in more detail in Chapter 5. 
 In addition to the morpheein model, PAH allostery was discussed in an early 
kinetic mechanism presented by Shiman and coworkers (Figure 1.26) (104).  This model 
described the L-Phe activation process as preceding the catalytic activity of the enzyme.  
The Trp mutant enzyme mechanisms seem more consistent with this model of PAH 
allostery, as the L-Phe binding steps occur rapidly and then there is subsequent allosteric 
conformational change or active site reorganization.  Four of the six Trp mutant enzymes 
also demonstrate a loss of cooperativity that may be involved in uncoupling L-Phe 
binding from conformational change or active site reorganization.  The loss of 
cooperativity may be a function of the structural perturbations that occur when a large 
tryptophan residue is replaced with a smaller phenylalanine residue.  The smaller space of 
the phenylalanine residue may alter protein function in an unknown way and need to be 
"repacked" with additional bulk from other side chains before cooperativity can be 
retained. 
4.4.3 Fluorescence quenching and resonance energy transfer 
 The signal intensities of the Trp mutants are quite varied as discussed above.  
Several of the enzymes (W120F-PAH, W326F-PAH, and W187F/W326F-PAH) all 
demonstrate fluorescence intensity changes of 10-15% at 3-5 ºC and concentrations of 10 
µM enzyme.  The other systems (W187F-PAH, W120F/W187F-PAH, and 
W120F/W326F-PAH) only exhibit fluorescence intensity changes of 2-4% at 3-5 ºC and 
concentrations of 30 µM enzyme.  The differences in the signal intensities of these 
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mutant enzymes may be caused by a combination of different reasons such as the relative 
signal intensity of the relative Trp residues, possible fluorescence quenching, or 
resonance energy transfer.  The absence of Trp120 may explain the relatively low signal 
intensity observed in W120F/W187F-PAH and W120F/W326F-PAH.   
 Additionally, fluorescence quenching and resonance energy transfer (RET) 
processes throughout the proteins may be involved in explaining the differences in signal 
intensity among the Trp mutant enzymes.  Fluorescence quenching can occur when an 
excited state fluorophore is deactivated by interaction with another molecule (the 
quencher) in solution.  Fluorescence quenching must occur when the two molecules are 
very close proximity and is very inefficient if the molecules are more than a few Å apart 
(214).  RET occurs when the emission spectrum of the fluorophore overlaps with the 
absorption spectrum of another molecule.  The original fluorophore is called the donor, 
and donates its fluorescence to the second, acceptor, molecule (214).  The molecules 
participating in RET can be much farther apart, and distances of up to 100 Å between the 
donor and acceptor can be used to detect resonance energy transfer in biological 
molecules (214, 219).  Crystal structures of PAH predict that Trp326 is about 4 Å from 
the active site L-Phe binding location (Figure 4.39), based on the binding site of for THA 
in ternary complex structures (56).  This 4 Å distance may be close enough to allow for 
quenching of Trp326 by L-Phe or other protein residues that undergo conformational 
changes upon L-Phe binding.  Two of the low intensity Trp mutant enzymes contain 
Trp326 (W187F-PAH, and W120F/W187F-PAH), and future studies should examine the 
extent to which fluorescence quenching plays a role in these enzymes.  Previous PAH 
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fluorescence studies have only examined L-Phe induced fluorescence shifts in the 
emission maxima of PAH, not any possible role of the individual Trp residues in 
quenching that fluorescent signal (91, 124).  It has also been reported that the more 
buried tryptophan residues have an exponentially decreased rate of quenching based on 
their distance from the surface (220).   Trp326 is found in a cleft that leads to the active 
site and is surface exposed.  None of the other Trp residues in PAH are surface exposed 
(Figure 4.40).  The surface exposure of Trp326 also suggests that it would be the most 
likely residue to be involved L-Phe induced fluorescence quenching. 
 
 
Figure 4.40 Location of Trp residues in PAH in relation to L-Phe binding sites possibly 
involved in fluorescence quenching.  THA is a substrate analog for L-Phe indicating the 
likely active site binding location of L-Phe.  The active site ligands are shown in cyan and 
the allosteric site is indicated in green.  Figure created in PyMol (23) using PDB files 
2PAH (84), 2PHM (14), and 1MMK (56). 
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Figure 4.41 Location of Trp residues in PAH on a surface map.  Trp residues are 
indicated in orange and the only surface exposed residue is W326, located in the active 
site cleft. a) Active site side of protein; b) reverse side of protein.  Figure created in 
PyMol (23) using PDB files 2PAH (84), 2PHM (14), and 1MMK (56). 
 
 
 The other two Trp residues in PAH, Trp120 and Trp187, are closer to 9-10 Å 
from the nearest L-Phe binding site.  This distance is likely too far away from the L-Phe 
binding sites to allow direct contact needed for L-Phe quenching of the tryptophan 
fluorescence.  These residues, however, may be involved in RET in PAH or the mutant 
enzymes.  The long range interactions that occur in RET happen because of dipolar 
interactions between the excited donor and the acceptor molecules (214).  The intra-
domain distance between Trp120 and Trp187 is about 40 Å, and the distance between 
Trp187 and the allosteric site L-Phe molecule is about 30 Å (Figure 4.41).  The inter-
subunit distance between Trp120 and Trp187 approximately 35 Å to the closer adjacent 
subunit, and approximately 55 Å to further adjacent subunit.  These distances are large 
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enough to undergo RET and possibly bleach the internal fluorescence signals.  If RET is 
occurring in PAH, labeling of individual Trp residues with a fluorescent compound that 
emits past 500 nm, might allow simultaneous observation of the L-Phe induced 
fluorescence changes in the protein and the bleaching of the fluorescent label by RET.  
RET has also been reported to occur from phenylalanine residues to tryptophan residues 
in proteins as the emission peak of L-Phe  (λmax,em: 282 nm) occurs near the excitation 
peak of Trp (λmax, ex: 285 nm) (214).  The RET signals in other proteins suggest that the 
substrate or allosteric L-Phe molecules themselves may contribute to the signal intensity 
decreases occurring in the Trp mutant enzymes.  The overall fluorescence intensity 
differences observed in the Trp mutants may come from variety of sources and are 
worthy of further examination in the future to determine if they are merely intensity 
related artifacts from the removal of certain residues or if they are involved in 
fluorescence quenching or RET. 
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Figure 4.42 Location of Trp residues in PAH in relation to L-Phe binding sites possibly 
involved in RET.  The active site ligands are shown in cyan and the allosteric site is 
indicated in green.  Figure created in PyMol (23) using PDB files 2PAH (84), 2PHM 
(14), and 1MMK (56).  
 
 
 
4.4.4 Future studies to test kinetic mechanisms 
 The mechanisms provided herein provide an initial understanding of the allosteric 
activation processes occurring in the Trp mutant enzymes of PAH.  The Trp mutant 
enzymes fall into two categories based on the results of the fluorescence titrations.  The 
first group (W187F/W326F-PAH, W187F-PAH, and W326F-PAH) binds L-Phe in the 
active site and then undergoes active site reorganization.  The second group 
(W120F/W187F-PAH, W120F/W326F-PAH, and W120F-PAH) all bind L-Phe in the 
allosteric site and then demonstrate allosteric conformational change in each subunit.  For 
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all of the mutant enzymes, the L-Phe binding steps occur very quickly and are completed 
within the first 500 ms.  Our stopped flow spectrometer when working in fluorescence 
mode has a dead time of about 10-15 ms.  This dead time is a significant limitation to our 
analysis of these ultra fast processes.  Further studies on the kinetics of the Trp mutant 
enzymes will likely require the use of laser flash photolysis to analyze the L-Phe binding 
signals that occur at extremely early time points.   Time resolved studies of Trp decay in 
single tryptophan proteins have often shown multiple exponential decays; multiple 
tryptophan proteins such as PAH, will obviously demonstrate more complicated spectra 
(214).  The fluorescence decay times for most Trp residues are either ~1.5 or ~4.0 ns 
respectively (221).  The decay time is much faster than what is observable in the stopped 
flow time scale.  Although we are not interested in observing the intrinsic L-Trp 
fluorescence decay, we are interested in rapid interactions that occur between PAH and 
L-Phe.  Further studies will require microsecond or even nanosecond time scales that are 
currently only attainable with laser-based experiments.  These experiments should be able 
to test the hypothesis that L-Phe binding occurs to all subunits before allosteric 
conformational change or active site reorganization.  Laser flash photolysis experiments 
can also study the dynamics of Trp residues in proteins.  These experiments should 
enable analysis of how Trp120 can sense and report L-Phe binding in the active site, 
while Trp187 reports L-Phe binding in the allosteric site, despite the large distances 
between these small molecules and Trp residues that report the binding events.  
 The kinetic rates provided by the stopped flow fluorescence studies herein can 
also provide a framework for further study by other spectroscopic methods.  The relative 
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rates for each process can provide build-up curves for various intermediate species 
formed when PAH and L-Phe react.  The mutant enzymes that are proposed to undergo 
active site reorganization (W187F/W326F-PAH, W187F-PAH, and W326F-PAH) could 
be tested with rapid freeze quench techniques.  NO-adducts of the PAH Trp mutant 
enzymes could be generated as has been previously performed for PAH (50).  The NO-
adducts would then be exposed to deuterated L-Phe and allowed to react until major 
species present is the species with L-Phe bound and a rearranged active site.  At this point 
the sample would be stopped with rapid freeze quenching techniques and the nitrosyl 
adducts would be analyzed by ESEEM.  If an active site rearrangement occurred, there 
should be a change in the distance of the deuterated L-Phe molecule in the active site.  
The mutants that only undergo allosteric conformational change should not demonstrate 
any change in signal in the NO-adducts by ESEEM as the allosteric binding site is 
located 23 Å from the active site iron-center and ESEEM is only sensitive to changes that 
occur within about 5 Å of the iron-center.  These experiments should help to confirm 
whether allosteric conformational change or active site reorganization is occurring in 
each of the Trp mutant enzymes studied herein.  
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4.5 Conclusion 
 The Trp to Phe mutant enzymes have provided a framework for understanding the 
L-Phe dependent conformational changes that occur in PAH upon active site and 
allosteric site binding.  These mutant enzymes were shown to have differential effects on 
the concentration dependent L-Phe induced fluorescence shifts, and in this chapter have 
been shown to have different effects on the time dependent L-Phe induced fluorescence 
signals.  The kinetics of the reaction of L-Phe with the mutant enzymes have all been 
shown to fit to mechanisms where L-Phe binds to the protein and then induces active site 
reorganization or conformational change within the protein.  These mechanisms will be 
the basis for understanding the global conformational changes that occur within the wild-
type enzyme upon reaction with L-Phe.  The understanding of these individual signals 
should allow for the development of a combined mechanism to understand allosteric 
activation by L-Phe in PAH, which will be discussed in greater detail in Chapter 5.   
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4.6 Appendix 
 
Figure 4.43 Normalized fluorescence shifts of wtPAH with L-Phe, fit to the following 
equations: a) Bi-Dose Response curve in Origin 9.0 for the full range of L-Phe 
concentrations (0-2000 µM), b-f) Hill equation in Origin 9.0 for the range from 300-2000 
µM L-Phe (panel b) or with  n fixed to 2, 3, 4, or 8 respectively  (panels c-f).  All fits 
were performed with equations as described in the Experimental Methods section in 
Chapter 3.  Residuals of each fit are shown in the insets.  
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Table 4.10 Thermodynamic and cooperativity parameters for L-Phe binding to the 
allosteric site as determined by Dose Response or Hill Fits in Origin 9.0 of the data in 
Figure 4.43. Uncertainty was determined from deviation of fits in Origin 9.0 and data 
points are averages of at least three independent values.  
Fitting Method (Figure) KD,app
on
 (µM) Hill Coefficient (n) 
Bi-dose Response (4.43a) 1160 ± 35 ---- 
Hill equation 300-2000 µM (4.43b) 1160 ± 25 14 ± 3.6 
Hill equation, n = 2 (4.43c) 1430 ± 1510 2 ± 3.5 
Hill equation, n = 3 (4.43d) 1220 ± 360 3 ± 2.9 
Hill equation, n = 4 (4.43e) 1170 ± 170 4 ± 2.6 
Hill equation, n = 8 (4.43f) 1150 ± 50 8 ± 2.5 
 
4.6.1 W120F/W187F-PAH temperature dependent stopped flow fluorescence fits 
 
Figure 4.44 Potential mechanism for W120F/W187F-PAH fluorescence with L-Phe that 
would not converge mathematically. 
Table 4.11 Rates and standard deviations for Eqs. 17-25, represented by Figures 4.11-
4.12. 
Rate Constant Rate  Standard Deviation  
k1 1.192E+05 M
-1
s
-1
 1.27E+02 M
-1
s
-1
 
k2 1.401E+02 M
-1
s
-1
 8.32E+00 M
-1
s
-1
 
k3 4.811E+04 M
-1
s
-1
 6.45E+02 M
-1
s
-1
 
k4 1.217E+05 M
-1
s
-1
 1.02E+01 M
-1
s
-1
 
k5 4.002E+02 s
-1
 4.652E+00 s
-1
 
k6 3.292E+01 s
-1
 1.183E+01 s
-1
 
k7 2.346E+01 s
-1
 5.914E+00 s
-1
 
k8 2.009E+00 s
-1
 1.168E+00 s
-1
 
k9 1.722E+01 M
-1
s
-1
 7.036E+01 M
-1
s
-1
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Figure 4.45 Kinetic fit of 30 µM W120F/W187F-PAH with 5 mM L-Phe at 8.8 ºC to the 
model proposed in Figure 4.10 (Eqs. 9-16). The data is shown in black while the fit is 
shown in red; the inset shows the residual of the fit. 
 
 
 
Figure 4.46 Kinetic fit of 30 µM W120F/W187F-PAH with 5 mM L-Phe at 13.3 ºC to 
the model proposed in Figure 4.10 (Eqs. 9-16). The data is shown in black while the fit 
is shown in red; the inset shows the residual of the fit. 
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Figure 4.47 Kinetic fit of 30 µM W120F/W187F-PAH with 5 mM L-Phe at 19.1 ºC to 
the model proposed in Figure 4.10 (Eqs. 9-16). The data is shown in black while the fit 
is shown in red; the inset shows the residual of the fit. 
 
 
 
Figure 4.48 Kinetic fit of 30 µM W120F/W187F-PAH with 5 mM L-Phe at 24.6ºC to the 
model proposed in Figure 4.10 (Eqs. 9-16). The data is shown in black while the fit is 
shown in red; the inset shows the residual of the fit. 
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Table 4.12 Rates of 30 µM W120F/W187F-PAH with 5 mM L-Phe as fit by the model 
proposed in Figure 4.10 (Eqs. 9-16) 
Temp. 
ºC 
k1 
(M
-1
s
-1
) 
k2 
(M
-1
s
-1
) 
k3 
(M
-1
s
-1
) 
k4 
(M
-1
s
-1
) 
k5 
(s
-1
) 
k6 
(s
-1
) 
k7   
(s
-1
) 
k8 
(s
-1
) 
3.1 1.19E+05 1.40E+02 4.81E+04 1.22E+05 4.00E+02 1.92E+01 2.25E+01 3.24E+00 
8.8 1.19E+05 1.40E+02 7.46E+04 1.22E+05 5.07E+02 1.49E+02 1.22E+02 5.29E+00 
13.3 1.15E+05 1.37E+02 6.54E+04 1.22E+05 4.93E+02 1.67E+02 1.22E+02 6.20E+00 
19.1 1.17E+05 1.28E+02 4.16E+04 1.29E+05 1.00E+03 1.20E+02 7.80E+01 7.94E+00 
24.6 1.65E+05 1.35E+02 4.18E+04 1.49E+05 1.00E+03 9.01E+01 8.78E+01 1.64E+01 
Temp. 
ºC 
Std. Dev 
k1 
Std. Dev 
k2 
Std. Dev 
k3 
Std. Dev 
k4 
Std. Dev 
k5 
Std. Dev 
k6 
Std. Dev 
k7 
Std. Dev 
k8 
3.1 1.27E+02 8.32E+00 6.45E+02 1.02E+01 4.66E+00 1.54E+00 5.38E+00 8.52E-01 
8.8 9.12E+01 1.50E+01 2.85E+03 5.74E+00 1.33E+01 3.35E+01 1.91E+01 1.02E+00 
13.3 2.00E+02 2.25E+00 2.14E+02 9.70E+01 1.14E+01 5.13E+01 3.66E+01 3.90E-01 
19.1 2.77E+02 3.72E+00 9.49E+02 2.25E+03 6.80E+01 1.92E+01 6.03E+00 1.79E-01 
24.6 3.50E+03 1.33E+01 5.24E+03 1.44E+04 4.20E+01 4.62E+00 7.79E+00 2.39E+00 
 
 
4.6.2 W120F/W326F-PAH temperature dependent stopped flow fluorescence fits 
 
 
 
Figure 4.49 Kinetic fit of 30 µM W120F/W326F-PAH with 5 mM L-Phe at 7.7 ºC to the 
model proposed in Figure 4.14 (Eqs. 26-33). The data is shown in black while the fit is 
shown in red; the inset shows the residual of the fit. 
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Figure 4.50 Kinetic fit of 30 µM W120F/W326F-PAH with 5 mM L-Phe at 13.2 ºC to 
the model proposed in Figure 4.14 (Eqs. 26-33).  The data is shown in black while the fit 
is shown in red; the inset shows the residual of the fit. 
 
 
 
Figure 4.51 Kinetic fit of 30 µM W120F/W326F-PAH with 5 mM L-Phe at 18.9 ºC to 
the model proposed in Figure 4.14 (Eqs. 26-33).  The data is shown in black while the fit 
is shown in red; the inset shows the residual of the fit. 
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Figure 4.52 Kinetic fit of 30 µM W120F/W326F-PAH with 5 mM L-Phe at 24.6 ºC to 
the model proposed in Figure 4.14 (Eqs. 26-33).  The data is shown in black while the fit 
is shown in red; the inset shows the residual of the fit. 
 
 
 
Figure 4.53 Kinetic fit of 30 µM W120F/W326F-PAH with 5 mM L-Phe at 30.4 ºC to 
the model proposed in Figure 4.14 (Eqs. 26-33).  The data is shown in black while the fit 
is shown in red; the inset shows the residual of the fit. 
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Table 4.13 Rates of 30 µM W120F/W326F-PAH with 5 mM L-Phe as fit by the model 
proposed in Figure 4.14 (Eqs. 26-33). 
Temp. 
ºC 
k1 
(M
-1
s
-1
) 
k2 
(M
-1
s
-1
) 
k3 
(M
-1
s
-1
) 
k4 
(M
-1
s
-1
) 
k5 
(s
-1
) 
k6 
(s
-1
) 
k7   
(s
-1
) 
k8 
(s
-1
) 
3.3 5.80E+01 8.65E+02 7.33E+04 4.49E+02 6.20E+01 2.80E+01 5.58E+02 1.12E+03 
7.7 1.06E+02 1.61E+03 8.31E+04 4.85E+02 4.27E+01 1.82E+01 7.12E+02 5.03E+02 
13.2 1.01E+02 1.06E+03 8.71E+04 4.78E+02 1.34E+01 1.88E+01 6.87E+02 4.29E+02 
18.9 1.03E+02 1.43E+03 8.00E+04 4.95E+02 1.07E+01 3.35E+01 6.42E+02 4.14E+02 
24.6 1.12E+02 1.05E+03 1.16E+05 4.57E+02 8.10E+01 3.40E+01 5.30E+02 5.74E+02 
30.4 1.22E+02 1.41E+03 1.13E+05 5.02E+02 6.49E+01 3.25E+01 5.03E+02 5.92E+02 
Temp. 
ºC 
Std. Dev 
k1 
Std. Dev 
k2 
Std. Dev 
k3 
Std. Dev 
k4 
Std. Dev 
k5 
Std. Dev 
k6 
Std. Dev 
k7 
Std. Dev 
k8 
3.3 2.20E+01 4.41E+02 3.96E+04 3.79E+01 1.95E+01 6.46E+00 7.20E+01 3.14E+02 
7.7 9.50E+00 5.48E+02 3.60E+04 1.11E+02 1.13E+01 5.53E+00 1.16E+01 1.40E+02 
13.2 5.03E+01 3.97E+02 2.51E+04 1.70E+02 1.17E+00 1.76E+00 1.12E+01 1.13E+02 
18.9 3.06E+01 7.09E+02 2.12E+04 7.79E+01 4.04E+00 6.30E+00 2.87E+01 1.12E+02 
24.6 2.88E+01 4.43E+02 1.97E+04 5.37E+01 1.28E+00 1.35E+01 1.36E+02 2.36E+02 
30.4 2.87E+01 3.73E+02 1.36E+04 1.31E+02 3.19E+00 1.50E+01 1.55E+02 2.01E+02 
 
4.6.3 W187F/W326F-PAH temperature dependent stopped flow fluorescence fits 
 
 
Figure 4.54 Kinetic fit of 10 µM W187F/W326F-PAH with 5 mM L-Phe at 7.9 ºC to the 
model proposed in Figure 4.22 (Eqs. 50-57). The data is shown in black while the fit is 
shown in red; the inset shows the residual of the fit. 
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Figure 4.55 Kinetic fit of 10 µM W187F/W326F-PAH with 5 mM L-Phe at 12.5 ºC to 
the model proposed in Figure 4.22 (Eqs. 50-57). The data is shown in black while the fit 
is shown in red; the inset shows the residual of the fit. 
 
Figure 4.56 Kinetic fit of 10 µM W187F/W326F-PAH with 5 mM L-Phe at 17.8 ºC to 
the model proposed in Figure 4.22 (Eqs. 50-57).  The data is shown in black while the fit 
is shown in red; the inset shows the residual of the fit. 
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Figure 4.57 Kinetic fit of 10 µM W187F/W326F-PAH with 5 mM L-Phe at 22.8 ºC to 
the model proposed in Figure 4.22 (Eqs. 50-57). The data is shown in black while the fit 
is shown in red; the inset shows the residual of the fit. 
 
 
Figure 4.58 Kinetic fit of 10 µM W187F/W326F-PAH with 5 mM L-Phe at 27.8 ºC to 
the model proposed in Figure 4.22 (Eqs. 50-57). The data is shown in black while the fit 
is shown in red; the inset shows the residual of the fit. 
 
 
311 
 
 
 
 
Figure 4.59 Kinetic fit of 10 µM W187F/W326F-PAH with 5 mM L-Phe at 30.8 ºC to 
the model proposed in Figure 4.22 (Eqs. 50-57). The data is shown in black while the fit 
is shown in red; the inset shows the residual of the fit. 
 
 
 
Table 4.14 Rates of 10 µM W187F/W326F-PAH with 5 mM L-Phe as fit by the model 
proposed in Figure 4.22 (Eqs. 50-57). 
 
Temp. 
ºC 
k1 
(M
-1
s
-1
) 
k2 
(M
-1
s
-1
) 
k3 
(M
-1
s
-1
) 
k4 
(M
-1
s
-1
) 
k5 
(s
-1
) 
k6 
(s
-1
) 
k7   
(s
-1
) 
k8 
(s
-1
) 
5.3 1.28E+02 3.72E+02 5.67E+03 1.36E+03 7.25E+02 2.75E+02 1.17E+02 6.05E+00 
7.9 2.33E+02 4.08E+02 5.82E+03 1.36E+03 7.28E+02 2.76E+02 1.14E+02 6.04E+00 
12.5 2.07E+02 4.26E+02 5.57E+03 1.36E+03 7.28E+02 2.76E+02 1.15E+02 6.94E+00 
17.8 2.25E+02 4.55E+02 5.67E+03 1.36E+03 7.29E+02 2.76E+02 1.15E+02 5.33E+00 
22.7 1.95E+02 4.09E+02 6.38E+03 1.41E+03 7.41E+02 2.83E+02 1.15E+02 5.66E+00 
27.7 2.16E+02 4.30E+02 6.96E+03 1.47E+03 7.65E+02 2.92E+02 1.18E+02 5.76E+00 
30.8 2.27E+02 4.43E+02 7.07E+03 1.47E+03 7.64E+02 2.91E+02 1.18E+02 6.92E+00 
Temp. 
ºC 
Std. Dev 
k1 
Std. Dev 
k2 
Std. Dev 
k3 
Std. Dev 
k4 
Std. Dev 
k5 
Std. Dev 
k6 
Std. Dev 
k7 
Std. Dev 
k8 
5.3 4.23E+00 1.14E+01 2.38E+02 2.70E+00 1.29E+00 1.57E-01 3.51E-01 7.34E-01 
7.9 1.79E+01 4.11E+01 7.04E+02 2.37E+01 1.19E+01 4.12E+00 1.39E+00 1.82E+00 
12.5 2.99E+01 4.82E+01 3.40E+02 7.24E+00 2.89E+00 6.78E-01 2.97E-01 1.10E+00 
17.8 7.32E+01 1.18E+02 6.85E+02 8.17E+00 1.78E+00 2.90E-01 1.15E+00 2.35E+00 
22.7 5.48E+01 8.79E+01 7.24E+02 9.17E+00 2.24E+00 2.71E-01 1.05E+00 2.09E+00 
27.7 4.35E+01 6.64E+01 6.05E+02 2.79E+00 2.72E+00 1.60E+00 1.30E+00 1.36E+00 
30.8 7.57E+01 1.14E+02 1.20E+03 4.11E+01 1.91E+01 6.01E+00 1.26E+00 2.11E+00 
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Figure 4.60 Possible mechanism attempted for W187F/W326F-PAH fluorescence with 5 
mM L-Phe. 
 
 
 
 
 
 
 
Figure 4.61 Possible mechanism attempted for W187F/W326F-PAH fluorescence with 5 
mM L-Phe. 
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4.6.4 W120F-PAH temperature dependent stopped flow fluorescence fits 
 
 
Figure 4.62 Possible dimer-tetramer equilibrium mechanism attempted for W120F-PAH 
fluorescence with 5 mM L-Phe. 
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Figure 4.63 Possible dimer-tetramer equilibrium mechanism attempted for W120F-PAH 
fluorescence with 5 mM L-Phe. 
 
 
Figure 4.64 Kinetic fit of 10 µM W120F-PAH with 5 mM L-Phe at 7.6 ºC to the model 
proposed in Figure 4.14 (Eqs. 26-33). The data is shown in black while the fit is shown 
in red; the inset shows the residual of the fit. 
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Figure 4.65 Kinetic fit of 10 µM W120F-PAH with 5 mM L-Phe at 13.0 ºC to the model 
proposed in Figure 4.14 (Eqs. 26-33). The data is shown in black while the fit is shown 
in red; the inset shows the residual of the fit. 
 
 
 
 
 
Figure 4.66 Kinetic fit of 10 µM W120F-PAH with 5 mM L-Phe at 19.6 ºC to the model 
proposed in Figure 4.14 (Eqs. 26-33). The data is shown in black while the fit is shown 
in red; the inset shows the residual of the fit. 
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Figure 4.67 Kinetic fit of 10 µM W120F-PAH with 5 mM L-Phe at 25.1 ºC to the model 
proposed in Figure 4.14 (Eqs. 26-33). The data is shown in black while the fit is shown 
in red; the inset shows the residual of the fit. 
 
 
 
 
 
Figure 4.68 Kinetic fit of 10 µM W120F-PAH with 5 mM L-Phe at 29.9 ºC to the model 
proposed in Figure 4.14 (Eqs. 26-33).  The data is shown in black while the fit is shown 
in red; the inset shows the residual of the fit. 
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Table 4.15 Rates of 10 µM W120F-PAH with 5 mM L-Phe as fit by the model proposed 
in Figure 4.14 (Eqs. 26-33). 
 
Temp. 
ºC 
k1 
(M
-1
s
-1
) 
k2 
(M
-1
s
-1
) 
k3 
(M
-1
s
-1
) 
k4 
(M
-1
s
-1
) 
k5 
(s
-1
) 
k6 
(s
-1
) 
k7   
(s
-1
) 
k8 
(s
-1
) 
4.0 8.54E+01 2.01E+03 5.10E+03 5.23E+03 1.24E+03 3.51E+01 3.06E+01 2.61E+02 
7.6 8.01E+01 3.47E+03 5.60E+03 6.07E+03 2.17E+03 2.31E+02 2.70E+01 2.59E+02 
13.0 8.06E+01 3.82E+03 4.98E+03 5.22E+03 1.83E+03 2.27E+02 2.50E+01 2.36E+02 
19.6 5.58E+01 2.32E+03 1.88E+04 8.14E+03 1.63E+03 2.29E+02 2.87E+01 2.68E+02 
25.1 9.15E+01 2.02E+03 2.01E+04 8.02E+03 2.24E+03 2.61E+02 2.74E+01 2.69E+02 
29.9 9.61E+01 3.43E+03 4.08E+04 1.22E+04 3.02E+03 3.75E+02 3.17E+01 3.15E+02 
Temp. 
ºC 
Std. Dev 
k1 
Std. Dev 
k2 
Std. Dev 
k3 
Std. Dev 
k4 
Std. Dev 
k5 
Std. Dev 
k6 
Std. Dev 
k7 
Std. Dev 
k8 
4.0 4.67E+00 1.90E+02 1.98E+02 1.22E+02 2.82E+01 7.82E-01 2.88E-01 9.83E-01 
7.6 1.05E+01 3.84E+02 5.43E+02 1.52E+02 5.47E+01 5.35E+00 1.55E+00 1.71E+01 
13.0 1.10E+01 1.04E+03 6.77E+02 1.22E+02 3.77E+01 3.40E+00 1.07E-01 1.29E+00 
19.6 6.58E+00 2.81E+02 1.31E+03 3.61E+02 7.42E+01 1.25E+01 3.44E+00 3.40E+01 
25.1 7.30E+00 4.71E+02 2.36E+03 3.40E+02 1.01E+02 1.69E+01 4.12E-01 2.66E+00 
29.9 6.48E+00 6.59E+02 4.14E+03 4.51E+02 8.83E+01 1.54E+01 4.80E+00 4.46E+01 
 
4.6.5 W187F-PAH temperature dependent stopped flow fluorescence fits 
 
 
Figure 4.69 Potential simple model for W187F-PAH fluorescence with 5 mM L-Phe that 
would not converge mathematically. 
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Figure 4.70 Potential dimer-tetramer equilibrium model for W187F-PAH fluorescence 
with 5 mM L-Phe that would not converge mathematically. 
 
Table 4.16 Rates and standard deviations for Eqs. 83-91, represented by Figures 4.35-
4.36. 
Rate Constant Rate  Standard Deviation  
k1 8.83E+04 M
-1
s
-1
 2.18E+02 M
-1
s
-1
 
k2 1.00E+02 M
-1
s
-1
 2.15E+01 M
-1
s
-1
 
k3 8.43E+00 M
-1
s
-1
 1.12E+00 M
-1
s
-1
 
k4 4.35E+03 M
-1
s
-1
 2.10E+02 M
-1
s
-1
 
k5 1.42E+03 s
-1
 1.62E+01 s
-1
 
k6 2.30E+03 s
-1
 1.42E+01 s
-1
 
k7 2.35E+03 s
-1
 1.05E-01 s
-1
 
k8 3.02E+00 s
-1
 6.94E-01 s
-1
 
k9 8.28E+01 M
-1
s
-1
 2.23E+02 M
-1
s
-1
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Figure 4.71 Kinetic fit of 30 µM W187F-PAH with 5 mM L-Phe at 7.0 ºC to the model 
proposed in Figure 4.22 (Eqs. 50-57). The data is shown in black while the fit is shown 
in red; the inset shows the residual of the fit. 
 
 
 
 
Figure 4.72 Kinetic fit of 30 µM W187F-PAH with 5 mM L-Phe at 12.3 ºC to the model 
proposed in Figure 4.22 (Eqs. 50-57). The data is shown in black while the fit is shown 
in red; the inset shows the residual of the fit. 
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Figure 4.73 Kinetic fit of 30 µM W187F-PAH with 5 mM L-Phe at 17.1 ºC to the model 
proposed in Figure 4.22 (Eqs. 50-57). The data is shown in black while the fit is shown 
in red; the inset shows the residual of the fit. 
 
 
 
 
Figure 4.74 Kinetic fit of 30 µM W187F-PAH with 5 mM L-Phe at 22.4 ºC to the model 
proposed in Figure 4.22 (Eqs. 50-57). The data is shown in black while the fit is shown 
in red; the inset shows the residual of the fit. 
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Figure 4.75 Kinetic fit of 30 µM W187F-PAH with 5 mM L-Phe at 27.2 ºC to the model 
proposed in Figure 4.22 (Eqs. 50-57). The data is shown in black while the fit is shown 
in red; the inset shows the residual of the fit. 
 
Table 4.17 Rates of 30 µM W187F-PAH with 5 mM L-Phe as fit by the model proposed 
in Figure 4.22 (Eqs. 50-57). 
Temp. 
ºC 
k1 
(M
-1
s
-1
) 
k2 
(M
-1
s
-1
) 
k3 
(M
-1
s
-1
) 
k4 
(M
-1
s
-1
) 
k5 
(s
-1
) 
k6 
(s
-1
) 
k7   
(s
-1
) 
k8 
(s
-1
) 
3.5 8.83E+04 1.00E+02 8.43E+00 4.34E+04 1.42E+03 2.30E+03 2.35E+03 2.52E+00 
7 9.72E+04 2.60E+02 8.08E+00 1.61E+05 1.42E+03 2.30E+03 2.35E+03 4.85E+00 
12.3 9.65E+04 2.34E+02 5.60E+00 1.79E+05 1.98E+03 2.50E+03 2.35E+03 6.73E+00 
17.1 1.18E+05 4.20E+02 7.99E+00 1.02E+05 2.50E+03 2.27E+03 2.37E+03 2.22E+00 
22.4 1.42E+05 7.72E+02 2.10E+01 2.00E+05 1.74E+03 2.50E+03 2.35E+03 6.73E+00 
27.2 1.61E+05 7.76E+02 2.58E+01 3.01E+05 3.06E+03 3.36E+03 2.85E+03 7.79E+00 
Temp. 
ºC 
Std. Dev 
k1 
Std. Dev 
k2 
Std. Dev 
k3 
Std. Dev 
k4 
Std. Dev 
k5 
Std. Dev 
k6 
Std. Dev 
k7 
Std. Dev 
k8 
3.5 2.18E+02 2.15E+01 1.12E+00 2.10E+02 1.62E+01 1.42E+01 1.21E+01 2.00E-01 
7 7.65E+02 2.03E+01 3.44E-01 1.64E+04 3.00E+01 1.03E+01 5.69E+02 1.16E+00 
12.3 8.82E+02 1.87E+02 1.60E+00 4.22E+04 4.01E+01 6.28E+02 1.68E+02 3.02E+00 
17.1 2.35E+03 2.30E+01 5.54E-01 2.89E+04 1.83E+01 1.54E+01 3.42E+01 9.00E-01 
22.4 2.39E+03 1.68E+01 7.23E+00 3.99E+04 1.31E+01 9.75E+01 7.35E+01 1.01E+00 
27.2 2.07E+03 2.59E+01 3.11E+00 2.76E+04 7.05E+02 4.86E+02 7.64E+02 4.65E+00 
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4.6.6 W326F-PAH temperature dependent stopped flow fluorescence fits 
 
 
Figure 4.76 Kinetic fit of 10 µM W326F-PAH with 5 mM L-Phe at 8.3 ºC to the model 
proposed in Figure 4.22 (Eqs. 50-57). The data is shown in black while the fit is shown 
in red; the inset shows the residual of the fit. 
 
 
 
 
 
 
Figure 4.77 Kinetic fit of 10 µM W326F-PAH with 5 mM L-Phe at 12.2 ºC to the model 
proposed in Figure 4.22 (Eqs. 50-57). The data is shown in black while the fit is shown 
in red; the inset shows the residual of the fit. 
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Figure 4.78 Kinetic fit of 10 µM W326F-PAH with 5 mM L-Phe at 17.4 ºC to the model 
proposed in Figure 4.22 (Eqs. 50-57). The data is shown in black while the fit is shown 
in red; the inset shows the residual of the fit. 
 
 
 
 
 
 
Figure 4.79 Kinetic fit of 10 µM W326F-PAH with 5 mM L-Phe at 23.3 ºC to the model 
proposed in Figure 4.22 (Eqs. 50-57). The data is shown in black while the fit is shown 
in red; the inset shows the residual of the fit. 
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Figure 4.80 Kinetic fit of 10 µM W326F-PAH with 5 mM L-Phe at 28.5 ºC to the model 
proposed in Figure 4.22 (Eqs. 50-57). The data is shown in black while the fit is shown 
in red; the inset shows the residual of the fit. 
 
 
 
 
 
Figure 4.81 Possible mechanism attempted for W326F-PAH fluorescence with 5 mM L-
Phe. 
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Figure 4.82 Possible mechanism attempted for W326F-PAH fluorescence with 5 mM L-
Phe. 
 
Table 4.18 Rates of 10 µM W326F-PAH with 5 mM L-Phe as fit by the model proposed 
in Figure 4.22 (Eqs. 50-57). 
 
Temp. 
ºC 
k1 
(M
-1
s
-1
) 
k2 
(M
-1
s
-1
) 
k3 
(M
-1
s
-1
) 
k4 
(M
-1
s
-1
) 
k5 
(s
-1
) 
k6 
(s
-1
) 
k7   
(s
-1
) 
k8 
(s
-1
) 
3.6 5.21E+01 5.48E+03 1.28E+04 2.87E+05 6.39E+01 1.37E+02 2.52E+01 9.52E+01 
8.3 6.81E+01 1.54E+04 1.04E+04 2.91E+05 5.23E+01 1.34E+02 4.26E+01 1.05E+02 
12.2 1.09E+02 1.91E+04 1.69E+04 3.30E+05 6.10E+01 2.11E+02 6.54E+01 2.45E+02 
17.4 9.02E+01 1.90E+04 1.42E+04 3.34E+05 1.11E+02 4.15E+02 8.43E+01 2.01E+02 
23.3 1.26E+02 1.90E+04 1.43E+04 3.45E+05 1.12E+02 4.22E+02 8.76E+01 2.10E+02 
28.5 1.31E+02 1.95E+04 1.45E+04 3.46E+05 1.19E+02 4.26E+02 9.14E+01 2.12E+02 
Temp. 
ºC 
Std. Dev 
k1 
Std. Dev 
k2 
Std. Dev 
k3 
Std. Dev 
k4 
Std. Dev 
k5 
Std. Dev 
k6 
Std. Dev 
k7 
Std. Dev 
k8 
3.6 2.28E+00 1.73E+03 2.66E+03 6.25E+04 2.97E+01 6.34E+01 2.49E+00 9.85E+00 
8.3 8.33E+00 6.85E+03 1.78E+03 5.10E+04 1.37E+01 3.97E+01 1.25E+01 1.59E+01 
12.2 1.01E+01 2.39E+03 1.66E+03 2.58E+03 2.16E+01 1.89E+01 1.06E+00 5.84E+00 
17.4 1.59E+01 4.05E+03 4.04E+02 7.20E+03 1.10E+01 5.40E+01 1.87E+01 5.22E+01 
23.3 2.63E+01 6.61E+03 4.74E+02 9.67E+03 2.53E+01 1.21E+02 4.64E+01 1.38E+01 
28.5 1.32E+01 1.64E+03 3.10E+03 1.26E+03 2.59E+01 2.48E+01 3.36E+01 4.86E+01 
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Figure 4.83 Relative intensity and spectral change of the fluorescence changes in wtPAH 
and the Trp mutant enzymes upon incubation with 2 mM L-Phe at 25 ºC when excited at 
290 nm. 
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CHAPTER 5 
Towards understanding the mechanistic basis of L-Phe induced phenylalanine 
hydroxylase allostery by stopped-flow fluorescence spectroscopy: Part II, 
Deciphering the full length enzyme pathway and discussing mechanistic 
implications 
5.1 Background and perspective 
 The presence of L-Phe has been shown by a wide variety of techniques 
(crystallography, fluorescence spectroscopy, SAW biosensors, centrifugation studies, 
etc.) to induce significant physical changes in tetrameric forms of PAH that prime the 
enzyme for catalytic activity.  These physical changes are part of the L-Phe induced 
allosteric activation process.  While this process has been known to exist for more than 
50 years, the mechanism of allosteric activation has not been well examined.  Earlier 
studies by Shiman and coworkers proposed a mechanism (Figure 1.26) that accounts for 
PAH regulation with both feedback inhibition by BH4 and allosteric activation by L-Phe 
(104, 119, 120).  This mechanism correlates catalytic activity with the regulation 
processes occurring in this enzyme.  The Shiman model (1994) represents the most 
complete mechanism proposed to date to understand the catalytic and allosteric activation 
processes in PAH.  However, the Shiman model was developed using traditional UV-vis 
spectroscopy, which prevented collection of data points prior to 10-15 seconds after 
coenzyme addition.  Rapid, stopped flow kinetic analysis has shown L-Phe induced 
activation processes that occur within the first 10 seconds of the reaction, even in the 
regulatory domain truncated enzyme (50).  If the Shiman model were updated to include 
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these activation processes, which could not be observed at the time of those experiments, 
a more complete model like the one in Figure 5.1 could be developed.  This modified 
model of PAH catalytic activity and regulation by L-Phe and BH4 also includes an 
unknown number of activation steps (shown in the green box).  It is presumed that the 
allosteric activation steps must occur before catalysis, as PAH has low or no enzymatic 
activity prior to L-Phe activation.  However, the ordering of L-Phe and BH4  binding in 
the active site is not known.  It was shown in Chapter 3 that the affinity of L-Phe for the 
active site, is much stronger than the affinity of L-Phe for the allosteric site, suggesting 
that L-Phe and BH4 are likely bound in the active site prior to allosteric activation.  It is 
not known whether active site binding of BH4 or L-Phe play any role in the activation 
process or are required to enable allosteric activation.   
 
 
 
Figure 5.1 Model for BH4 and L-Phe allosteric regulation of PAH and affects on 
catalysis with additional allosteric activation processes shown in the green box.  Adapted 
from ref. (104). 
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 The only other published model of PAH allostery is the recently proposed 
morpheein model (134, 136, 222).  This model (Figures 1.30, 1.32) proposes that the 
PAH tetramer dissociates to form inactive dimers that undergo conformational changes to 
form an active dimer and then ultimately reform an active tetramer.  Furthermore, it is 
proposed that the active tetrameric form of PAH contains the allosteric effector binding 
site (136).  This model is not well supported by the current data as applied to our current 
understanding of the properties of PAH.  As the results presented in Chapter 2 indicate, 
the T-state allosteric binding site is present in the enzyme (even in the inactive T-state 
crystal structures).  While the binding site shape and overall location may change in the 
active R-state structure, the binding site is already present in the resting-state enzyme 
quaternary structure.  Additionally, dimeric enzyme is known to be catalytically active as 
shown by lysolecthin activated enzyme, NEM modified enzyme, the effects of high pH, 
and proteolytic cleavage of the enzyme, which removes a 12 kDa amino terminal 
fragment and a 3 kDa carboxyl terminal (tetramerization domain) fragment (88, 110, 130, 
133) (Section 1.3.1.4).  Finally, the morpheein allostery model is not supported by the 
stopped flow fluorescence behavior of the Trp mutant enzymes.  Interestingly, the 
morpheein model has not been successfully applied to the well-characterized hemoglobin 
system. 
 The work in Chapter 4 showed that mutant enzymes of PAH that contain only 
one of the three tryptophan residues normally found in PAH report the features of 
allosteric activation.  The features present in each mutant enzyme depend on the reporting 
Trp residues present in that particular mutant.  The Trp120 residue appears to report 
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active site binding of L-Phe and an active site reorganization step, which has been 
reported to also occur in regulatory domain truncated PAH (50).   The Trp187 residue 
reports allosteric site binding of L-Phe indirectly through its sensitivity to the subsequent 
allosteric conformational change.  Finally, the Trp326 residue appears to contain a 
combination of both signals, although the total contribution of Trp326 to the overall 
fluorescence change is quite small, making these signals significantly harder to detect.   
 The development of a wild-type PAH mechanism of allosteric activation requires 
synthesis of the Trp mutant enzyme data with information already known for PAH 
activation from other techniques.  The signals of the individual Trp residues of PAH will 
be used as a basis set to initiate the  building of a more complete kinetic model for the 
allosteric activation processes.  Such efforts will then be combined with the currently 
proposed catalytic model (Figure 1.25).  The goal of this chapter is to examine the 
stopped flow fluorescence signatures of wtPAH with L-Phe in order to develop a kinetic 
model for L-Phe induced activation and catalysis in PAH, that can serve as the basis for 
future spectroscopic experiments through these time-dependent species predictions.   
5.2 Experimental section 
5.2.1 Materials 
 All commercial materials were of the highest grade available and were used 
without further purification unless specified.  Glycerol was purified by filtration through 
activated carbon as discussed in Chapter 3.  Glycerol, L-Phe, MOPS, catalase, and DTT 
were all purchased from Sigma-Aldrich (St. Louis, MO).  Potassium chloride and iron 
atomic absorption standards were purchased from Fisher-Scientific (Pittsburgh, PA).  
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Monobasic and dibasic potassium phosphate salts were purchased from VWR (Radnor, 
PA). 
5.2.2 Protein expression and purification 
Recombinant wtPAH was over expressed in Escherichia coli BL21(DE3) cells 
that has been described previously (91, 110) and in Chapter 2.  Purification of wtPAH 
followed the previously described procedure using phenyl-sepharose affinity 
chromatography (GE Healthcare) followed by DEAE-cellulose anion-exchange 
chromatography (Sigma-Aldrich) (91, 123).  The purified enzyme was characterized for 
total iron by atomic absorption, catalytically competent iron by assays with catechol, and 
enzymatic activity assays following the formation of L-Tyr at 275 nm, as discussed in 
Chapter 2.  The characterized enzyme was stored at -80°C until use. 
5.2.3 Stopped flow fluorescence spectroscopy 
 Stopped flow fluorescence spectroscopy of wtPAH was conducted to directly 
determine the activation energy for allosteric activation in wtPAH and to determine an 
overall kinetic mechanism of allosteric activation.  These measurements were conducted 
using a Hi-Tech SF-61DX2 double mixing stopped-flow spectrophotometer (Salisbury, 
United Kingdom) with thermal attachments set up in fluorescence mode as in Chapter 4.  
The instrument was operated in single mixing mode with the first syringe containing the 
protein solution (about 20 μM in 50 mM MOPS/0.3 M KCl pH 7.2) and the second 
syringe containing 10 mM L-Phe (also in 50 mM MOPS/0.3 M KCl pH 7.2).  These 
solutions were mixed and diluted 1:1 before kinetic assays were obtained.  The data was 
collected with excitation of the instrument at 290 nm using a cutoff filter at 320 nm.  Due 
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to the configuration of the instrumental set up, it was not possible to monitor a particular 
spectral range, so instead absolute fluorescence intensity changes after excitation at 290 
nm were observed.  The absolute intensity shifts are given percentage intensity of the 
solution used to blank the instrument.  In these assays, the instrument was blanked with 
10-30 µM protein in 50 mM MOPS/0.3 M KCl pH 7.2, and the 100% intensity of the 
sample comes from tryptophan residues in the protein sample before the addition of L-
Phe.  These spectra were obtained over a wide range of temperatures (3-30 ºC).  For each 
data set, 640 data points were obtained in log time base and data was fit using 
ReactLabKINETICS for global kinetic analysis. 
5.3 Results 
5.3.1 wtPAH with L-Phe stopped flow fluorescence 
 The Trp mutant enzymes provided a framework for understanding the L-Phe 
induced fluorescence changes in PAH.  The Trp mutant enzymes demonstrated that L-
Phe binding, individual subunit conformational changes, and active site reorganization 
steps could be observed in the fluorescent signatures of the reporting Trp residues.  All of 
these features must be considered in a mechanism for wtPAH.  Initial fits of the wtPAH 
and L-Phe fluorescence kinetic models prior to the construction and investigation of the 
Trp mutants employed single or double exponential models that clearly did not account 
for all of the complexity observed in the Trp mutant enzymes.  These models did not fit 
the data well at any temperature as they missed early time steps that occurred within the 
first 1.0 s.  (Examples of these fits are included in the Appendix, Figures 5.30-5.33.)  
Additionally, several dimer - tetramer equilibrium models were also examined, as 
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suggested by (i) the known 2*dimer ↔ tetramer PAH equilibrium, (ii) studies of 
hemoglobin kinetics (148), and (iii) the recent morpheein allostery model for PAH (136).  
None of these models gave adequate fits to the data.  These results were not surprising 
given that the Trp mutant enzymes would not fit well to dimer or dimer - tetramer 
equilibrium models.  The fits to these models are also provided in the Appendix (Figures 
5.33-5.37).  The lowest temperature data sets (3.7 ºC) were used initially to probe the 
kinetic models, as the wtPAH/L-Phe fluorescence spectra was the most complex at low 
temperatures. Higher temperature data were also analyzed, but it was observed that the 
higher temperature data were easily fit to any model that fits at low temperature. 
 Following the analysis of the Trp mutant enzymes, it was assumed that any model 
for the wtPAH enzyme would need to include active and allosteric site L-Phe binding, 
allosteric conformational change, and active site reorganization steps.  At physiological 
conditions, L-Phe binding to the active site is presumed to occur before L-Phe binding to 
the allosteric site; however, in our model we are using such high excesses of L-Phe that is 
possible for L-Phe to bind in both binding sites essentially simultaneously.  Additionally, 
we also assumed that because of the high L-Phe concentrations, that L-Phe could bind to 
all of the subunits of the protein effectively simultaneously, despite being four separate 
binding events (i.e. A + B  C, B + C  D, B + D  E, and B + E  F, are all modeled 
as one process, A + B  C, because the processes occur so rapidly).  A relatively simple 
model to include all of those steps is proposed in Figure 5.2 (Eqs. 92-98).  This model 
includes simultaneous L-Phe binding in the four active sites, followed by active site 
reorganization in all subunits.  The protein subsequently binds L-Phe in the allosteric sites 
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simultaneously and undergoes allosteric conformational change in all subunits.  This 
model can be represented by the following set of equations: 
     A + B → C  k1   (Eq. 92) 
     C → D  k2   (Eq. 93) 
     B + D → E  k3   (Eq. 94) 
     E → F   k4   (Eq. 95) 
     F → G  k5   (Eq. 96) 
     G → H  k6   (Eq. 97) 
     H → I   k7   (Eq. 98) 
This model did not fit well to the data at various time intervals as shown in Figure 5.3 
and this model and its assumptions were rejected. 
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Figure 5.2 Possible mechanism for wtPAH with L-Phe fluorescence. Active site 
rearrangement is indicated by the * in the mechanism.  
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Figure 5.3 Kinetic fit of 11.5 µM wtPAH with 5 mM L-Phe at 3.7 ºC to the model 
proposed in Figure 5.2 (Eqs. 92-98). The data is shown in black while the fit is shown in 
red; the inset shows the residual of the fit. 
 
 
 
 The next tested kinetic mechanism for wtPAH fluorescence with L-Phe, modeled 
L-Phe binding to all subunits followed by allosteric conformational change in each 
subunit and then finally L-Phe binding to the active site and active site reorganization.  
The ordering of kinetic steps is presented in Eqs. 99-105; we have represented this as a 
model with physical processes in Figure 5.4.  This model accounts for L-Phe binding to 
the allosteric site before L-Phe binding to the active site, despite the higher affinity of L-
Phe for the active site.  This model would not be expected to fit well to the data, since L-
Phe is expected to bind to the active site before the allosteric site.  This model was a 
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better fit to the data than the previously presented model; however, a somewhat 
sinusoidal residual was still observed (Figure 5.5) indicating that additional processes 
may be occurring or that steps are mis-assigned. 
     A + B → C  k1   (Eq. 99) 
     C → D  k2   (Eq. 100) 
     D → E  k3   (Eq. 101) 
     E → F   k4   (Eq. 102) 
     F → G  k5   (Eq. 103) 
     B + G → H  k6   (Eq. 104) 
     H → I   k7   (Eq. 105) 
 
 
Figure 5.4 Possible mechanism for wtPAH with L-Phe fluorescence. Active site 
rearrangement is indicated by the * in the mechanism. 
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Figure 5.5 Kinetic fit of 11.5 µM wtPAH with 5 mM L-Phe at 3.7 ºC to the model 
proposed in Figure 5.4 (Eqs. 99-105). The data is shown in black while the fit is shown 
in red; the inset shows the residual of the fit. 
 
 Another proposed model for the wtPAH and L-Phe fluorescence data was the 
eight-step kinetic mechanism that was found to adequately model the time-dependence of 
the Trp mutant enzyme fluorescence results.  It was proposed that that L-Phe could bind 
simultaneously in the active and allosteric sites and then subsequent allosteric 
conformational changes and active site reorganization would occur in each subunit (i.e., 
allosteric reorganization is coupled to, or causes, the active site L-Phe changes).  Both the 
allosteric conformational changes and active site reorganizations were proposed to occur 
at the same time (Figure 5.6, Eqs. 106-113), which is feasible since the L-Phe 
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concentration is 5 mM in our stopped flow fluorescence studies, greatly exceeding the 
binding affinity of L-Phe for the active and allosteric sites.  This model allows for 
essentially simultaneous, rather than sequential, binding of L-Phe.  Additionally, binding 
to the allosteric site is not directly observed as the fluorescence changes only occur upon 
structural reorganization within the protein, while the L-Phe active site binding is directly 
observed. 
     A + B → C  k1   (Eq. 106) 
     B + C → D  k2   (Eq. 107) 
     B + D → E  k3   (Eq. 108) 
     B + E → F  k4   (Eq. 109) 
     F → G  k5   (Eq. 110) 
     G → H  k6   (Eq. 111) 
     H → I   k7   (Eq. 112) 
     I → J   k8   (Eq. 113) 
This model did not fit the data well at very early time points (<1 s), as shown in Figure 
5.7.  The fit suggested that additional processes were occurring and that it was unlikely 
that both the active site reorganization and allosteric conformational change steps were 
occurring simultaneously.  It was though that the active site reorganization and allosteric 
conformational steps might occur separately as Δ1-117-PAH does not undergo allosteric 
conformational change, but has been shown to require active site reorganization (50). 
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Figure 5.6 Possible mechanism for wtPAH with L-Phe fluorescence. Active site 
rearrangement is indicated by the * in the mechanism. 
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Figure 5.7 Kinetic fit of 11.5 µM wtPAH with 5 mM L-Phe at 3.7 ºC to the model 
proposed in Figure 5.6 (Eqs. 106-113). The data is shown in black while the fit is shown 
in red; the inset shows the residual of the fit. 
 
 An additional model was proposed that built upon the previously proposed eight-
step model (Figure 5.6, Eqs. 106-113).  In this model, L-Phe binds to each allosteric site 
individually, followed by allosteric conformational change in each subunit.  
Subsequently, in a single step, L-Phe binds to all the active sites and undergoes active site  
reorganization.   This single step was proposed due to a limitation in the global kinetic 
fitting software, ReactLabKINETICS, which limits the number of species present in 
mechanism to 11 species.  This model is presented in Figure 5.8 and Eqs. 114-122. 
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     A + B → C  k1   (Eq. 114) 
     B + C → D  k2   (Eq. 115) 
     B + D → E  k3   (Eq. 116) 
     B + E → F  k4   (Eq. 117) 
     F → G  k5   (Eq. 118) 
     G → H  k6   (Eq. 119) 
     H → I   k7   (Eq. 120) 
     I → J   k8   (Eq. 121) 
     B + J → K  k9   (Eq. 122) 
This model fit the data slightly better than the eight step model presented above, but the 
fit still demonstrated significant deviation from the data in the first ~1.0 s (Figure 5.9). 
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Figure 5.8 Possible mechanism for wtPAH with L-Phe fluorescence. Active site 
rearrangement is indicated by the * in the mechanism. 
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Figure 5.9 Kinetic fit of 11.5 µM wtPAH with 5 mM L-Phe at 3.7 ºC to the model 
proposed in Figure 5.8 (Eqs. 114-122). The data is shown in black while the fit is shown 
in red; the inset shows the residual of the fit. 
 
 Another possible model to the data allowed for two separate pathways to occur.  
The bi-directional kinetic model (Figure 5.10, Eqs. 123-132) model was shown to give 
the best fit to the data and the most random residuals of any model tested for wtPAH 
fluorescence with L-Phe.  This bi-directional model follows two pathways, which both 
contain a fast initial binding step.  This binding step is associated with L-Phe binding to 
either the active or allosteric sites.  Subsequent steps involve L-Phe induced 
conformational changes in the allosteric site and active sites.   
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     A + B → C  k1   (Eq. 123) 
     C → D  k2   (Eq. 124) 
     D → E  k3   (Eq. 125) 
     E → F   k4   (Eq. 126) 
     F → G  k5   (Eq. 127) 
     B + G → H  k6   (Eq. 128) 
     H → I   k7   (Eq. 129) 
     A + B → J  k8   (Eq. 130) 
     J → K   k9   (Eq. 131) 
     B + K → I  k10   (Eq. 132) 
 
 
Figure 5.10 Proposed mechanism for wtPAH with L-Phe fluorescence. Active site 
rearrangement is indicated by the * in the mechanism. 
 
 This model fit very well to the data at 3.7 ºC as shown in Figure 5.11.  The 
residual for this process is quite random and shows little deviation.  This model was then 
fit to wtPAH with L-Phe fluorescence data from 3.7-30.0 ºC (Figures 5.11-5.16).   In all 
cases very good fits to the data were observed with random residuals.  This model allows 
the most flexibility of the models tested, in that L-Phe could bind to either the active or 
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allosteric binding sites immediately and then undergo the appropriate conformational 
change for that binding site.  This model is severely limited by the number of species able 
to be tested in ReactLabKINETICS and is the maximum number of species that can be fit 
by the program.   
  
 
Figure 5.11 Kinetic fit of 11.5 µM wtPAH with 5 mM L-Phe at 3.7 ºC to the model 
proposed in Figure 5.10 (Eqs. 123-132). The data is shown in black while the fit is 
shown in red; the inset shows the residual of the fit. 
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Figure 5.12 Kinetic fit of 11.5 µM wtPAH with 5 mM L-Phe at 10.0 ºC to the model 
proposed in Figure 5.10 (Eqs. 123-132). The data is shown in black while the fit is 
shown in red; the inset shows the residual of the fit. 
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Figure 5.13 Kinetic fit of 11.5 µM wtPAH with 5 mM L-Phe at 15.1 ºC to the model 
proposed in Figure 5.10 (Eqs. 123-132). The data is shown in black while the fit is 
shown in red; the inset shows the residual of the fit. 
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Figure 5.14 Kinetic fit of 11.5 µM wtPAH with 5 mM L-Phe at 20.0 ºC to the model 
proposed in Figure 5.10 (Eqs. 123-132). The data is shown in black while the fit is 
shown in red; the inset shows the residual of the fit. 
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Figure 5.15 Kinetic fit of 11.5 µM wtPAH with 5 mM L-Phe at 25.3 ºC to the model 
proposed in Figure 5.10 (Eqs. 123-132). The data is shown in black while the fit is 
shown in red; the inset shows the residual of the fit. 
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Figure 5.16 Kinetic fit of 11.5 µM wtPAH with 5 mM L-Phe at 30.0 ºC to the model 
proposed in Figure 5.10 (Eqs. 123-132). The data is shown in black while the fit is 
shown in red; the inset shows the residual of the fit. 
 
 In this kinetic model (Figure 5.10, Eqs. 123-132), it is likely that the steps from 
k2 - k5 correspond to allosteric conformational change, but the exact identity of these 
steps cannot be determined solely from kinetic data.  Additionally, the SAW studies 
suggest that L-Phe binding in the active site should occur before L-Phe binding in the 
allosteric site, but this cannot be discriminated by our kinetic mechanism, as the L-Phe 
concentration is in great excess (5 mM) and rapidly binds to both binding sites.  
Additional stopped flow fluorescence studies to discriminate the order of L-Phe binding 
to the active and allosteric sites, should be performed with lower concentrations of L-Phe 
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(200 µM or less) to saturate the active site, but not saturate the allosteric site.  The 
process occurring in step k10, which is a required kinetic step of L-Phe binding, may be a 
combination of additional processes corresponding to binding and conformational 
change, as this is slow step kinetically (Rates in Table 5.1 and Table 5.3), which is 
unlikely for a binding only step.  Additional two stage mixing stopped flow experiments, 
where the enzyme is first incubated with low concentrations of L-Phe (200 µM), and then 
mixed with higher concentrations of L-Phe (>1 mM), may be required to properly 
differentiate the kinetic pathways involving active site and allosteric site L-Phe binding 
and conformation change.  
 In order to further probe this model, additional permutations of the model in 
Figure 5.10 were tested.  In order to test the bi-directionality of this kinetic model, 
additional mechanisms were proposed in the attempt to connect the two simultaneous 
pathways proposed in Figure 5.10.  One of these mechanisms, shown in Figure 5.17, 
Eqs. 133-139, still allowed for bi-directional binding of L-Phe to either binding site (k1 or 
k4), however, all conformational change steps occur in sequence, rather than as two 
pathways as reported in the kinetic mechanism in Figure 5.10. 
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     A + B → C  k1   (Eq. 133) 
     C → D  k2   (Eq. 133) 
     B + D → E  k3   (Eq. 134) 
     A + B → E  k4   (Eq. 135) 
     E → F   k5   (Eq. 136) 
     F → G  k6   (Eq. 137) 
     G → H  k7   (Eq. 138) 
     H → I   k8   (Eq. 139) 
The kinetic fit to this mechanism, Figure 5.18, was a poor fit the data and suggested that 
the additional processes occurring in step k10 of Figure 5.10 are real processes that must 
be accounted for in the model.  Additionally, this kinetic model indicated a slow binding 
step for L-Phe (Table 5.4), which seems unlikely given the rapid binding of L-Phe in Trp 
mutant enzymes. 
 
 
Figure 5.17 Possible mechanism for wtPAH with L-Phe fluorescence. Active site 
rearrangement is indicated by the * in the mechanism. 
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Figure 5.18 Kinetic fit of 11.5 µM wtPAH with 5 mM L-Phe at 3.7 ºC to the model 
proposed in Figure 5.17 (Eqs. 133-139). The data is shown in black while the fit is 
shown in red; the inset shows the residual of the fit. 
 
 One additional model was proposed to eliminate the bi-directionality of L-Phe 
binding initially to both the active and allosteric sites, as in the models proposed in 
Figure 5.10 or 5.17.  This model contains two binding steps in a sequential fashion, 
followed by several conformational change steps.  This model also has a slow rate for one 
of the L-Phe binding steps (Table 5.4), which was not expected based on the rates of L-
Phe binding to the Trp mutant enzymes.  This model (Figure 5.19, Eqs. 140-146) also 
exhibited a poor fit to the data at low temperatures (Figure 5.20), which suggested that 
the bi-directional binding of L-Phe to both the active and allosteric sites is warranted by 
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the enzyme at high saturating concentrations of L-Phe at which these experiments are 
being performed.  Further stopped flow fluorescence studies at lower L-Phe 
concentrations will be required to analyze whether L-Phe binding to both sites always 
occurs in PAH.   
     A + B → C  k1   (Eq. 140) 
     C → D  k2   (Eq. 141) 
     B + D → E  k3   (Eq. 142) 
     E → F   k4   (Eq. 143) 
     F → G  k5   (Eq. 144) 
     G → H  k6   (Eq. 145) 
     H → I   k7   (Eq. 146) 
 
 
Figure 5.19 Possible mechanism for wtPAH with L-Phe fluorescence. Active site 
rearrangement is indicated by the * in the mechanism. 
 
 
356 
 
 
 
 
Figure 5.20 Kinetic fit of 11.5 µM wtPAH with 5 mM L-Phe at 3.7 ºC to the model 
proposed in Figure 5.19 (Eqs. 140-146). The data is shown in black while the fit is 
shown in red; the inset shows the residual of the fit. 
      
 The model in Figure 5.10 was accepted as the current working kinetic mechanism 
for the L-Phe induced fluorescence changes in wPAH, as this combination of kinetic 
steps was best able to fit the data.  Future studies will need to examine the simultaneous 
active site vs. allosteric site population and induced fluorescence changes by 
concentration dependent stopped flow fluorescence in order to provide an explanation of 
physical processes that describe these kinetic steps.  Stopped flow fluorescence at low 
concentrations of L-Phe (200 µM) should only observe L-Phe binding to active site, while 
higher concentrations of L-Phe will observe L-Phe binding to both the active and 
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allosteric sites.  It would also be interesting to examine stopped flow fluorescence of the 
K113R-PAH mutant (studied in Chapters 2 and 3), that blocks access of L-Phe to the 
allosteric site.  The effect of equilibria instead of irreversible steps will also need to be 
carefully examined.   
 Using the kinetic mechanism developed in Figure 5.10 (Eqs. 123-132), an 
Arrhenius activation energy plot (Figure 5.21) was constructed.  The activation energies, 
extrapolated from the slopes of this plot, are calculated for each step of the kinetic 
mechanism (Table 5.1).  Speciation plots for each of the predicted species are provided 
as well (Figure 5.22 or Appendix, Figures 5.39-5.43).  According to the speciation plot 
at 3.7 ºC (Figure 5.22), there is a large build up of species D at early time points.  This 
species corresponds to the first conformational change species and suggests that the first 
conformational change is the most challenging step kinetically.  The rates increase 
significantly for steps k4, k5, and k6, as species D undergoes conformational change.  
Additionally, there is a large build up of species K that remains over the entire monitored 
time scale (10 s), which suggests that this species may be a buildup of enzyme with L-
Phe bound in the active site, which has undergone active site rearrangement, and will 
later undergo allosteric conformational change.  We cannot fully address what happens to 
this species in our current kinetic mechanism due to the limits our fitting parameters, 
however future stopped flow studies should be able to provide insight into the processes 
occurring with this species.  
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Figure 5.21 Temperature dependent Arrhenius activation energy plot for the reaction of 
wtPAH with L-Phe. 
 
Table 5.1 Temperature dependent Arrhenius activation energies for intermediates in the 
reaction of wtPAH with L-Phe, as depicted in Figure 5.10, with rates for the reaction 
steps at 3.7 ºC. 
Reaction Rate 
Constant 
Rates at 3.7 ºC 
(s
-1
 or M
-1
s
-1
) 
Activation Energy 
(kcal/mol) 
A + B → C k1 8.0 x 10
4 
±
 
1.7 x 10
3 
M
-1
s
-1
 14.3 ± 3.4 
C → D k2 1.1 x 10
1
 ± 1.2 x 10
0
 s
-1 
3.9 ± 0.9 
D → E k3 3.5 x 10
-1 
± 2.1 x 10
-1
 s
-1 
10.4 ± 2.9 
E → F k4 1.4 x 10
0
 ± 1.7 x 10
-1
 s
-1 
6.0 ± 1.4 
F → G k5 1.4 x 10
2 
± 7.9 x 10
1
 s
-1 
11.1 ± 3.1 
B + G → H k6 1.0 x 10
4
 ± 5.5 x 10
3
 M
-1
s
-1 
7.4 ± 2.8 
H → I k7 1.0 x 10
8
 ±  2.7 x 10
7
 s
-1 
0.0 ± 0.0 
A + B → J k8 1.1 x 10
4
 ± 4.9 x 10
3
 M
-1
s
-1 
16.6 ± 4.9 
J → K k9 6.6 x 10
0
 ± 2.7 x 10
-1
 s
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Figure 5.22 Speciation plot for predicted species in the reaction of 11.5 µM wtPAH with 
5 mM L-Phe at 3.7 ºC according to the model shown in Figure 5.10 (Eqs. 123-132). 
 
5.4 Discussion  
5.4.1 General discussion 
 The fluorescence of wtPAH with L-Phe is a multi-step process that demonstrates 
the most interesting signals at low temperature.  At 3.7 ºC, the spectra rapidly decrease in 
intensity in the first 100 ms, and then slowly increase in intensity.  At 10.0ºC, the spectra 
are noisy for the first 500 ms, indicating that that several rapid processes may be 
occurring, and then gradually increases in intensity after that point.  The role of Trp 
quenching and the effect of such processes under these conditions will be important to 
understand as part of the development of any kinetic model.  At temperatures of 15.1 ºC 
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and above, there is no observable intensity decrease at early time points, and the data 
appear as increasingly fast exponential curves.  Early analysis of the higher temperature 
data suggested that the wtPAH with L-Phe fluorescence could be fit to single or double 
exponential equation, suggesting a one or two-step fit.  When those models were applied 
to the higher temperature data, it was possible to obtain reasonable fits to the data; 
however, when those models were tested at 3.7 ºC, the models did not fit at all (Figures 
5.31, 5.33).  The complexity of the early temperature data required a model that 
accounted for both allosteric activation by L-Phe and active site reorganization upon L-
Phe binding.  Models that accounted for both these steps were able to fit the data much 
more closely and were used to develop the working kinetic model presented herein. 
5.4.2 Correlation with Trp mutant enzymes 
 The Trp mutant enzymes all demonstrated fluorescence with L-Phe that fit to 
eight-step mechanisms corresponding to L-Phe binding in each subunit followed by 
active site reorganization or allosteric site conformational change.  The wild-type enzyme 
fluorescence with L-Phe reports both of these processes.  The overall fluorescence spectra 
at low temperature (3-5 ºC) are similar for wtPAH and the Trp mutant enzymes.  At 
higher temperatures, wtPAH with L-Phe displays much more remarkable spectra than the 
Trp mutant enzymes, as there is still an exponential increase in intensity with time.  The 
major differences in the kinetic fits for the wtPAH and the Trp mutant enzymes are the 
presence of all of the reporting Trp residues.  The replacement of one or more Trp 
residues with L-Phe residues has been shown to drastically affect signaling and 
communication within PAH, as Trp187 reports allosteric conformational change and 
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Trp120 reports active site binding despite being 40 Å and 23 Å from the active and 
allosteric sites respectively.  In the case of the Trp mutants, the removal of one or more 
reporting Trp residues facilitates the observation of only one of the L-Phe activation 
processes.  In wtPAH, all Trp residues are present and can report the L-Phe induced 
activation changes and therefore both the allosteric conformational change and active site 
reorganization can be observed.  Additionally among the Trp PAH mutant enzymes, only 
W187F-PAH and W326F-PAH maintain cooperativity. The lack of cooperativity in four 
of the enzymes may explain some of the lack of intra-protein communication occurring in 
the Trp mutant enzymes.  It is still unclear why W187F-PAH and W326F-PAH maintain 
cooperativity that cannot be better explained by the wtPAH fluorescence data.  
5.4.3 Potential biological implications for working kinetic mechanism in PAH  
5.4.3.1 Potential biological explanation of working kinetic mechanism 
 A current challenge involves the interpretation or assignment of the individual 
steps in the kinetic mechanism to chemical steps that describe an enzymatic mechanism.  
Note that the kinetic mechanism relates a series of steps, and the order or assignment of 
specific enzymatic states and levels of L-Phe loading will require independent 
experimental data to either support or refute any assigned species.  With this significant 
caveat in mind, it is nonetheless interesting to postulate possible chemical implications of 
the kinetic model in order to frame the next set of mechanistic experiments.   
 The working kinetic mechanism for the fluorescence of wtPAH with L-Phe can be 
explained as a potential representation of physical processes occurring in PAH (Figure 
5.23).  This potential biological explanation is founded on the kinetic fits that suggested 
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the presence of a bi-directional pathway in the enzyme; removal of the bi-directional 
pathway leads to poor kinetic fits.  The first of the pathways is referred to as the dominant 
pathway, due to the speciation plot (Figure 5.22) suggesting a large build up of species D 
which then goes on to ultimately form species I.  In this pathway, L-Phe is proposed to 
bind in the allosteric site followed by allosteric conformational change in each subunit (k1 
- k5).  These steps are followed by subsequent active site L-Phe binding and 
reorganization (k6 - k7).  The relative timescale of these processes show that initial L-Phe 
binding to the allosteric site occurs quite quickly (k1 = 8.0x10
4
 M
-1
s
-1
 at 3.7 ºC, Table 
5.1) and then subsequent conformational changes steps occur slower, but at increasing 
rates with each conformational change.  These rates are consistent with a cooperative 
process for the L-Phe induced allosteric conformational change, wherein the 
conformational change in one subunit facilitates the conformational change in other 
subunits.  The activation energies of these processes, however, do not decrease with the 
increasing rates during the conformational change steps.  Similar energy barriers have 
been observed for hemoglobin, wherein the enthalpy of binding the fourth oxygen 
molecule, is the greatest (-16 kcal/O2), while the first oxygen molecule is the lowest (-6.6 
kcal/O2).  The second and third oxygen molecules are intermediate (-12.2 kcal/O2) (223, 
224).  In the case of PAH, the activation energies of the first and third conformational 
change steps are require less energy than the second or fourth step.  The activation energy 
stabilization of the first and third conformational change steps may indicate some role of 
dimers in stabilizing particular activation steps that requires further examination.  The 
binding of L-Phe to active site occurs at approximately the same rate as L-Phe binding to 
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the allosteric site (k6 = 1.0x10
4
 M
-1
s
-1
 at 3.7 ºC), and then the conformational change for 
active site reorganization occurs very rapidly (k7 = 1.0x10
8
 s
-1
).  These data suggest that 
the active site organization is a relatively low energy process that occurs nearly 
spontaneously when L-Phe binds in the active site.   
 
 
 
Figure 5.23 Potential biological explanation of the working kinetic mechanism for 
allosteric activation as representation of physical processes, which is adapted from the 
proposed mechanism for wtPAH fluorescence with L-Phe in Figure 5.10.  
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 The other pathway observed in this potential biological mechanism for L-Phe 
induced fluorescence with wtPAH is referred to as the alternative pathway, due to the 
buildup of species K in the speciation plot (Figure 5.22).  The alternative pathway for L-
Phe induced activation of PAH occurs when L-Phe binds in the active site first.  The rate 
of L-Phe binding in the active site is also approximately the same as the other L-Phe 
binding steps (k8 = 1.1x10
4
 M
-1
s
-1
).  Much slower steps are observed for active site 
reorganization, and L-Phe binding in the allosteric site with subsequent allosteric 
conformational change.  These two steps are likely a combination of additional steps that 
we cannot differentiate with our current kinetic mechanism.  While our kinetic 
mechanism describes the binding of L-Phe and allosteric conformational change as one 
step due to the limits on the number of species in ReactLabKINETICS, this step is 
probably several processes in the wild-type enzyme.  This could be as many as five steps 
for L-Phe binding, and each individual subunit conformational change.  The alternative 
pathway processes occur with a relatively small percentage of the overall enzyme, and 
even less enzyme undergoes this final activation step.  The vast majority of the enzyme 
that follows the alternative pathway remains at species K (the L-Phe bound and active 
site rearranged species) according to the speciation plot in Figure 5.22.  The speciation 
plot suggests that the alternative pathway may be a secondary pathway in the enzyme.  It 
is possible that the enzyme will use this pathway to fill the active site with L-Phe first and 
then pause the activation process if there is a low concentration (<500 µM) of L-Phe 
present.  At higher concentrations, L-Phe can immediately bind in the allosteric site and 
undergo allosteric conformational change.  This working kinetic mechanism is consistent 
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with the SAW data provided in Chapter 3, where it was demonstrated L-Phe binds in the 
active site at ~100 µM, but does not bind in the allosteric site until ~700 µM.   
 In the stopped flow fluorescence experiments, we have always used a large excess 
of L-Phe (83-250 fold, depending on enzyme concentration) to simplify the kinetic 
analysis and enable the application of pseudo-first order kinetics.  Future experiments 
could probe the binding of L-Phe to the active and allosteric sites, by using physiological 
concentrations of L-Phe.  Fluorescence experiments at 100-200 µM L-Phe should observe 
binding of L-Phe in the active site and subsequent active site rearrangement, but may not 
observe L-Phe binding in the allosteric site.  Concentration dependent stopped flow 
fluorescence experiments should help determine the ordering of L-Phe binding in the 
active and allosteric sites of PAH and determine whether step k10 in the working kinetic 
mechanism in Figure 5.23 is a real a single step, a combination of additional steps, or an 
artifact of the fitting parameters.  
  Stopped flow fluorescence experiments at lower concentration with the wild-type 
enzyme should also help sort out whether the second set of processes occurring in the 
working kinetic mechanism from steps k8 - k10 are able to be fit independently assuming 
that active site reorganization is the only process being observed at low concentrations of 
L-Phe or whether additional steps are required.  Whether multiple steps are required is an 
especially important question for step k10, which could be easily drawn in as many as five 
steps.  Use of the allosteric site knockout mutants from Chapter 2, such as K113R-PAH, 
may assist with this study, by enabling analysis of only the L-Phe active site binding and 
reorganization steps. 
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 Rapid freeze quench experiments could be performed to stop the kinetic reaction 
after the binding of L-Phe.  If these experiments are performed on iron-nitrosyl adducts of 
PAH, ESSEM can be used to monitor active site rearrangement near the iron center.  At 
higher L-Phe concentrations, allosteric activation and active site rearrangement will occur 
as L-Phe should bind in both binding sites, but only the active site rearrangement should 
be observed.  At low L-Phe concentrations, however, L-Phe should only bind in the active 
site, resulting in an active site reorganization.  These experiments would be a good way 
to confirm that the active site L-Phe binding and active site rearrangement occurs at low 
L-Phe concentrations. 
 Previous experiments by Shiman and Gray have reported that the activation 
energy for allosteric activation of PAH is 33.5 kcal/mol (88).  These experiments were 
performed indirectly from enzyme activity assays where L-Phe as added as the last 
component of the activity assay and the activation lag time could be observed in the 
assay.  The first data point was collected 10.0 s after the addition of L-Phe (88).  Our 
stopped flow fluorescence of wtPAH with L-Phe enabled the analysis of much earlier 
timescale processes.  In our data, the largest fluorescence intensity changes occur within 
the first 100 ms after wtPAH and L-Phe mixing.  This rapid data analysis allows us to be 
able to interpret steps that were not observable under the absorbance time scale.  We have 
found that the stopped flow time scale, with limitations of a 10-15 ms dead time in 
fluorescence mode, may be too slow to properly analyze all of the processes occurring 
and we may need to perform laser based experiments to better analyze the rapid processes 
occurring in the enzyme.  From our kinetic model we have determined the Arrhenius 
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activation energy for each step of the working kinetic mechanism, and we have found 
that various steps have relatively high activation energies (Table 5.1), but no single step 
is close the 33.5 kcal/mol activation energy observed by Shiman (88).  The initial binding 
of L-Phe to either the active or allosteric site has a significant activation barrier (k1 and k8, 
14.3 and 16.6 kcal/mol respectively).  The individual subunit conformational changes 
have smaller activation barriers (3.9, 10.4, 6.0, 11.1 kcal/mol for k2-k5 respectively).  The 
binding of L-Phe after allosteric conformational change has a smaller activation barrier 
(k6, 7.5 kcal/mol), that is similar to what was observed for the L-Phe dependent active site 
reorganization in Δ1-117-PAH  of 5 ± 1 kcal/mol (50).  Additionally, after L-Phe binding 
in the active site, there is essentially no activation barrier to the active site rearrangement 
in the dominant pathway (k7, 0.0 kcal/mol).  The last two steps of the alternative pathway, 
active site rearrangement followed by L-Phe binding in the allosteric site and activation 
are associated with relatively large activation barriers (17.2 and 10.1 kcal/mol 
respectively for k9 and k10). These activation energies suggest that this pathway (as 
written) is not the dominant pathway as more energy is required to undergo activation 
through this route.  
5.4.3.2 Physical constraints on the working kinetic mechanism 
 The working kinetic mechanism requires particular physical constraints on PAH.  
First, this kinetic mechanism requires that only the tetrameric enzyme undergoes 
traditional allosteric activation.  It is well established that dimeric PAH can perform 
catalysis (49); however dimeric PAH behaves as if it is already activated and does not 
require the same activation steps as tetrameric wtPAH (131, 133).  It is unclear if the 
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active site binding of L-Phe in the dimeric enzyme undergoes a conformational change as 
observed in tetrameric Δ1-117-PAH (50).  The working kinetic mechanism proposed 
here, requires a tetrameric state for allosteric activation and conformational change.  This 
species the dominant species in solution and demonstrates fluorescence changes observed 
in solution.  Fluorescence titrations with NEM-modified PAH, which is a chemically 
modified dimer (see Chapter 3), demonstrated no shift in the fluorescence maximum of 
the protein upon incubation with L-Phe.  These results show that the dimeric species 
cannot be observed in the stopped flow fluorescence studies and therefore can be 
excluded from this kinetic mechanism. PAH always exists as a dimer - tetramer 
equilibrium in solution, which can be shifted to one predominant species by altering the 
pH (91).  While the dimer is present in our system, we are unable to observe it.  The 
process by which the dimer species is activated and able to perform catalysis has not been 
well studied and should be further examined.   
 Another physical constraint of the working kinetic mechanism is that each subunit 
individually and sequentially undergoes allosteric conformational change in the dominant 
pathway, followed by active site reorganization.  This constraint requires physical 
changes upon allosteric activation to occur sequentially in each subunit.  This process 
may allow the allosteric site of one subunit to move to closer to the allosteric site of 
another subunit as indicated in Figure 5.24.  This process could occur sequentially in all 
subunits as shown in the sequence of potential protein movements in Figure 5.25.  This 
process would allow the activated state of the enzyme to have interactions between the 
regulatory domains.  These interactions are observed in most of the crystallographically 
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characterized ACT domain proteins, where at least two ACT domains subunits interact to 
induce allosteric regulation (68, 160).  If these types of changes are indeed occurring 
during allosteric activation, it would explain why crystal structures of the activated 
enzyme have been so hard to obtain (57).  In order to obtain crystal structures of the R-
state activated enzyme, large excesses of L-Phe should co-crystallized with the enzyme to 
fully activate the enzyme before crystallization and prevent further conformational 
changes once the crystals have formed.  
 
 
Figure 5.24 Surface map of the wtPAH tetramer.  Allosteric site of the green monomer is 
outlined in a box; the allosteric site of the cyan monomer is outlined in an oval.  Possible 
direction of subunit movement during allosteric activation is indicated with an arrow. 
Figure was created in PyMol (23) using PDB files 2PAH (84) and 2PHM (14). 
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Figure 5.25 Surface maps of wtPAH indicating the location of each allosteric site 
(indicated in a box, oval, triangle, or pentagon on each monomer), and the direction of 
potential allosteric conformational changes with L-Phe.  Arrows indicate the relative 
movement within the tetrameric enzyme.  Figure was created in PyMol (23) using PDB 
files 2PAH (84) and 2PHM (14). 
 
 An additional physical limitation of this kinetic mechanism is the active site 
reorganization step proposed both at the end of the primary pathway and at the beginning 
of the alternative pathway.  This active site reorganization step upon L-Phe binding may 
facilitate small conformational changes that enhance the accessibility of gaseous 
substrates (nitric oxide or dioxygen) or alter the hydrogen bonding network near the 
active site (50).  In our proposed kinetic mechanism, this step can occur before, 
concurrent with, or after allosteric conformational change depending on whether the 
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dominant or alternative pathways are followed.  This assessment agrees with previous 
studies, suggesting that even Δ1-117-PAH, which behaves although it is already activated 
at 25 ºC, undergoes this active site reorganization step at low temperature (50). 
5.5 Conclusions and future directions 
5.5.1 Allosteric activation and catalytic mechanisms for PAH 
 The working kinetic mechanism for the L-Phe induced activation processes in 
PAH provides a pathway for allosteric activation and conformational change and for 
active site reorganization upon the binding of L-Phe.  Figure 5.26 describes how these 
processes are organized in the scheme of PAH catalytic activity. 
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Figure 5.26 Scheme for regulation by L-Phe and BH4. 
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 This scheme for PAH regulation by L-Phe and BH4 combines the regulation 
mechanism of Xia, Gray, and Shiman (104) with our current work for understanding 
allosteric activation.   The previous regulation mechanism was developed primarily 
through the use steady-state kinetic analyses of wtPAH with L-Phe and BH4.  These 
assays demonstrated that BH4 binding prior to allosteric activation by L-Phe leads to an 
inactive enzyme that can release BH4 to return to the inactive free enzyme state and then 
undergo allosteric activation by L-Phe to form the catalytic competent enzyme.  The 
activated enzyme then would bind L-Phe, BH4, and dioxygen as described in Figure 5.1 
(104).  Our model presented herein agrees well with previously presented model, but 
further extends the model to account for the additional observed L-Phe induced activation 
steps.  Note, the use of 5-deaza-6MPH4 or 6MPH4 in kinetic and spectroscopic studies 
will not act as a negative allosteric effector like BH4 (49). 
 The left side of the scheme in Figure 5.26 accounts for the dimer - tetramer 
equilibrium in PAH.  While it is known that dimeric forms of PAH are catalytically 
active and turnover L-Phe to L-Tyr (49), the activation process is still unknown.  Dimeric 
PAH behaves as if it is already activated at 25ºC, however it has not been well studied by 
temperature dependent stopped flow absorption to determine the activation energy for the 
this process, as has been done for wtPAH (88, 91) or Δ1-117-PAH (50).  The current 
working mechanism describes the catalytic process in dimeric PAH as occurring without 
any activation step, as there is no current evidence for an activation step.   
 The second column from the left in the scheme in Figure 5.26 accounts for the 
flexible inactivation steps that were observed by Xia, Gray, and Shiman in the earlier 
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studies of inactivation by coenzyme (104).  Our working kinetic mechanism leaves these 
steps as they were previously reported as we have focused the reaction of wtPAH with L-
Phe and the subsequent activation steps.  This process is reported to lead to an inactive 
complex with BH4 or BH4 and L-Phe bound in the active site, but can be reversed with 
release of those compounds from the enzyme (104, 120).   
 The last part of the scheme for regulation of PAH by L-Phe and BH4 is our 
working kinetic mechanism for wtPAH and L-Phe as determined by stopped flow 
fluorescence and its implications for catalysis.  In this working mechanism, L-Phe can 
bind to PAH in the allosteric site and follow the dominant pathway of L-Phe induced 
conformational change in each subunit followed by L-Phe binding in the active site and 
active site reorganization.  Additionally, L-Phe can bind in the active site first, following 
the alternative pathway, and undergo active site reorganization and subsequent L-Phe 
binding in the allosteric site and allosteric conformational change.  
 Our working kinetic mechanism of allosteric activation was shown to only apply 
to the tetrameric enzyme, and dimer or dimer - tetramer models did not fit well to the data 
(Figures 5.35-5.38).  These models suggest that L-Phe induced activation of wtPAH as 
described our analysis do not support the morpheein model (134, 222).  As discussed 
with the L-Trp mutant enzymes in Chapter 4, the morpheein model of PAH allostery 
requires an inactive dimeric species to undergo conformational changes to an active 
dimeric species before forming the allosteric binding site in an active tetramer (136).  
This model disagrees with our understanding of the wild-type enzyme on several levels.  
First, the allosteric binding site is present all forms of the enzyme as is shown in Chapter 
375 
 
 
 
2.  The binding site was located using computational mapping and docking software 
using the currently available T-state crystal structures. Second, dimeric PAH is 
catalytically active, as discussed above.  While the activation mechanism or processes are 
unknown, it is likely that some L-Phe induced activation process is required as has been 
observed for Δ1-117-PAH (50).  An activation process in dimeric PAH would suggest 
that allosteric binding site would need to be maintained in dimeric PAH, which is 
contrary to the morpheein argument.  Finally, the morpheein model proposes that are 
only two allosteric L-Phe binding sites in the activated tetrameric species.  Our work does 
not support this conclusion, as we have showed that there is an allosteric L-Phe binding 
site in each subunit (see Chapter 2).  Additionally previous 
14
C-labeling studies have 
indicated that there are allosteric four L-Phe binding sites per tetramer (76).  Jaffe and 
coworkers proposed reasonable homology models for PAH interactions in the T-state 
using other ACT domain proteins (136).  These models suggest that two of the activated 
R-state regulatory domains come in close contact with each other (Figure 5.27) as has 
been observed for other ACT domain proteins (67, 68).  This model should be tested by 
X-ray crystallography with the R-state enzyme to determine whether the domain 
movements proposed by Jaffe and coworkers are actually occurring in PAH or whether 
PAH exhibits a more rotation based movement in the tetramer upon allosteric activation 
as discussed in Section 5.4.3.2. 
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Figure 5.27 Possible domain movement predicted in PAH from homology models with 
other ACT domain proteins (136).  The regulatory domains (gray) are predicted to move 
closer together to form interactions between ACT domains as shown by the blue arrows.  
L-Phe molecules are modeled in the allosteric site in orange; the catalytic domains are 
shown in green and the tetramerization domains are shown in magenta.  Figure was 
created in PyMol (23) using PDB files 2PAH (84) and 2PHM (14). 
 
 
 The proposed catalytic mechanism for tetrameric PAH is shown in Figure 5.28.  
This mechanism requires that PAH is allosterically activated via the regulatory 
mechanism (Figure 5.26) that occurs in intermediates A and B in Figure 5.28.  The 
activation process binds L-Phe in the active and allosteric sites of the protein.  Binding of 
L-Phe to the allosteric site induces allosteric conformational change in each subunit.  The 
structural effects of the allosteric mechanism are indicated in the blue boxes in the right 
hand corner of each intermediate, using the square to circle nomenclature that has 
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previously been used for the PAH activation mechanism.  The presence of both L-Phe 
and coenzyme in the allosterically activated enzyme (intermediate B), is associated with a 
loss of water ligand from the active site iron center from MCD and XAS studies (109, 
110).  The active site rearrangement that occurs when L-Phe binds in the active site, 
causes the coenzyme binding site to move about 1.8 Å closer to the iron center and flips 
or alters the orientation of the substrate to bring it in the correct direction for 
hydroxylation (50).  Dioxygen then binds to the activated, fully loaded enzyme 
(intermediate C), forming a putative C4a-peroxypterin-iron(II) species, which still has 
not been spectroscopically observed.  This species undergoes heterolytic cleavage of the 
O-O bond to form the hydroxylating iron(IV)-oxo intermediate (61) and a C4a-
hydroxydihydropterin species (intermediate D) (62, 113).  Finally, the substrate L-Phe is 
hydroxylated to form L-Tyr and the active site returns to the pre-active site reorganization 
orientation (intermediate E).  The coenzyme can then be regenerated as discussed in 
Section 1.2.2.   
  
378 
 
 
 
 
Figure 5.28 Proposed catalytic mechanism for tetrameric PAH. The blue boxes indicate 
the activation state of the enzyme at each step. 
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 The enzyme will remain allosterically activated with L-Phe until the L-Phe 
concentration is low enough to release L-Phe from the allosteric effector binding site, 
which occurs slowly from about 800-400 µM, according to the decreasing L-Phe SAW 
titrations from Chapter 3.  At sufficient L-Phe concentrations, the enzyme will continue 
to turnover L-Phe to L-Tyr indefinitely.  Once L-Phe levels drop below about 300 µM, 
the enzyme should fully release L-Phe from the allosteric site, effectively stopping 
enzyme turnover.  Blood plasma levels of L-Phe are approximately 50-100 µM in humans 
(79), suggesting that L-Phe may remain bound in the active site of the enzyme at all 
times.  L-Phe may be released from the active site at times of L-Phe starvation, as SAW 
titrations show that L-Phe release from the active site occurs with KD,app
off
 = 90 ± 20 µM. 
 While the catalytic mechanism is quite well understood, there are still outstanding 
questions and many unknowns in the activation mechanism and ordering of the activation 
and catalytic processes.  In terms of the catalytic mechanism, the identity of the sixth 
ligand at the iron center is still unknown.  There is a glutamic acid residue, Glu286 that is 
located about 4.3 Å from the iron center in the T-state crystal structures (58).  This 
residue has been proposed to be transient ligand that may bind to the iron center in some 
activation states of the enzyme (Figure 5.29).  ESEEM studies are currently underway 
with an E286A-PAH mutant to elucidate the role of Glu286 in the catalytic cycle of PAH.  
In addition, the order of addition of substrate and coenzyme for catalysis has still not 
been determined.  Dioxygen is not expected to readily bind in the enzyme active site until 
allosteric activation, coenzyme and L-Phe active site binding, and active site 
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reorganization have occurred.  Active site reorganization after L-Phe binding has been 
shown to enhance NO accessibility to the active site, and has been suggested to open a 
gas channel or pathway for dioxygen binding in the active site (50).  The role of L-Phe 
allosteric activation on the active site processes should be further examined.  From the 
SAW titrations it is assumed that L-Phe will bind in the active site before binding in the 
allosteric site.  Further stopped flow fluorescence studies should examine whether the 
fluorescence signatures are the same the presence and absence of coenzyme, to determine 
if active site reorganization is influenced by the presence of coenzyme and if the order of 
substrate and coenzyme addition matters in the catalytic activity of the enzyme.  We 
predict that 6MPH4 will have no effect on the activity of the enzyme, while BH4 will 
enhance the activation barrier and inhibit the activation process. 
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Figure 5.29 Location of Glu286 near active site of PAH. Figure created in PyMol (23) 
using PDB file 1J8U (58). 
 
5.5.2 Implications of allosteric activation on PKU 
 The role of phenylalanine hydroxylase in metabolism is L-Phe homeostasis.  L-
Phe levels in the bloodstream must be maintained at a low level (50-100 µM) (79).  
Failure of PAH to clear L-Phe from the blood leads to the metabolic condition PKU that 
can result from more than 500 known missense, nonsense, deletion, and frame shift 
mutations of the PAH gene (80).  This condition occurs when L-Phe enters tyrosine 
transaminase instead of PAH to form phenylpyruvate (Figure 5.30) (49).  The buildup of 
phenylpyruvate and other L-Phe metabolites leads to permanent brain damage and mental 
retardation in patients with PKU.  The most common treatment for PKU is an L-Phe 
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restricted diet for life, which is quite hard for patients to live with for an extended period 
of time.  More recently, supplementation with artificial coenzyme (Sapropterin 
dihydrochloride) has become a treatment option to help some patients who have PKU 
mutations near the active site of the enzyme or that disorient the coenzyme (81).  As 
discussed in Section 2.4.2, PKU also occurs in patients who have mutations that are quite 
distinct from the active site of the enzyme and there are at least 13 PKU-inducing 
mutations located within 10 Å of the allosteric effector binding site (Figure 2.14, Table 
2.8).  One of the mutations located in close proximity to the allosteric site is the most 
common clinical mutation causing PKU, R408W (83).  These mutations likely alter the 
allosteric binding site in PAH so that the protein cannot bind L-Phe in the allosteric site.  
These enzymes should have a catalytically competent active site since the mutations 
about 20 Å from the iron center.  Studies in Chapter 2 began an initial screening of 
possible small molecules that would activate the enzyme but not serve as substrates.  
More intense screening of small aromatic compounds by high throughput or other 
methods may help elucidate small molecules that can re-activate PAH, and allow 
recovery of catalytic activity.   
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Figure 5.30 Pathways leading to buildup of toxic L-Phe metabolites that cause PKU. 
 
 The Trp residues in PAH have been shown in Chapter 3 to be reporters for L-Phe 
in the active and allosteric sites of PAH.  Mutations to the Trp residues in PAH are all 
known PKU inducing mutations (Table 5.2) (80).  These results suggest that alteration of 
any Trp residue to another residue inhibits the intra-protein communication of L-Phe 
binding in the active and allosteric sites.  Trp120 reports active site binding of L-Phe, but 
is physically located close to the allosteric site.  Alteration of Trp120 could both change 
the structure of the allosteric effector binding site, which could potentially be recovered 
with an additional effector molecule as discussed above, and alters the intra-protein 
signaling required to recognize L-Phe binding in the active site.  Trp187 reports allosteric 
activation, but is located about 40 Å from the allosteric binding site and 17 Å from the 
active site.  Mutation of Trp187 to another residue appears to prevent communication of 
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the allosteric activation state of the enzyme.  This means that the enzyme active site will 
not recognize the activation state of the enzyme and never become catalytically 
competent.  Trp326 demonstrates small effects in the reporting of both active site and 
allosteric site binding, and therefore mutations to Trp326 may alter communication of 
allosteric conformational change and active site reorganization.  The Trp mutant enzymes 
may not be able to be reactivated with a small molecule effector as the overall signaling 
pathways in the protein are altered.  It is also interesting to note that mutations to Trp 
residues result in several nonsense mutations that may alter protein folding or stability to 
a greater extent than a single amino acid missense mutation.    
 
 
 
Table 5.2 Trp residues in PAH involved in PKU from the PKU Database (80). 
Trp Residue PKU Mutant Enzymes Type of Mutation 
W120 W120X Nonsense 
W187 W187X  
W187R 
W187C 
T186_W187 
Nonsense 
Missense 
Missense 
Frame shift 
W326 W326X Nonsense 
 
  
 
  
 The studies on the allosteric effector binding site herein have given additional 
insight to the chemical basis of PKU and may lead to the development of better 
treatments for PKU for some patients.  Due to the diverse chemical nature of the 
mutations causing PKU, future treatment may be individualized to the particular type of 
mutation causing the disease.  Through targeted screening of potential allosteric effectors, 
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it is hoped that we can re-engineer allosteric activation in some patients that would allow 
them to live normal life free from a phenylalanine restricted diet without neurological 
defects.  
5.5.3 Future directions 
 This project leaves many unanswered questions and future areas of additional 
research.  The stopped flow fluorescence studies with the Trp mutant enzymes and 
wtPAH have demonstrated very rapid kinetic processes that are mostly completed within 
the first 100-500 ms, while the dead time our of stopped flow spectrometer in 
fluorescence mode is about 10-15 ms.  This instrumentation time-scale may be too slow 
to have good resolution of the early processes occurring in the reaction of L-Phe and 
PAH, and faster techniques that can analyze ns to µs time scales may be necessary to 
definitively resolve the steps occurring the L-Phe activation process.  Laser flash 
photolysis experiments can analyze early time scale processes and typically have 
nanosecond resolution.  These experiments have been previously used to analyze protein 
folding and other rapid processes (225).   
 The active site reorganization processes that we have observed in wtPAH and the 
Trp mutant enzymes are processes that have not been well examined.  To gain a better 
understanding of the ordering of these processes, NO-adducts could be generated for 
wtPAH and the Trp mutant enzymes.  Using the buildup curves that have been generated 
from the stopped flow kinetic studies of the enzymes we can could react the NO-adducts 
of PAH with L-Phe and stop them using rapid freeze quench methods at the active site 
reorganization step.  ESSEM could then be used to follow the active site reorganization 
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as has been previously observed for the wild-type enzyme with L-Phe (50).  In the wild-
type working activation mechanism, there are two pathways for active site 
reorganization.  In the alternative pathway, L-Phe would bind in the active site first, and 
then undergo active site reorganization before the dominant pathway.  The reaction of L-
Phe with wtPAH could be stopped at the point where the alternative pathway builds up L-
Phe bound in the active site and the reorganization in the active site could be monitored 
by ESEEM.  The relative amount of sample following each pathway should be able to be 
simulated by this data.  
 The rates of the conformational change steps of the dominant pathway of L-Phe 
induced allosteric activation mechanism in wtPAH generally increase as each subunit 
undergoes conformational change.  These rates are likely correlated with the 
cooperativity of the enzyme, as the activation of each subsequent subunit is faster.  Small 
angle X-ray scattering would allow examination of the conformational changes occurring 
upon L-Phe induced activation.  A flow small angle X-ray scattering technique would 
allow increasing concentrations of L-Phe to pass through the sample to observe the 
conformational changes as a function of L-Phe concentration. 
 The role of the dimer in the PAH activation process is still unknown.  Our SAW 
and fluorescence data have only elucidated activation pathways for the tetrameric 
enzyme.  Dimeric PAH is catalytically active and may undergo active site reorganization 
upon L-Phe binding, like Δ1-117-PAH (50), or undergo some other activation process.  
Low temperature stopped flow kinetics may help determine if there are any activation 
processes occurring within the dimeric enzyme.  These experiments should help to 
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elucidate the functional role of the dimeric enzyme in PAH.  We should also study kinetic 
models that account for dimer and dimer-tetramer equilibria like the models that have 
been studied by Ackers and coworkers for hemoglobin (148, 154, 155). 
 Finally, structural information is necessary to understand the conformational 
changes occurring in wtPAH upon L-Phe activation.  Previous efforts by the Caradonna 
Lab to co-crystallize wtPAH with L-Phe have been unsuccessful, but structural 
information will necessary to fully describe the physical implications of the kinetic 
mechanisms described herein.  Structural information is necessary to understand the role 
of the regulatory domain in controlling access to the active site and facilitating L-Phe 
induced conformational change at the allosteric sites.  The structural insight provided by 
the homology modeling by Jaffe and coworkers (136) as well as other ACT domain 
enzymes (67) suggests that regulatory domains must move in a direction such that at least 
two domains must interact in the activated R-state enzyme.  This interaction would also 
serve to open access to the active site, facilitating dioxygen or coenzyme binding in the 
active site for catalysis.  Allosteric activation has also been proposed to open a gas 
channel that facilitates dioxygen access to the active site (50).  The presence of a gas 
channel could be probed with crystallography by pressurizing the crystals with xenon or 
krypton gas (226).  These X-ray crystal structures would help to explain how substrates 
are able to reach the enzyme active site, and whether the active site accessibility is altered 
by the activation state of the enzyme. 
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5.5.4 Conclusion 
 This dissertation has studied the location and effects of allosteric activation on 
phenylalanine hydroxylase.  This work has elucidated the location of the allosteric 
effector binding site in PAH that was unknown for the last 50-plus years.  In addition, 
SAW measurements have enabled determination of the binding affinity of L-Phe for the 
active and allosteric sites in PAH (KD,app
on
 110 ± 10, KD,app
off
 90 ± 20 µM, active site 
KD,app
on
 680 ± 20 µM, allosteric site respectively).  Mutant enzymes containing all 
combinations of either one or two Trp residues were prepared and used to examine the 
fluorescence changes that occur in PAH upon allosteric activation.  Fluorescence 
titrations with varying concentrations of L-Phe demonstrated the roles of the individual 
Trp residues in reporting L-Phe binding and conformational changes in the protein.  
Trp120 reports active site binding of L-Phe, while Trp187 report allosteric 
conformational change.  Trp326 reports small effects of both active site L-Phe binding 
and allosteric conformational changes.  The fluorescence signatures of the Trp mutant 
enzymes were used to interpret time dependent stopped flow fluorescence of the Trp 
mutant enzymes and wtPAH with L-Phe.  The time dependent fluorescence data was used 
to determine a working kinetic mechanism for allosteric activation and active site 
reorganization in PAH and this activation mechanism was correlated with the catalytic 
mechanism for PAH.  These mechanisms for L-Phe induced activation in PAH will 
provide a framework for additional studies on the ordering on the steps of L-Phe induced 
activation needed for catalysis.  The insight of the location and working kinetic 
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mechanism of allosteric activation will also help develop new treatments for some 
patients with PKU. 
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5.6  Appendix 
 
 
Figure 5.31 Possible simple model for wtPAH with L-Phe fluorescence. 
 
 
 
Figure 5.32 Kinetic fit of 11.5 µM wtPAH with 5 mM L-Phe at 3.7 ºC to the model 
proposed in Figure 5.31. The data is shown in black while the fit is shown in red; the 
inset shows the residual of the fit. 
 
391 
 
 
 
 
Figure 5.33 Possible simple model for wtPAH with L-Phe fluorescence. 
 
 
 
Figure 5.34 Kinetic fit of 11.5 µM wtPAH with 5 mM L-Phe at 3.7 ºC to the model 
proposed in Figure 5.33. The data is shown in black while the fit is shown in red; the 
inset shows the residual of the fit. 
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Figure 5.35 Possible model for wtPAH with L-Phe fluorescence based on a dimer - 
tetramer initial equilibrium model. Active site rearrangement is indicated by the * in the 
mechanism. 
 
 
Figure 5.36 Kinetic fit of 11.5 µM wtPAH with 5 mM L-Phe at 3.7 ºC to the model 
proposed in Figure 5.35. The data is shown in black while the fit is shown in red; the 
inset shows the residual of the fit. 
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Figure 5.37 Possible model for wtPAH with L-Phe fluorescence based on an initial dimer 
model.  Active site rearrangement is indicated by the * in the mechanism. 
 
 
Figure 5.38 Kinetic fit of 11.5 µM wtPAH with 5 mM L-Phe at 3.7 ºC to the model 
proposed in Figure 5.37. The data is shown in black while the fit is shown in red; the 
inset shows the residual of the fit. 
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Figure 5.39 Speciation plot for predicted species in the reaction of 11.5 µM wtPAH with 
5 mM L-Phe at 10.0 ºC according to the model shown in Figure 5.10 (Eqs. 123-132). 
 
 
 
 
Figure 5.40 Speciation plot for predicted species in the reaction of 11.5 µM wtPAH with 
5 mM L-Phe at 15.1 ºC according to the model shown in Figure 5.10 (Eqs. 123-132). 
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Figure 5.41 Speciation plot for predicted species in the reaction of 11.5 µM wtPAH with 
5 mM L-Phe at 20.0 ºC according to the model shown in Figure 5.10 (Eqs. 123-132). 
 
 
 
Figure 5.42 Speciation plot for predicted species in the reaction of 11.5 µM wtPAH with 
5 mM L-Phe at 25.3 ºC according to the model shown in Figure 5.10 (Eqs. 123-132). 
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Figure 5.43 Speciation plot for predicted species in the reaction of 11.5 µM wtPAH with 
5 mM L-Phe at 30.0 ºC according to the model shown in Figure 5.10 (Eqs. 123-132). 
 
Table 5.3 Rates of 11.5 µM wtPAH with 5 mM L-Phe as fit by the model proposed in 
Figure 5.10 (Eqs. 123-132). 
Temp. 
ºC 
k1 
(M
-1
s
-1
) 
k2 
(s
-1
) 
k3 
(s
-1
) 
k4 
(s
-1
) 
k5 
(s
-1
) 
k6 
(M
-1
s
-1
) 
k7 
(s
-1
) 
k8 
(M
-1
s
-1
) 
k9 
(s
-1
) 
k10 
(M
-1
s
-1
) 
3.7 8.0E+0
4 
1.1E+0
1 
3.5E-
01 
1.4E+0
0 
1.4E+0
2 
1.0E+0
4 
1.0E+0
8 
1.1E+0
4 
6.6E+0
0 
6.1E+0
0 
10.0 9.0E+0
4 
1.3E+0
1 
1.1E+0
0 
1.3E+0
0 
1.6E+0
2 
1.4E+0
4 
1.0E+0
8 
5.8E+0
4 
1.0E+0
1 
1.5E+0
1 
15.1 1.2E+0
5 
1.2E+0
1 
1.3E+0
0 
1.1E+0
0 
2.0E+0
2 
1.0E+0
4 
1.0E+0
8 
1.1E+0
5 
2.2E+0
1 
1.9E+0
1 
20.0 1.3E+0
5 
1.5E+0
1 
2.2E+0
0 
3.7E+0
0 
6.2E+0
2 
1.2E+0
4 
1.0E+0
8 
2.1E+0
5 
2.3E+0
1 
3.9E+0
1 
25.3 3.6E+0
5 
1.7E+0
1 
2.2E+0
0 
1.2E+0
0 
3.3E+0
2 
3.3E+0
4 
1.0E+0
8 
2.1E+0
5 
8.2E+0
1 
2.8E+0
1 
30.0 8.5E+0
5 
2.3E+0
1 
1.9E+0
0 
4.5E+0
0 
8.4E+0
2 
3.1E+0
4 
1.0E+0
8 
1.4E+0
5 
8.1E+0
1 
3.1E+0
1 
Temp. 
ºC 
St Dev 
k1 
St Dev 
k2 
St Dev 
k3 
St Dev 
k4 
St Dev 
k5 
St Dev 
K6 
St Dev 
k7 
St Dev 
k8 
St Dev 
k9 
St Dev 
k10 
3.7 1.7E+0
3 
1.2E+0
0 
2.1E-
01 
1.7E+0
1 
7.9E+0
1 
5.5E+0
3 
2.8E+0
7 
4.9E+0
3 
2.7E-
01 
3.9E-
01 
10.0 2.2E+0
3 
6.3E-
01 
9.0E-
01 
4.6E-
01 
6.1E+0
1 
9.9E+0
2 
5.0E+0
7 
9.0E+0
3 
3.1E-
01 
5.5E+0
0 
15.1 1.2E+0
4 
8.3E-
01 
5.2E-
01 
4.2E-
01 
1.3E+0
2 
4.4E+0
3 
5.0E+0
7 
1.5E+0
4 
2.0E+0
0 
2.9E+0
0 
20.0 3.7E+0
4 
3.2E-
01 
2.4E-
01 
1.2E+0
0 
3.4E+0
2 
6.4E+0
3 
5.0E+0
7 
3.9E+0
4 
5.0E-
01 
8.0E+0
0 
25.3 2.7E+0
4 
9.0E-
01 
5.5E-
01 
6.9E-
01 
1.9E+0
2 
2.2E+0
3 
5.0E+0
7 
1.9E+0
3 
3.4E+0
0 
2.6E+0
0 
30.0 3.1E+0
4 
1.2E+0
0 
2.1E-
01 
2.9E+0
0 
4.6E+0
2 
3.9E+0
3 
5.0E+0
7 
1.7E+0
4 
3.9E+0
0 
1.4E+0
0 
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Table 5.4 Rates of 11.5 µM wtPAH with 5 mM L-Phe at 3.7 ºC as fit by the models 
proposed in Figure 5.17 (Eqs. 133-139) and Figure 5.19 (Eqs. 140-146). Rates with * 
are in M
-1
s
-1
, rates with ** are in s
-1
. 
Figure 5.17, Eqs. 133-139 Figure 5.19, Eqs. 140-146 
Reaction Rate 
Constant 
Rates (M
-1
s
-1
 or s
-1
) Reaction Rate 
Constant 
Rates (M
-1
s
-1
 or s
-1
) 
A + B → C k1 3.4E+04 ± 1.7E+03*  A + B → C k1 3.0E+04 ± 5.9E+02* 
C → D k2 4.7E+01 ± 2.9E+00** C → D k2 5.1E+01 ± 2.3E+00** 
B + D → E k3 3.8E+01 ± 3.6E-01* B + D → E k3 5.3E+01 ± 2.6E+00* 
A + B → E k4 2.9E+03 ± 5.5E+02* E → F k4 2.7E+06 ± 1.4E+08** 
E → F k5 1.3E+05 ± 2.6E+04** F → G k5 2.8E+11 ± 1.6E+13** 
F → G k6 4.5E+02 ± 6.2E+01** G → H k6 1.1E+02 ± 1.9E+01** 
G → H k7 1.8E+03 ± 6.1E+02** H → I k7 2.4E+03 ± 7.0E+02** 
H → I k8 4.6E+10 ± 3.2E+16**  
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